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ABSTRACT 
The method by which a drug is delivered can have a significant effect on the drug's 
therapeutic efficacy. Pulsatile delivery of certain drugs and molecules (such as hormones) has 
been shown to more efficacious than continuous delivery, as the fluctuation in concentration 
levels in vivo more closely mimics the natural physiological processes of the human body. 
However, there is a shortage of systems that are capable of delivering drugs in this manner, 
particularly if it is desired to have a self-contained system that does not require external 
stimulation to trigger device function. 
 The objectives of this thesis were to design, fabricate, test, and characterize a 
biodegradable polymeric microreservoir device that is capable of delivering multiple pulses of 
drugs in a reproducible manner. This polymeric microreservoir device contains an array of 
reservoirs that are each covered by a thin membrane of a degradable polymer. Control over the 
release of drugs from the device was achieved by changing the molecular weight of the reservoir 
membranes. The current prototypes have 36 reservoirs, but the size and geometry of the 
polymeric chip could be designed to optimize device performance depending on the application 
for which it will be used. Changing the membrane materials or thicknesses could change the time 
at which the chemicals are released from the reservoirs. Each reservoir on the device could 
potentially have a different set of membrane characteristics, enabling release of the contents of 
each reservoir at a different time. 
A fabrication process for these devices was developed, that consists of two compression-
molding steps, followed by microinjection of the reservoir membranes from solution and 
subsequent drying of the membranes under vacuum and elevated temperature. The devices are 
then loaded with the drugs to be released and sealed at room temperature. This fabrication 
process avoids exposure of the drugs to solvents and high temperatures that may adversely affect 
their stability. Further, the compression-molding process used to fabricate the main body of the 
device, as well as minimal solvent used in the fabrication of the reservoir membranes, were 
designed to minimize adverse effects upon in vivo implantation due to residual solvent. 
 Poly(L-lactic acid) was selected as the component material for the device substrate, while 
the reservoir membranes were made from copolymers of poly(lactic-co-glycolic acid) having 
varying molecular weights. The degradation behaviors of these materials have been extensively 
studied both in vitro and in vivo, and they have been shown to be quite biocompatible. Studies 
showed that the degradation of the reservoir membranes in vitro and subsequent release times of 
chemicals from the reservoirs is a function of both the membrane thicknesses and environmental 
temperature. 
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 Proof-of-principle release studies showed up to four pulses of radiolabeled molecules 
(14C-dextran, 3H-heparin, and 125I-HGH) from single devices, both with one chemical per device 
(four pulses per chemical) as well as two chemicals per device (two pulses per chemical). 
Bioactivity measurements showed that heparin released from the devices in vitro retains activity 
up to at least 143 days. In vitro release studies and characterization of partition coefficients 
showed that the pulsatile delivery of smaller, more lipophilic molecules is more challenging, and 
may require further device modification. 
Proof-of-principle in vivo release studies demonstrated delivery of two pulses of 14C-
mannitol in rats from prototype devices having reservoir membranes made from two different 
polymers. More pulses could be achieved in vivo by increasing the number of different reservoir 
membrane materials used. The more rapid release kinetics observed in vivo compared to the in 
vitro results suggests more rapid degradation of the reservoir membranes. This hypothesis was 
supported by results obtained from in vivo biodegradation studies.  
 A greater understanding of the mechanisms by which the reservoir membranes open will 
aid in attaining greater reproducibility of device performance. Additionally, more thorough study 
of the interactions between the drug and the membrane materials may help to develop a 
framework for understanding how device performance and release time can be predicted based 
on the chemistry of the drugs of interest. Finally, optimization of the membrane materials for in 
vivo device usage is paramount for progress towards achieving a clinically useful drug delivery 
system. 
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 Errata – p. 2 
page 15, Figure 5.25 caption, line 2 
Original text: “WITH 14C-MANNITOL AND HAVING 150 µM THICK PLGA11 AND PLGA64 RESERVOIR MEMBRANES 
WITH” 
Corrected text: “WITH 14C-MANNITOL AND HAVING 318−327 µM THICK PLGA11 AND PLGA64 RESERVOIR 
MEMBRANES WITH” 
 
page 17, Figure 9.1 caption, line 2 
Original text: “DEVICES HAVING PLGA11 AND PLGA64 RESERVOIR MEMBRANES, EACH LOADED WITH …” 
Corrected text: “DEVICES HAVING 318−327 µM THICK PLGA11 AND PLGA64 RESERVOIR MEMBRANES, EACH 
LOADED WITH …” 
 
page 17, Figure 9.2 caption, line 2 
Original text: “DEVICES (□○) HAVING PLGA11 AND PLGA64 RESERVOIR MEMBRANES, EACH LOADED 
WITH…” 
Corrected text: “DEVICES (□○) HAVING 321−330 µM THICK PLGA11 AND PLGA64 RESERVOIR 
MEMBRANES, EACH LOADED WITH…” 
 
page 42, paragraph 2, line 2 
Original text: “experiments reported in this thesis. The volume of membrane solution…” 
Corrected text: “experiments reported in this thesis, although occasionally devices with 
membranes of 175−330 µm thickness were used. The volume of membrane solution…” 
 
page 44, paragraph 1, last line 
Original text: “volumes ranged from 100 to 200 nL, for predicted final membrane thicknesses 
of 150 µm.” 
Corrected text: “volumes ranged from approximately 110 to 265 nL for predicted final 
membrane thicknesses of 150 µm, and up to 500 nL were injected for thicker membranes.” 
 
page 149, paragraph 2, line 3 
Original text: “Error! Reference source not found. also shows longer t1/2 values for 150 µm 
thick films that” 
Corrected text: “Table 5-3 also shows longer t1/2 values for 150 µm thick films that” 
 Errata – p. 3 
 
page 152, paragraph 2, lines 1−3 
Original text: “Similarly, comparison of release results at 37°C in vitro from devices having 
150 µm thick PLGA11 and PLGA64 membranes and loaded with 
14
C-mannitol (experimental 
methods are presented in Chapter 9) show excellent agreement with results obtained…” 
Corrected text: “Similarly, release results at 37°C in vitro from devices having 318−327 µm 
thick PLGA11 and PLGA64 membranes and loaded with 
14
C-mannitol (experimental methods 
are presented in Chapter 9) can be compared with results obtained…”  
 
page 153, Figure 5.25 caption, line 2 
Original text: “mannitol and having 150 µm thick PLGA11 and PLGA64 reservoir membranes…” 
Corrected text: “mannitol and having 318−327 µm thick PLGA11 and PLGA64 reservoir membranes…” 
 
page 153, paragraph 1 below Figure 5.25 
Original text: “These results suggest that perhaps once the molecular weight of the membrane 
material drops below a critical value, in the range of 4,000 to 7,000 daltons, the membrane 
becomes so mechanically weak that it ruptures and releases the contents of the reservoir. It seems 
unlikely that the membrane opens due to simple dissolution of the low molecular weight chains, 
as others have reported a critical weight average molecular weight of 1,050 to 1,150 for water 
solubility of poly(D,L-lactic acid) oligomers
15
, which is much lower than the 4,000–7,000 
molecular weight that seems to be significant for membrane opening in the studies reported 
here.” 
Corrected text: “A prediction of the molecular weight range for PLGA11 and PLGA64 
membrane failure at 37°C must take into account the possibility of size-dependent degradation 
related to the differences in thicknesses of the device membranes in Figure 5.25 and the films 
used in the degradation study. For the PLGA11 material, Table 5-3 shows that 150 µm films 
degraded slightly slower, as indicated by a longer half-life, than 50 µm films at 25°C with no 
media change. The release times at 25°C summarized in Table 5-2 show that PLGA11 
membranes of thicknesses ranging from 150 to 275 µm do not consistently show a size-
dependence of degradation rate. Therefore it is unclear whether 150 µm membranes would 
 Errata – p. 4 
release earlier or later than the 318−327 µm membranes shown in Figure 5.25. In the most 
extreme case, assuming faster degradation of thinner membranes, immediate release of 150 µm 
PLGA11 membranes would correlate to a molecular weight of 12,700 daltons, the highest 
measured molecular weight for this polymer at the start of the degradation study. If PLGA11 
does exhibit size-dependent degradation and a consequent faster degradation of thicker objects, 
however, the expected release time of 150 µm membranes would occur after that observed for 
the 318−327 µm membranes at days four to six. The molecular weight for failure of 150 µm thick 
PLGA11 membranes would therefore be equal to or less than the measured molecular weight 
range of 4,400−6,500 daltons measured between days four and seven for the 150 µm films at 
37°C with media change. 
PLGA64 clearly appears to undergo size-dependent degradation at 25°C and at the length 
scale of interest (150−330 µm) for Figure 5.25, in contrast to PLGA11. The release times 
summarized in Table 5-2 for the PLGA64 membranes at 25°C show faster degradation of 250 
and 275 µm membranes than for 175 and 150 µm membranes, respectively. If this size dependent 
degradation were extrapolated to 37°C and thicker membranes we would expect that 150 µm 
membranes would show release later than that observed for the 318−327 µm membranes 
between days 12 to 15 in Figure 5.25. The molecular weight for failure of 150 µm thick 
PLGA64 membranes would therefore be similar to or less than the measured molecular weight 
of 5,300 daltons at 14 days for 150 µm thick PLGA64 films at 37°C with media change. 
The comparison of release and degradation results at 25 and 37°C suggests that perhaps 
once the molecular weight of the membrane material drops below a critical value, in the range of 
5,000 to 13,000 daltons, the membrane becomes so mechanically weak that it ruptures and 
releases the contents of the reservoir. The upper limit of molecular weight for membrane rupture 
may in fact be lower than estimated here, however molecular weight data for degradation of 150 
µm thick PLGA28 and PLGA64 films beyond 49 days at 25°C, and 150 µm membrane release 
data at 37°C would be required to determine the upper limit more precisely. It seems unlikely 
that the membrane opens due to simple dissolution of the low molecular weight chains, as others 
have reported a critical weight average molecular weight of 1,050 to 1,150 for water solubility of 
poly(D,L-lactic acid) oligomers
15
, which is much lower than the 5,000–13,000 molecular weight 
that seems to be significant for membrane opening in the studies reported here. 
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page 230, paragraph 1, lines 6−7  
Original text: “…Predicted membrane thicknesses were 150 µm for all devices. On each 
device…” 
Corrected text: “…Predicted membrane thicknesses were 318−327 µm for devices tested in 
vitro, and 321−330 µm for devices tested in vivo. On each device…” 
 
page 232, Figure 9.1 caption, line 2 
Original text: “PLGA11 and PLGA64 reservoir membranes, each loaded with…” 
Corrected text: “318−327 µm thick PLGA11 and PLGA64 reservoir membranes, each loaded with…” 
 
page 233, Figure 9.2 caption, line 2 
Original text: “having PLGA11 and PLGA64 reservoir membranes, each loaded with…” 
Corrected text: “having 321−330 µm thick PLGA11 and PLGA64 reservoir membranes, each loaded with…” 
 
page 267, paragraph 4, lines 2−3 
Original text: “…the polymer molecular weight dropping below 5,000–7,000 daltons, the 
results reported in Chapter 7…” 
Corrected text: “…the polymer molecular weight dropping below 5,000–13,000 daltons, the 
results reported in Chapter 7…” 
5 
TABLE OF CONTENTS 
1 BACKGROUND AND INTRODUCTION...........................................................................................................23 
1.1 OVERVIEW OF CONTROLLED RELEASE ..............................................................................................................23 
1.2 A RESORBABLE POLYMERIC MICRORESERVOIR DEVICE FOR DRUG DELIVERY.................................................24 
1.3 THESIS OBJECTIVES ...........................................................................................................................................26 
1.4 REFERENCES ......................................................................................................................................................27 
2 DEVICE FABRICATION .....................................................................................................................................31 
2.1 INTRODUCTION AND MOTIVATION.....................................................................................................................31 
2.1.1 Introduction...............................................................................................................................................31 
2.1.2 Motivation .................................................................................................................................................31 
2.2 MATERIALS AND METHODS ...............................................................................................................................33 
2.2.1 Materials ...................................................................................................................................................33 
2.2.2 Methods.....................................................................................................................................................34 
2.2.2.1 Substrate Fabrication........................................................................................................................................... 34 
2.2.2.1.1 Poly(L-lactic acid) Purification................................................................................................................... 34 
2.2.2.1.2 Substrate Molding....................................................................................................................................... 35 
2.2.2.1.3 Visual Inspection ........................................................................................................................................ 38 
2.2.2.1.4 Density Measurements................................................................................................................................ 38 
2.2.2.2 Reservoir Membrane Fabrication........................................................................................................................ 40 
2.2.2.2.1 Reservoir Membrane Microinjection .......................................................................................................... 40 
2.2.2.2.2 Near-Infrared Characterization of Membranes ........................................................................................... 44 
2.2.2.2.3 Residual Solvent Determination ................................................................................................................. 46 
2.3 RESULTS AND DISCUSSION ................................................................................................................................47 
2.3.1 Substrate Fabrication................................................................................................................................47 
2.3.1.1 Visual Inspection................................................................................................................................................. 47 
2.3.1.2 Density Measurements ........................................................................................................................................ 52 
2.3.2 Reservoir Membrane Fabrication.............................................................................................................53 
2.3.2.1 Reservoir Membrane Microinjection .................................................................................................................. 53 
2.3.2.2 Near-Infrared Characterization of Membranes.................................................................................................... 54 
2.3.2.3 Residual Solvent Determination.......................................................................................................................... 58 
2.4 SUMMARY AND CONCLUSIONS ..........................................................................................................................63 
2.5 ACKNOWLEDGEMENTS ......................................................................................................................................64 
2.6 REFERENCES ......................................................................................................................................................64 
3 CHEMICAL LOADING AND DEVICE SEALING...........................................................................................67 
3.1 INTRODUCTION AND MOTIVATION.....................................................................................................................67 
3.1.1 Introduction...............................................................................................................................................67 
3.1.2 Motivation .................................................................................................................................................67 
3.2 MATERIALS AND METHODS ...............................................................................................................................68 
3.2.1 Materials ...................................................................................................................................................68 
3.2.2 Methods.....................................................................................................................................................68 
3.2.2.1 Reservoir Filling ................................................................................................................................................. 68 
3.2.2.1.1 Effect of Solvent ......................................................................................................................................... 69 
3.2.2.1.2 Effect of Surface Geometry ........................................................................................................................ 71 
3.2.2.2 Device Sealing .................................................................................................................................................... 72 
3.3 RESULTS AND DISCUSSION ................................................................................................................................73 
3.3.1 Reservoir Filling .......................................................................................................................................73 
3.3.1.1 Effect of Solvent ................................................................................................................................................. 73 
3.3.1.2 Effect of Surface Geometry................................................................................................................................. 78 
3.3.2 Device Sealing...........................................................................................................................................80 
3.4 CONCLUSIONS....................................................................................................................................................81 
3.5 REFERENCES ......................................................................................................................................................82 
4 IN VITRO RELEASE EXPERIMENTS...............................................................................................................83 
4.1 INTRODUCTION AND MOTIVATION.....................................................................................................................83 
6 
4.2 MATERIALS AND METHODS ...............................................................................................................................83 
4.2.1 Materials ...................................................................................................................................................83 
4.2.2 Selection of Release Chemicals.................................................................................................................84 
4.2.3 Methods.....................................................................................................................................................85 
4.2.3.1 Device Fabrication .............................................................................................................................................. 85 
4.2.3.2 In Vitro Release Studies ...................................................................................................................................... 87 
4.2.3.2.1 Single Chemical Release Studies ................................................................................................................ 87 
4.2.3.2.2 Double Chemical Release Studies .............................................................................................................. 89 
4.3 RESULTS AND DISCUSSION ................................................................................................................................91 
4.3.1 Device Design and Fabrication ................................................................................................................91 
4.3.2 In Vitro Release Studies ............................................................................................................................91 
4.3.2.1 Single Chemical Release Studies ........................................................................................................................ 91 
4.3.2.1.1 14C-dextran .................................................................................................................................................. 91 
4.3.2.1.2 3H-heparin ................................................................................................................................................... 92 
4.3.2.1.3 125I-HGH ..................................................................................................................................................... 94 
4.3.2.1.4 125I-IL-2....................................................................................................................................................... 95 
4.3.2.1.5 14C-BCNU................................................................................................................................................... 96 
4.3.2.1.6 14C-IAP ....................................................................................................................................................... 98 
4.3.2.1.7 Discussion................................................................................................................................................. 100 
4.3.2.2 Double Chemical Release Studies..................................................................................................................... 102 
4.3.2.2.1 125I-HGH and 14C-dextran ......................................................................................................................... 103 
4.3.2.2.2 3H-heparin and 14C-dextran ....................................................................................................................... 106 
4.3.2.2.3 Discussion................................................................................................................................................. 108 
4.4 SUMMARY AND CONCLUSIONS ........................................................................................................................112 
4.5 REFERENCES ....................................................................................................................................................113 
5 POLY(LACTIC-CO-GLYCOLIC ACID) DIMENSION AND TEMPERATURE-DEPENDENT 
DEGRADATION.....................................................................................................................................................117 
5.1 INTRODUCTION AND MOTIVATION...................................................................................................................117 
5.1.1 Introduction.............................................................................................................................................117 
5.1.2 Motivation ...............................................................................................................................................118 
5.2 MATERIALS AND METHODS .............................................................................................................................118 
5.2.1 Materials .................................................................................................................................................118 
5.2.2 Methods...................................................................................................................................................119 
5.2.2.1 In vitro measurement of release time as a function of membrane thickness...................................................... 119 
5.2.2.2 In vitro degradation: GPC characterization and mass loss of membrane polymers........................................... 120 
5.3 RESULTS AND DISCUSSION ..............................................................................................................................122 
5.3.1 In vitro measurement of release time as a function of membrane thickness ...........................................122 
5.3.1.1 14C-dextran ........................................................................................................................................................ 122 
5.3.1.2 3H-heparin ......................................................................................................................................................... 124 
5.3.2 In vitro degradation: GPC characterization and mass loss of membrane polymers ..............................126 
5.3.2.1 PLGA4.4 .......................................................................................................................................................... 127 
5.3.2.2 PLGA11 ........................................................................................................................................................... 132 
5.3.2.3 PLGA28 ........................................................................................................................................................... 137 
5.3.2.4 PLGA64 ........................................................................................................................................................... 142 
5.3.2.5 Discussion ......................................................................................................................................................... 147 
5.4 CONCLUSIONS..................................................................................................................................................153 
5.5 ACKNOWLEDGEMENTS ....................................................................................................................................154 
5.6 REFERENCES ....................................................................................................................................................154 
6 CALCULATION OF PARTITION COEFFICIENTS .....................................................................................157 
6.1 INTRODUCTION AND MOTIVATION...................................................................................................................157 
6.1.1 Introduction.............................................................................................................................................157 
6.1.2 Motivation ...............................................................................................................................................157 
6.2 MATERIALS AND METHODS .............................................................................................................................158 
6.2.1 Materials .................................................................................................................................................158 
6.2.2 In vitro measurement of partition coefficients.........................................................................................158 
6.3 RESULTS AND DISCUSSION ..............................................................................................................................160 
7 
6.3.1 Stock Solution Activities and Film Characterization ..............................................................................160 
6.3.2 Small molecules (14C-iodiantipyrine and 14C-carmustine)......................................................................161 
6.3.3 Polysaccharides (14C-dextrans and 3H-heparin).....................................................................................162 
6.3.4 Proteins (125I-IL-2) ..................................................................................................................................164 
6.3.5 Discussion ...............................................................................................................................................165 
6.4 CONCLUSIONS..................................................................................................................................................166 
6.5 REFERENCES ....................................................................................................................................................167 
7 CHEMICAL RELEASE: CHARACTERIZATION OF MEMBRANE SWELLING AND DEPENDENCE 
OF CHEMICAL RELEASE ON OSMOTIC PRESSURE AND MOLECULAR CHEMISTRY....................169 
7.1 INTRODUCTION AND MOTIVATION...................................................................................................................169 
7.1.1 Introduction.............................................................................................................................................169 
7.1.2 Motivation ...............................................................................................................................................170 
7.2 MATERIALS AND METHODS .............................................................................................................................170 
7.2.1 Materials .................................................................................................................................................170 
7.2.2 Methods...................................................................................................................................................170 
7.3 RESULTS AND DISCUSSION ..............................................................................................................................175 
7.3.1 In vitro release and swelling measurements of radiolabel loaded devices .............................................175 
7.3.1.1 Control device ................................................................................................................................................... 175 
7.3.1.2 14C-glucose ........................................................................................................................................................ 178 
7.3.1.3 14C-dextran: Mw~10,000.................................................................................................................................... 182 
7.3.1.4 14C-dextran: Mw~40,000.................................................................................................................................... 186 
7.3.1.5 14C-dextran: Mw~70,000.................................................................................................................................... 189 
7.3.1.6 14C-glycerol ....................................................................................................................................................... 199 
7.3.1.7 14C-glycerol 3-phosphate................................................................................................................................... 203 
7.3.1.8 14C-glycerol trioleate ......................................................................................................................................... 208 
7.3.1.9 Discussion ......................................................................................................................................................... 211 
7.4 CONCLUSIONS..................................................................................................................................................217 
7.5 REFERENCES ....................................................................................................................................................217 
8 MEASURED BIOLOGICAL ACTIVITY OF HEPARIN AFTER RELEASE FROM MICRORESERVOIR 
DEVICES .................................................................................................................................................................221 
8.1 INTRODUCTION AND MOTIVATION...................................................................................................................221 
8.1.1 Introduction.............................................................................................................................................221 
8.1.2 Motivation ...............................................................................................................................................222 
8.2 MATERIALS AND METHODS .............................................................................................................................222 
8.2.1 Materials .................................................................................................................................................222 
8.2.2 Methods...................................................................................................................................................222 
8.2.2.1 Device Fabrication ............................................................................................................................................ 222 
8.2.2.2 In Vitro Release and Activity Measurements .................................................................................................... 223 
8.3 RESULTS AND DISCUSSION ..............................................................................................................................224 
8.3.1 Device Fabrication..................................................................................................................................224 
8.3.2 In Vitro Release.......................................................................................................................................225 
8.3.3 In Vitro Activity Measurements...............................................................................................................226 
8.4 CONCLUSIONS..................................................................................................................................................227 
8.5 REFERENCES ....................................................................................................................................................228 
9 IN VIVO RELEASE STUDIES ...........................................................................................................................229 
9.1 INTRODUCTION AND MOTIVATION...................................................................................................................229 
9.2 MATERIALS AND METHODS .............................................................................................................................229 
9.2.1 Materials .................................................................................................................................................229 
9.2.2 Methods...................................................................................................................................................230 
9.2.2.1 Device Fabrication ............................................................................................................................................ 230 
9.2.2.2 In Vitro 14C-Mannitol Control Release Study ................................................................................................... 230 
9.2.2.3 In Vivo 14C-Mannitol Release Study.................................................................................................................. 230 
9.3 RESULTS AND DISCUSSION ..............................................................................................................................232 
9.4 CONCLUSIONS..................................................................................................................................................235 
8 
9.5 ACKNOWLEDGEMENTS ....................................................................................................................................235 
9.6 REFERENCES ....................................................................................................................................................235 
10 IN VIVO BIODEGRADATION OF RESERVOIR MEMBRANE POLYMERS.........................................237 
10.1 INTRODUCTION AND MOTIVATION.................................................................................................................237 
10.2 MATERIALS AND METHODS ...........................................................................................................................237 
10.2.1 Materials ...............................................................................................................................................237 
10.2.2 Methods.................................................................................................................................................238 
10.2.2.1 Film Casting.................................................................................................................................................... 238 
10.2.2.2 Cage Fabrication ............................................................................................................................................. 238 
10.2.2.3 Film Implantation............................................................................................................................................ 239 
10.2.2.3.1 Subcutaneous Cage Implant.................................................................................................................... 239 
10.2.2.3.2 Direct Subcutaneous Implant .................................................................................................................. 239 
10.2.2.3.3 In Vitro Controls..................................................................................................................................... 240 
10.2.2.4 Gel Permeation Chromatography (GPC)......................................................................................................... 240 
10.2.2.5 Differential Scanning Calorimetry (DSC)....................................................................................................... 241 
10.3 RESULTS AND DISCUSSION ............................................................................................................................242 
10.3.1 Film Casting..........................................................................................................................................242 
10.3.2 Gel Permeation Chromatography (GPC) .............................................................................................242 
10.3.2.1 Mylar® and HFIP ........................................................................................................................................... 243 
10.3.2.2 Fibrous Capsule Tissue With Implants............................................................................................................ 244 
10.3.2.3 PLA ................................................................................................................................................................ 244 
10.3.2.4 PGA ................................................................................................................................................................ 246 
10.3.2.5 PLGA4.4 ........................................................................................................................................................ 248 
10.3.2.6 PLGA64 ......................................................................................................................................................... 250 
10.3.3 Differential Scanning Calorimetry (DSC).............................................................................................252 
10.3.3.1 Mylar®............................................................................................................................................................ 252 
10.3.3.2 PLA ................................................................................................................................................................ 252 
10.3.3.3 PGA ................................................................................................................................................................ 253 
10.3.3.4 PLGA4.4 ........................................................................................................................................................ 254 
10.3.3.5 PLGA64 ......................................................................................................................................................... 255 
10.3.4 Discussion .............................................................................................................................................256 
10.3.4.1 Mylar®, HFIP, and Tissue Samples................................................................................................................ 256 
10.3.4.2 Biodegradable Polymers ................................................................................................................................. 257 
10.3.4.2.1 PLA......................................................................................................................................................... 257 
10.3.4.2.2 PGA ........................................................................................................................................................ 260 
10.3.4.2.3 PLGA4.4................................................................................................................................................. 261 
10.3.4.2.4 PLGA64.................................................................................................................................................. 262 
10.4 SUMMARY AND CONCLUSIONS ......................................................................................................................263 
10.5 ACKNOWLEDGEMENTS ..................................................................................................................................263 
10.6 REFERENCES ..................................................................................................................................................264 
11 CONCLUSIONS AND FUTURE WORK........................................................................................................267 
11.1 SUMMARY OF RESULTS..................................................................................................................................267 
11.2 FUTURE WORK ..............................................................................................................................................267 
11.2.1 Membrane Degradation and Opening ..................................................................................................267 
11.2.2 Drug Chemistry.....................................................................................................................................268 
11.2.3 In Vivo Drug Release ............................................................................................................................268 
11.3 CONCLUSIONS................................................................................................................................................269 
APPENDICES..........................................................................................................................................................271 
A FACTORS AFFECTING MEASURED FLUORESCENCE ..........................................................................273 
A.1 INTRODUCTION ...............................................................................................................................................273 
A.2 MATERIALS AND METHODS ............................................................................................................................273 
A.2.1 Materials.................................................................................................................................................273 
A.2.2 Methods ..................................................................................................................................................273 
A.2.2.1 Photobleaching: Microinjected Cuvettes.......................................................................................................... 273 
A.2.2.2 Photobleaching: Pipetted Cuvettes ................................................................................................................... 274 
9 
A.2.2.3 Ionic Strength and pH ...................................................................................................................................... 275 
A.2.2.4 pH and Conductivity: Release Studies ............................................................................................................. 275 
A.3 RESULTS AND DISCUSSION..............................................................................................................................275 
A.3.1 Photobleaching: Microinjected Cuvettes................................................................................................275 
A.3.2 Photobleaching: Pipetted Cuvettes.........................................................................................................277 
A.3.3 Ionic Strength and pH.............................................................................................................................279 
A.3.4 pH and Conductivity ...............................................................................................................................280 
A.4 SUMMARY AND CONCLUSIONS .......................................................................................................................284 
A.5 REFERENCES ...................................................................................................................................................284 
B MICROINJECTOR ACCURACY.....................................................................................................................285 
B.1 INTRODUCTION................................................................................................................................................285 
B.2 MATERIALS AND METHODS ............................................................................................................................285 
B.2.1 Materials.................................................................................................................................................285 
B.2.2 Methods ..................................................................................................................................................285 
B.2.2.1 Effect of Syringe Volume................................................................................................................................. 285 
B.2.2.2 Effect of Elapsed Time Between Microinjections ............................................................................................ 287 
B.3 RESULTS AND DISCUSSION..............................................................................................................................287 
B.3.1 Effect of Syringe Volume ........................................................................................................................287 
B.3.2 Effect of Elapsed Time Between Microinjections ...................................................................................290 
B.4 CONCLUSIONS .................................................................................................................................................292 
 
 
10 
11 
LIST OF FIGURES 
 
FIGURE 1.1 SCHEMATIC OF POLYMERIC MICRORESERVOIR DEVICE. FIGURE BY ERICA BEADE.....................................24 
FIGURE 2.1 SCHEMATIC OF FIRST COMPRESSION MOLDING STEP AT ROOM TEMPERATURE, IN WHICH THE PLA POLYMER 
PREFORM THAT WILL BECOME THE DEVICE SUBSTRATE IS FORMED.....................................................................35 
FIGURE 2.2 SCHEMATIC SHOWING FABRICATION PROCESS FOR POLYMERIC MICRORESERVOIR DEVICE: (A) SECOND 
COMPRESSION MOLDING STEP AT T>TG OF THE POLYMER, IN WHICH THE CONICAL RESERVOIRS ARE FORMED IN 
THE POLYMER PREFORM THAT WAS COMPRESSION MOLDED AT 25°C BY COMPRESSION MOLDING WITH AN 
ALUMINUM DIE HAVING CONICAL PROTRUSIONS ON IT, (B) CUT-AWAY SCHEMATIC OF DEVICE SUBSTRATE 
SHOWING PARTIAL PENETRATION OF CONICAL RESERVOIRS INTO SUBSTRATE, (C) DEVICE SUBSTRATE AFTER 
BEING POLISHED WITH SILICON CARBIDE PAPER, SHOWING TRUNCATION OF CONICAL RESERVOIRS (COMPLETE 
PENETRATION OF RESERVOIRS THROUGH DEVICE SUBSTRATE), (D) CUT-AWAY SCHEMATIC SHOWING 
RESERVOIRS WITH MICROINJECTED MEMBRANES, (E) CUT-AWAY SCHEMATIC SHOWING DEVICE AFTER 
MICROINJECTION OF CHEMICAL TO BE RELEASED. ENLARGEMENT OF RESERVOIR SHOWS MENISCUS SHAPE OF 
RESERVOIR MEMBRANE AND TYPICAL DIMENSIONS OF DEVICE FEATURES, (F) CUT-AWAY SCHEMATIC SHOWING 
DEVICE AFTER SEALING WITH A LAYER OF ELECTROPLATING MASK TAPE. FIGURE BY ERICA BEADE. ................36 
FIGURE 2.3 SCHEMATIC OF ALUMINUM SURFACE TREATED WITH (TRIDECAFLUORO-1,1,2,2-TETRAHYDROOCTYL) 
TRICHLOROSILANE. .............................................................................................................................................37 
FIGURE 2.4 PHOTOGRAPH OF 6 × 6 ARRAY OF CONICAL PROTRUSIONS (1000 µM TALL, BASE ANGLE OF CONES = 70°) 
ON ALUMINUM DIE PLATE. TICK MARKS ON RULER INDICATE 1/16” (~1600 µM). PHOTO BY RICHARD HOLMAN.
...........................................................................................................................................................................37 
FIGURE 2.5 SCHEMATIC OF RESERVOIR GEOMETRY SHOWING MICROINJECTION OF MEMBRANE SOLUTION INTO 
RESERVOIR AND FORMATION OF A FLUID VOLUME HAVING RADII OF CURVATURE R1 AND R2, AND SUBSEQUENT 
DRYING OF THE SOLUTION AS CAPILLARY PRESSURE DRAGS THE FLUID VOLUME TO THE SMALL END OF THE 
RESERVOIR..........................................................................................................................................................42 
FIGURE 2.6 CONICAL FRUSTUM, TAKEN AS MODEL GEOMETRY FOR RESERVOIR MEMBRANES, HAVING HEIGHT 
(MEMBRANE THICKNESS) H, BASE ANGLE A, AND RADII R1 AND R2. ....................................................................43 
FIGURE 2.7 PHOTOGRAPH OF PLA PREFORM AFTER COMPRESSION MOLDING OF POLYMER POWDER IN 15/32" 
CYLINDRICAL DIE AT 11,500 PSI FOR ONE MINUTE AND THIRTY SECONDS AT ROOM TEMPERATURE. PHOTO BY 
RICHARD HOLMAN. ............................................................................................................................................47 
FIGURE 2.8 OPTICAL MICROSCOPY PHOTOGRAPH AT 37.5X OF DEVICE 070799-03 (HOT COMPRESSION MOLDED AT 
66°C), SHOWING SIX CONICAL RESERVOIRS WITH ENTRAPPED AIR BUBBLES (PORES) LOCALIZED AROUND THE 
RESERVOIRS. .......................................................................................................................................................48 
FIGURE 2.9 OPTICAL MICROSCOPY PHOTOGRAPH AT 37.5X OF DEVICE 070799-06 (HOT COMPRESSION-MOLDED AT 
82°C), SHOWING SIX CONICAL RESERVOIRS AND AIR BUBBLES LOCALIZED NEAR RESERVOIRS AND SPREADING 
BETWEEN RESERVOIRS. .......................................................................................................................................48 
FIGURE 2.10 OPTICAL MICROSCOPY PHOTOGRAPH AT 37.5X OF DEVICE 070799-09 (HOT COMPRESSION-MOLDED AT 
99°C) SHOWING SIX RESERVOIRS WITH DISTRIBUTED POROSITY THROUGHOUT THE DEVICE SUBSTRATE............49 
FIGURE 2.11 OPTICAL MICROSCOPY PHOTOGRAPH OF DEVICE 123102-01 SHOWING FOUR RESERVOIRS AFTER 
POLISHING STEP. DARK REGIONS IN RESERVOIR OPENINGS ARE POLYMER DEBRIS FROM POLISHING (REMOVED 
BEFORE MEMBRANE MICROINJECTION). LINES ON DEVICE SURFACE ARE POLISHING ARTIFACTS. .......................50 
FIGURE 2.12 OPTICAL MICROSCOPY PHOTOGRAPH OF DEVICE 123102-02 SHOWING FOUR RESERVOIRS AFTER 
POLISHING STEP. DARK REGIONS IN RESERVOIR OPENINGS ARE POLYMER DEBRIS FROM POLISHING (REMOVED 
BEFORE MEMBRANE MICROINJECTION). LINES ON DEVICE SURFACE ARE POLISHING ARTIFACTS. .......................50 
FIGURE 2.13 OPTICAL MICROSCOPY PHOTOGRAPH OF DEVICE 123102-03 SHOWING FOUR RESERVOIRS AFTER 
POLISHING STEP. DARK REGIONS IN RESERVOIR OPENINGS ARE POLYMER DEBRIS FROM POLISHING (REMOVED 
BEFORE MEMBRANE MICROINJECTION). LINES ON DEVICE SURFACE ARE POLISHING ARTIFACTS. .......................51 
FIGURE 2.14 PHOTOGRAPH OF PROTOTYPE DEVICE AFTER POLISHING, SHOWING 6 × 6 ARRAY OF TRUNCATED CONICAL 
RESERVOIRS. PHOTO BY RICHARD HOLMAN. ......................................................................................................52 
FIGURE 2.15 SEM OF PLGA64 RESERVOIR MEMBRANE ON PLA DEVICE. PHOTOGRAPH TAKEN OF FRONT SIDE OF 
MEMBRANE THAT IS EXPOSED TO RELEASE ENVIRONMENT, OPPOSITE THE SIDE OF THE RESERVOIR INTO WHICH 
THE MEMBRANE SOLUTION WAS MICROINJECTED................................................................................................53 
FIGURE 2.16 NEAR-INFRARED CHARACTERIZATION OF PGA MEMBRANE ON PLA DEVICE. IMAGE OF RESERVOIR WITH 
PGA MEMBRANE, SHOWING PLS SCORE OF PGA RANGING FROM ZERO ON THE SUBSTRATE OF THE DEVICE TO 
12 
ONE IN THE MEMBRANE REGION. HORIZONTAL LINE INDICATES ROW 120, FROM WHICH THE PLS SCORES ARE 
PLOTTED IN FIGURE 2.18 ALONG WITH PLS SCORE FROM PLA CHARACTERIZATION SHOWN IN FIGURE 2.17.....55 
FIGURE 2.17 NEAR-INFRARED CHARACTERIZATION OF PGA MEMBRANE ON PLA DEVICE. IMAGE OF RESERVOIR WITH 
PGA MEMBRANE, SHOWING PLS SCORE OF PLA RANGING FROM CLOSE TO ONE ON THE SUBSTRATE OF THE 
DEVICE TO ZERO IN THE MEMBRANE REGION. HORIZONTAL LINE INDICATES ROW 120, FROM WHICH THE PLS 
SCORES ARE PLOTTED IN FIGURE 2.18 ALONG WITH PLS SCORE FROM PGA CHARACTERIZATION SHOWN IN 
FIGURE 2.16........................................................................................................................................................56 
FIGURE 2.18 1-D PROJECTION OF PLS IMAGE SCORES ALONG HORIZONTAL AXIS AT VERTICAL CENTER, ROW 120. 
SOLID LINE INDICATES PGA SCORE AND DOTTED LINE INDICATES PLA SCORE. .................................................57 
FIGURE 2.19 SCHEMATIC OF EXPERIMENTAL GEOMETRY USED FOR COLLECTION OF NEAR-INFRARED SPECTRA, 
SHOWING DEVICE RESTING ON GOLD MIRROR, AND DIFFUSE REFLECTANCE OF QUARTZ TUNGSTEN HALOGEN 
ILLUMINATION THROUGH THE DEVICE THICKNESS. IN THE SUBSTRATE REGION OF THE DEVICE, THE INFRARED 
SIGNAL THAT IS COLLECTED IS DUE SOLELY TO THE SUBSTRATE (PLA), WHILE IN THE CENTER OF THE RESERVOIR 
MEMBRANE THE SIGNAL WILL BE DUE SOLELY TO THE MEMBRANE (PGA). IN THE TAPER REGION OF THE 
RESERVOIR, HOWEVER, THE DETECTED SIGNAL IS DUE TO BOTH THE MEMBRANE AND THE SUBSTRATE REGIONS 
THROUGH WHICH THE ILLUMINATION PASSES. IN THE IDEALIZED SCHEMATIC, FOR EXAMPLE, THE SIGNAL WILL 
BE 50% PGA AND 50% PLA SPECTRA, AS THE LINEAR THICKNESSES OF THE PGA AND PLA REGIONS THROUGH 
WHICH THE ILLUMINATION PASSES ARE EQUAL...................................................................................................57 
FIGURE 2.20 TGA DECOMPOSITION CURVES FROM 30–850°C FOR (A) 19.463 MG OF PLGA4.4, (B) 16.902 MG OF 
PLGA11, (C) 16.301 MG OF PLGA28, (D) 30.086 MG OF PLGA64 IN PLATINUM PANS. SOLID LINES INDICATE 
THE WEIGHTS OF THE SAMPLES, DOTTED LINES INDICATE THE DERIVATIVE WEIGHTS (MG/MIN) OF THE SAMPLES.
...........................................................................................................................................................................59 
FIGURE 2.21 TGA DECOMPOSITION CURVES FROM 30–260°C AND WEIGHT LOSSES FROM 30 TO 100°C FOR (A) 
PLGA4.4, (B) PLGA11, (C) PLGA28, AND (D) PLGA64. SOLID LINES INDICATE WEIGHTS OF SAMPLES, DASHED 
LINES INDICATE DERIVATIVE WEIGHTS (MG/MIN) OF SAMPLES............................................................................60 
FIGURE 2.22 TGA DECOMPOSITION CURVES FOR PLGA11 SAMPLE HELD AT 80°C FOR 22 HOURS: (A) TGA CURVE 
(WEIGHT LOSS VERSUS TEMPERATURE) FROM APPROXIMATELY 30 TO 850°C, (B) CLOSE-UP OF TGA CURVE 
FROM APPROXIMATELY 30 TO 105°C SHOWING CALCULATED WEIGHT LOSS OF 0.321 MG FROM 40 TO 80°C, (C) 
TGA CURVE OF WEIGHT LOSS OVER TIME FOR THE ENTIRE COURSE OF THE EXPERIMENT. SOLID LINES INDICATE 
WEIGHTS OF SAMPLES, DASHED LINES INDICATE DERIVATIVE WEIGHTS (MG/MIN) OF SAMPLES. .........................61 
FIGURE 3.1 EXPERIMENTAL SETUP USED FOR MICROINJECTION. THE DEVICE TO BE LOADED IS PLACED ON THE STAGE 
OF THE STEREOMICROSCOPE, AND THE CHEMICAL IS LOADED INTO THE RESERVOIRS FROM A SYRINGE THAT IS 
SEATED IN A MICROMANIPULATOR THAT CAN BE TILTED TO ALLOW OPTIMAL POSITIONING OF THE NEEDLE TIP. 
PHOTO BY REBECCA SHAWGO. ...........................................................................................................................69 
FIGURE 3.2 MEASURED VS. PREDICTED MICROINJECTED VOLUME FOR 14C-IODOANTIPYRINE IN ETHANOL, INJECTED 
FROM A TEN µL SYRINGE: ○ 20 NL INJECTIONS, □ 40 NL INJECTIONS, ● 60 NL INJECTIONS, ■ 80 NL 
INJECTIONS, × 100 NL INJECTIONS, + 120 NL INJECTIONS, SOLID LINE INDICATES THEORETICAL PREDICTED 
MICROINJECTED VOLUME, DASHED LINE INDICATES LEAST-SQUARES BEST FIT LINE TO DATA POINTS. ...............74 
FIGURE 3.3 MEASURED VS. PREDICTED MICROINJECTED VOLUME FOR 14C-DEXTRAN IN WATER, INJECTED FROM A TEN 
µL SYRINGE: ○ 20 NL INJECTIONS, □ 40 NL INJECTIONS, ● 60 NL INJECTIONS, ■ 80 NL INJECTIONS, × 100 NL 
INJECTIONS, + 120 NL INJECTIONS, SOLID LINE INDICATES THEORETICAL PREDICTED MICROINJECTED VOLUME, 
DASHED LINE INDICATES LEAST-SQUARES BEST FIT LINE TO DATA POINTS. .........................................................75 
FIGURE 3.4 CUMULATIVE PERCENTAGE OF INITIAL LOADING OF 14C-DEXTRAN DETECTED OVER 100 DAYS FROM THREE 
UNPOLISHED CONTROL DEVICES THAT HAD NO RESERVOIR MEMBRANES AND THAT WERE SEALED WITH 9144 
MASKING TAPE. NOTE Y-AXIS MAXIMUM IS 5%. .................................................................................................81 
FIGURE 4.1 CUMULATIVE PERCENTAGE OF INITIAL 14C-DEXTRAN LOADING RELEASED FROM THREE DEVICES HAVING 
PLGA4.4, PLGA11, PLGA28, AND PLGA64 RESERVOIR MEMBRANES IN SALINE SOLUTION AT 28–33°C IN 
VITRO. .................................................................................................................................................................92 
FIGURE 4.2 CUMULATIVE PERCENTAGE OF INITIAL 3H-HEPARIN LOADING RELEASED OVER TIME FROM THREE DEVICES 
HAVING PLGA4.4, PLGA11, PLGA28, AND PLGA64 RESERVOIR MEMBRANES IN SALINE SOLUTION AT 28–
33°C IN VITRO. ....................................................................................................................................................93 
FIGURE 4.3 CUMULATIVE PERCENTAGE OF INITIAL 125I-HGH LOADING RELEASED OVER TIME FROM THREE DEVICES 
HAVING PLGA4.4, PLGA11, PLGA28, AND PLGA64 RESERVOIR MEMBRANES IN SALINE SOLUTION AT 28–
33°C IN VITRO. ....................................................................................................................................................94 
13 
FIGURE 4.4 CUMULATIVE PERCENTAGE OF INITIAL 125I-IL-2 LOADING RELEASED OVER TIME FROM FOUR DEVICES 
HAVING RESERVOIR MEMBRANES MADE FROM PLGA4.4, PLGA11, PLGA28, AND PLGA64 IN SALINE 
SOLUTION AT 28–33°C IN VITRO. .........................................................................................................................95 
FIGURE 4.5 CUMULATIVE PERCENTAGE OF INITIAL 14C-CARMUSTINE (BCNU) LOADING RELEASED OVER TIME FROM 
FOUR DEVICES HAVING PLGA4.4, PLGA11, PLGA28, AND PLGA64 RESERVOIR MEMBRANES IN SALINE 
SOLUTION AT 28–33°C IN VITRO. .........................................................................................................................97 
FIGURE 4.6 CHEMICAL STRUCTURE OF 1,3-BIS(2-CHLOROETHYL)-1-NITROSOUREA (BCNU) OR CARMUSTINE............98 
FIGURE 4.7 CUMULATIVE PERCENTAGE OF INITIAL 14C-IODOANTIPYRINE (IAP) LOADING RELEASED OVER TIME FROM 
FOUR DEVICES HAVING PLGA4.4, PLGA28, AND PLGA64 RESERVOIR MEMBRANES IN SALINE SOLUTION AT 28–
33°C IN VITRO. ....................................................................................................................................................99 
FIGURE 4.8 CHEMICAL STRUCTURE OF IODOANTIPYRINE (IAP)..................................................................................100 
FIGURE 4.9 CUMULATIVE PERCENTAGES OF INITIAL 125I-HGH (×) AND 14C-DEXTRAN (○) LOADINGS RELEASED OVER 
TIME FROM A SINGLE DEVICE. 125I-HGH RELEASED FROM RESERVOIRS HAVING PLGA4.4 AND PLGA28 
MEMBRANES. 14C-DEXTRAN RELEASED FROM RESERVOIRS HAVING PLGA11 AND PLGA64 MEMBRANES. 
EXPERIMENT PERFORMED IN SALINE SOLUTION AT 28–33°C IN VITRO. .............................................................103 
FIGURE 4.10 CUMULATIVE PERCENTAGES OF INITIAL 125I-HGH (×) AND 14C-DEXTRAN (○) LOADINGS RELEASED OVER 
TIME FROM A SINGLE DEVICE. 125I-HGH RELEASED FROM RESERVOIRS HAVING PLGA11 AND PLGA64 
MEMBRANES. 14C-DEXTRAN RELEASED FROM RESERVOIRS HAVING PLGA4.4 AND PLGA28 MEMBRANES. THE 
RESERVOIR HAVING A MEMBRANE MADE FROM THE PLGA64 POLYMER OPENED EARLIER THAN THE RESERVOIR 
HAVING A MEMBRANE MADE FROM THE PLGA28 POLYMER ON THIS DEVICE. EXPERIMENT PERFORMED IN 
SALINE SOLUTION AT 28–33°C IN VITRO............................................................................................................105 
FIGURE 4.11 CUMULATIVE PERCENTAGES OF INITIAL 3H-HEPARIN (●) AND 14C-DEXTRAN (×) LOADINGS RELEASED 
OVER TIME FROM A SINGLE DEVICE. 3H-HEPARIN RELEASED FROM RESERVOIRS HAVING PLGA4.4 AND PLGA28 
MEMBRANES, 14C-DEXTRAN RELEASED FROM RESERVOIRS HAVING PLGA11 AND PLGA64 MEMBRANES. 
EXPERIMENT PERFORMED IN SALINE SOLUTION AT 28–33°C IN VITRO. .............................................................107 
FIGURE 4.12 CUMULATIVE PERCENTAGES OF INITIAL 3H-HEPARIN (●) AND 14C-DEXTRAN (×) LOADINGS RELEASED 
OVER TIME FROM A SINGLE DEVICE. 3H-HEPARIN RELEASED FROM RESERVOIRS HAVING PLGA4.4 AND PLGA28 
MEMBRANES, 14C-DEXTRAN RELEASED FROM RESERVOIRS HAVING PLGA11 AND PLGA64 MEMBRANES. THE 
RESERVOIR HAVING A MEMBRANE MADE FROM THE PLGA64 POLYMER OPENED EARLIER THAN THE RESERVOIR 
HAVING A MEMBRANE MADE FROM THE PLGA28 POLYMER ON THIS DEVICE. EXPERIMENT PERFORMED IN 
SALINE SOLUTION AT 28–33°C IN VITRO............................................................................................................108 
FIGURE 4.13 COMPILED RELEASE TIMES FOR SINGLE AND DOUBLE LOADED DEVICES HAVING PLGA4.4 (MW 4400), 
PLGA11 (MW 11,000), PLGA28 (MW 28,000) AND PLGA64 (MW 64,000) ~150 µM THICK RESERVOIR 
MEMBRANES. 125I-HGH: ○ EXPERIMENTAL DATA, SOLID LINE IS LINEAR LEAST-SQUARES FIT. 14C-DEXTRAN: □ 
EXPERIMENTAL DATA, DASHED LINE IS LINEAR LEAST-SQUARES FIT. 3H-HEPARIN: × EXPERIMENTAL DATA, 
DOTTED AND DASHED LINE IS LINEAR LEAST-SQUARES FIT. ..............................................................................111 
FIGURE 5.1 CUMULATIVE PERCENTAGE OF INITIAL 14C-DEXTRAN LOADING RELEASED OVER TIME IN VITRO AT 25°C 
FROM TWO DEVICES HAVING ~175 µM THICK MEMBRANES MADE FROM PLGA4.4, PLGA11, PLGA28, AND 
PLGA64. ..........................................................................................................................................................123 
FIGURE 5.2 CUMULATIVE PERCENTAGE OF INITIAL 14C-DEXTRAN LOADING RELEASED OVER TIME IN VITRO AT 25°C 
FROM TWO DEVICES HAVING ~250 µM THICK MEMBRANES MADE FROM PLGA4.4, PLGA11, PLGA28, AND 
PLGA64. ..........................................................................................................................................................123 
FIGURE 5.3 CUMULATIVE PERCENTAGE OF INITIAL 3H-HEPARIN LOADING RELEASED OVER TIME IN VITRO AT 25°C 
FROM DEVICES HAVING 150 µM THICK MEMBRANES: { PLGA4.4, ° PLGA11, U PLGA28, AND  PLGA64.
.........................................................................................................................................................................125 
FIGURE 5.4 CUMULATIVE PERCENTAGE OF INITIAL 3H-HEPARIN LOADING RELEASED OVER TIME IN VITRO AT 25°C 
FROM DEVICES HAVING 275 µM THICK MEMBRANES: { PLGA4.4, ° PLGA11, U PLGA28, AND  PLGA64.
.........................................................................................................................................................................125 
FIGURE 5.5 MW OVER TIME OF PLGA4.4 FILM SAMPLES DEGRADED IN VITRO: ● 50 µM FILMS AT 25°C WITH NO MEDIA 
CHANGE, ○ 150 µM FILMS AT 25°C WITH NO MEDIA CHANGE, ■ 150 µM FILMS AT 25°C WITH MEDIA CHANGE, 
□ 150 µM FILMS AT 37°C WITH MEDIA CHANGE...............................................................................................127 
FIGURE 5.6 PH OVER TIME OF MEDIA SURROUNDING PLGA4.4 FILM SAMPLES DEGRADED IN VITRO: ○ 150 µM FILMS 
AT 25°C WITH NO MEDIA CHANGE, ■ 150 µM FILMS AT 25°C WITH MEDIA CHANGE, □ 150 µM FILMS AT 37°C 
WITH MEDIA CHANGE. .......................................................................................................................................129 
14 
FIGURE 5.7 MASS REMAINING OVER TIME OF PLGA4.4 FILM SAMPLES DEGRADED IN VITRO: ● 50 µM FILMS AT 25°C 
WITH NO MEDIA CHANGE, ○ 150 µM FILMS AT 25°C WITH NO MEDIA CHANGE, ■ 150 µM FILMS AT 25°C WITH 
MEDIA CHANGE, □ 150 µM FILMS AT 37°C WITH MEDIA CHANGE.....................................................................130 
FIGURE 5.8 MASS LOSS (MG/CM2) AT EACH TIME POINT FOR PLGA4.4 FILMS DEGRADED IN PBS IN VITRO: ● 50 µM 
FILMS AT 25°C WITH NO MEDIA CHANGE, ○ 150 µM FILMS AT 25°C WITH NO MEDIA CHANGE, ■ 150 µM FILMS 
AT 25°C WITH MEDIA CHANGE, □ 150 µM FILMS AT 37°C WITH MEDIA CHANGE. ............................................131 
FIGURE 5.9 PDI OVER TIME OF PLGA4.4 FILM SAMPLES DEGRADED IN VITRO: ● 50 µM FILMS AT 25°C WITH NO 
MEDIA CHANGE, ○ 150 µM FILMS AT 25°C WITH NO MEDIA CHANGE, ■ 150 µM FILMS AT 25°C WITH MEDIA 
CHANGE, □ 150 µM FILMS AT 37°C WITH MEDIA CHANGE................................................................................132 
FIGURE 5.10 MW OVER TIME OF PLGA11 FILM SAMPLES DEGRADED IN VITRO: ● 50 µM FILMS AT 25°C WITH NO MEDIA 
CHANGE, ○ 150 µM FILMS AT 25°C WITH NO MEDIA CHANGE, ■ 150 µM FILMS AT 25°C WITH MEDIA CHANGE, 
□ 150 µM FILMS AT 37°C WITH MEDIA CHANGE...............................................................................................133 
FIGURE 5.11 PH OVER TIME OF MEDIUM SURROUNDING PLGA11 FILM SAMPLES DEGRADED IN VITRO: ○ 150 µM FILMS 
AT 25°C WITH NO MEDIA CHANGE, ■ 150 µM FILMS AT 25°C WITH MEDIA CHANGE, □ 150 µM FILMS AT 37°C 
WITH MEDIA CHANGE. .......................................................................................................................................134 
FIGURE 5.12 MASS REMAINING OVER TIME OF PLGA11 FILM SAMPLES DEGRADED IN VITRO: ● 50 µM FILMS AT 25°C 
WITH NO MEDIA CHANGE, ○ 150 µM FILMS AT 25°C WITH NO MEDIA CHANGE, ■ 150 µM FILMS AT 25°C WITH 
MEDIA CHANGE, □ 150 µM FILMS AT 37°C WITH MEDIA CHANGE.....................................................................135 
FIGURE 5.13 MASS LOSS (MG/CM2) AT EACH TIME POINT FOR PLGA11 FILMS DEGRADED IN PBS IN VITRO: ● 50 µM 
FILMS AT 25°C WITH NO MEDIA CHANGE, ○ 150 µM FILMS AT 25°C WITH NO MEDIA CHANGE, ■ 150 µM FILMS 
AT 25°C WITH MEDIA CHANGE, □ 150 µM FILMS AT 37°C WITH MEDIA CHANGE. ............................................136 
FIGURE 5.14 PDI OVER TIME OF PLGA11 FILM SAMPLES DEGRADED IN VITRO: ● 50 µM FILMS AT 25°C WITH NO 
MEDIA CHANGE, ○ 150 µM FILMS AT 25°C WITH NO MEDIA CHANGE, ■ 150 µM FILMS AT 25°C WITH MEDIA 
CHANGE, □ 150 µM FILMS AT 37°C WITH MEDIA CHANGE................................................................................137 
FIGURE 5.15 MW OVER TIME OF PLGA28 FILM SAMPLES DEGRADED IN VITRO: ● 50 µM FILMS AT 25°C WITH NO 
MEDIA CHANGE, ○ 150 µM FILMS AT 25°C WITH NO MEDIA CHANGE, ■ 150 µM FILMS AT 25°C WITH MEDIA 
CHANGE, □ 150 µM FILMS AT 37°C WITH MEDIA CHANGE................................................................................138 
FIGURE 5.16 MEASURED PH OVER TIME OF MEDIA SURROUNDING PLGA28 FILM SAMPLES DEGRADED IN VITRO: ○ 150 
µM FILMS AT 25°C WITH NO MEDIA CHANGE, ■ 150 µM FILMS AT 25°C WITH MEDIA CHANGE, □ 150 µM FILMS 
AT 37°C WITH MEDIA CHANGE. .........................................................................................................................139 
FIGURE 5.17 MASS REMAINING OVER TIME OF PLGA28 FILM SAMPLES DEGRADED IN VITRO: ● 50 µM FILMS AT 25°C 
WITH NO MEDIA CHANGE, ○ 150 µM FILMS AT 25°C WITH NO MEDIA CHANGE, ■ 150 µM FILMS AT 25°C WITH 
MEDIA CHANGE, □ 150 µM FILMS AT 37°C WITH MEDIA CHANGE.....................................................................140 
FIGURE 5.18 MASS LOSS (MG/CM2) AT EACH TIME POINT FOR PLGA28 FILMS DEGRADED IN PBS IN VITRO: ● 50 µM 
FILMS AT 25°C WITH NO MEDIA CHANGE, ○ 150 µM FILMS AT 25°C WITH NO MEDIA CHANGE, ■ 150 µM FILMS 
AT 25°C WITH MEDIA CHANGE, □ 150 µM FILMS AT 37°C WITH MEDIA CHANGE. ............................................141 
FIGURE 5.19 PDI OVER TIME OF PLGA28 FILM SAMPLES DEGRADED IN VITRO: ● 50 µM FILMS AT 25°C WITH NO 
MEDIA CHANGE, ○ 150 µM FILMS AT 25°C WITH NO MEDIA CHANGE, ■ 150 µM FILMS AT 25°C WITH MEDIA 
CHANGE, □ 150 µM FILMS AT 37°C WITH MEDIA CHANGE................................................................................142 
FIGURE 5.20 MW OVER TIME OF PLGA64 FILM SAMPLES DEGRADED IN VITRO: ● 50 µM FILMS AT 25°C WITH NO MEDIA 
CHANGE, ○ 150 µM FILMS AT 25°C WITH NO MEDIA CHANGE, ■ 150 µM FILMS AT 25°C WITH MEDIA CHANGE, 
□ 150 µM FILMS AT 37°C WITH MEDIA CHANGE...............................................................................................143 
FIGURE 5.21 MEASURED PH OVER TIME OF MEDIUM SURROUNDING PLGA64 FILM SAMPLES DEGRADED IN VITRO: ○ 
150 µM FILMS AT 25°C WITH NO MEDIA CHANGE, ■ 150 µM FILMS AT 25°C WITH MEDIA CHANGE, □ 150 µM 
FILMS AT 37°C WITH MEDIA CHANGE................................................................................................................144 
FIGURE 5.22 MASS REMAINING OVER TIME OF PLGA64 FILM SAMPLES DEGRADED IN VITRO: ● 50 µM FILMS AT 25°C 
WITH NO MEDIA CHANGE, ○ 150 µM FILMS AT 25°C WITH NO MEDIA CHANGE, ■ 150 µM FILMS AT 25°C WITH 
MEDIA CHANGE, □ 150 µM FILMS AT 37°C WITH MEDIA CHANGE.....................................................................145 
15 
FIGURE 5.23 MASS LOSS (MG/CM2) AT EACH TIME POINT FOR PLGA64 FILMS DEGRADED IN PBS IN VITRO: ● 50 µM 
FILMS AT 25°C WITH NO MEDIA CHANGE, ○ 150 µM FILMS AT 25°C WITH NO MEDIA CHANGE, ■ 150 µM FILMS 
AT 25°C WITH MEDIA CHANGE, □ 150 µM FILMS AT 37°C WITH MEDIA CHANGE. ............................................146 
FIGURE 5.24 PDI VALUES OVER TIME OF PLGA64 FILM SAMPLES DEGRADED IN VITRO: ● 50 µM FILMS AT 25°C WITH 
NO MEDIA CHANGE, ○ 150 µM FILMS AT 25°C WITH NO MEDIA CHANGE, ■ 150 µM FILMS AT 25°C WITH MEDIA 
CHANGE, □ 150 µM FILMS AT 37°C WITH MEDIA CHANGE................................................................................147 
FIGURE 5.25 COMPARISON OF RELEASE RESULTS OBTAINED IN VITRO AT 37°C FOR FOUR DEVICES (▲■●♦) LOADED 
WITH 14C-MANNITOL AND HAVING 150 µM THICK PLGA11 AND PLGA64 RESERVOIR MEMBRANES WITH 
MOLECULAR WEIGHT DATA OBTAINED FOR 150 µM THICK PLGA11 (□) AND PLGA64 (○) FILM SAMPLES 
DEGRADED AT 37°C IN VITRO WITH MEDIA CHANGE. HORIZONTAL DASHED LINES INDICATE RANGE OF 5,000 TO 
7,000 MOLECULAR WEIGHT ON RIGHT Y-AXIS. ..................................................................................................153 
FIGURE 6.1 PARTITION COEFFICIENTS OF SMALL MOLECULES IN VARIOUS POLYMERS: □ 14C-IAP, ○ 14C-BCNU. ...161 
FIGURE 6.2 PARTITION COEFFICIENTS OF POLYSACCHARIDES IN VARIOUS POLYMERS: □ 14C-DEXTRAN MW~40,000, ■ 
14C-DEXTRAN MW~70,000, ° 3H-HEPARIN. ......................................................................................................163 
FIGURE 6.3 PARTITION COEFFICIENTS OF 125I-IL-2 IN VARIOUS POLYMERS. ...............................................................164 
FIGURE 7.1 MAXIMUM MEASURED MEMBRANE HEIGHT RELATIVE TO DEVICE SURFACE FOR ~150 µM THICK PLGA4.4 
(DOTTED LINE) AND PLGA11 (SOLID LINE) MEMBRANES ON UNLOADED CONTROL DEVICE..............................175 
FIGURE 7.2 ~150 µM THICK MEMBRANES ON CONTROL (UNLOADED) DEVICE, VIEWED UNDER OPTICAL MICROSCOPE: 
(A) PLGA4.4 MEMBRANE AT DAY ZERO, (B) PLGA4.4 MEMBRANE AT DAY FIVE, (C) PLGA4.4 MEMBRANE AT 
DAY 12, (D) PLGA11 MEMBRANE AT DAY ZERO, (E) PLGA11 MEMBRANE AT DAY FIVE, (F) PLGA11 MEMBRANE 
AT DAY SIX........................................................................................................................................................176 
FIGURE 7.3 CUMULATIVE PERCENTAGE OF 14C-GLUCOSE LOADING RELEASED OVER TIME FROM THREE DEVICES 
HAVING ~150 µM THICK PLGA4.4 AND PLGA11 RESERVOIR MEMBRANES. ....................................................178 
FIGURE 7.4 MAXIMUM MEASURED MEMBRANE HEIGHT RELATIVE TO DEVICE SURFACE FOR ~150 µM THICK PLGA4.4 
(DOTTED LINE) AND PLGA11 (SOLID LINE) MEMBRANES ON DEVICE LOADED WITH 14C-GLUCOSE. ..................179 
FIGURE 7.5 ~150 µM THICK MEMBRANES ON DEVICE LOADED WITH 14C-GLUCOSE, VIEWED UNDER OPTICAL 
MICROSCOPE OR VIEWED UNDER SEM: (A) PLGA4.4 MEMBRANE AT DAY ZERO, (B) PLGA4.4 MEMBRANE AT 
DAY FIVE, (C) PLGA4.4 MEMBRANE AT DAY SEVEN, (D) SEM OF PLGA4.4 MEMBRANE AFTER 30 DAYS IN 
SALINE SOLUTION, (E) PLGA11 MEMBRANE AT DAY ZERO, (F) PLGA11 MEMBRANE AT DAY FIVE, (G) PLGA11 
MEMBRANE AT DAY NINE, (H) SEM OF PLGA11 MEMBRANE AFTER 30 DAYS IN SALINE SOLUTION. ................181 
FIGURE 7.6 CUMULATIVE PERCENTAGE OF 14C-DEXTRAN (MW~10,000) LOADING RELEASED OVER TIME FROM THREE 
DEVICES HAVING ~150 µM THICK PLGA4.4 AND PLGA11 MEMBRANES..........................................................182 
FIGURE 7.7 MAXIMUM MEASURED HEIGHT OF RESERVOIR MEMBRANES RELATIVE TO DEVICE SURFACE FOR ~150 µM 
THICK PLGA4.4 (DOTTED LINE) AND PLGA11 (SOLID LINE) MEMBRANES ON DEVICE LOADED WITH 14C-
DEXTRAN (MW~10,000). ...................................................................................................................................183 
FIGURE 7.8 ~150 µM THICK PLGA4.4 MEMBRANE ON DEVICE LOADED WITH 14C-DEXTRAN (MW~10,000) VIEWED 
UNDER OPTICAL MICROSCOPE OR VIEWED UNDER SEM: (A) PLGA4.4 MEMBRANE AT DAY ZERO, (B) PLGA4.4 
MEMBRANE AT DAY TWO, (C) SEM OF PLGA4.4 MEMBRANE AFTER BEING IN SALINE SOLUTION FOR 30 DAYS.
.........................................................................................................................................................................183 
FIGURE 7.9 ~150 µM THICK PLGA11 MEMBRANE ON DEVICE LOADED WITH 14C-DEXTRAN (MW~10,000) VIEWED 
UNDER OPTICAL MICROSCOPE OR VIEWED UNDER SEM: (A) PLGA11 MEMBRANE AT DAY ZERO, (B) PLGA11 
MEMBRANE AT DAY EIGHT, (C) PLGA11 MEMBRANE AT DAY TEN, BOX INDICATES REGION ENLARGED IN (D) 
SHOWING PINHOLE AND FISSURE IN PLGA11 MEMBRANE AT DAY TEN, (E) PLGA11 MEMBRANE AT DAY 11 
SHOWING LARGE HOLE IN MEMBRANE, (F) SEM OF PLGA11 MEMBRANE AFTER 30 DAYS IN SALINE SOLUTION.
.........................................................................................................................................................................185 
FIGURE 7.10 CUMULATIVE PERCENTAGE OF 14C-DEXTRAN (MW~40,000) LOADING RELEASED OVER TIME FROM THREE 
DEVICES HAVING ~150 µM THICK PLGA4.4 AND PLGA11 MEMBRANES..........................................................186 
FIGURE 7.11 MAXIMUM MEASURED MEMBRANE HEIGHT RELATIVE TO DEVICE SURFACE FOR ~150 µM PLGA4.4 
(DOTTED LINE) AND PLGA11 (SOLID LINE) MEMBRANES ON DEVICE LOADED WITH 14C-DEXTRAN (MW~40,000).
.........................................................................................................................................................................187 
FIGURE 7.12 ~150 µM THICK PLGA4.4 MEMBRANE ON DEVICE LOADED WITH 14C-DEXTRAN HAVING A MOLECULAR 
WEIGHT OF 40,000 DALTONS, VIEWED UNDER OPTICAL MICROSCOPE OR VIEWED UNDER SEM: (A) PLGA4.4 
MEMBRANE AT DAY ZERO, (B) PLGA4.4 MEMBRANE AT DAY ONE, (C) PLGA4.4 MEMBRANE AT DAY THREE, (D) 
SEM OF PLGA4.4 MEMBRANE AFTER BEING IN SALINE SOLUTION FOR 30 DAYS..............................................188 
16 
FIGURE 7.13 ~150 µM THICK PLGA11 MEMBRANE ON DEVICE LOADED WITH 14C-DEXTRAN HAVING A MOLECULAR 
WEIGHT OF 40,000 DALTONS, VIEWED UNDER OPTICAL MICROSCOPE OR VIEWED UNDER SEM: (A) PLGA11 
MEMBRANE AT DAY ZERO, (B) PLGA11 MEMBRANE AT DAY 12, (C) PLGA11 MEMBRANE AT DAY 15 WITH 
ARROW INDICATING LOCATION OF PINHOLE, (D) PLGA11 MEMBRANE AT DAY 28, (E) SEM OF PLGA11 
MEMBRANE AFTER BEING IN SALINE SOLUTION FOR 30 DAYS............................................................................189 
FIGURE 7.14 CUMULATIVE PERCENTAGE OF 14C-DEXTRAN (MW~70,000) RELEASED FROM THREE DEVICES HAVING 
~150 µM THICK PLGA4.4 AND PLGA11 MEMBRANES. SOLID LINE = 20 KPA LOADING, DASHED LINE = 40 KPA 
LOADING, DOTTED LINE = 80 KPA LOADING......................................................................................................190 
FIGURE 7.15 MAXIMUM MEASURED MEMBRANE HEIGHT RELATIVE TO DEVICE SURFACE FOR ~150 µM THICK PLGA4.4 
(DOTTED LINE) AND PLGA11 (SOLID LINE) MEMBRANES ON DEVICE LOADED WITH 14C-DEXTRAN (MW~70,000) 
CORRESPONDING TO OSMOTIC PRESSURE OF 20 KPA. ........................................................................................191 
FIGURE 7.16 ~150 µM THICK MEMBRANES ON DEVICE LOADED WITH 14C-DEXTRAN HAVING A MOLECULAR WEIGHT OF 
70,000 DALTONS (LOADING CORRESPONDS TO AN OSMOTIC PRESSURE OF 20 KPA), MEMBRANES VIEWED UNDER 
OPTICAL MICROSCOPE OR VIEWED UNDER SEM: (A) PLGA4.4 MEMBRANE AT DAY ZERO, (B) PLGA4.4 
MEMBRANE AT DAY ONE, (C) SEM OF PLGA4.4 MEMBRANE AFTER 30 DAYS IN SALINE SOLUTION, (D) PLGA11 
MEMBRANE AT DAY ZERO, (E) PLGA11 MEMBRANE AT DAY 14, (F) PLGA11 MEMBRANE AT DAY 15, (G) 
PLGA11 MEMBRANE AT DAY 21, (H) SEM OF PLGA11 MEMBRANE AFTER 30 DAYS IN SALINE SOLUTION......192 
FIGURE 7.17 MAXIMUM MEASURED MEMBRANE HEIGHT RELATIVE TO DEVICE SURFACE FOR ~150 µM THICK PLGA4.4 
(DOTTED LINE) AND PLGA11 (SOLID LINE) MEMBRANES ON DEVICE LOADED WITH 14C-DEXTRAN (MW~70,000) 
CORRESPONDING TO AN OSMOTIC PRESSURE OF 40 KPA....................................................................................194 
FIGURE 7.18 ~150 µM THICK PLGA4.4 MEMBRANES ON DEVICE LOADED WITH 14C-DEXTRAN HAVING A MOLECULAR 
WEIGHT OF 70,000 DALTONS (LOADING CORRESPONDING TO 40 KPA OSMOTIC PRESSURE), VIEWED UNDER 
OPTICAL MICROSCOPE OR VIEWED UNDER SEM: (A) PLGA4.4 MEMBRANE AT DAY TWO, (B) SEM OF PLGA4.4 
MEMBRANE AFTER 30 DAYS IN SALINE SOLUTION. ............................................................................................195 
FIGURE 7.19 ~150 µM THICK PLGA11 MEMBRANES ON DEVICE LOADED WITH 14C-DEXTRAN HAVING A MOLECULAR 
WEIGHT OF 70,000 DALTONS (LOADING CORRESPONDING TO 40 KPA OSMOTIC PRESSURE), VIEWED UNDER 
OPTICAL MICROSCOPE OR VIEWED UNDER SEM: (A) PLGA11 MEMBRANE AT DAY TWO, (B) PLGA11 
MEMBRANE AT DAY TEN, (C) PLGA11 MEMBRANE AT DAY 17, (D) PLGA11 MEMBRANE AT DAY 20, (E) 
PLGA11 MEMBRANE AT DAY 28, (F) SEM OF PLGA11 MEMBRANE AFTER 30 DAYS IN SALINE SOLUTION, (G) 
SEM OF PLGA11 MEMBRANE AFTER 30 DAYS IN SALINE SOLUTION, STAGE TILTED 66°. .................................196 
FIGURE 7.20 MAXIMUM MEASURED MEMBRANE HEIGHT RELATIVE TO CHIP SURFACE FOR ~150 µM THICK PLGA4.4 
(DOTTED LINE) AND PLGA11 (SOLID LINE) MEMBRANES ON DEVICE LOADED WITH 14C-DEXTRAN (MW~70,000) 
CORRESPONDING TO OSMOTIC PRESSURE OF 80 KPA. ........................................................................................197 
FIGURE 7.21 ~150 µM PLGA4.4 MEMBRANES ON DEVICE LOADED WITH 14C-DEXTRAN HAVING A MOLECULAR WEIGHT 
OF 70,000 DALTONS (LOADING CORRESPONDS TO 80 KPA OSMOTIC PRESSURE), VIEWED UNDER OPTICAL 
MICROSCOPE OR VIEWED UNDER SEM: (A) PLGA4.4 MEMBRANE AT DAY TWO, (B) PLGA4.4 MEMBRANE AT 
DAY TWO SHOWN AT HIGHER MAGNIFICATION, ARROW INDICATES HOLE IN MEMBRANE, (C) PLGA4.4 
MEMBRANE AT DAY TWO VIEWED AT YET HIGHER MAGNIFICATION, ARROW INDICATES HOLE IN MEMBRANE, (D) 
SEM OF PLGA4.4 MEMBRANE AFTER 30 DAYS IN SALINE SOLUTION. ..............................................................198 
FIGURE 7.22 ~150 µM PLGA11 MEMBRANES ON DEVICE LOADED WITH 14C-DEXTRAN HAVING A MOLECULAR WEIGHT 
OF 70,000 DALTONS (LOADING CORRESPONDS TO 80 KPA OSMOTIC PRESSURE), VIEWED UNDER OPTICAL 
MICROSCOPE OR VIEWED UNDER SEM: (A) PLGA11 MEMBRANE AT DAY TWO, (B) PLGA11 MEMBRANE AT DAY 
15, (C) PLGA11 MEMBRANE AT DAY 22, (D) PLGA11 MEMBRANE AT DAY 28, (E) SEM OF PLGA11 MEMBRANE 
AFTER 30 DAYS IN SALINE SOLUTION. ...............................................................................................................199 
FIGURE 7.23 CUMULATIVE PERCENTAGE OF 14C-GLYCEROL RELEASED FROM THREE DEVICES HAVING ~150 µM THICK 
PLGA4.4 AND PLGA11 MEMBRANES. .............................................................................................................200 
FIGURE 7.24 MAXIMUM MEASURED HEIGHT OF MEMBRANES RELATIVE TO CHIP SURFACE FOR ~150 µM THICK 
PLGA4.4 (DOTTED LINE) AND PLGA11 (SOLID LINE) MEMBRANES ON DEVICE LOADED WITH 14C-GLYCEROL.201 
FIGURE 7.25 ~150 µM PLGA4.4 MEMBRANES ON DEVICE LOADED WITH 14C-GLYCEROL, VIEWED UNDER OPTICAL 
MICROSCOPE OR VIEWED UNDER SEM: (A) PLGA4.4 MEMBRANE AT DAY ZERO, (B) PLGA4.4 MEMBRANE AT 
DAY ONE, (C) PLGA4.4 MEMBRANE AT DAY THREE, ARROW INDICATES LOCATION OF HOLE, WHICH CAN BE SEEN 
IN THE ENLARGEMENT OF BOXED REGION IN (D) SHOWING PLGA4.4 MEMBRANE AT DAY THREE WITH THE HOLE 
IN THE MEMBRANE CLEARLY VISIBLE AS INDICATED BY THE ARROW, (E) SEM OF PLGA4.4 MEMBRANE AFTER 
30 DAYS IN SALINE SOLUTION. ..........................................................................................................................202 
17 
FIGURE 7.26 ~150 µM PLGA11 MEMBRANES ON DEVICE LOADED WITH 14C-GLYCEROL, VIEWED UNDER OPTICAL 
MICROSCOPE OR VIEWED UNDER SEM: (A) PLGA11 MEMBRANE AT DAY ZERO, (B) PLGA11 MEMBRANE AT DAY 
EIGHT, (C) PLGA11 MEMBRANE AT DAY TEN, (D) SEM OF PLGA11 MEMBRANE AFTER 30 DAYS IN SALINE 
SOLUTION..........................................................................................................................................................203 
FIGURE 7.27 CUMULATIVE PERCENTAGE OF 14C-GLYCEROL 3-PHOSPHATE RELEASED OVER TIME FROM THREE DEVICES 
HAVING ~150 µM THICK PLGA4.4 AND PLGA11 MEMBRANES........................................................................204 
FIGURE 7.28 MAXIMUM MEASURED MEMBRANE HEIGHT RELATIVE TO CHIP SURFACE FOR ~150 µM THICK PLGA4.4 
(DOTTED LINE) AND PLGA11 (SOLID LINE) MEMBRANES ON DEVICE LOADED WITH 14C-GLYCEROL 3-PHOSPHATE.
.........................................................................................................................................................................205 
FIGURE 7.29 ~150 µM THICK PLGA4.4 MEMBRANES ON DEVICE LOADED WITH 14C-GLYCEROL 3-PHOSPHATE VIEWED 
UNDER OPTICAL MICROSCOPE OR VIEWED UNDER SEM: (A) PLGA4.4 MEMBRANE AT DAY ZERO, (B) PLGA4.4 
MEMBRANE AT DAY ONE, (C) SEM OF PLGA4.4 MEMBRANE AFTER 30 DAYS IN SALINE SOLUTION..................206 
FIGURE 7.30 ~150 µM THICK PLGA11 MEMBRANES ON DEVICE LOADED WITH 14C-GLYCEROL 3-PHOSPHATE VIEWED 
UNDER OPTICAL MICROSCOPE OR VIEWED UNDER SEM: (A) PLGA11 MEMBRANE AT DAY ZERO, (B) PLGA11 
MEMBRANE AT DAY EIGHT, (C) PLGA11 MEMBRANE AT DAY NINE, (D) PLGA11 MEMBRANE AT DAY 28, (E) 
SEM OF PLGA11 MEMBRANE AFTER 30 DAYS IN SALINE SOLUTION, (F) SEM OF PLGA11 MEMBRANE AFTER 30 
DAYS IN SALT SOLUTION, STAGE TILTED 66°. ....................................................................................................207 
FIGURE 7.31 CUMULATIVE PERCENTAGE OF 14C-GLYCEROL TRIOLEATE RELEASED OVER TIME FROM THREE DEVICES 
HAVING ~150 µM THICK PLGA4.4 AND PLGA11 MEMBRANES........................................................................208 
FIGURE 7.32 MAXIMUM MEASURED MEMBRANE HEIGHT RELATIVE TO CHIP SURFACE FOR ~150 µM THICK PLGA4.4 
(DOTTED LINE) AND PLGA11 (SOLID LINE) MEMBRANES ON DEVICE LOADED WITH 14C-GLYCEROL TRIOLEATE.
.........................................................................................................................................................................209 
FIGURE 7.33 ~150 µM THICK PLGA4.4 MEMBRANE ON DEVICE LOADED WITH 14C-GLYCEROL TRIOLEATE, VIEWED 
UNDER OPTICAL MICROSCOPY OR VIEWED UNDER SEM: (A) PLGA4.4 MEMBRANE AT DAY ZERO, (B) PLGA4.4 
MEMBRANE AT DAY ONE, (C) SEM OF PLGA4.4 MEMBRANE AFTER 30 DAYS IN SALINE SOLUTION..................210 
FIGURE 7.34 ~150 µM THICK PLGA11 MEMBRANE ON DEVICE LOADED WITH 14C-GLYCEROL TRIOLEATE, VIEWED 
UNDER OPTICAL MICROSCOPE OR VIEWED UNDER SEM: (A) PLGA11 MEMBRANE AT DAY ZERO, (B) PLGA11 
MEMBRANE AT DAY SEVEN, (C) PLGA11 MEMBRANE AT DAY 14, (D) PLGA11 MEMBRANE AT DAY 21, (E) 
PLGA11 MEMBRANE AT DAY 23, (F) SEM OF PLGA11 MEMBRANE AFTER 30 DAYS IN SALINE SOLUTION. .....211 
FIGURE 8.1 CUMULATIVE PERCENTAGE OF 3H-HEPARIN LOADING RELEASED OVER TIME FROM THREE DEVICES HAVING 
PLGA4.4, PLGA11, AND PLGA28 RESERVOIR MEMBRANES. EXPERIMENTS CONDUCTED AT 25°C. ...............225 
FIGURE 8.2 CUMULATIVE PERCENTAGE OF 3H-HEPARIN LOADING RELEASED OVER TIME FROM THREE DEVICES HAVING 
PLGA4.4, PLGA11, AND PLGA64 RESERVOIR MEMBRANES. EXPERIMENTS CONDUCTED AT 25°C. ...............226 
FIGURE 9.1 CUMULATIVE PERCENTAGE OF INITIAL 14C-MANNITOL LOADING RECOVERED OVER TIME FROM FOUR 
DEVICES HAVING PLGA11 AND PLGA64 RESERVOIR MEMBRANES, EACH LOADED WITH 0.2 µCI OF 14C-
MANNITOL AND MAINTAINED IN VITRO IN PBS AT 37°C. ...................................................................................232 
FIGURE 9.2 CUMULATIVE PERCENTAGE OF INITIAL 14C-MANNITOL LOADING RECOVERED OVER TIME FROM FOUR 
DEVICES (□U○) HAVING PLGA11 AND PLGA64 RESERVOIR MEMBRANES, EACH LOADED WITH 0.2 µCI OF 
14C-MANNITOL AND IMPLANTED SUBCUTANEOUSLY IN RATS, AND FROM ONE SUBCUTANEOUS INJECTION (×) OF 
0.1 µCI IN A RAT. ..............................................................................................................................................233 
FIGURE 10.1 MEASURED PEAK MOLECULAR WEIGHT FOR PLA SAMPLES: - - - POWDER CONTROL SAMPLES,  IN VITRO 
SAMPLES, ● IN VIVO DIRECT SUBCUTANEOUS IMPLANTS, ○ IN VIVO CAGE IMPLANTS. .....................................245 
FIGURE 10.2 MEASURED PEAK MOLECULAR WEIGHT FOR PGA SAMPLES: - - - POWDER CONTROL SAMPLES,  IN VITRO 
SAMPLES, ● IN VIVO DIRECT SUBCUTANEOUS IMPLANTS, ○ IN VIVO CAGE IMPLANTS. .....................................247 
FIGURE 10.3 MEASURED PEAK MOLECULAR WEIGHT FOR PLGA4.4 SAMPLES: - - - POWDER CONTROL SAMPLES,  IN 
VITRO SAMPLES, ● IN VIVO DIRECT SUBCUTANEOUS IMPLANTS, ○ IN VIVO CAGE IMPLANTS.............................249 
FIGURE 10.4 MEASURED PEAK MOLECULAR WEIGHT FOR PLGA64 SAMPLES: - - - POWDER CONTROL SAMPLES,  IN 
VITRO SAMPLES, ● IN VIVO DIRECT SUBCUTANEOUS IMPLANTS, ○ IN VIVO CAGE IMPLANTS.............................250 
FIGURE 10.5 MEASURED TG FOR PLA SAMPLES: - - - POWDER CONTROL SAMPLES, ■ IN VITRO SAMPLES, ● IN VIVO 
DIRECT SUBCUTANEOUS IMPLANTS, ○ IN VIVO CAGE IMPLANTS. ......................................................................253 
FIGURE 10.6 MEASURED TG FOR PGA SAMPLES: - - - POWDER CONTROL SAMPLES,  IN VITRO SAMPLES, ● IN VIVO 
DIRECT SUBCUTANEOUS IMPLANTS, ○ IN VIVO CAGE IMPLANTS. ......................................................................254 
FIGURE 10.7 MEASURED TG FOR PLGA4.4 SAMPLES: - - - POWDER CONTROL SAMPLES,  IN VITRO SAMPLES, ● IN 
VIVO DIRECT SUBCUTANEOUS IMPLANTS, ○ IN VIVO CAGE IMPLANTS. ..............................................................255 
18 
FIGURE 10.8 MEASURED TG FOR PLGA64 SAMPLES: - - - POWDER CONTROL SAMPLES, IN VITRO SAMPLES, ● IN VIVO 
DIRECT SUBCUTANEOUS IMPLANTS, ○ IN VIVO CAGE IMPLANTS. ......................................................................256 
FIGURE A.1 MEASURED MICROINJECTED VOLUME VERSUS PREDICTED MICROINJECTED VOLUME (SOLID LINE) FOR 
BLEACHED SODIUM FLUORESCEIN MICROINJECTED FROM A 10 µL SYRINGE: ○ 19.57 NL INJECTIONS, × 49.72 NL 
INJECTIONS, ● 99.98 NL INJECTIONS, ■ 149.7 NL INJECTIONS. SOLID LINE INDICATES THEORETICAL PREDICTED 
MICROINJECTED VOLUME, DASHED LINE IS LINEAR LEAST SQUARES FIT TO EXPERIMENTAL DATA POINTS. .......276 
FIGURE A.2 MEASURED MICROINJECTED VOLUME VS. PREDICTED MICROINJECTED VOLUME (SOLID LINE) FOR 
UNBLEACHED SODIUM FLUORESCEIN MICROINJECTED FROM A 10 µL SYRINGE: ○ 19.57 NL INJECTIONS, × 49.72 
NL INJECTIONS, ● 99.98 NL INJECTIONS, ■ 149.7 NL INJECTIONS. SOLID LINE INDICATES THEORETICAL 
PREDICTED MICROINJECTED VOLUME, DASHED LINE IS LINEAR LEAST SQUARES FIT TO EXPERIMENTAL DATA 
POINTS. .............................................................................................................................................................276 
FIGURE A.3 MEASURED FLUORESCENCE OF VARIOUS MICROINJECTED AMOUNTS OF SODIUM FLUORESCEIN (● 1.1 
NMOL, ■ 2.2 NMOL, × 4.4 NMOL) IN PBS OF DIFFERENT IONIC STRENGTHS. IONIC STRENGTH IS GREATEST FOR 
10X PBS...........................................................................................................................................................279 
FIGURE A.4 MEASURED FLUORESCENCE OF CUVETTES HAVING DIFFERENT AMOUNTS OF SODIUM FLUORESCEIN (● 1.1 
NMOL, ■ 2.2 NMOL, × 4.4. NMOL ) IN DIFFERENT IONIC STRENGTHS OF PBS, AS A FUNCTION OF PH. ...............280 
FIGURE A.5 MEASURED MEDIA PH OVER TIME FOR VARIOUS RELEASE EXPERIMENTS................................................281 
FIGURE A.6 CUMULATIVE PERCENTAGE OF INITIAL FLUORESCEIN LOADING MEASURED AT THE CONCLUSION OF 
VARIOUS RELEASE EXPERIMENTS. .....................................................................................................................282 
FIGURE A.7 PERCENTAGE OF INITIAL FLUORESCEIN LOADING MEASURED AT THE CONCLUSION OF VARIOUS RELEASE 
EXPERIMENTS, AS A FUNCTION OF PH................................................................................................................282 
FIGURE A.8 PERCENTAGE OF INITIAL FLUORESCEIN LOADING MEASURED AT THE CONCLUSION OF VARIOUS RELEASE 
STUDIES, AS A FUNCTION OF RELEASE MEDIA CONDUCTIVITY. ..........................................................................283 
FIGURE B.1 MEASURED VS. PREDICTED MICROINJECTED VOLUME FOR MULTIPLE INJECTIONS OF SODIUM FLUORESCEIN 
SOLUTION FROM A TEN µL SYRINGE: ○ 20 NL INJECTIONS, × 50 NL INJECTIONS, ● 100 NL INJECTIONS, ■ 150 
NL INJECTIONS, SOLID LINE INDICATES THEORETICAL PREDICTED MICROINJECTED VOLUME, DASHED LINE 
INDICATES LEAST-SQUARES BEST FIT TO DATA POINTS......................................................................................288 
FIGURE B.2 MEASURED (CALCULATED) VS. PREDICTED MICROINJECTED VOLUME FOR MULTIPLE INJECTIONS OF 
SODIUM FLUORESCEIN SOLUTION FROM A 50 µL SYRINGE: ○ 20 NL INJECTIONS, × 50 NL INJECTIONS, ● 100 NL 
INJECTIONS, ■ 150 NL INJECTIONS, SOLID LINE INDICATES THEORETICAL PREDICTED MICROINJECTED VOLUME, 
DASHED LINE INDICATES LEAST-SQUARES BEST FIT TO DATA POINTS. R2 AND SLOPE VALUES CALCULATED 
WITH/WITHOUT 95.04 NL OUTLIER....................................................................................................................289 
FIGURE B.3 MEASURED FLUORESCENCE AS A FUNCTION OF ELAPSED TIME BETWEEN MICROINJECTIONS. .................290 
 
19 
LIST OF TABLES 
 
TABLE 2-1 MOLECULAR WEIGHTS, COPOLYMER MOLE RATIOS, AND APPROXIMATE DEGRADATION TIMES REPORTED BY 
THE MANUFACTURER FOR THE PLGA4.4, PLGA11, PLGA28, AND PLGA64 POLY(LACTIC-CO-GLYCOLIC ACID) 
COPOLYMERS USED TO MAKE THE RESERVOIR MEMBRANES ON THE MICRORESERVOIR DEVICES. .......................33 
TABLE 2-2 EXPERIMENTAL PARAMETERS FOR TGA ANALYSIS OF MEMBRANE POLYMERS...........................................46 
TABLE 2-3 RESIDUAL SOLVENT IN PLGA4.4, PLGA11, PLGA28, AND PLGA64 POLYMERS AFTER DRYING FOR 48 
HOURS AT 77°C. SOLVENT DETERMINED AS WEIGHT CHANGE FROM 30 TO 100°C..............................................60 
TABLE 3-1 VAPOR PRESSURES AT 270°K OF ETHANOL AND WATER FOR VARIOUS DROPLET SIZES. ..............................76 
TABLE 3-2 CONCENTRATIONS OF SOLUTIONS OF 14C-IODOANTIPYRINE IN ETHANOL AND 14C-DEXTRAN IN WATER 
ADJUSTED FOR SOLVENT EVAPORATION DUE TO CURVATURE OF DROPLETS........................................................76 
TABLE 3-3 MEASURED VOLUME OF FLUORESCEIN, FLUORESCEIN-DEXTRAN, 14C-IODOANTIPYRINE, AND 14C-DEXTRAN 
SOLUTIONS MICROINJECTED ONTO THE SURFACE OF PLA DEVICE SUBSTRATES, CALCULATED USING 
CONCENTRATIONS OF MICROINJECTED SOLUTIONS. ............................................................................................78 
TABLE 3-4 MEASURED VOLUME OF FLUORESCEIN, FLUORESCEIN-DEXTRAN, 14C-IODOANTIPYRINE, AND 14C-DEXTRAN 
SOLUTIONS MICROINJECTED INTO RESERVOIRS IN PLA DEVICE SUBSTRATES, CALCULATED USING 
CONCENTRATIONS OF MICROINJECTED SOLUTIONS. ............................................................................................78 
TABLE 4-1 MOLECULAR WEIGHTS, COPOLYMER MOLE RATIOS, AND APPROXIMATE DEGRADATION TIMES REPORTED BY 
THE MANUFACTURER FOR THE PLGA4.4, PLGA11, PLGA28, AND PLGA64 POLY(LACTIC-CO-GLYCOLIC ACID) 
COPOLYMERS USED TO MAKE THE RESERVOIR MEMBRANES ON THE MICRORESERVOIR DEVICES. .......................86 
TABLE 4-2 EXPERIMENTAL PARAMETERS FOR IN VITRO RELEASE DEVICES LOADED WITH ONE OF 14C-DEXTRAN, 3H-
HEPARIN, 125I-HGH, 125I-IL-2, 14C-BCNU, OR 14C-IAP.......................................................................................88 
TABLE 4-3 EXPERIMENTAL PARAMETERS FOR IN VITRO RELEASE DEVICES LOADED WITH 125I-HGH AND 14C-DEXTRAN, 
OR 3H-HEPARIN AND 14C-DEXTRAN.....................................................................................................................90 
TABLE 4-4 AVERAGE RELEASE TIMES ± STANDARD DEVIATIONS (IN DAYS) FROM RESERVOIRS ON DEVICES LOADED 
WITH ONE OF 14C-DEXTRAN, 3H-HEPARIN, OR 125I-HGH AND HAVING MEMBRANES MADE FROM PLGA4.4, 
PLGA11, PLGA28, AND PLGA64. ..................................................................................................................101 
TABLE 4-5 AVERAGE RELEASE TIMES ± STANDARD DEVIATIONS (IN DAYS) FROM RESERVOIRS ON DEVICES LOADED 
WITH ONE OF 14C-DEXTRAN, 3H-HEPARIN, OR 125I-HGH AND HAVING MEMBRANES MADE FROM PLGA4.4, 
PLGA11, PLGA28, AND PLGA64. (REPRODUCED FROM TABLE 4-4)..............................................................109 
TABLE 4-6 RANGE OF OBSERVED RELEASE TIMES (IN DAYS) FROM RESERVOIRS ON DEVICES LOADED WITH EITHER 125I-
HGH AND 14C-DEXTRAN, OR 3H-HEPARIN AND 14C-DEXTRAN, AND HAVING MEMBRANES MADE FROM PLGA4.4, 
PLGA11, PLGA28, AND PLGA64. ..................................................................................................................109 
TABLE 5-1 EXPERIMENTAL MATRIX FOR IN VITRO DEGRADATION STUDY. ..................................................................121 
TABLE 5-2 SUMMARY OF OBSERVED RELEASE TIMES (IN DAYS) OF DEVICES HAVING PLGA RESERVOIR MEMBRANES 
OF VARIOUS THICKNESSES AND MOLECULAR WEIGHTS, LOADED WITH 14C-DEXTRAN OR 3H-HEPARIN..............122 
TABLE 5-3 CALCULATED HALF-LIVES (TIME IN DAYS AT WHICH MOLECULAR WEIGHT IS PREDICTED TO BE ONE-HALF 
THE INITIAL MOLECULAR WEIGHT) FOR 50 AND 150 µM THICK PLGA4.4, PLGA11, PLGA28, AND PLGA64 
FILMS DEGRADED IN VITRO UNDER VARIOUS CONDITIONS. ................................................................................148 
TABLE 5-4 RELEASE TIMES IN VITRO AT 25°C FOR DEVICES LOADED WITH 14C-DEXTRAN AND HAVING ~150-175 µM 
THICK PLGA4.4, PLGA11, PLGA28, AND PLGA64 MEMBRANES COMPARED WITH MOLECULAR WEIGHT 
RESULTS FROM IN VITRO DEGRADATION STUDY OF 150 µM THICK FILMS AT 25°C WITH MEDIA CHANGE. .........152 
TABLE 6-1 SAMPLE LABELS FOR PARTITION COEFFICIENT EXPERIMENT. ....................................................................159 
TABLE 6-2 SPECIFIC ACTIVITIES OF RADIOLABELED STOCK SOLUTIONS USED TO DETERMINE PARTITION COEFFICIENTS.
.........................................................................................................................................................................160 
TABLE 7-1 MAXIMUM MEASURED MEMBRANE HEIGHT, CALCULATED % WATER UPTAKE, TMAX SWELLING, TRELEASE, AND TOPEN 
FOR PLGA4.4 MEMBRANES ON UNLOADED CONTROL DEVICE, AS WELL AS DEVICES LOADED WITH 14C-GLUCOSE 
AND 14C-DEXTRAN HAVING MOLECULAR WEIGHTS OF 10,000 AND 40,000. ......................................................212 
TABLE 7-2 MAXIMUM MEASURED MEMBRANE HEIGHT, CALCULATED % WATER UPTAKE, TMAX SWELLING, TRELEASE, AND TOPEN 
FOR PLGA11 MEMBRANES ON UNLOADED CONTROL DEVICE, AS WELL AS DEVICES LOADED WITH 14C-GLUCOSE 
AND 14C-DEXTRAN HAVING MOLECULAR WEIGHTS OF 10,000 AND 40,000. ......................................................212 
TABLE 7-3 MAXIMUM MEASURED MEMBRANE HEIGHT, CALCULATED % WATER UPTAKE, TMAX SWELLING, TRELEASE, AND TOPEN 
FOR PLGA4.4 MEMBRANES ON DEVICES HAVING THREE DIFFERENT LOADINGS OF 70,000 MOLECULAR WEIGHT 
14C-DEXTRAN....................................................................................................................................................213 
20 
TABLE 7-4 MAXIMUM MEASURED MEMBRANE HEIGHT, CALCULATED % WATER UPTAKE, TMAX SWELLING, TRELEASE, AND TOPEN 
FOR PLGA11 MEMBRANES ON DEVICES HAVING THREE DIFFERENT LOADINGS OF 70,000 MOLECULAR WEIGHT 
14C-DEXTRAN....................................................................................................................................................213 
TABLE 7-5 MAXIMUM MEASURED MEMBRANE HEIGHT, CALCULATED % WATER UPTAKE, TMAX SWELLING, TRELEASE, AND TOPEN 
FOR PLGA4.4 MEMBRANES ON DEVICES LOADED WITH 14C-GLYCEROL, 14C-GLYCEROL 3-PHOSPHATE, AND 14C-
GLYCEROL TRIOLEATE. .....................................................................................................................................214 
TABLE 7-6 MAXIMUM MEASURED MEMBRANE HEIGHT, CALCULATED % WATER UPTAKE, TMAX SWELLING, TRELEASE, AND TOPEN 
FOR PLGA11 MEMBRANES ON DEVICES LOADED WITH 14C-GLYCEROL, 14C-GLYCEROL 3-PHOSPHATE, AND 14C-
GLYCEROL TRIOLEATE. .....................................................................................................................................214 
TABLE 8-1 MEASURED BIOLOGICAL ACTIVITY OF HEPARIN RELEASED FROM POLYMERIC MICRORESERVOIR DEVICES 
HAVING RESERVOIR MEMBRANES MADE FROM PLGA4.4, PLGA11, PLGA28, OR PLGA64. ...........................227 
TABLE 10-1 SUMMARY OF EXPERIMENTAL PARAMETERS FOR DSC ANALYSIS OF POLYMER FILM SAMPLES DEGRADED 
IN VITRO AND IN VIVO. ........................................................................................................................................241 
TABLE 10-2 CORRECTION FACTORS USED IN GPC CALCULATIONS OF MOLECULAR WEIGHT FOR PLGA4.4, PLGA64, 
PLA, AND PGA SAMPLES. ................................................................................................................................243 
TABLE 10-3 HALF-LIVES (TIME IN DAYS AT WHICH THE AVERAGE MOLECULAR WEIGHT OF A SAMPLE GROUP WAS ONE-
HALF THE INITIAL MOLECULAR WEIGHT) FOR ~100 µM THICK PLA, PGA, PLGA4.4, AND PLGA64 FILMS 
DEGRADED UNDER VARIOUS CONDITIONS. ........................................................................................................257 
TABLE A-1 MEASURED FLUORESCENCE OF SODIUM FLUORESCEIN SOLUTION PIPETTED INTO CUVETTES. SET A 
CUVETTES RECEIVED ONLY EIGHT MINUTES OF EXPOSURE TO MICROSCOPE STAGE LIGHTING, WHILE SET B HAD 
AN INITIAL FIVE-MINUTE EXPOSURE TO THE MICROSCOPE STAGE LIGHTING, FOLLOWED BY A SECOND EXPOSURE 
OF EIGHT MINUTES. ...........................................................................................................................................277 
TABLE B-1 CALCULATED CONCENTRATIONS OF FLUORESCEIN SODIUM DROPLETS AFTER ONE, TWO, THREE, OR FOUR 
MINUTES ELAPSED TIME BETWEEN MICROINJECTIONS. ......................................................................................291 
 
21 
ACKNOWLEDGEMENTS 
 
 After so many years at MIT, it is difficult to believe that I am finally leaving. The line 
that runs through my mind these days is “Boston, you’re my home,” from the song “Dirty 
Water” by the Standells. After four years as an undergraduate at MIT and another six (!) as a 
graduate student, I really do feel like Boston is my home, and my family can vouch for my 
acquired Boston accent. I’ve lived here for ten out of my 27 years, which is longer than I have 
lived anywhere else! But now it is time to move on to other things, and to do that I must thank all 
those without whom I could not have made it this far. 
 
Bob Langer and Michael Cima, for your guidance and patience and helping me to grow as a 
scientist, researcher, engineer, and person. Thank you for taking a chance on me, when I really 
had no idea what I was getting into and just wanted to work on this project because I thought it 
was really cool. I have learned so many valuable things, not just about research, from both of you. 
 
My thesis committee members (past and present), Chris Scott, Paul Laibinis, Michael Rubner, 
and Darrell Irvine. Thank you for your insights and suggestions and making sure that I knew my 
stuff. And thank you for your willingness to serve in the departmental rotation know as “Amy’s 
thesis committee.” 
 
My collaborators, Betty Tyler and Dr. Henry Brem at Johns Hopkins University, and Gabriela 
Voskerician and Dr. James Anderson at Case Western Reserve University. Our work together on 
the in vivo studies has been invaluable in giving me a broader perspective of biomaterials and 
drug-delivery systems. 
 
Lenny Rigione and John Centorino, for always being willing to help me learn how to use 
equipment, and seeming genuinely interested in my answers to your questions about how my 
experiments were going. 
 
Barbara Layne, Connie Beal, and Ilda Moura Thompson, for your invaluable work to make sure 
that all rules and budgets were followed, equipment was purchased when I needed it, and for 
your help with scheduling appointments and meetings. 
 
Those who have gone before me in Langer Lab, for showing me that it really is possible to 
graduate: Karen, Sachiko, Amir, and Jennifer.  
 
Those who will come after me in the Langer and Cima labs, for sharing your enthusiasm with an 
old and bitter nth year student: Grace and Yawen. 
 
My compatriots and fellow students in both the Langer and Cima labs, for commiseration, 
mutual support, and laughter: Joe, Tommy, Eric, Audrey, Rebecca, Mindy, and Ryan. 
 
My UROPS, Rebecca, Joyce, and Casey, for all of the hard work, weekend pipetting, and 
radiation safety training that you endured. The data you collected were an important part of this 
thesis, and I truly would have gone crazy without your help to take off a few weekends from the 
lab. 
22 
 
My course 3 buddies, Ben, Neil, and Vicky, we have finally all made it! 
 
Insung, your discussions and insights truly helped me to refocus when I desperately needed it. 
 
John Santini, first my tutor, then my friend, mentor, and microchip predecessor, thank you for 
your scientific insights, as well as for always taking a moment out of your day to talk to me when 
I needed it. 
 
The students of 2nd East at East Campus where I was a graduate resident tutor, for letting me get 
to know you and watch you grow. I appreciate the friendships we formed and I thank you for 
keeping me young at heart for a little while longer. 
 
My friends from Ashdown, swim team, and water polo, thank you for reminding me that there is 
life and fun outside of lab. 
 
Diana and Deb, for lending an ear to listen whenever I needed it. 
 
My family: Mom, Dad, Jess, and Chuck, for being there no matter what, and having faith that I 
would get through this. 
 
And to my husband, 
Jay, 
What would I do without you? 
I’m finally done! 
 
23 
1 Background and Introduction 
1.1 Overview of Controlled Release 
The method by which a drug is delivered can have a significant effect on the drug's 
therapeutic efficacy1,2. Conventional drug delivery systems such as tablets3–5, pumps6–8, implants 
(Gliadel, for example9,10), injectable microspheres (such as Lupron Depot11), and patches12 often 
produce a sharp initial increase in concentration to a peak above the therapeutic range, followed 
by a fast decrease in concentration to a level below the therapeutic range. Many polymeric 
implants achieve pulsatile release of a chemical via triggering by specific stimuli (changes in 
pH13–15 or temperature16–18, exposure to ultrasound19,20, enzymes21, or light22, or changes in 
electric23–27 or magnetic19,28 fields or molecules present in the human body, such as antigens29 or 
water). Externally-worn pumps are also used for pulsatile delivery. A newer approach uses 
microfabricated silicon devices for controlled release of drugs30,31. These devices potentially 
allow the release of hundreds of individual doses of drugs or chemicals (including both liquids 
and solids) with no moving parts from a single device on demand. However, these devices are 
not self-contained or biodegradable, and require components such as a power supply and clock 
or timer.  
In certain applications it may be desirable for a drug delivery system to release pulses of 
drug without the application of an external stimulus or a change in the local environment 
surrounding the device. For example, many hormones such as insulin32, gonadotropin releasing 
hormone and growth hormone releasing hormone are more effective when delivered in pulses 
over the course of a day33,34, but this is cumbersome and inconvenient to achieve by using an 
externally-triggered device. Therefore, there is a therapeutic need that could potentially be met 
by polymeric drug delivery systems that are capable of releasing pulses of drugs without the 
device performance being tied to an environmental change (such as local pH or application of a 
current). 
Thus far, the only reports in the literature of a polymeric system that can achieve pulsatile 
release without the application of an external stimulus or change in the local environment of the 
device, are of PLGA devices that have concentrically compression-molded alternating layers of 
polymer loaded with drug, or having no drug35,36. Two pulses of model drugs have been 
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demonstrated from these devices in vitro, as well as one pulse in vivo. However, this system may 
be limited in the number of dosages that it could deliver, due to the fabrication process by which 
it is made.  
1.2 A Resorbable Polymeric Microreservoir Device for Drug Delivery 
We propose here a resorbable polymeric microreservoir device, shown schematically in 
Figure 1.1 below, that could be used to deliver multiple pulses of drug. 
 
Figure 1.1 Schematic of polymeric microreservoir device. Figure by Erica Beade. 
The goal of our polymeric microreservoir device is to reproducibly achieve multiple 
pulses of drugs from a single device, with no initial burst effect. This device concept is based on 
previous work that has been done to develop an active, silicon-based microchip for controlled 
release30. The polymeric microreservoir device presented in this thesis contains an array of 
reservoirs that are each covered by a thin membrane of a degradable polymer. Control over the 
release of drugs from the device is achieved by changing the characteristics of the reservoir 
membranes. Increasing the thickness or the molecular weight of the membrane material, or using 
a more slowly degraded polymer, for example, could change the time at which the chemicals are 
released from the reservoirs. Each reservoir on the device could potentially have a different set of 
membrane characteristics, enabling release of the contents of each reservoir at a different time. 
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While the current prototypes shown in Figure 1.1 have 36 reservoirs, the size and geometry of 
the polymeric chip could be tailored depending on the application for which it will be used. For 
example, an 18 mm x 18 mm square device having 289 conical reservoirs (each with a large 
opening 500 µm in diameter and a small opening 45 µm in diameter) could hold enough ethinyl 
estradiol for one year of estrogen replacement therapy. Similar applications involving potent 
hormones (contraception, for example) or other chemicals could be envisioned. 
One of the unique advantages of this drug delivery system is that it allows separation of 
the components that control device performance from those that affect drug stability. The 
formulation that controls the drug release (the reservoir membranes) is to a first approximation 
independent of any formulation that may be included in the reservoir to control the drug stability. 
This is vastly different from other drug delivery systems that have been developed. Lupron 
Depot, for example, is a commercially available injectable microsphere formulation that releases 
leuprorelin acetate, a superagonist of luteinizing hormone releasing hormone (LH-RH), for 
treatment of hormone-dependent cancers and endocrine diseases11,37. Sustained blood levels of 
leuprorelin acetate have been found to be more effective for treating the disorders of interest, and 
therefore a constant release rate of drug from the microspheres is ideal. However, the release 
characteristics of the drug (amount of initial burst and sustained release rate) from the 
microspheres are affected by the drug loading, oligomer content, and particle size of the 
microspheres. In one study of numerous formulations made from varying molecular weights of 
PLA and PLGA, for example, optimal results were obtained for leuprorelin acetate delivered 
from PLA microspheres having an average molecular weight of 15,000, < 0.1% of water-soluble 
oligomer content, and with a drug loading of 12%. But even this “optimized” formulation 
showed a burst of leuprorelin acetate (<10% of the initial drug loading) on the first day in vivo37. 
The limitations of formulation specificity are not unique to Lupron Depot. Although PLA, PGA, 
and PLGA copolymers are widely studied and used for drug delivery systems, the flexibility that 
can be achieved through variation of molecular weight, oligomer content, copolymer ratio, 
particle size, and drug loading, is often underutilized when a formulation must be optimized for a 
specific drug release profile. In contrast, the flexibility offered by PLA, PGA, and PLGA 
copolymers can be fully exploited by the polymeric microreservoir device by simply changing 
the reservoir membrane characteristics independently of the drug formulation that is to be 
released from the device, and vice versa. Increasing the drug loading of the microreservoir 
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device, for example, can be achieved simply by loading more of the drug into each reservoir, or 
loading more reservoirs with the drug. This would not affect the drug release rate and would 
require no redesign of the membrane formulation. In contrast, changing the drug loading of 
Lupron Depot microspheres would require changing the polymer molecular weight or any 
number of other variables in order to maintain the drug release rate. This flexibility of the 
polymeric microreservoir device may offer an additional degree of freedom when considering 
the design of a drug delivery system for a given application, as the drug formulation will not be 
intimately tied to the release formulation. This may potentially allow greater utility of the 
microreservoir device as a platform for a broad range of drug-delivery applications, rather than 
being limited to treatment of only one or a few specific conditions. 
The microreservoir device has a number of other advantages. It has no moving parts and 
thus is not susceptible to mechanical failure, unlike external pumps and internal micropumps. 
Additionally, it could potentially deliver a wide variety of chemicals in solid, liquid, or gel form 
(this is not the case with pumps or patches), and could also achieve release of a desired substance 
or substances over a prolonged period of time, from days to weeks to even months or years, 
depending on the number of reservoirs that are filled with the substance and the characteristics of 
the reservoir membranes. This offers a distinct advantage over tablets used for oral delivery of 
drugs, which typically can achieve only one to three pulses of drug over the course of a day as 
the tablet passes through the gastrointestinal tract. The microchip is also an improvement over 
existing implantable, polymeric, controlled release systems due to the fact that it is not limited to 
the release of only one or a few chemical substances. In theory, every reservoir on the chip could 
be filled with a different substance or drug. Additionally, the fabrication and filling processes for 
the microchip are such that the drugs put into the chip are not exposed to any high temperatures 
or harsh chemicals. Thus the stability of the drugs is not compromised, in contrast to solvent-
intensive fabrication procedures for microspheres and some other types of polymeric implants. 
1.3 Thesis Objectives 
The specific goals of this Ph.D. thesis are as follows: 
1) To develop a fabrication process and select appropriate component materials for the 
microreservoir device substrate and reservoir membranes, as well as to develop a 
method for filling the devices with the drug to be released (Chapters 2 and 3).  
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2) To demonstrate chemical release from the microreservoir devices in vitro (Chapter 4). 
3) To characterize the degradation of the membrane materials in vitro and to determine 
the effect of membrane thickness and environmental temperature on their degradation 
rates (Chapter 5). 
4) To characterize the factors affecting the kinetics of drug release, specifically the 
partition coefficients, molecular weights, and reservoir loadings (osmotic P effects) of 
the drugs of interest (Chapters 6 and 7). 
5) To demonstrate biological activity of molecules released from the microreservoir 
device in vitro (Chapter 8). 
6) To demonstrate chemical release from the devices in vivo (Chapter 9). 
7) To characterize the biodegradation and biocompatibility of reservoir membrane 
materials in vivo in order to better understand their in vivo performance (Chapter 10). 
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2 Device Fabrication 
2.1 Introduction and Motivation 
2.1.1 Introduction 
The polymeric microreservoir device currently consists of a reservoir-containing 
substrate made out of poly(lactic acid) (PLA), and reservoir membranes made from copolymers 
of PLA and poly(glycolic acid) (PGA). These materials were selected as components of the 
device due to their biocompatibility and biodegradation characteristics, but other materials could 
also be used to fabricate devices similar in concept and operation to the device discussed here. 
This chapter describes the fabrication methods that were used to manufacture the devices, 
specifically substrate fabrication by compression molding and the formation of reservoir 
membranes by microinjection.  
2.1.2 Motivation 
A variety of biodegradable polymers have been used in drug delivery applications, most 
commonly poly(ε-caprolactone), polyanhydrides, poly(lactic acid) (PLA), poly(glycolic acid) 
(PGA), and copolymers of PLA and PGA (PLGA). The fabrication methods that are used often 
depend on the desired final geometry of the drug delivery device, as well as the thermal (Tg and 
Tm), physical (density and modulus), and chemical (solubility) properties of the polymer. Solvent 
film casting, melt spinning of fibers, and extrusion of rods1 have been reported for objects made 
from PLGA. However, with the exception of compression- and other molding techniques, most 
fabrication methods are capable of producing only very simple shapes (films and cylinders, for 
example). Solvent evaporation, spray drying, and emulsion techniques are common for 
microsphere systems2–4 (Lupron Depot®, for example5). Larger depot systems are often 
fabricated by compression molding6, melt casting7, or solvent casting8 of a mixture of the 
polymer and drug of interest, or by encapsulating a drug within a semipermeable membrane 
(such as the Norplant system9). Significant burst release upon implantation (or commencement 
of an in vitro release study)6,10, is typically followed by sustained release (constant release rate) 
of the drug from many of these systems. This may be undesirable for certain therapeutic 
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applications in which pulsatile release of the active agent, or the absence of an initial burst 
release, are desired for maximum therapeutic efficacy.  
Several considerations are of importance in the development of a fabrication method for 
our polymeric microreservoir device. First, the goal of delivering multiple pulses of active 
substances from a number of small reservoirs necessitates a more complex geometry than can be 
formed by spray drying, extrusion, or film casting. Second,  it is desired for the microreservoir 
device to be completely dense (nonporous), as well as have good mechanical strength and a 
degradation time of at least one month in the body. Low or no porosity, as well as a long 
degradation time, are desired in order to prevent drug leakage or dose dumping from the device. 
Good mechanical strength is desired in order to prevent fracture or fragility of the device for 
commercial production and loading, shelf stability, and ease of implantation by the surgeon in a 
patient. Third, it is highly desirable to minimize the amount of residual solvent in our device, 
given the long-term goal of implantation in a human patient. The U.S. Food and Drug 
Administration (FDA) has very strict requirements on residual solvent concentrations, typically 
requiring less than a few hundred parts per million (ppm) of the types of solvents (chloroform 
and dichloromethane, for example) in which the component materials of our microreservoir 
device are soluble11. Injection and compression molding provide solventless fabrication methods 
that allow the production of a device that satisfies all of the above requirements. Lab-scale 
injection molding equipment was not available through MIT’s facilities at the time the polymer 
microreservoir prototypes were developed. Therefore, compression-molding was selected as the 
optimal fabrication method for the substrate. 
The two most important considerations for the fabrication of the reservoir membranes are 
reproducibility of the fabrication method, and the ability to fabricate the membranes (the 
formulation that controls drug release) separately from loading the device with the drug 
formulation (which controls the drug stability). Maximal control over device performance can be 
attained by limiting the number of factors that affect drug release. In the case of our device, the 
reservoir membranes are the feature by which the drug release is controlled. Therefore, the 
fabrication process for the reservoir membranes must be applicable to a variety of different 
materials, yet allow precise control over the characteristics of the membranes (thickness, porosity, 
and geometry) while providing some degree of physical separation of the membrane from the 
drug formulation. While other methods such as ultrasonic bonding or solvent welding could be 
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used to fabricate the membranes that seal the reservoirs, microinjection is a relatively 
straightforward and simple one-step process. 
Based on these considerations, a fabrication procedure was developed that consisted of 
solventless two-step compression molding of the substrate, followed by microinjection of the 
membrane polymers in solution and subsequent drying under vacuum to form the reservoir 
membranes. Details of these procedures are discussed in the following sections. 
2.2 Materials and Methods 
2.2.1 Materials 
Poly(L-lactic acid) (PLA, Mw 194 Kilodaltons (Kd), Medisorb® 100 L), poly(glycolic 
acid) (PGA, Medisorb® 100 PGA) and poly(D,L-lactic-co-glycolic acid) polymer powders of 
molecular weights (Mw) 4.4 Kd (PLGA4.4, Medisorb® 5050 DL 1A), 11 Kd (PLGA11, 
Medisorb® 5050 DL 2A), 28 Kd (PLGA28, Medisorb® 5050 DL 3A), and 64 Kd (PLGA64, 
Medisorb® 5050 DL 4A) were obtained from Alkermes (Cincinnati, Ohio). The properties of the 
polymers that were used to make the membranes on the microreservoir devices are summarized 
in Table 2-1 below. Reagent grade dichloromethane (methylene chloride), 1,1,1,3,3,3-
hexafluoro-2-propanol (HFIP), and HPLC grade methyl alcohol were purchased from Sigma-
Aldrich (St. Louis, MO). Ethyl alcohol, 190 proof, was obtained from Pharmco (Brookfield, CT). 
Ideal 9144 Masking Tape was obtained from American Biltrite, Inc. (Lowell, MA). 
Table 2-1 Molecular weights, copolymer mole ratios, and approximate degradation times reported by the 
manufacturer for the PLGA4.4, PLGA11, PLGA28, and PLGA64 poly(lactic-co-glycolic acid) copolymers used to 
make the reservoir membranes on the microreservoir devices. 
Polymer 
designation 
Mw L:G mole
ratio 
Chain 
End Group 
Degradation time 
in vitro at 37°C 
PLGA4.4 4,400 51:49 -COOH 1-2 weeks 
PLGA11 11,000 53:47 -COOH 2-3 weeks 
PLGA28 28,000 54:46 -COOH 3-4 weeks 
PLGA64 64,000 54:46 -COOH 3-4 weeks 
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2.2.2 Methods 
2.2.2.1 Substrate Fabrication 
2.2.2.1.1 Poly(L-lactic acid) Purification 
Poly(L-lactic acid) (PLA) as received from the manufacturer was purified and processed 
into a powder form. This was done for two reasons. First, it was desired to remove any residual 
lactide monomer (between 0.4 and 4.1% as reported by the manufacturer) in the polymer. The 
presence of residual lactide in the final device could affect the degradation rate of the polymer, 
as well as contribute to the formation of porosity. Diffusion of residual lactide from the substrate 
of the final device into the environment surrounding the device (saline solution in vitro, for 
example) might leave behind pores, through which the drug loaded into the device could diffuse. 
Second, the purification step provides a powder form of the polymer, which is more easily 
molded than the granules that were received from the manufacturer. 
The PLA was purified by first placing approximately ten grams of the polymer in a 250 
mL glass beaker, along with a magnetic stir bar and approximately 200 to 250 mL of 
dichloromethane. The solution was gently mixed on a magnetic stir plate until complete 
dissolution of the polymer was achieved. The solution was then slowly poured into 
approximately 1.5 L of methanol (a nonsolvent for PLA, but a solvent for lactide monomer) that 
was magnetically stirred in a 2 L beaker. The PLA solution was poured into this larger beaker in 
a slow steady stream, causing the formation of a continuous thin fiber as the PLA precipitated 
out of solution, similar to a wet fiber spinning process12. The fibrous mats were periodically 
removed from the solution using a pair of tweezers. When the methanol solution became cloudy, 
due to the increasing amounts of dichloromethane and lactide monomer in solution, the solution 
was poured out of the beaker and replaced with fresh methanol before the precipitation process 
was continued. 
After precipitation of the PLA was complete, the fibers were dried under approximately 
93.5% vacuum (~6.7 kPa) for at least five days in order to allow complete evaporation of the 
methanol. The fibers were then chilled either on dry ice, or immersed in liquid nitrogen. Fibers 
were placed in a Tekmar A-10 Analytical Mill attached to a Cole-Parmer Polystat refrigerated 
recirculator with the temperature set to 0°C, and chopped into powder. 
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2.2.2.1.2 Substrate Molding 
Schematics showing the device fabrication procedure are shown in Figure 2.1 and 
Figure 2.2. Device substrates were fabricated from approximately 0.38–0.4 g of purified PLA 
(Tg = 53°C, Tm = 176°C). The powder was loaded into a 15/32” (11.9 mm) inner diameter die, as 
shown in Figure 2.1, and molded in a Carver Lab Press, Type C, for one minute and 30 seconds 
at approximately 2,000 load pounds and 25°C. This load (pounds-force) is applied to the area of 
the die plunger having a diameter of 15/32” and an area of 0.1726 in2, and therefore is 
commensurate with an applied pressure to the powder within the die of 11,500 psi or 80 MPa. 
This step produces a round white disk, or preform, similar to a tablet. 
 
Figure 2.1 Schematic of first compression molding step at room temperature, in which the PLA polymer preform 
that will become the device substrate is formed. 
Early efforts to fabricate devices included an intermediate compression step, in which the 
preform was molded above the Tg of the polymer between two Teflon sheets, either with or 
without the presence of aluminum shims. The preform is next molded at 182°C on an aluminum 
die plate for ten minutes to form a completely dense substrate. A pressure of approximately 
2,500 pounds-force was applied to the die once the polymer preform had completely melted, 
after five or six minutes. The aluminum die plate was treated with (tridecafluoro-1,1,2,2-
tetrahydrooctyl) trichlorosilane for eight hours at room temperature to functionalize the surface 
with a fluorocarbon, as shown schematically in Figure 2.3. This functionalization aided in 
release of the devices from the die plate. Surface functionalization was used instead of 
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application of a mold release agent (such as myristic or stearic acid) to avoid the introduction of 
a molecule that might adhere to or leave a residue on the surface of the device. 
 
Figure 2.2 Schematic showing fabrication process for polymeric microreservoir device: (a) Second compression 
molding step at T>Tg of the polymer, in which the conical reservoirs are formed in the polymer preform that was 
compression molded at 25°C by compression molding with an aluminum die having conical protrusions on it, (b) 
Cut-away schematic of device substrate showing partial penetration of conical reservoirs into substrate, (c) Device 
substrate after being polished with silicon carbide paper, showing truncation of conical reservoirs (complete 
penetration of reservoirs through device substrate), (d) Cut-away schematic showing reservoirs with microinjected 
membranes, (e) Cut-away schematic showing device after microinjection of chemical to be released. Enlargement of 
reservoir shows meniscus shape of reservoir membrane and typical dimensions of device features, (f) Cut-away 
schematic showing device after sealing with a layer of electroplating mask tape. Figure by Erica Beade. 
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Figure 2.3 Schematic of aluminum surface treated with (tridecafluoro-1,1,2,2-tetrahydrooctyl) trichlorosilane. 
 
Figure 2.4 Photograph of 6 × 6 array of conical protrusions (1000 µm tall, base angle of cones = 70°) on aluminum 
die plate. Tick marks on ruler indicate 1/16” (~1600 µm). Photo by Richard Holman. 
Conical protrusions on the aluminum die plate, shown in Figure 2.4 above, formed 
reservoirs in the PLA substrate. The reservoirs had a diameter at the large end of the cone of 728 
µm, an angle of 70°, and an approximate depth of 1000 µm. The molding setup consists of three 
aluminum plates. The first (base) plate has four sets of these conical protrusions. A second plate 
sits on top of the base plate. This second plate is 2 mm thick and has four ½” diameter holes in 
which the preforms are placed, and which are located directly over the arrays of conical indenters 
on the base plate. Finally, a third flat plate that does not have any holes or protrusions is placed 
on top of the whole assembly. This entire assembly, with four preforms loaded in it, is placed in 
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the lab press that has both platens heated to a specified temperature. A thermocouple (Omega 
HH21 microprocessor thermometer, J-K-T thermocouple) is placed in a small hole machined 
through the base plate, lying directly under the center of the plate, in order to monitor the 
temperature close to the performs. The conical reservoirs initially penetrated partially through 
the substrate. 
Substrate material was removed from one side of the device, truncating the conical 
reservoirs and providing two openings for reservoirs, one on each side of the device. The 
material was removed by polishing the devices on an Ecomet IV polisher/grinder with an 
attached Euromet I Power Head, 50-6150 Controlled Material Removal Accessory, 60-5455 
Specimen Loading Plate, and 60-5450 Maxi-Lok Chuck Assembly (Beuhler Ltd., Lake Bluff, IL). 
Diamond stops on the 50-6150 were set so that the thickness of the devices was reduced by 
approximately 1.2 mm. Samples were polished with 240 grit Carbimet paper until the diamond 
stops contacted the surface of the polishing wheel, typically between one minute and one minute 
and forty-five seconds. The diamond stops were then removed from the 50-6150, and the devices 
were polished for thirty seconds using 600 grit Carbimet paper, and thirty seconds using 1200 
grit MicroCut paper. All polishing media were silicon carbide paper obtained from Buehler Ltd. 
The thickness of the devices after polishing typically ranged from 400 to 825 µm, but variation 
within a given batch of devices was normally less than this.  
2.2.2.1.3 Visual Inspection 
Devices were inspected using an Olympus BH2 optical microscope with Olympus TH3 
light source (Olympus, Melville, NY). Photos were taken either with Polaroid film using an 
Olympus PM-10AK camera, or with a Pixera digital camera using Pixera Viewfinder software 
on a Dell Dimension L566cx computer. Microscopy was performed in order to check for 
porosity, as well as to measure the size of the reservoir openings. The reservoir opening size was 
then used to calculate the volume of polymer solution needed for a membrane of a specified 
thickness, as discussed in section 2.2.2.2.1 below.  
2.2.2.1.4 Density Measurements 
The densities of the devices were determined from several measurements of their weights, 
performed using a Mettler model AE 160 balance with Mettler 33360 Density Determination Kit. 
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Typically a device was dried in a desiccator attached to a Precision Vacuum Pump Model DD50 
for approximately 13 minutes (experimentally determined as sufficient time for drying via 
periodic measurements of the change in weight), and then weighed to determine the dry weight 
(Wdry). The device was then immersed in a beaker of 90 or 100% (190 or 200 proof) ethanol and 
left under vacuum for another 20 minutes or until no out gassing of air from the device was 
observed, in order to completely saturate the device with ethanol. The device was then suspended 
in a beaker of ethanol (same % as was used for initial saturation) and weighed (Wsusp). The 
device was blotted dry to remove any excess liquid from the surface, and finally weighed a third 
time to determine the saturated weight (Wsat). The ambient temperature was recorded in order to 
determine the density of the ethanol. The apparent, bulk, and relative densities, as well as the 
percentages of open and closed porosity, can be determined from application of the Archimedean 
Principle, which states that the buoyant force (Fb) on a submerged object is equal to the weight 
of the fluid that is displaced by the object. This can be expressed mathematically as follows: 
 
apparent
EtOHdry
b
W
F ρ
ρ×=  
Equation 2-a 
where Wdry = dry weight of the microreservoir device, ρEtOH is the density of ethanol at the 
ambient temperature, and ρapparent is the apparent density of the microreservoir device. The 
buoyant force is related to the dry and suspended weights of the device according to the 
following relation: 
 
suspdryb WWF −=  
Equation 2-b 
Combining Equation 2-a and Equation 2-b, the apparent density can be calculated from 
the experimentally determined values as follows: 
 
suspdry
EtOHdry
apparent WW
W
−
×= ρρ  
Equation 2-c 
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Similarly, the bulk density, which is the weight per unit volume of a sample including 
any pore space, can be calculated as follows: 
 
suspsat
EtOHdry
bulk WW
W
−
×= ρρ  
Equation 2-d 
The percentage of open porosity (Po) is then found from the equation: 
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Equation 2-e 
The density (ρrelative) of the microreservoir device relative to the theoretical density (ρtheoretical) of 
the polymer from which it is fabricated is found according to the relation: 
 
100×


=
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relative ρ
ρρ  
Equation 2-f 
Finally, the percentage of closed porosity (Pc) can be found via subtraction as follows: 
 
orelativec PP −−= ρ100  
Equation 2-g 
2.2.2.2 Reservoir Membrane Fabrication 
It was desired to use a membrane fabrication process that would allow precise control 
over the thickness of the membranes, as well as allowing flexibility to change the membrane 
material if desired. Further, it was desirable for the membranes to be nonporous, as well as have 
a small residual solvent volume, as discussed in section 2.1.2. Microinjection meets both of these 
requirements.  
2.2.2.2.1 Reservoir Membrane Microinjection 
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 The accuracy of the microinjector is a function of several variables. The first is the 
mechanical step size that is programmed into the micro pump controller. An internal seated 
screw having a set number of turns (steps) rotates and thus moves the plunger of the syringe. 
Because the number of steps is fixed, the volume per step varies depending on the size of the 
syringe used. For example, a volume per step of 0.529 nL/step is used for a ten µL syringe, while 
5.29 nL/step is used for a 100 µL syringe. The second factor is the solvent used. Due to the small 
volumes that are injected (typically from 20–150 nL), evaporation of the solvent due to the vapor 
pressure may cause a significant decrease in the droplet volume, and corresponding increase in 
the concentration of the droplet. Additionally, variation in the amount of elapsed time between 
injections may cause evaporation of different volumes and thus change the local concentration of 
the solute or chemical in the needle tip.  
Membranes were prepared in the reservoirs by injection of PLGA in 1,1,1,3,3,3-
hexafluoro-2-propanol solutions (12%v/v). Solutions of PLGA4.4, PLGA11, PLGA28, and 
PLGA64 were used to make four different types of membranes in each device. Injection was 
performed using a system purchased from World Precision Instruments (Sarasota, FL), 
consisting of a UMP-1 Ultra Micro Pump with a Micro-4 controller, Kite-R micromanipulator 
with a TB-1 tilting base and 5464 five pound weight for the tilting base, and a PZMT Trinocular 
stereo microscope with 13338 Adapter Ring Light, R-8-8-WPI01 fiber optic ring light, and 
NOVA Novaflex fiber optic light source. Solutions were injected from a 1710RN 100 µL gas 
tight glass syringe with a 0160831 1" 31 gauge removable needle, blunt tip (both items from 
Hamilton Co., Reno, NV).  
A conical shape was chosen for the reservoirs in order to aid in membrane formation. The 
membrane solution was injected into the side of the device having the larger diameter reservoir 
openings. The Young-Laplace equation offers a physical explanation for what will happen to the 
membrane solution once it is injected into a reservoir. For a truncated conical reservoir 
containing a volume of liquid that has radii of curvature R1 and R2, where R1>R2 (shown 
schematically in Figure 2.5 below), the Young-Laplace equation is13: 
 



 −=∆
12
22
RR
P γ  
Equation 2-h 
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where ∆P = the pressure difference (proportional to the stress) between the two sides of the 
interface and γ  = surface tension of the liquid.  
 
Figure 2.5 Schematic of reservoir geometry showing microinjection of membrane solution into reservoir and 
formation of a fluid volume having radii of curvature R1 and R2, and subsequent drying of the solution as capillary 
pressure drags the fluid volume to the small end of the reservoir. 
There will be a corresponding pressure or stress that pulls the droplet in the direction of the 
narrow end of the reservoir, since the radius of curvature (R2) of the liquid is smaller on that side 
of the droplet. Thus, capillary action will drag the membrane solution to the narrow end of the 
conical reservoirs, forming the membrane close to the opposite surface of the device upon drying. 
Wetting of the membrane solution on the reservoir walls was observed experimentally. The 
conical shape of the reservoirs also minimizes the area of the membrane that is exposed to the 
release environment. This geometry may be beneficial in helping to control the degradation of 
the membrane and release of the chemical, as it minimizes effects from the pressure of the fluid 
or mechanical disturbances to the membrane from the surrounding environment. 
Reservoir membranes were typically designed to be approximately 150 µm thick in the 
experiments reported in this thesis. The volume of membrane solution injected into each device 
varied due to the slight variations in device thickness and the corresponding size of the reservoir 
openings. The volume of solution injected into each reservoir was calculated from the volume 
fraction of polymer in the solution, the specific geometry of each device, and the desired final 
membrane thickness. We assumed that (1) upon drying, the surface of the membrane at the small 
end of the cone frustum is coplanar with the surface of the device, i.e. that there is no meniscus, 
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(2) that the two surfaces of the membrane are parallel and flat, and (3) that the membrane is 
completely dense after drying. The frustum of a cone having a height (membrane thickness) h 
has bases with radii R1 for the larger radius and R2 for the smaller radius. The value of h is 
calculated as: 
 
( ) ARRh tan21 ×−=  
Equation 2-i 
where A = angle of the base of the cone = 70° for our geometry. A conical frustum with the 
relevant dimensions indicated is shown in Figure 2.6 below. 
 
Figure 2.6 Conical frustum, taken as model geometry for reservoir membranes, having height (membrane thickness) 
h, base angle A, and radii R1 and R2. 
The total volume (V) of the frustum of the cone, which is the volume of the reservoir 
membrane, is calculated as: 
 
( )21222131 RRRRhV ×++×= π  
Equation 2-j 
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The volume of membrane solution that must be injected (Vinj) to achieve this membrane volume 
and thus the desired membrane thickness is: 
 
poly
inj f
VV =  
Equation 2-k 
where fpoly is the volume fraction of polymer in the solution to be injected. Typical injected 
volumes ranged from 100 to 200 nL, for predicted final membrane thicknesses of 150 µm.  
The devices were dried in a vacuum oven at 74–81°C and 93.5% (6.7 kPa) vacuum for 
approximately 48 hours after microinjection of the membrane solutions. Devices were suspended 
on glass slides so that the truncated ends of the reservoirs in which the membranes were located 
faced the bottom of the vacuum oven, but were not touching the surface of the oven. Typically 
no sagging of the membrane (membrane bulging out from the surface of the device) was 
observed after the membranes were dried. The membranes were inspected for defects after 
drying (such as air bubbles and pinholes) at 80X magnification using a PZMT Trinocular stereo 
microscope with 13338 Adapter Ring Light, R-8-8-WPI01 fiber optic ring light, and NOVA 
Novaflex fiber optic light source. Reservoirs having defect-free membranes were considered 
viable for use in release experiments, and selected reservoirs were loaded with the chemical(s) to 
be released.  
2.2.2.2.2 Near-Infrared Characterization of Membranes 
It is desirable to ensure that significant mixing between the reservoir membrane polymer 
and the substrate polymer does not occur during the microinjection process. In the case of the 
materials used in our prototype devices, poly(lactic acid) (PLA) and poly(lactic-co-glycolic acid) 
(PLGA), the degradation rates of these polymers are a function of both copolymer ratio 
(polymers having a higher ratio of PLA have slower degradation rates), as well as molecular 
weight (higher molecular weight polymers have longer degradation times, see Chapter 5 for a 
more thorough discussion). The substrate polymer not only is pure PLA, but also has a higher 
molecular weight than the membrane polymers. Both of these factors could lead to a decrease in 
the degradation rates of the reservoir membranes. Further, the solvent that is used to make the 
membrane polymer solutions (1,1,1,3,3,3-hexafluoro-2-propanol) is also a solvent for the 
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substrate polymer (PLA). While use of a co-solvent will allow a small amount of beneficial 
mixing between the membrane and substrate polymers and therefore ensure that the reservoir is 
completely sealed, significant mixing would be highly undesirable.  
Near-infrared (NIR) spectroscopy was used to characterize a representative 
microreservoir device in order to determine if significant mixing of the membrane and substrate 
polymers occurred during membrane microinjection. Near-infrared chemical imaging data was 
obtained with MatrixNIR (Spectral Dimensions, Inc., Olney, MD). The imaging system used in 
this study consists of a reflectance illumination source, a Liquid Crystal Tunable Filter (LCTF) 
for wavelength selection, collection and focusing optics, and an NIR sensitive Focal Plane Array 
(FPA). The focal plane array is a 320 × 240 pixel Indium Gallium Arsenide (InGaAs) array. 
Each pixel on the array corresponds to ~ 2.5 × 2.5 µm on the sample, providing a field of view 
(FOV) of approximately 0.8 × 0.6 mm.  
The sample was illuminated in reflectance mode with four quartz tungsten halogen 
(QTH) sources. The diffuse reflected NIR energy was collected by a 15X Cassegrain objective, 
passed through the LCTF, and focused onto the FPA. The LCTF was tuned across the spectral 
range of interest, and images were recorded from the FPA at each selected wavelength. The 
LCTF had a 6 nm bandpass over the spectral range of interest. 
The MatrixNIR instrument was controlled with data acquisition software, MatrixAcquire 
V 0.5.10 (Spectral Dimensions, Inc., Olney, MD). Data was collected over the spectral range 
1100 ~ 1700 nm, at 10 nm increments. Sixteen frames were co-added at each wavelength step, 
and for each data set, two complete scans were co-added. Complete background data sets were 
also recorded on a Spectralon (SRS-99-010, Labsphere Inc., North Sutton, NH), an NIR 
reflectance standard. The data was analyzed with Isys V 2.0.0 (Spectral Dimensions, Inc., Olney, 
MD).   
The raw sample data cubes were divided by spectralon data sets to eliminate the 
instrument response function, and then converted to standard reflectance units, log (1/R), by 
taking the inverse logarithm. The data was then analyzed using a multivariate method, Partial 
Least Squares (PLS) type II analysis14, which is commonly used in chemometric analyses. Pure 
component spectra were taken from samples of pure poly(lactic acid) (PLA) powder molded at 
room temperature, and at room temperature and subsequently at 182°C, and poly (glycolic acid) 
(PGA) microinjected onto Mylar film, and PGA cast on and then removed from Mylar film 
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(freestanding film). These reference samples were selected because they mimic the processing 
conditions that the PLA and PGA components of the microreservoir device are exposed to 
during fabrication. Spectra from both of the PLA reference samples were similar, as were spectra 
from both of the PGA reference samples. Reference spectra from the PLA sample molded at 
room temperature and 182°C, and from the PGA freestanding film, were used to build a library, 
which was then used to analyze the sample data sets. The resulting PLS scores are correlated 
with the amounts of each component (PLA or PGA) that are present at a given location in the 
sample15. The PLS score images showed the relative concentrations of the library components. 
These scores were plotted as a function of the location on the sample. 
2.2.2.2.3 Residual Solvent Determination 
Membrane polymer samples were analyzed on a PerkinElmer Thermogravimetric 
Analyzer (model TGA7) to determine the residual solvent after experiencing similar processing 
conditions as those that reservoir membranes on a device are exposed to. Empty platinum TGA 
pans were filled with one of four solutions, having between 11.7 and 12.1% by volume of 
PLGA4.4, PLGA11, PLGA28, or PLGA64 in 1,1,1,3,3,3-hexafluoro-2-propanol. The pans 
were dried under approximately 90% house vacuum for 48 hours at 77°C, and then sequentially 
run on a PerkinElmer TGA7 using nitrogen purge gas. The heating program is summarized in 
Table 2-2 below. The residual solvent was determined as the percentage of weight lost over a 
temperature range (30–100°C) that encompasses the boiling temperature of 1,1,1,3,3,3-
hexafluoro-2-propanol (58°C). 
Table 2-2 Experimental parameters for TGA analysis of membrane polymers. 
 
 
Condition 
Starting  
Temperature 
(°C) 
Ending  
Temperature 
(°C) 
 
Rate  
(°C/min)
 
Time  
(min:sec) 
Isothermal 30 30  3:00 
Ramp 30 900 15 60:00 
End  30   
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2.3 Results and Discussion 
2.3.1 Substrate Fabrication 
2.3.1.1 Visual Inspection 
Devices formed cohesive tablets after the initial compression-molding step at room 
temperature. The mechanical strength of the devices was such that no breakage or crumbling of 
the devices occurred during normal manipulation with tweezers or by hand. A photograph of a 
representative device (preform) at this point of the fabrication process is shown in Figure 2.7 
below.  
 
Figure 2.7 Photograph of PLA preform after compression molding of polymer powder in 15/32" cylindrical die at 
11,500 psi for one minute and thirty seconds at room temperature. Photo by Richard Holman. 
A variety of molding temperatures, pressures, and times were tried in an attempt to 
optimize the experimental parameters for the second compression-molding step. Representative 
samples from some batches are discussed here. Early prototypes were fabricated with P-L-LGA 
(Mw 36,000, Tg 38°C) and had an intermediate hot compression molding step on Teflon sheets. 
These devices had insignificant pressure applied during the hot compression molding step on the 
aluminum die plate, and they showed porosity no matter what the temperature at which they 
were molded.  
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Figure 2.8 Optical microscopy photograph at 37.5X of device 070799-03 (hot compression molded at 66°C), 
showing six conical reservoirs with entrapped air bubbles (pores) localized around the reservoirs. 
Figure 2.8, for example, shows a device that was compression molded on the aluminum 
plate at approximately 66°C, while Figure 2.9 shows a device molded at 82°C, and Figure 2.10 
shows a device molded at 99°C.  
 
Figure 2.9 Optical microscopy photograph at 37.5X of device 070799-06 (hot compression-molded at 82°C), 
showing six conical reservoirs and air bubbles localized near reservoirs and spreading between reservoirs. 
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Figure 2.10 Optical microscopy photograph at 37.5X of device 070799-09 (hot compression-molded at 99°C) 
showing six reservoirs with distributed porosity throughout the device substrate. 
It is clear from the photographs above that significant porosity was evident at all of the 
molding temperatures investigated in this particular batch of devices. The application of pressure 
during the molding process was found to drastically reduce the amount of porosity in the devices. 
Further, better results were obtained when the polymer was allowed to nearly completely melt 
before the load pressure was applied. One explanation for this might be that application of 
pressure to the die while the polymer was still solid actually nucleated air bubbles at the sites of 
the conical protrusions on the aluminum die as the preform was pressed onto the surface. When 
the polymer later melted, these air bubbles could have become entrapped in the polymer matrix. 
If no additional load pressure were applied, there would be no driving force, other than surface 
tension, to eliminate the air bubbles. However, if the order of processes were reversed (heating 
followed by the application of pressure), application of load pressure after the polymer had 
already melted would force the air bubbles through the liquid matrix and out to the surface of the 
device. 
 It was also observed that at short times, the visible porosity decreased as the length of 
time under load increased. However, after a certain point it was found that additional time under 
load did not appear to have any effect on eliminating the few remaining air bubbles. Devices 
were typically completely transparent and showed only a few air bubbles after being 
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compression molded at 182°C for 10 minutes and 2,500 load pounds. Sample devices having no 
visible porosity near the reservoirs are shown in Figure 2.11 to Figure 2.13. 
 
Figure 2.11 Optical microscopy photograph of device 123102-01 showing four reservoirs after polishing step. Dark 
regions in reservoir openings are polymer debris from polishing (removed before membrane microinjection). Lines 
on device surface are polishing artifacts. 
 
Figure 2.12 Optical microscopy photograph of device 123102-02 showing four reservoirs after polishing step. Dark 
regions in reservoir openings are polymer debris from polishing (removed before membrane microinjection). Lines 
on device surface are polishing artifacts. 
 
 
200 µm 
200 µm 
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Figure 2.13 Optical microscopy photograph of device 123102-03 showing four reservoirs after polishing step. Dark 
regions in reservoir openings are polymer debris from polishing (removed before membrane microinjection). Lines 
on device surface are polishing artifacts. 
 Some variation in final device thickness was typical due to the variability in the polishing 
process. Diamond stops are used during the first polishing step, in which the coarsest polishing 
paper (240 grit) is used, but the stops are removed prior to polishing with the finer grits of paper 
(600 and 1200 grit) in subsequent steps. Load pressure was typically maintained at 14 pounds-
force, but slight variations in device placement or pressure can affect how much material is 
removed from the surface of the devices. This, in turn, can affect the final thickness of a device 
and the size of the reservoir openings, as can be seen in a comparison of Figure 2.11, Figure 
2.12, and Figure 2.13. One batch of devices, for example, had reservoir openings (small end of 
truncated conical reservoirs) that ranged from 170 to 385 µm in diameter, as measured by optical 
microscopy. The variation in reservoir diameters was minimized as much as possible when 
selecting devices from a given device batch for release studies. One representative batch of 
devices used for a release study had a ±40 µm variation in reservoir diameters, for example. As 
discussed in section 2.2.2.2.1, however (see Equations i-k), the volume of membrane solution 
that was injected into each reservoir was calculated based on the reservoir opening size and 
volume fraction of polymer in solution in order to give approximately the same desired 
membrane thickness for all devices, regardless of the size of the reservoir openings. No 
significant variation in release time due to variation in reservoir opening size was seen in the in 
200 µm 
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vitro release studies presented in Chapter 4. A photograph of a sample device after polishing is 
shown in Figure 2.14. 
 
Figure 2.14 Photograph of prototype device after polishing, showing 6 × 6 array of truncated conical reservoirs. 
Photo by Richard Holman. 
 Optical microscopy of devices was used to determine which reservoirs were suitable for 
microinjection of membranes. Reservoirs that had air bubbles near or connected to them were 
deemed unsuitable for microinjection due to the possibility of nonuniform dissolution of the 
substrate material and consequent deformities in the reservoir membranes. Typical yield of 
usable reservoirs on a given device ranged from 70 to 100%, with 80–90% being more common.  
2.3.1.2 Density Measurements 
Density measurements were performed on early prototype devices fabricated from PLGA 
65:35. Devices that had visible porosity (such as those in Figure 2.8, Figure 2.9, and Figure 
2.10) typically had calculated relative densities of 94–99%. Open porosities ranged from 0.4–
3.9%, and closed porosities from 0.02–1.7%. Density measurements were also performed on the 
PLA devices shown in Figure 2.11 to Figure 2.13. These devices had a few air bubbles at their 
edges, as well as localized near a few reservoirs. The calculated relative densities, however, were 
much higher than for the PLGA devices that had visible porosity. Typical relative densities of 
99–100% were measured, with open porosity values of 0–0.50%, and closed porosity of 0–
0.92%. These devices were similar in appearance to many others that were fabricated and thus 
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these results can be considered representative. While the devices were not completely dense, the 
most important consideration is that typically very little porosity was seen in the regions 
surrounding the reservoirs, yielding a high percentage of usable reservoirs as discussed in 2.3.1.1. 
2.3.2 Reservoir Membrane Fabrication 
2.3.2.1 Reservoir Membrane Microinjection 
Reservoir membranes were inspected using optical microscopy after they had been 
completely dried. Both sides of the membranes were inspected for defects such as air bubbles, 
pinholes, or surface irregularities such as wrinkles or dimples. Membranes that exhibited any of 
these features were considered unusable, as the degradation behavior and membrane opening 
times might be affected. SEM analysis of some device membranes was performed. An example 
membrane is shown in Figure 2.15 below.  
 
Figure 2.15 SEM of PLGA64 reservoir membrane on PLA device. Photograph taken of front side of membrane 
that is exposed to release environment, opposite the side of the reservoir into which the membrane solution was 
microinjected. 
As can be seen in Figure 2.15, the surface of the membrane on the side of the device that 
is exposed to the release environment (opposite to the side of the device that was microinjected) 
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is concave rather than planar, as was assumed in our calculations of the volume of membrane 
solution required to form a membrane of a desired thickness (see section 2.2.2.2.1 above). This 
was observed for most of the devices that were used for release studies, but attempts to 
cryomicrotome the devices in order to gain a better understanding of the membrane geometry 
were unsuccessful. The simplifying assumptions used in the calculations of membrane solution 
volume (see 2.2.2.2.1) were therefore left unchanged. 
Membrane yield varied widely, depending on the size of the reservoir openings and the 
polymers from which the membranes were fabricated. The membrane solutions often did not 
form a cohesive structure in reservoirs that had very large openings (greater than ~375 µm at the 
small end of the reservoir), possibly due to rapid wetting of the large surface area. Additionally, 
although the membrane solutions typically had similar volume fractions of polymer regardless of 
the polymer that was used, it was found that the higher molecular weight polymers (PLGA64 
and PLGA28) produced more viscous solutions. These solutions sometimes did not completely 
wet the reservoir, as the high viscosity prevented the solution from coating the reservoir before 
the solvent evaporated. Additionally, the high viscosity at times prevented entrapped air bubbles 
from coalescing and bursting at the membrane surface, resulting in entrapped air bubbles within 
the reservoir membranes. On the other hand, the low viscosity (low molecular weight) solutions 
sometimes wetted the surface of the reservoir rapidly and broke in the center, and did not form a 
cohesive structure. Entrapped air bubbles, however, were not often seen in membranes made 
from the lower molecular weight polymers (specifically the PLGA4.4).  
2.3.2.2 Near-Infrared Characterization of Membranes 
A device was analyzed using near-IR spectroscopy to determine whether the membrane 
material (PLGA) blended with the substrate material (PLA) during membrane fabrication. It was 
desired to determine whether microinjection of the membrane polymer in a co-solvent for the 
membrane and substrate polymers caused mixing of the two polymers in the central region of the 
membrane during fabrication of the membranes. This mixing might affect the degradation time 
of the membrane and thus perhaps the release time of the chemicals from the reservoir. The 
substrate was fabricated from PLA and the membranes from PGA, instead of the PLGA 
copolymers used in the devices for the release studies, for maximum contrast in the spectra of the 
membrane and the substrate of the device. Pure component spectra were taken from a PLA 
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substrate that was fabricated in the same fashion as the sample device, and a pure PGA film. 
Spectra taken from the surface of the PLA sample device and the center of the PGA membrane 
on the sample device were identical to the PLA and PGA reference spectra.  
The partial least squares (PLS) scores measure the correlation of the sample spectra with 
the reference spectra and indicate the relative contribution of each material (PLA and PGA) to 
the overall composition of the sample at a given location. The PLS scores obtained during the IR 
membrane characterization are shown in Figure 2.16 and Figure 2.17. As is expected, the 
spectra obtained from the membrane region show a high correlation with the PGA reference 
spectra (Figure 2.16), while the spectra obtained from the substrate of the device show a high 
correlation with the PLA reference spectra (Figure 2.17), as indicated by the high PLS scaled 
score values. 
 
Figure 2.16 Near-infrared characterization of PGA membrane on PLA device. Image of reservoir with PGA 
membrane, showing PLS Score of PGA ranging from zero on the substrate of the device to one in the membrane 
region. Horizontal line indicates row 120, from which the PLS Scores are plotted in Figure 2.18 along with PLS 
Score from PLA characterization shown in Figure 2.17. 
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.  
Figure 2.17 Near-infrared characterization of PGA membrane on PLA device. Image of reservoir with PGA 
membrane, showing PLS Score of PLA ranging from close to one on the substrate of the device to zero in the 
membrane region. Horizontal line indicates row 120, from which the PLS Scores are plotted in Figure 2.18 along 
with PLS Score from PGA characterization shown in Figure 2.16. 
 Figure 2.18 shows a one-dimensional projection of the PLS scores along the horizontal 
centerlines (row 120) indicated in Figure 2.16 and Figure 2.17. The PLA and PGA signals 
appear quite different in both the membrane region and the device substrate region, at the 
extreme edges of graph. The PLA and PGA signals also vary linearly in the taper region, which 
is the region in which the sidewall of the reservoir is at a 70° angle to the device surface. This 
result is expected, as the spectra that are collected in this region are due to the infrared radiation 
as is passes through both the substrate and the underlying reservoir region with PGA, as shown 
schematically in Figure 2.19 below.  
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Figure 2.18 1-D projection of PLS Image Scores along horizontal axis at vertical center, row 120. Solid line 
indicates PGA score and dotted line indicates PLA score.  
 
Figure 2.19 Schematic of experimental geometry used for collection of near-infrared spectra, showing device 
resting on gold mirror, and diffuse reflectance of quartz tungsten halogen illumination through the device thickness. 
In the substrate region of the device, the infrared signal that is collected is due solely to the substrate (PLA), while 
in the center of the reservoir membrane the signal will be due solely to the membrane (PGA). In the taper region of 
the reservoir, however, the detected signal is due to both the membrane and the substrate regions through which the 
illumination passes. In the idealized schematic, for example, the signal will be 50% PGA and 50% PLA spectra, as 
the linear thicknesses of the PGA and PLA regions through which the illumination passes are equal. 
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These results suggest that no significant mixing of the membrane polymer with PLA 
from the substrate occurred in the central region of the reservoir membrane during the fabrication 
of the membranes. This supports the hypothesis that the degradation time or opening of the 
membrane and the subsequent release of the chemicals from the reservoirs are not a function of 
mixing of the substrate and membrane materials. 
2.3.2.3 Residual Solvent Determination 
Microinjected reservoir membranes on polymeric devices were not used for this 
experiment, as the amount of polymer that is typically injected into a reservoir is too small to 
show a significant change in mass due to residual solvent evaporation. Typically 100–150 nL of 
a membrane polymer solution is injected into a reservoir on a device. For conditions of 12% 
volume fraction of polymer in the solution, and an approximate polymer density of 1.3 g/mL, 
this corresponds to a mass of 23.4 µg of polymer in a reservoir. If the residual solvent were 1% 
by weight (10,000 ppm), this would correspond to a mass change of 0.234 µg when the solvent 
was vaporized, which is not considerably larger than the microbalance sensitivity of 0.1 µg for 
the TGA that was used. Additionally, the TGA manufacturer recommends using samples 40–50 
mg in size for residual solvent measurements. Therefore, larger membrane polymer masses than 
would be present in a microinjected device were used for these studies.  
Sample sizes (polymer + solvent) ranged from approximately 14 to 30 mg, and the 
polymer samples were approximately 1–2 mm thick. The decomposition curves from 30 to 
850°C for each material are shown in Figure 2.20. Although the decomposition of the polymers 
is clearly evident as a large decrease in the sample weight, there is no noticeable change in 
sample weight at 58°C, the boiling temperature of the HFIP. These preliminary results suggest 
that the amount of residual HFIP in the polymer samples is quite small. 
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(a)  (b)  
(c)  (d)  
Figure 2.20 TGA decomposition curves from 30–850°C for (a) 19.463 mg of PLGA4.4, (b) 16.902 mg of 
PLGA11, (c) 16.301 mg of PLGA28, (d) 30.086 mg of PLGA64 in platinum pans. Solid lines indicate the weights 
of the samples, dotted lines indicate the derivative weights (mg/min) of the samples. 
More quantitative results were obtained upon closer inspection of the curves. Enlarged 
views of the decomposition curves from 30 to 260°C are shown in Figure 2.21. The mass of 
solvent lost was calculated as the change in weight as the temperature was increased from 30 to 
100°C. The results are summarized in Table 2-3 below. 
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(a)  (b)  
(c)  (d)  
Figure 2.21 TGA decomposition curves from 30–260°C and weight losses from 30 to 100°C for (a) PLGA4.4, (b) 
PLGA11, (c) PLGA28, and (d) PLGA64. Solid lines indicate weights of samples, dashed lines indicate derivative 
weights (mg/min) of samples. 
Table 2-3 Residual solvent in PLGA4.4, PLGA11, PLGA28, and PLGA64 polymers after 
drying for 48 hours at 77°C. Solvent determined as weight change from 30 to 100°C. 
Polymer Initial Weight 
(mg) 
∆ weight from
30–100°C 
(mg) 
Solvent weight
(%) 
Solvent weight
(ppm) 
PLGA4.4 19.463 5.686 × 10-3 2.92 × 10-2 292 
PLGA11 16.902 8.827 × 10-3 5.22 × 10-2 522 
PLGA28 16.301 1.131 × 10-2 6.94 × 10-2 694 
PLGA64 30.086 1.176 × 10-2 3.91 × 10-2 391 
 
 Overall, the measured quantities of residual solvent over the specified time period and 
temperature range are quite low. However, it is well known that some polymers will retain 
solvent for long periods of time. A more extended TGA study was therefore performed on one of 
the membrane polymer materials (PLGA11) to more accurately determine the residual solvent 
content. This sample had a mass of 14.08 mg and was held at 80°C for 22 hours. The TGA 
results are shown in Figure 2.22 below. 
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(a)  (b)  
(c)  
Figure 2.22 TGA decomposition curves for PLGA11 sample held at 80°C for 22 hours: (a) TGA curve (weight loss 
versus temperature) from approximately 30 to 850°C, (b) close-up of TGA curve from approximately 30 to 105°C 
showing calculated weight loss of 0.321 mg from 40 to 80°C, (c) TGA curve of weight loss over time for the entire 
course of the experiment. Solid lines indicate weights of samples, dashed lines indicate derivative weights (mg/min) 
of samples. 
The weight loss of 0.321 mg over the temperature range of 40–80°C shown in Figure 
2.22(b) is much larger for this sample than was seen for the other samples which were not held at 
80°C, and in fact corresponds to a residual solvent amount of 2.28%, or approximately 22800 
ppm. Additionally, as can be seen from Figure 2.22(c), even after 22 hours at 80°C the sample 
weight was still decreasing, although the rate of mass loss appears to be diminishing as 
evidenced by the curvature of the line. These results suggest that complete evaporation of 
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residual solvent from the membrane polymers takes place over an extended period of time, and 
that for commercial applications a prolonged out gassing time is desirable. 
Although HFIP is not classified by the FDA as a Class 1, 2, or 3 type solvent (solvent to 
be avoided, solvent to be limited, or solvent with low toxic potential), chloroform and 
dichloromethane are designated as Class 2 solvents and could be used instead of HFIP to 
fabricate the reservoir membranes and to ensure that the membrane fabrication process will be 
compatible with FDA guidelines. The higher vapor pressures of these two solvents, however, 
might make reproducible microinjection of the polymer solutions more difficult. The ppm values 
specified by the FDA for these two solvents range from 60 ppm for chloroform to 600 ppm for 
dichloromethane. 
The FDA also specifies permissible daily exposure (PDE) limits for Class 2 solvents16. 
The PDE, in mg/day, can be found as follows: 
 
PDEdoseppm =×


1000
max  
Equation 2-l 
where ppmmax = the maximum allowable ppm concentration according to the FDA and dose = 10 
g. For the microreservoir devices, the daily exposure can be found from the total mass of 
membrane polymer in the device and the ppm values obtained through our TGA analyses. A 
device having 36 reservoirs that each have 23.4 µg of membrane polymer would have a total 
membrane polymer mass of 842.4 µg, or 8.424 × 10-4 g. If we assume a maximum concentration 
of 22800 ppm of solvent within each of those membranes (according to the PLGA11 sample that 
was held at 80°C for an extended period of time), then the total dosage of solvent can be 
calculated from Equation 2-l as: 
 
( ) daygdaymggppm /19/019.010424.8
1000
22800 4 µ==××

 −  
 
This is well below the range of PDE values (0.5 to 48.4 mg/day) specified for Class 2 solvents by 
the FDA11. Additionally, for a patient weighing approximately 150 lbs (68 kg), the 19.21 µg of 
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residual 1,1,1,3,3,3-hexafluoro-2-propanol calculated above for a prototype device would 
correspond to a dosage of: 
 
kgg
kg
g /28.0
18.68
21.19 µµ =  
 
which is much lower than the intraperitoneal LD50 (lethal dose at which 50% of test subjects are 
killed) reported for mice of 300 mg/kg. Additionally, the PDE specified by the FDA is the 
maximum allowable amount of solvent per day that can be released from a pharmaceutical body, 
for example a tablet that is administered daily. The microreservoir device, however, is designed 
for implantation and use over a much longer time period than one day, with possible device 
lifetimes up to a few years. It is highly unlikely that all of the residual solvent would be released 
in one day, given the extended period of time required for out gassing in the TGA studies 
reported here, and moreover the device would not be repeatedly administered to a patient. 
Finally, it is likely that the residual solvent in the reservoir membranes is actually lower 
than the concentrations found during this study, as the membranes have a much smaller volume 
and thickness than the polymer samples in our TGA pans, and would therefore allow more rapid 
out gassing of the solvent. The samples analyzed in this study had masses of membrane polymers 
that were larger by a factor of nearly 103 and thicknesses that were approximately six times 
larger than those typically present in a microreservoir device.  
2.4 Summary and Conclusions 
We have developed a fabrication process for polymeric microreservoir devices that 
consists of two compression-molding steps, a polishing step, and microinjection of polymer 
solutions into the reservoirs to form the reservoir membranes. This process yields a device that 
fulfills our criteria of being able to deliver multiple pulses, as well as having low porosity 
(typical relative densities of 99–100% were obtained). The amount of residual solvent in 
membrane polymer samples appears to decrease quite slowly even at 80°C. Using a more 
volatile solvent or extending the curing time of the membranes prior to device loading may help 
to further minimize the amount of residual solvent. Additionally, near-infrared characterization 
of microinjected membranes on a device showed no significant mixing between membrane and 
64 
substrate materials, indicating that the release time of the reservoirs will be controlled by the 
characteristics of the membrane polymer and not by mixing phenomena. Although some 
variation in device thickness and corresponding reservoir opening diameter occurs as a 
consequence of the fabrication procedure, devices selected for a release experiment typically 
showed on average ±40 µm variation in reservoir diameter. The yield of usable reservoirs on a 
given device is generally between 80–90%, but the yield of microinjected membranes was found 
to vary widely, depending on the size of the reservoir and the polymer from which the membrane 
was made. Overall, the fabrication processes that were developed are applicable for a variety of 
materials, and do not appear to adversely affect the performance of the devices. 
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3 Chemical Loading and Device Sealing 
3.1 Introduction and Motivation 
3.1.1 Introduction 
 The method of microinjection is used to load devices with the chemicals to be released. 
This method is used to load proteins into cells, and can reliably deliver volumes down to 52 pL 
according to the manufacturer of the microinjector. Microinjection has also been used to load 
silicon microreservoir devices similar to these polymeric microreservoir devices1. Microinjection 
allows loading of different chemicals into different reservoirs on an individual basis, unlike other 
filling methods such as discontinuous dewetting2. Inkjet printing may also be used to load 
individual reservoirs with different chemicals, but the solution viscosity and composition 
strongly affect the volume of solution that is delivered from the inkjet printhead1. The accuracy 
of the microinjector, however, is also dependent on several factors that may vary according to 
the chemical that is loaded into the reservoirs. 
 A variety of methods are available for sealing the polymeric microreservoir devices. 
While microinjection of a sealant layer on the backside of the devices is most likely not feasible 
due to the complication of depositing the polymer solution on top of the drug within the reservoir, 
other methods may be considered. Solvent or ultrasonic bonding of thin polymer films to the 
backside of the device is the most obvious method. Ultrasonic bonding has been widely used in 
wire bonding, but has also been studied for application to plastic parts3, as has solvent bonding4. 
Ultrasonic welding, however, may generate heat within the polymer5–7 which could be 
detrimental to the drugs loaded in the microreservoir device, while solvent welding raises the 
issue of residual solvent, as discussed in section 2.1.2.  
3.1.2 Motivation 
A number of factors may affect the performance of the microinjector and therefore the 
amount of drug that is loaded into the reservoirs. Both the solvent in which the drug is dissolved 
and the geometry of the surface onto which the solution is microinjected may affect the volume 
of solution that is delivered from the microinjector. Therefore, the goal of the microinjector 
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studies reported here was to quantify the effect of these variables on the microinjector 
performance in order to determine whether or not their effect on the amount of drug loaded into 
the device was significant. This will enable accurate quantitation of the device performance later 
on, as typically it is desired to achieve mass balance (ideally 100% of the initial loading should 
be detected as released from the device) over the course of a release experiment.  
Similarly, it is vitally important for the sealing method to produce a hermetic seal on the 
devices. Should this seal fail or leak, device performance cannot be confidently assessed. 
Leakage or breakage of the seal would make it impossible to determine if a detected release from 
a device was due to opening of the reservoir membranes or simply failure of the seal. The goal of 
the sealing experiments discussed below was therefore to ascertain whether the sealing method 
used was robust (no diffusion, leakage, or breakage) over the course of a typical release 
experiment. 
3.2 Materials and Methods 
3.2.1 Materials 
Poly(L-lactic acid) (PLA, Mw 194 Kilodaltons (Kd), Medisorb® 100 L) was obtained 
from Alkermes (Cincinnati, Ohio). Fluorescein-dextran, Mw~70,000 daltons, was obtained from 
Molecular Probes (Eugene, OR). Fluorescein sodium salt and 14C-dextran were obtained from 
Sigma-Aldrich (St. Louis, MO). 14C-iodoantipyrine was obtained from Perkin Elmer Life 
Sciences (Boston, MA). Ideal 9144 Masking Tape was obtained from American Biltrite, Inc. 
(Lowell, MA). 
3.2.2 Methods 
3.2.2.1 Reservoir Filling 
Reservoirs on devices were loaded with a solution of the chemical to be released via 
microinjection. Microinjection was performed using a system purchased from World Precision 
Instruments (Sarasota, FL), consisting of a UMP-1 Ultra Micro Pump with a Micro-4 controller, 
Kite-R micromanipulator with a TB-1 tilting base and 5464 five pound weight for the tilting base, 
and a PZMT Trinocular stereo microscope with 13338 Adapter Ring Light, R-8-8-WPI01 fiber 
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optic ring light, and NOVA Novaflex fiber optic light source. The experimental setup is shown 
in Figure 3.1.  
 
Figure 3.1 Experimental setup used for microinjection. The device to be loaded is placed on the stage of the 
stereomicroscope, and the chemical is loaded into the reservoirs from a syringe that is seated in a micromanipulator 
that can be tilted to allow optimal positioning of the needle tip. Photo by Rebecca Shawgo. 
Solutions were injected from a variety of gastight syringes and needles. Typically ten, 50, 
or 100 µL syringes were used with gastight needles (all items from Hamilton Company, Reno, 
NV).  
3.2.2.1.1 Effect of Solvent 
One factor that may affect the microinjected volume is the solvent in which the drug 
solution is prepared. Evaporation of the solvent due to its vapor pressure may cause a decrease in 
the volume of the droplet at the end of the needle, and a corresponding increase in the 
concentration of the droplet. Additionally, the concentration of the drug in the solution that 
resides locally at the needle tip may also increase. Microinjection of radiolabeled solutions 
having different solvents was performed in order to determine the effect of vapor pressure on the 
measured microinjected amounts of radiolabeled chemicals. 
Solutions of 14C-iodoantipyrine (in ethanol) and 14C-dextran, Mw~70,000 (in water) were 
injected into 7-mL glass scintillation vials. Five mL of ScintiSafe Plus, 50% (Fisher Scientific, 
Atlanta, GA) were added to each vial. The amount of radiolabel in each vial was quantified using 
a 14C counting protocol on a Packard Tri-Carb liquid scintillation counter, Model U2200. Raw 
data (disintegrations per minute, DPM) were converted to microcuries (µCi) by using the 
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conversion factor 2.2 × 106 dpm = 1 µCi. The measured µCi value was then divided by the 
concentration, in µCi/mL, of the injected stock solution (Cinit) to give the measured microinjected 
volume (Vmeas) as follows: 
 


 ×


 ×
=
init
meas
C
Ci
dpm
DPMV
µ
6102.2
 
Equation 3-a 
The small size of the solution droplets (typically 20 to 150 nL) may cause the vapor 
pressure to be changed by the droplet curvature. The vapor pressure of a solvent over a curved 
surface can be calculated from the Kelvin Equation8: 
 
m
m
R
V
P
PRT γ=



0
ln  
Equation 3-b 
where R = ideal gas constant, T = temperature, P = vapor pressure observed over curved surface, 
P0 = normal vapor pressure of liquid, γ  = surface tension, Vm = molar volume of liquid, and Rm = 
mean radius of curvature of the surface. The evaporation rate, Z (in moles/(m2*sec)), due to the 
vapor pressure can then be found using the equation8: 
 
2
1
2
1 

=
MRT
PZ π  
Equation 3-c 
where P = vapor pressure of the liquid, M = molar mass of the liquid, R = ideal gas constant and 
T = temperature. The number of molecules that evaporate in a given time interval from a droplet 
can be calculated using the results of Equation 3-c as follows: 
 
tSZN AL ××=  
Equation 3-d 
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where NL = number of molecules evaporated in time t (the time between consecutive 
microinjections), SA = surface area of droplet, and Z = evaporation rate as calculated from 
Equation 3-c. These equations were used to determine whether or not the evaporation of the 
different solvents and subsequent increase in solution concentration were predicted to be 
significant under the experimental conditions that were used. 
3.2.2.1.2 Effect of Surface Geometry 
The geometry of the surface onto which the solution is microinjected may also affect the 
accuracy of the microinjector. The interfaces between the liquid solution, solid surface, and 
surrounding air are constrained by Young’s equation8: 
 
( )
LV
SLSV
γ
γγθ −=cos  
Equation 3-e 
where θ = contact angle between liquid and solid surfaces, γSV = surface tension between solid 
and gas (vapor) phases, γSL = surface tension between solid and liquid phases, and γLV = surface 
tension between liquid and gas (vapor) phases. The contact angle of the solution on curved and 
flat surfaces remains the same, but the solution droplet may break off from the needle differently 
for different surface geometries. Put another way, the droplet will break off from the needle tip 
such that the most energetically favorable state (minimized surface free energy) is achieved both 
for the liquid that remains on the needle tip and the liquid that is deposited on the surface of the 
device. This state will be different for liquid deposited in a reservoir compared to liquid 
deposited on a flat surface of the device.  
 In order to determine whether this effect is significant for the microreservoir devices, four 
different chemicals (fluorescein, fluorescein dextran, 14C-dextran, and 14C-iodoantipyrine) were 
injected onto the planar surfaces of poly(lactic acid) device substrates, as well as into the 
reservoirs of the devices. The devices were cut into pieces a few millimeters on a side prior to 
microinjection so that one device could be used for several measurements. A ten µL syringe was 
used to inject the solutions. Injection volumes were 24.87 nL and 99.48 nL (with the exception 
of fluorescein dextran). After microinjection, samples with fluorescent chemicals were placed in 
4.5 mL polystyrene cuvettes along with 3 mL of 1X PBS. Cuvettes were covered with Parafilm 
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M® and gently shaken to allow the fluorescent molecules to dissolve in the saline solution. The 
fluorescence was measured on a PTI spectrofluorometer and the amount of fluorescent molecule 
in each cuvette was calculated using a standard curve. The microinjected volumes were then 
calculated based on the known molarities of the fluorescent stock solutions that were 
microinjected. Device pieces that were microinjected with radiolabeled solutions were placed in 
7-mL scintillation vials. Five mL of ScintiSafe Plus 50% were added to each vial, and the 
amount of radiolabel present in each vial was measured using a 14C counting protocol on a 
Packard Tri-Carb liquid scintillation counter, Model U2200. The microinjected volumes were 
then calculated using the known concentrations of the radiolabel stock solutions. 
3.2.2.2 Device Sealing 
The devices that were used in release studies were sealed using Ideal 9144 Masking Tape 
after microinjection and drying of the chemical solutions within the reservoirs. This procedure 
was performed using the PZMT stereo microscope. Tweezers and scissors were used to cut the 
tape to the appropriate size and affix the tape to the backsides (side opposite the membranes) of 
the devices. A hard object, such as the handle of the scissors or a metal spatula, was used to 
firmly press the tape to the surface of the device and to eliminate any air bubbles that were 
trapped between the tape and the device. The tape was inspected under the microscope to ensure 
that no air bubbles remained. This tape is designed for use in the production of printed circuit 
boards and provides protection from chemicals used in tin/lead stripping and gold finger plating 
operations. 
An experiment was performed to test the stability of the tape used to seal the devices. 
Three unpolished devices (the conical reservoirs penetrated only partially through the substrate, 
as shown schematically in Figure 2.2(b)) with no reservoir membranes were each loaded with 
approximately 0.073 µCi of 14C-dextran (Mw = 70,000). The backsides of the devices were then 
sealed with the 9144 masking tape and the devices were affixed to glass slides for stability. 
Devices were placed in jars containing 20 mL of 1X PBS and magnetically stirred at 
approximately 28–33°C. Samples of 1 mL of the release media were taken once daily, five days 
per week, from each of the jars. Fresh PBS was added back to the jars to replace the media that 
was removed. The media aliquots were assayed on the scintillation counter using a 14C protocol 
to monitor the amount of 14C-dextran that was released from the devices.  
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3.3 Results and Discussion 
3.3.1 Reservoir Filling 
3.3.1.1 Effect of Solvent  
 Two different radiolabeled solutions were microinjected in order to determine the effect 
of solvent vapor pressure on the accuracy of microinjection. A 100 µCi/mL solution of 14C-
iodoantipyrine (Mw = 314, model molecule for carmustine, a chemotherapy drug) in ethanol was 
microinjected into glass scintillation vials. A solution of 50 µCi/mL of 14C-dextran (Mw ~ 
70,000) in water was also microinjected into glass scintillation vials. Prior to injection into a vial, 
at least one injection was performed onto the surface of a glass slide in order to eliminate effects 
from any evaporation that may have occurred in the time that elapsed while switching vials. The 
MICRO4 controller was programmed to deliver 20, 40, 60, 80, 100, or 120 nL of solution. This 
corresponded to 19.57, 39.68, 59.79, 79.98, 99.48, and 119.5 nL injected based on the syringe 
volume of ten µL.  
The measured microinjected volume for each set of injections was calculated according 
to Equation 3-a. The results are shown by the data points and dashed line (least squares fit) in 
Figure 3.2 (14C-iodoantipyrine) and Figure 3.3 (14C-dextran). The solid lines in Figure 3.2 and 
Figure 3.3 indicate the predicted theoretical microinjected volumes that were listed above and 
are based on the microinjector settings, step size, and syringe volume. 
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Figure 3.2 Measured vs. predicted microinjected volume for 14C-iodoantipyrine in ethanol, injected from a ten µL 
syringe: ○ 20 nL injections, □ 40 nL injections, ● 60 nL injections, ■ 80 nL injections, × 100 nL injections, + 120 
nL injections, solid line indicates theoretical predicted microinjected volume, dashed line indicates least-squares best 
fit line to data points. 
The measured microinjected volume for iodoantipyrine samples was typically 20% 
greater than the predicted value (slope of trendline = 1.2080), as can be seen from Figure 3.2. In 
contrast, the measured microinjected volume for the dextran samples was only about 80% of the 
predicted value (slope of trendline = 0.8476), as can be seen in Figure 3.3. At smaller injection 
volumes (20 and 40 nL injections), the measured volume was typically closer to 60% of the 
predicted value. 
75 
0
100
200
300
400
500
0 100 200 300 400 500
Predicted Microinjected Volume (nL)
M
ea
su
re
d 
M
ic
ro
in
je
ct
ed
V
ol
um
e 
(n
L)
R2 = 0.8476
Slope = 0.8283
 
Figure 3.3 Measured vs. predicted microinjected volume for 14C-dextran in water, injected from a ten µL syringe: ○ 
20 nL injections, □ 40 nL injections, ● 60 nL injections, ■ 80 nL injections, × 100 nL injections, + 120 nL 
injections, solid line indicates theoretical predicted microinjected volume, dashed line indicates least-squares best fit 
line to data points. 
The larger measured volume seen for the 14C-iodoantipyrine samples may be due to 
solvent evaporation and consequent concentration of the solution in the local area of the needle 
tip. The vapor pressures for ethanol and water droplets of various volumes at 20°C (270°K) were 
calculated according to Equation 3-b, neglecting solute effects. The results are shown below in 
Table 3-1. The curvature due to the small droplet sizes does not appear to cause a large change 
in the vapor pressure of the two solvents at the temperature and volumes of interest.  
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Table 3-1 Vapor pressures at 270°K of ethanol and water for various droplet sizes. 
Solvent Data Vinj (nL) Rm (mm) P (kPa)
P o  = 7.87 kPa 19.57 0.16717349 7.8700274
γ  = 22.39 dyn/cm 39.68 0.21158962 7.8700217
M w  = 46.0688 g/mol 59.79 0.24257534 7.8700189
ρ  = 0.789 g/cm3 79.98 0.26727865 7.8700171
V m  = 58.3888 cm
3/mol 99.48 0.28744123 7.8700159
T  = 270°K 119.5 0.30555761 7.8700150
P o  = 3.2 kPa 19.57 0.16717349 3.2000113
γ  = 72.94 dyn/cm 39.68 0.21158962 3.2000089
M w  = 18.0152 g/mol 59.79 0.24257534 3.2000078
ρ  = 0.995 g/cm3 79.98 0.26727865 3.2000070
V m  = 18.1057 cm
3/mol 99.48 0.28744123 3.2000065
T  = 270°K 119.5 0.30555761 3.2000062
Ethanol
Water
 
 The vapor pressures shown in Table 3-1 can be used along with Equation 3-c and 
Equation 3-d to calculate the number of solvent molecules that evaporate in a given period of 
time. The adjusted concentration of the solute can then be calculated based on the remaining 
volume of solvent. This calculation was performed for the injected volumes listed in Table 3-1, 
assuming a temperature of 270°K and estimating an elapsed time of three seconds between 
microinjections. The results are summarized in Table 3-2 below. 
Table 3-2 Concentrations of solutions of 14C-iodoantipyrine in ethanol and 14C-
dextran in water adjusted for solvent evaporation due to curvature of droplets. 
Adjusted
Solution Vinj (nL) P (kPa) Concentration (µ Ci/mL)
19.57 7.870027417 100.0009365
39.68 7.870021662 100.0007399
59.79 7.870018895 100.0006454
79.98 7.870017148 100.0005857
99.48 7.870015945 100.0005446
119.5 7.870015 100.0005123
19.57 3.200011261 50.00009441
39.68 3.200008897 50.00007459
59.79 3.200007761 50.00006506
79.98 3.200007044 50.00005905
99.48 3.20000655 50.00005491
119.5 3.200006161 50.00005165
14C-
iodoantipyrine in 
ethanol
14C-dextran in 
water
 
The evaporation rate and corresponding increased concentrations of the droplets do not 
appear significant at these short times. The most obvious reason for this is that the vapor pressure 
calculations do not account for the continuing decrease in the size of a given droplet due to 
evaporation. As the droplet shrinks, the vapor pressure will increase, thereby further increasing 
the vapor pressure and hence the evaporation rate.  
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The simplifying assumption of a pendant droplet at the needle tip seems to be justified. In 
actuality there is no pendant drop and the solution simply fills the shaft of the needle up to the tip. 
The needle shaft has a smaller inner diameter (0.13 mm) than the droplets assumed in our 
calculations. This does not appear to significantly affect the calculated results, however. By 
using R = 0.13 mm in Equation 3-b, Equation 3-c, and Equation 3-d, the calculated adjusted 
concentrations are only 100.000936458 µCi/mL for 14C-iodoantipyrine in ethanol, and 
50.000096227 µCi/mL for 14C-dextran in water, which are quite similar to the values obtained 
for the 19.57 nL injections shown in Table 3-2.  
The calculated concentrations due to evaporation of the solvents do not fully explain the 
20% increase in activity measured for the 14C-iodoantipyrine samples. Additionally, the 14C-
dextran samples showed a lower measured activity than is expected, with a correspondingly 
smaller measured microinjected volume. One possible reason for this is that the temperature at 
the tip of the needle may be higher than the 270°K that was used in the calculations. The 
fiberoptic light source used with the stereomicroscope generates a noticeable amount of heat on 
the stage of the microscope, and the metal surface of the needle may act as a conductor of that 
heat. This would affect the vapor pressure of the ethanol solution to a greater degree than that of 
the water, as can be seen from Equation 3-b, perhaps further concentrating the solution than is 
indicated by Table 3-2. 
The discrepancies in observed microinjected activities and calculated adjusted solution 
concentrations may also be partially explained by the surface tensions of the two solvents. First, 
the surface tension values may actually be lower than those used to calculate P and the adjusted 
concentrations in Table 3-1 and Table 3-2, as we assumed the experimental setup was at 270°K 
and this may not be entirely accurate, as discussed above. Secondly, ethanol has a much lower 
surface tension at room temperature than water. The lower surface tension of the ethanol solution 
compared to water may have caused the ethanol solution to more fully wet the glass surface of 
the scintillation vial than the dextran solution. Slight bleeding of the solution from the 
microsyringe needle when it was touched to the surface of a glass slide has been observed in 
other studies in which ethanol solutions were used. Therefore, possible bleeding of the ethanol 
solution in this study may account for some of the observed increase in measured activity and 
microinjected volume compared to the predicted microinjected volume. Additionally, the 
presence of dextran in the water solution, while not exceedingly high, slightly increases the 
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viscosity (due to the high molecular weight chains) and thus the wetting angle of the solution on 
the surface of the glass scintillation vials into which the solutions were microinjected. The 
dextran solution may therefore have wetted the glass surfaces less than expected, resulting in a 
lower measured microinjected volume than expected.  
3.3.1.2 Effect of Surface Geometry 
A series of experiments was performed to determine the effect of surface geometry on the 
measured microinjected volume. Four different chemicals (fluorescein, fluorescein dextran, 14C-
dextran, and 14C-iodoantipyrine) were injected onto the planar surface of poly(lactic acid) 
devices, as well as into the reservoirs of the devices. Injection volumes were 24.87 nL and 99.48 
nL (with the exception of fluorescein dextran). As shown in Table 3-3 and Table 3-4, the 
measured microinjected volumes on the surfaces of the devices were consistently larger than for 
injections into the reservoirs of the devices, with the exception of the 24.87 nL fluorescein 
injections. Additionally, the error (as indicated by the percentage of predicted volume that was 
measured) was larger for the 24.87 nL injections than for the 99.48 nL injections.  
Table 3-3 Measured volume of fluorescein, fluorescein-dextran, 14C-iodoantipyrine, and 14C-
dextran solutions microinjected onto the surface of PLA device substrates, calculated using 
concentrations of microinjected solutions. 
Predicted Average Standard % of Predicted
Microinjected Measured Deviation Volume 
Volume (nL) Volume (nL) (nL) Measured
surface 24.87 28.27 4.05 113.67
surface 99.48 108.45 14.55 109.02
fluorescein dextran surface 24.87 16.77 4.98 67.42
surface 24.87 33.43 1.52 134.41
surface 99.48 120.32 6.37 120.95
surface 24.87 30.99 7.93 124.62
surface 99.48 86.09 25.52 86.54
Chemical Type of injection
fluorescein
14C-iodoantipyrine
14C-dextran
 
Table 3-4 Measured volume of fluorescein, fluorescein-dextran, 14C-iodoantipyrine, and 14C-
dextran solutions microinjected into reservoirs in PLA device substrates, calculated using 
concentrations of microinjected solutions. 
Predicted Average Standard % of Predicted
Microinjected Measured Deviation Volume 
Volume (nL) Volume (nL) (nL) Measured
reservoir 24.87 33.20 2.34 133.48
reservoir 99.48 80.01 61.22 80.42
fluorescein dextran reservoir 24.87 14.43 12.33 58.00
reservoir 24.87 23.63 5.26 95.00
reservoir 99.48 91.25 12.69 91.73
reservoir 24.87 28.11 1.38 113.02
reservoir 99.48 67.73 20.39 68.08
Type of 
injection
fluorescein
14C-iodoantipyrine
14C-dextran
Chemical
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The lower average volumes measured for the dextran solutions (both fluorescein and 14C 
labeled) compared to the measured volumes of the fluorescein and 14C-iodoantipyrine solutions 
are consistent with the hypothesis presented in section 3.3.1.1 that the dextran solutions have a 
higher viscosity and therefore do not wet the surface as thoroughly as the lower viscosity 
solutions of smaller molecules.  
One possible explanation for the difference in results seen for the surface and reservoir 
topographies may be the minimization of surface free energy. In the case of the planar surface, 
the microinjected solution will form a spherical section on the surface of the device. This droplet 
will have only one surface in contact with air. The droplet that is microinjected into the reservoir, 
however, will form a conical frustum that has menisci instead of planar bases. This volume has 
two surfaces in contact with air. If we assume that it is more energetically favorable for the 
solution to form an interface with the polymer surface than with air, then it seems logical that the 
frustum is overall a less energetically favorable configuration than the spherical section, as it has 
two air-solution interfaces. When considering the surface free energy of the two systems as a 
whole (solution droplet on needle tip and droplet on polymer surface), the energetic minimum 
for the system with the conical frustum shape must necessarily require leaving a larger droplet 
remnant on the needle tip (in order to minimize the surface free energy of the system) than in the 
case of the spherical section on the planar surface. 
Another possible explanation for the observed results is that there may be some residue 
within the reservoirs that is hydrophobic or otherwise unsuitable for wetting of the chemical 
solutions. More specifically, it is possible that some of the surface-functionalized fluorocarbon 
moieties (see section 2.2.2.1.2) detached from the aluminum mold during compression-molding 
of the device, and adhered to the inner walls of the reservoirs. This could make the reservoir 
walls more repulsive to the chemical solutions, leading to behavior that is more beading or 
nonwetting in nature. 
 Although the 24.87 nL injections of fluorescein show a larger measured volume for 
microinjections into the reservoir than on the planar surface of the device, the average measured 
volumes for surface and reservoir injections are within two standard deviations of each other. 
Therefore, this result does not seem significantly different from the trend shown by the other 
solutions. 
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 As was discussed in section 3.3.1.1, evaporation of the solvent from the needle tip may 
affect the accuracy of the microinjector. This may also account for the fact that the 24.87 nL 
injections showed a consistently larger measured percentage of predicted volume than the 99.48 
nL injections. The vapor pressure effects discussed above are more significant for smaller 
droplets and might cause greater concentration of the solution, which would appear as a greater 
measured percentage of predicted volume (“overinjected volume”) compared to the larger 
droplets. Devices prepared for in vitro and in vivo release studies (presented in Chapters 4 and 9) 
were always filled with at least one injection of 90 nL or greater. Thus we would expect the 
device loading to be closer to the predicted amount than was seen for the smaller injections of 
24.87 nL in this study. 
 Overall, the injections on the planar surfaces of the devices were on average 108% of the 
predicted volume, while the injections in the reservoirs were on average 91% if the predicted 
volume. While greater accuracy will be desired when loading devices for clinical use in a patient, 
the microinjection method provides a relatively easy and rapid way to load the microreservoir 
devices with small volumes of solution. 
3.3.2 Device Sealing 
A control experiment was performed to test the stability of the tape used to seal the 
devices. The results are shown in Figure 3.4. 
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Figure 3.4 Cumulative percentage of initial loading of 14C-dextran detected over 100 days from three unpolished 
control devices that had no reservoir membranes and that were sealed with 9144 masking tape. Note y-axis 
maximum is 5%. 
 The experiment indicated that a maximum of 0.5% of the total initial loading of 
approximately 0.073 µCi of 14C-dextran (Mw = 70,000) was detected over 100 days from three 
unpolished PLA microchips having no membranes and having eight reservoirs loaded with 14C-
dextran. This suggests excellent stability of the seal under typical conditions and durations 
experienced during an in vitro release experiment. 
3.4 Conclusions 
The studies presented here clearly show that the microinjection method that is used to load 
the devices with chemicals is affected by several variables. The solvent vapor pressure and 
surface tension appear to affect the microinjected volume, with larger microinjected volumes 
measured for a solvent (ethanol) having high vapor pressure and low surface tension. 
Additionally, the geometry of the surface onto which the solutions are microinjected also appears 
to affect the measured microinjected volume, with larger amounts of solute measured for a given 
volume microinjected onto a planar surface as compared to into a reservoir, possibly due to 
wetting and minimization of surface free energy. However, as will be seen in Chapter 4, in 
general the amount of drug loading recovered from a given device over the course of a release 
study was relatively high (80–100% for 14C-dextran and 3H-heparin). 
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 While these effects may simply be a nuisance for lab-scale production of in vitro 
prototypes, they become critical issues when considering scale-up for commercial production 
and end-stage clinical use. A more accurate, reproducible loading process is clearly needed in 
order to enable accurate dosing and quantitative recovery of drugs from the microreservoir 
device. 
 The technique that is used to seal the devices appears to be robust. Only 0.5% of the 
radiolabeled loading in test devices was detected after 100 days in saline solution at room 
temperature in vitro. While ultimately a completely sterile and hermetic sealing method will need 
to be developed for devices that will be used in vivo, the masking tape used for these studies 
appears to more than adequately fulfill the current performance requirements (no breakage, 
leakage, or diffusion). 
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4 In Vitro Release Experiments 
4.1 Introduction and Motivation 
Although a number of polymeric controlled drug delivery systems have been developed, 
tested, and commercialized, many of these devices can deliver only one or possibly two doses of 
drug. Additionally, pulsatile release from polymeric devices has traditionally been difficult in the 
absence of an externally applied stimulus, and thus most devices rely on stimuli such as 
ultrasound1,2, a change in pH3–5, temperature6,7, analyte concentrations8,9, and electric10–12 or 
magnetic13,14 fields to trigger drug release. Therefore, the goal of the experiments described here 
was to demonstrate the feasibility and reproducibility of achieving multiple pulsatile releases of 
model drugs from the polymeric microreservoir devices, without the application of a stimulus. 
We tested both single and double chemical releases to demonstrate the versatility of the device 
through multidosing. 
4.2 Materials and Methods 
4.2.1 Materials 
Poly(L-lactic acid) (PLA, Mw 194 Kilodaltons (Kd), Medisorb® 100 L), poly(glycolic 
acid) (PGA, Medisorb® 100 PGA) and poly(D,L-lactic-co-glycolic acid) polymer powders of 
molecular weights (Mw) 4.4 Kd (PLGA4.4, Medisorb® 5050 DL 1A), 11 Kd (PLGA11, 
Medisorb® 5050 DL 2A), 28 Kd (PLGA28, Medisorb® 5050 DL 3A), and 64 Kd (PLGA64, 
Medisorb® 5050 DL 4A) were obtained from Alkermes (Cincinnati, Ohio). 14C-carmustine (1,3-
bis(2-chloroethyl)-1-nitrosourea, or BCNU) was purchased from Moravek Biochemicals (Brea, 
CA). 14C-iodoantipyrine (14C-IAP) was obtained from New England Nuclear (Boston, MA). 14C-
methylated dextran, Mw 70,000, was purchased from Sigma-Aldrich (St. Louis, MO). 125I-human 
growth hormone (125I-HGH), 125I-Interleukin-2 (125I-IL-2), and 3H-heparin, sodium salt, were 
purchased from Perkin Elmer Life Sciences (Boston, MA). ScintiSafe Plus 50% was purchased 
from Fisher Scientific (Suwanee, GA). Ideal 9144 Masking Tape was obtained from American 
Biltrite, Inc. (Lowell, MA).  
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4.2.2 Selection of Release Chemicals 
A number of factors were considered when selecting chemicals for these in vitro proof-of 
principle release studies. The small size of the reservoirs on the device (typically 120-130 nL) 
necessitates the use of a marker molecule that can be accurately quantitated at low concentrations 
in the aqueous release solution. While fluorescent markers are extremely attractive in this regard, 
with detection possible at concentrations as low as 0.1 nmol/L when using a spectrofluorometer, 
the instability of many common fluorescent labels makes them less than ideal for release studies 
that are longer than a few days. Photobleaching may become significant when precautions are 
not taken to isolate the experimental apparatus from ambient light (see Appendix A), which will 
make accurate quantitation of the released loading (as a percentage of the initial loading) quite 
difficult. Sodium fluorescein, which is widely used as a marker molecule and was used to 
quantitate microinjector performance (see Chapter 3), not only photobleaches but also has pH-
dependent fluorescence. This makes it even more problematic for release studies from the 
polymeric microreservoir devices, as the degradation of the devices will generate acidic 
degradation products (see Chapter 5 for a more thorough discussion of the degradation processes 
of the PLGA membrane materials). Although buffered saline is typically used in vitro for release 
experiments, the pH change due to these acidic moieties can be significant over the course of a 
typical in vitro release experiment (see section 5.3.2), and this could affect the measured amount 
of fluorescence during the course of a typical release study. 
Radiolabeled chemicals are a much more attractive alternative than fluorescently labeled 
chemicals for two reasons. First, the sensitivity of the detection method combined with the high 
specific activity of the molecules allows detection resolution in the range of tens of nanograms. 
For example, the 14C-dextran that was used in vitro for release studies had a specific activity of 
1.09 mCi/g (1090 µCi/mg) and a molecular weight of 70,000 g/mol. Assuming that the 
scintillation counter measures a background of approximately 25 disintegrations per minute 
(dpm), even 100 dpm in a 1 mL sample could easily be detected. Using the conversion factor of 
2.2 × 106 dpm/µCi, we find that this corresponds to a concentration of: 
 
( )( )( ) ( )( ) LnmolLmolggCiCidpm molnmoldpm /5957.0001.0/000,70/1090/102.2 /1011006
9
=××××
××
µµ  
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This detection limit compares favorably with that of the spectrofluorometer. 
 The second advantage of using radiolabeled molecules is that the change in activity over 
time can easily be quantified, unlike the changes in fluorescence due to photobleaching or pH. 
The half-life of the isotope (14C, 3H, or 125I) can be used to determine the fraction of activity 
present after a specified amount of time has elapsed since the original concentration was assayed 
by the manufacturer. In the case of 14C (t1/2 = 5730 years) and 3H (t1/2 = 12.3 years) labeled 
moieties, decay is insignificant over the course of a typical release experiment (a few weeks to 
months). Although 125I has a much shorter half-life (t1/2 = 60 days), the raw data obtained from 
the scintillation counter (dpm) can quickly be corrected for decay and the amount of material 
released from a microreservoir device can be accurately quantitated. 
 The particular molecules that were used in these studies were selected based on a number 
of criteria. IL-2 and BCNU were selected due to their utility in chemotherapy. BCNU is 
currently used to treat glioblastoma mutiforme, a type of brain cancer15,16. Preliminary results 
from other studies in animals have shown efficacy of IL-2 in treating cancer17–19. Therefore, it 
might be of interest to deliver these molecules in a pulsatile manner. 14C-iodoantipyrine was 
initially used in our release studies as a model chemical for BCNU, as they have similar 
molecular weights (214 for BCNU, 314 for iodoantipyrine) and partition coefficients (this is 
discussed in more detail in Chapter 6). Human growth hormone and heparin were both selected 
due to their biological activity, as well as because of an interest in trying to deliver both proteins 
and polysaccharides in a pulsatile fashion over extended periods of time from the microreservoir 
device. Dextran was selected as a model molecule due to the variety of molecular weights (later 
release studies in Chapter 7 look at the effect of drug molecular weight on the release 
characteristics from the devices) and labels (14C and various fluorescent markers) that are 
available from chemical suppliers. 
4.2.3 Methods 
4.2.3.1 Device Fabrication 
Devices were fabricated according to the procedures described in Chapter 2. Membranes 
were prepared in the reservoirs by injection of four different PLGA polymers in 1,1,1,3,3,3-
hexafluoro-2-propanol solutions (12% by volume), as described in Chapter 3. The properties of 
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the polymers that were used are summarized in Table 4-1 below. These polymers were chosen as 
suitable reservoir membrane materials based on previous release experiments (results not 
reported here) that used polymers having various molecular weights and ratios of lactic 
acid:glycolic acid as the membrane materials. Additionally, reports in the literature have shown 
that copolymers having a 50:50 ratio of lactic acid:glycolic acid have the fastest degradation 
rates20,21, and therefore they were deemed appropriate for proof-of-principle release studies in 
vitro. 
Table 4-1 Molecular weights, copolymer mole ratios, and approximate degradation times reported by the 
manufacturer for the PLGA4.4, PLGA11, PLGA28, and PLGA64 poly(lactic-co-glycolic acid) copolymers used to 
make the reservoir membranes on the microreservoir devices. 
Polymer  
designation 
Mw L:G mole
ratio 
Chain  
End Group
Degradation time  
in vitro at 37°C 
PLGA4.4 4,400 51:49 -COOH 1-2 weeks 
PLGA11 11,000 53:47 -COOH 2-3 weeks 
PLGA28 28,000 54:46 -COOH 3-4 weeks 
PLGA64 64,000 54:46 -COOH 3-4 weeks 
 
Solutions of PLGA4.4, PLGA11, PLGA28, and PLGA64 were used to make four 
different types of membranes in each device. Solutions were injected from a 1710RN 100 µL gas 
tight glass syringe with a 1" 31 gauge removable needle, blunt tip (part numbers 81030 and 
0160831, both items from Hamilton Co., Reno, NV).  
All reservoir membranes were designed to be approximately 150 µm thick in this study. 
The volume of membrane solution injected into each device varied due to the slight variations in 
thickness of the device and size of the reservoir openings. The volume of solution injected into 
each reservoir was calculated from the volume fraction of polymer in the solution, the specific 
geometry of each device, and the desired membrane thickness.  
The devices were dried in a vacuum oven at 71–74°C and 6.7 kPa vacuum for 
approximately 48 hours after microinjection of the membrane solutions, with the exception of 
devices loaded with 14C-iodoantipyrine. These devices had PLGA28 and PLGA64 membranes 
that were dried at 68°C for 16 hours, and PLGA4.4 membranes that were subsequently dried at 
room temperature for five days. Devices were suspended on glass slides so that the truncated 
ends of the reservoirs in which the membranes were located faced the bottom of the vacuum 
oven, but were not touching the surface of the oven. The membranes were inspected for defects 
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after drying (such as air bubbles and pinholes) at 80X magnification using a PZMT Trinocular 
stereo microscope with 13338 Adapter Ring Light, R-8-8-WPI01 fiber optic ring light, and 
NOVA Novaflex fiber optic light source. Reservoirs having defect-free membranes were 
considered viable for use in release experiments, and selected reservoirs were loaded with the 
chemical(s) to be released.  
The chemical solutions were allowed to dry in the reservoirs for approximately 24 hours 
at room temperature and pressure. The devices were sealed opposite the membranes and attached 
to glass microscope slides for stability with Ideal Masking Tape 9144. 
4.2.3.2 In Vitro Release Studies 
4.2.3.2.1 Single Chemical Release Studies 
Devices were microinjected with solutions of 14C-dextran, 3H-heparin sodium salt, 125I-
HGH, 125I-IL-2, 14C-BCNU, or 14C-IAP for release studies. The specific activities of the 
radiolabeled molecules, amount of drug loaded into the devices, and membrane materials and 
thicknesses are summarized in Table 4-2 below. The maximum loading for these microreservoir 
devices is approximately 125 nL, or 125 µg for a drug having an approximate density of 1 g/mL. 
However, the device reservoirs were not completely filled with drug in these studies, as device 
loadings were selected based on the minimum amount of activity (µCi) required to be above the 
detection sensitivity of the scintillation counters. Multiple injections of smaller volumes were 
performed in cases where the volume of microinjected solution was larger than the volume of the 
reservoir (120–130 nL), allowing time in between injections for the solution to dry (evaporation 
of the solutions could be observed through the microscope when loading devices). 
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Table 4-2 Experimental parameters for in vitro release devices loaded with one of 14C-dextran, 3H-heparin, 125I-
HGH, 125I-IL-2, 14C-BCNU, or 14C-IAP. 
 
Device #’s Radiolabel 
Specific 
Activity of 
Radiolabeled 
Molecule 
(µCi/mg) 
Loading 
Per 
Reservoir 
# of 
Reservoirs 
Loaded 
Total 
Loading 
Per Device 
Reservoir 
Membrane 
Materials 
Predicted 
Range 
Of  
Membrane 
Thicknesses 
(µm) 
1–3 14C-dextran 1.09 
9.1 nCi 
8.4 µg 4 
36.4 nCi 
33.4 µg 
PLGA4.4 
PLGA11 
PLGA28 
PLGA64 
153–155 
4–6 3H-heparin 320 
18.0 nCi 
0.06 µg 4 
72.0 nCi 
0.23 µg 
PLGA4.4 
PLGA11 
PLGA28 
PLGA64 
150–155 
7–9 125I-HGH 91023 
8.8 nCi 
9.7 × 10-5 µg 4 
35.0 nCi 
3.8×10-4 µg 
PLGA4.4 
PLGA11 
PLGA28 
PLGA64 
153–154 
10–13 125I-IL-2 36600 
9.6 nCi 
2.6 × 10-4 µg 4 
38.5 nCi 
1.1×10-3 µg 
PLGA4.4 
PLGA11 
PLGA28 
PLGA64 
152–153 
14–17 14C-BCNU 293 
9.2 nCi 
0.03 µg 4 
36.6 nCi 
0.12 µg 
PLGA4.4 
PLGA11 
PLGA28 
PLGA64 
151–153 
18–21 14C-IAP 161 
17.9 nCi 
0.11 µg 3 
53.8 nCi 
0.33 µg 
PLGA4.4 
PLGA28 
PLGA64 
145–156 
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Each device was placed in a screw-cap jar containing 20 mL stirred 1X phosphate-
buffered saline (PBS) at 28–33°C after drying and sealing. One mL samples of the medium were 
pipetted from the jars twice daily, at eight- and sixteen-hour intervals, and fresh PBS was added 
to the release vessels to replace the volume of solution removed. 14C-dextran, 3H-heparin, 125I-
IL-2, 14C-BCNU, and 14C-IAP samples were pipetted into 7-mL glass scintillation vials, and five 
milliliters of Fisher Scientific ScintiSafe Plus 50% scintillation cocktail were added to each vial. 
The samples were analyzed on a Packard Tri-Carb liquid scintillation counter, Model U2200, 
using a 125I, 14C or 3H counting protocol. 125I-HGH samples were pipetted into 13 mm culture 
tubes, capped, and analyzed on a Packard Cobra II Auto Gamma scintillation counter.  
4.2.3.2.2 Double Chemical Release Studies 
Devices were loaded using the same procedure as described for the single chemical 
studies in the section above. Three devices were loaded with both 125I-HGH and 14C-dextran, 
while four devices were loaded with 3H-heparin and 14C-dextran. Experiments were conducted at 
28–33°C. Representative results will be presented below for two devices from each batch. Table 
4-3 below summarizes the experimental matrix for the devices that will be discussed. Release 
media samples were analyzed on a Packard Tri-Carb liquid scintillation counter, Model U2200 
using double label protocols to count both 14C and 3H. Devices loaded with 125I-HGH and 14C-
dextran had two one-milliliter media samples removed and replaced at each time point. One 
sample was pipetted into a 7-mL glass scintillation vial and analyzed on the Packard Tri-Carb 
liquid scintillation counter, Model U2200 using a 14C counting protocol, while one sample was 
pipetted into a 13 mm culture tube, capped, and analyzed on a Packard Cobra II Auto Gamma 
scintillation counter to quantify the 125I label present. 
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Table 4-3 Experimental parameters for in vitro release devices loaded with 125I-HGH and 14C-dextran, or 3H-heparin 
and 14C-dextran. 
 
Device #’s Radiolabel 
Specific 
Activity 
Of 
Radiolabeled 
Molecule 
(µCi/mg) 
 
Loading  
per 
Reservoir 
# of 
Reservoirs 
Loaded 
Total 
Loading 
Per 
Device 
Reservoir 
Membrane 
Materials 
Predicted 
Range 
Of 
Membrane 
Thicknesses 
(µm) 
125I-HGH 91023 
8.8 nCi 
9.6×10-5 µg 
2 
17.5 nCi 
1.9×10-4 µg 
PLGA4.4 
PLGA28 
151–152 
22 
14C-dextran 1.09 
9.1 nCi 
8.3 µg 
2 
18.2 nCi 
16.7 µg 
PLGA11  
PLGA64 
151–152 
125I-HGH 91023 
8.8 nCi 
9.6×10-5 µg 
2 
17.5 nCi 
1.9×10-4 µg 
PLGA11 
PLGA64 
149–150 
23 
14C-dextran 1.09 
9.1 nCi 
8.3 µg 
2 
18.2 nCi 
16.7 µg 
PLGA4.4  
PLGA28 
149–150 
3H-heparin 320 
18 nCi 
0.06 µg 
2 
36.0 nCi 
0.11 µg 
PLGA4.4 
PLGA28 
152–156 24 
and  
25 14C-dextran 1.09 
9.1 nCi 
8.3 µg 
2 
18.2 nCi 
16.7 µg 
PLGA11 
PLGA64 
152–156 
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4.3 Results and Discussion 
4.3.1 Device Design and Fabrication 
Control over the release times was achieved in this study by varying the molecular weight 
of the materials from which the reservoir membranes were fabricated. Devices were fabricated 
and loaded with chemicals via two compression molding steps, and two microinjection steps, as 
detailed in Chapters 2 and 3. The devices were approximately 11.9 mm in diameter and between 
470 and 645 µm thick (reservoir openings ranged in size from 389 to 259 µm in diameter, 
respectively). Membrane thicknesses (approximately 150 µm) and molecular weights (Mws of 
4,400, 11,000, 28,000, and 64,000 daltons) were chosen which would provide chemical releases 
from the devices over a period of approximately eight weeks, based on results from previous in 
vitro release studies that were performed.  
4.3.2 In Vitro Release Studies 
4.3.2.1 Single Chemical Release Studies 
The objective of initial release experiments was to determine if pulsatile release of a 
single compound could be obtained from the microreservoir device. The following sections 
present the results obtained for devices loaded with one of the following radiolabeled chemicals: 
14C-dextran, 3H-heparin, 125I-HGH, 125I-IL-2, 14C-BCNU, or 14C-IAP. 
4.3.2.1.1 14C-dextran 
The results for the three devices loaded with 14C-dextran are shown in Figure 4.1. The 
first release was detected from the reservoirs having PLGA4.4 membranes on the first day of the 
study. The reservoirs having PLGA11 membranes showed the onset of release between 13 and 
15 days. The reservoirs having PLGA28 membranes showed release between 27 and 34 days, 
followed by the PLGA64 membranes at 30 to 37 days. 
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Figure 4.1 Cumulative percentage of initial 14C-dextran loading released from three devices having PLGA4.4, 
PLGA11, PLGA28, and PLGA64 reservoir membranes in saline solution at 28–33°C in vitro. 
 An interesting point of note is that although the PLGA64 membrane had more than 
double the molecular weight of the PLGA28 membrane (similar to the relation between the 
PLGA11 and PLGA4.4 membrane materials), the separation in release times was not as large as 
that seen for the lower molecular weight membranes. However, this is not a completely 
unexpected result, as the process of random chain scission by which the polymers are hydrolyzed 
and degraded will cause higher molecular weight polymers to end up with broader molecular 
weight distributions and consequent greater variation in the release time. The range of release 
times for the PLGA28 and PLGA64 membrane materials actually overlapped from 30 to 34 
days. Similar results were obtained for the other experiments in this study, as will be discussed 
below. Further characterization of the in vitro degradation of the membrane polymers is 
presented in Chapter 5. All of the devices, however, clearly showed four pulses of 14C-dextran, 
and the total cumulative amounts of loading recovered were 92–99% at 40 days.  
4.3.2.1.2 3H-heparin 
The three devices loaded with 3H-heparin showed similar results to those loaded with 
14C-dextran, both in terms of release times and reproducibility. 
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Figure 4.2 Cumulative percentage of initial 3H-heparin loading released over time from three devices having 
PLGA4.4, PLGA11, PLGA28, and PLGA64 reservoir membranes in saline solution at 28–33°C in vitro. 
The reservoirs having membranes made from PLGA4.4 showed release on the first day 
of the study, followed by the PLGA11 membranes between 16 and 18 days. The reservoirs 
having PLGA28 membranes showed release much later, between 37 and 40 days, followed 
closely by the PLGA64 reservoir membranes at 40–47 days. The total cumulative amount of 
initial 3H-heparin loading detected was 83–89% at 60 days. The slightly lower cumulative 
measured loading may be due to the lower counting efficiency of the scintillation counter for 3H 
as compared to 14C. 
One of the 3H-heparin loaded devices (U symbol in Figure 4.2) did not show separate 
pulses for the reservoirs having PLGA28 and PLGA64 membranes. Additionally, a third device 
(○ symbol in Figure 4.2) showed a prolonged release for the reservoir with a PLGA64 
membrane, from approximately 46 to 56 days. It is not clear why this occurred, and this behavior 
was seldom seen for other large radiolabeled molecules. However, somewhat sustained release 
curves, similar to the curve in question, were seen for smaller radiolabeled molecules, and are 
discussed in sections 4.3.2.1.5 and 4.3.2.1.6 below. 
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4.3.2.1.3 125I-HGH 
The results for three devices loaded with 125I-HGH are shown in Figure 4.3. The first 
release occurred at day one, when the reservoirs having membranes made from PLGA4.4 
opened. Detection of the second release, from the reservoirs having PLGA11 membranes, 
occurred between days six to ten. Greater variation was seen for the reservoirs having PLGA28 
(17 to 22 days) and PLGA64 (20 to 30 days) membranes. The fluctuations in the release curve 
are most likely due to the high gamma radiation background, which decreases the detection 
sensitivity of the scintillation counter. This may also explain the high cumulative total 
percentages of the initial loading that were detected at day 40, which ranged from 108 to 134%. 
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Figure 4.3 Cumulative percentage of initial 125I-HGH loading released over time from three devices having 
PLGA4.4, PLGA11, PLGA28, and PLGA64 reservoir membranes in saline solution at 28–33°C in vitro. 
Overall, however, two out of the three devices showed four distinct pulses of 125I-HGH. 
The third device (U symbol in Figure 4.3) showed a large pulse starting at day 19 that appeared 
to be the release of 125I-HGH from both of the reservoirs having PLGA28 and PLGA64 
membranes. This result is similar to that seen for one of the devices loaded with 3H-heparin, as 
discussed in section 4.3.2.1.2.  
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4.3.2.1.4 125I-IL-2 
The results presented thus far clearly demonstrate the feasibility of using the polymeric 
microreservoir device for multi-pulse delivery of molecules. The possibility of delivering a 
number of other molecules, however, was also tested, based on the considerations presented in 
section 4.2.2. While the studies presented in the next three sections for 125I-IL-2, 14C-BCNU, and 
14C-IAP were not as successful in demonstrating pulsatile release as those previously presented 
for 14C-dextran, 3H-heparin, and 125I-HGH, they are nevertheless important as they illustrate 
some of the limitations of the device, and therefore serve to delineate some of the factors that 
control device performance. 
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Figure 4.4 Cumulative percentage of initial 125I-IL-2 loading released over time from four devices having reservoir 
membranes made from PLGA4.4, PLGA11, PLGA28, and PLGA64 in saline solution at 28–33°C in vitro. 
The cumulative release results for four devices loaded with 125I-IL-2 are shown in Figure 
4.4 above. The release curves for these devices are more similar to those shown in Figure 4.3 for 
125I-HGH than for either the 14C-dextran or 3H-heparin. This is not surprising, as both HGH and 
IL-2 are proteins, with similar molecular weights (~21,500 daltons for HGH, ~15,000 daltons for 
IL-2). The first two releases can be seen quite clearly in Figure 4.4, with the reservoirs having 
PLGA4.4 membranes releasing their contents on the first day of the study, and the reservoirs 
96 
having PLGA11 membranes opening between days four and ten. The releases for the reservoirs 
having the PLGA28 and PLGA64 membranes, however, appear to overlap so significantly that 
there is no discernible separation of the curves into two distinct pulses. This result is no doubt 
partially explained by the similar opening times of the PLGA28 and PLGA64 reservoir 
membranes, as was seen for the other devices in this study (14C-dextran, 3H-heparin, and 125I-
HGH loadings). In the case of 125I-IL-2, however, the apparent merging of the third and fourth 
pulses from these devices may be the result of the fact that IL-2 adsorbs to glass and plastic22. 
Although the jars in which the experiments took place were silanized to prevent surface 
adsorption, the devices themselves, as well as the glass slides to which they were affixed and the 
pipet tips that were used to take the release samples, were not silanized. Therefore, it is likely 
that although there was not significant IL-2 loss due to sticking during the early portion of the 
experiments, at later times the amount lost may have become significant. This hypothesis is 
consistent with the clear pulses seen from the reservoirs having PLGA4.4 and PLGA11 
membranes, as well as the lack of clear pulses from the reservoirs having PLGA28 and PLGA64 
membranes, and the low total amount of 125I-IL-2 detected (<100%).  
4.3.2.1.5 14C-BCNU 
The release results for four devices having PLGA4.4, PLGA11, PLGA28, and PLGA64 
reservoir membranes and loaded with 14C-BCNU are shown in Figure 4.5 below.  
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Figure 4.5 Cumulative percentage of initial 14C-carmustine (BCNU) loading released over time from four devices 
having PLGA4.4, PLGA11, PLGA28, and PLGA64 reservoir membranes in saline solution at 28–33°C in vitro. 
In contrast to the other data presented thus far, the devices loaded with BCNU showed 
essentially no distinguishable pulses. However, it does not appear that all of the membranes 
opened immediately at the start of the experiment. If this had been the case, we would expect to 
see nearly 100% of the loading detected at day one. The shape of the curve, however, is very 
similar to that characteristic of diffusion curves (∝t1/2). The lipophilicity/hydrophobicity of this 
molecule, combined with its small molecular weight (see the chemical structure in Figure 4.6 
below), may have caused it to partition into and diffuse through the membranes. In fact, studies 
to determine the partition coefficient of this molecule in the membrane polymers (see Chapter 6) 
showed that it does indeed partition into the membranes, albeit less so for the PLGA11, 
PLGA28, and PLGA64 materials than for the PLGA4.4 polymer. Although the partitioning 
coefficient in the higher molecular weight polymers may be less significant than that in the 
PLGA4.4, diffusion of the molecule through the membranes may become more significant at the 
longer times scales on which the higher molecular weight polymers degrade, and this may 
explain the sustained release curve seen in Figure 4.5. 
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Figure 4.6 Chemical structure of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) or carmustine. 
Another factor which may contribute to the atypical release behavior for this chemical is 
that BCNU is known to undergo hydrolysis in aqueous solutions, forming acetaldehyde, 
hydrochloric acid, nitrogen gas, and derivatives of 2-chloroethyl isocyanate23. Although later 
experiments (see Chapter 7) suggest that permeation of water into the reservoirs is minimal prior 
to membrane opening, the presence of some water in the reservoirs may cause degradation of the 
BCNU. Acidic products such as the hydrochloric acid might therefore cause more rapid 
degradation of the membrane materials, but it does not appear that this effect is significant, as the 
time to achieve nearly complete release of the drug from the reservoirs is comparable for these 
devices loaded with BCNU as for the other devices presented in this chapter. 
4.3.2.1.6 14C-IAP 
The release data for four devices having PLGA4.4, PLGA28, and PLGA64 membranes 
and loaded with 14C-IAP are shown in Figure 4.7 below. These experiments were performed 
prior to the others presented here, and as such only three membrane polymers were used on the 
device. A comparison of the curves for 14C-IAP in Figure 4.7 with the 14C-BCNU curves in 
Figure 4.5, however, clearly shows that the kinetics of release are quite similar. A relatively 
larger plateau is evident after the release of 14C-IAP from the reservoirs having PLGA4.4 
membranes, due to the absence of a reservoir with a PLGA11 membrane. The curve assumes a 
diffusion-type shape towards the end of the study, similar to that seen in Figure 4.5 for the 14C-
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BCNU. Similar to BCNU, later experiments (see Chapter 6) determined that this molecule 
partitions into the membrane polymers, which might explain the results seen here. The chemical 
structure of this compound is shown in Figure 4.8 below, and it is clear that the molecule is 
much smaller than the large proteins and polysaccharides that were used in the release studies 
presented previously. Optical microscopy of the devices after completion of the experiment 
showed that all of the reservoir membranes were open or ruptured. 
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Figure 4.7 Cumulative percentage of initial 14C-iodoantipyrine (IAP) loading released over time from four devices 
having PLGA4.4, PLGA28, and PLGA64 reservoir membranes in saline solution at 28–33°C in vitro. 
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Figure 4.8 Chemical structure of iodoantipyrine (IAP). 
The release results seem to indicate that the time and temperature of the drying step in the 
oven do not significantly affect the release characteristics of the device within the sensitivity of 
the analysis. Although the PLGA28 and PLGA64 reservoir membranes on these four devices 
were dried for only 16 hours at 68°C, instead of at 71–74°C for 48 hours as was the case for the 
other devices presented in this chapter, the release profiles of the 14C-iodoantipyrine are quite 
similar to the profiles seen for 14C-BCNU shown in Figure 4.5. Additionally, although the 
PLGA4.4 membranes were not dried under vacuum, as they were microinjected into the device 
after the PLGA28 and PLGA64 reservoirs had been loaded with 14C-IAP, this did not affect the 
release time from the reservoirs, as evidenced by the uniform release from the reservoirs having 
PLGA4.4 membranes at day one in this as well as all of the other in vitro release studies 
presented in this thesis. 
4.3.2.1.7 Discussion 
The initial experiments presented here confirm that it is possible to release up to four 
pulses of a single chemical from the polymeric microreservoir devices. The larger molecules 
(14C-dextran, 3H-heparin, 125I-HGH, and 125I-IL-2) showed release that was more clearly pulsatile 
than the smaller molecules (14C-BCNU and 14C-IAP). The devices loaded with 14C-dextran and 
3H-heparin had on average the best recovery of the initial loading, with 83–99% of the initial 
loading recovered over the course of the study.  
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The release times of the different chemicals are summarized in Table 4-4 below. The 
release times are similar at relatively short elapsed times, but at longer time periods there is more 
variation in the release times of the reservoirs having PLGA28 and PLGA64 membranes for a 
device with a given chemical loading. Additionally, the release times for the reservoirs having 
PLGA28 and PLGA64 membranes showed greater variation when the chemical loading was 
changed than did the reservoirs with PLGA4.4 and PLGA11 membranes. These observations 
indicate that the degradation mechanisms of the membrane polymers are somewhat complex. A 
more in-depth study of the degradation of the membrane polymers is presented in Chapter 5. 
Table 4-4 Average release times ± standard deviations (in days) from reservoirs on devices loaded with one of 14C-
dextran, 3H-heparin, or 125I-HGH and having membranes made from PLGA4.4, PLGA11, PLGA28, and PLGA64. 
  Membrane Polymer 
Device #’s
Molecule  
(single chemical loading expts)
PLGA4.4 PLGA11 PLGA28 PLGA64 
1-3 14C-dextran 1±0 14±1 30±4 33±3 
4-6 3H-heparin 1±0 17±1 38±2 43±3 
7-9 125I-HGH 1±0 8±2 19±2 25±6 
It is unlikely that the difference in release times between the devices loaded with different 
chemicals can be attributed to membrane material or fabrication variation, as the membranes 
were fabricated from the same materials and by the same operator in a single day. Further, the 
injected volume of membrane solution was adjusted to account for small variations in reservoir 
size in an effort to keep the membrane thicknesses constant. The results we obtained therefore 
suggest that the structure and chemistry of the molecules released from the devices may be an 
important component in explaining the disparity in their release times. Others have reported 
differences in release rates for neutral capped amino acids and positively-charged cyclic 
hexapeptides from PLGA microspheres, and have hypothesized that this is due to specific 
interactions between the molecules and the PLGA (adsorption on hydrophobic regions of the DL-
PLGA)24. No effect on release kinetics was seen, however, as a result of changes in the size, 
charge, or conformational flexibility of the model peptides released from the microspheres. 
Evaluation of the interactions between the PLGA membranes and chemicals used in the 
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experiments reported here (as reflected by the partition coefficient), and the effects of molecule 
size on the observed release time and are more fully explored in Chapters 6 and 7, respectively.  
Different molecular weights of PLGA (50:50) with carboxylic acid chain end groups 
were used to control the release time for these initial release experiments of a single compound 
loaded into a device. Changing the end group of the polymer, however, could change the 
degradation rate of the polymers and consequently modulate the release time. For example, in an 
experiment similar to the ones described here, 14C-methylated dextran (Mw 70,000) was released 
from a device having reservoirs with membranes made from the PLGA 50:50 PLGA4.4, 
PLGA11, PLGA28, and PLGA64 polymers. Additionally, one reservoir had a membrane made 
from PLGA 50:50, having a molecular weight of 7,500 daltons and ester end groups 
(PLGA7.5e). This device showed release from the reservoir having a PLGA7.5e membrane 
between the releases of reservoirs having PLGA11 and PLGA28 membranes (data not shown), 
even though the molecular weight of the PLGA7.5e was much smaller than that of the PLGA11 
or PLGA28 polymers. The apparent slower degradation of the PLGA7.5e when compared to the 
PLGA11 membrane is most likely due to the presence of ester end groups on the PLGA7.5e 
chains, which are less reactive and therefore are hydrolyzed more slowly. Although these ester 
groups represent only two bonds in the entire chain, the significantly less electrophilic nature of 
the ester end groups compared to typical carboxylic acid end groups causes the ester end groups 
to act as end caps on the chain, resulting in significantly slower degradation rate of the polymer. 
Other factors that may potentially be changed to tailor the observed release time of chemicals 
from the reservoirs on this device are the thicknesses of the membranes, copolymer composition, 
or membrane materials. 
4.3.2.2 Double Chemical Release Studies 
Subsequent release experiments were performed in order to determine if the independent 
release of multiple compounds from single devices could be achieved, as well as to further 
elucidate the behavior of the PLGA28 and PLGA64 membranes. These devices contained 14C-
dextran and 125I-HGH, or 14C-dextran and 3H-heparin. On each device, a total of four reservoirs 
had PLGA membranes made from PLGA4.4, PLGA11, PLGA28, and PLGA64. In general, 
reservoirs having PLGA11 and PLGA64 membranes were loaded with 14C-dextran, while 
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reservoirs having PLGA4.4 and PLGA28 membranes were usually loaded with either 125I-HGH 
or 3H-heparin. 
4.3.2.2.1 125I-HGH and 14C-dextran 
The release results from a representative device loaded with 125I-HGH and 14C-dextran 
(device 22 from Table 4-3) are shown in Figure 4.9 below. The reservoir having a PLGA4.4 
membrane and containing 125I-HGH showed release at day one. The reservoir having a PLGA11 
membrane and loaded with 14C-dextran opened on day 16. This was followed by the opening of 
the reservoir that had a PLGA28 membrane and that was loaded with 125I-HGH at day 23, and 
finally the reservoir with a PLGA64 membrane that was loaded with 14C-dextran at day 36. 
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Figure 4.9 Cumulative percentages of initial 125I-HGH (×) and 14C-dextran (○) loadings released over time from a 
single device. 125I-HGH released from reservoirs having PLGA4.4 and PLGA28 membranes. 14C-dextran released 
from reservoirs having PLGA11 and PLGA64 membranes. Experiment performed in saline solution at 28–33°C in 
vitro. 
Totals of 102% of the initial 14C-dextran loading and 117% of the initial 125I-HGH 
loading were measured after 45 days. The small plateaus (approximately 3% of the total loading 
for each plateau) in the 14C-dextran curves beginning at days zero and 23, when the 125I-HGH 
pulses occur, suggest a contribution to the 14C counts from the 125I present in the sample. Two 
104 
different scintillation counters were used to measure the 125I (Packard Cobra II Auto Gamma) 
and 14C (Packard Tri-Carb) counts. Although a 14C only counting protocol was used for the 
samples analyzed on the Tri-Carb counter, the 125I isotope emits gamma particles within the 
energy range used to detect the 14C (from 0 to 156 keV). Therefore, the small plateaus in the 14C-
dextran curve starting at days zero and 23 are likely due to the presence of the 125I-HGH in the 
release medium. 
The large percentage of 125I-HGH measured by the Cobra II Auto Gamma may be due to 
the low sensitivity of the scintillation counter at such small measured activities, which were on 
average between 0.1 and 0.2 nCi. The typical measured error was between 7 and 25%, and up to 
40% for samples with readings similar to background. Further, although a standard curve was 
run with each batch of samples that were analyzed, the short half-life (60 days) of 125I may have 
created additional uncertainty at the low activities that were used. 
One out of three of the devices that were loaded with both 125I-HGH and 14C-dextran 
showed release from the reservoir having a PLGA64 membrane earlier than from the reservoir 
having a PLGA28 membrane. The release results for this device (device 23 from Table 4-3) are 
shown in Figure 4.10 below. This device was slightly different than the other two that were 
loaded with both 125I-HGH and 14C-dextran, as the 125I-HGH was loaded into the reservoirs that 
had PLGA11 and PLGA64 membranes, while the 14C-dextran was loaded into the reservoirs 
that had PLGA4.4 and PLGA28 membranes. Therefore, we would expect the order of releases 
to be dextran (from the reservoir with a PLGA4.4 membrane), followed by HGH (PLGA11 
membrane), then dextran again (PLGA28 membrane), and finally HGH again (PLGA64 
membrane). As can be seen in Figure 4.10, however, the order of releases was dextran, then 
HGH, then the second HGH pulse, and finally the second dextran release, clearly indicating that 
the reservoir with the PLGA64 membrane (loaded with HGH) released earlier than the reservoir 
with the PLGA28 membrane (loaded with dextran). 
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Figure 4.10 Cumulative percentages of initial 125I-HGH (×) and 14C-dextran (○) loadings released over time from a 
single device. 125I-HGH released from reservoirs having PLGA11 and PLGA64 membranes. 14C-dextran released 
from reservoirs having PLGA4.4 and PLGA28 membranes. The reservoir having a membrane made from the 
PLGA64 polymer opened earlier than the reservoir having a membrane made from the PLGA28 polymer on this 
device. Experiment performed in saline solution at 28–33°C in vitro. 
Although the PLGA64 polymer has a higher molecular weight than the PLGA28 
polymer, it does not always appear to take a longer time to degrade. It is unlikely that a 
difference in device manufacture, membrane fabrication, or device loading can account for the 
observed result of faster PLGA64 degradation compared to the PLGA28 degradation, as all of 
the devices in this batch (125I-HGH and 14C-dextran loading) were fabricated at the same time 
and in an identical manner. Additionally, analyses performed by the manufacturer to characterize 
the PLGA28 and PLGA64 polymers provide no explanation for the observed behavior. These 
two polymers were nearly identical in chemical composition; both were 54 mole% D,L-lactic 
acid and 46 mole% glycolic acid (confirmed by 1H-NMR analysis), with 1.2% residual D,L-
lactide monomer. The PLGA28 had 0.2% residual glycolide monomer, while the PLGA64 had 
0.1% residual glycolide monomer. Given the nearly identical chemistries of the two polymers, 
we would expect the degradation rates to be controlled by the molecular weights of the two 
materials and that therefore the PLGA64 material would take longer to degrade. However, the 
apparently faster degradation rate of the PLGA64 polymer on some devices could perhaps be 
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explained by differing degrees of monomer block length within the polymer chains. While the 
PLGA polymers used to fabricate the membranes are supposed to be random copolymers 
(alternating, randomly sized blocks of lactic acid and glycolic acid units in the polymer chain 
backbones), the presence of longer blocks of lactic acid or particularly glycolic acid could cause 
the formation of crystallites as the oligomer blocks associate. Crystallites formed from PLA and 
PGA oligomers during the degradation of PLA25–27 and PGA28,29 homopolymers have been 
shown to be quite resistant to further hydrolysis and degradation. Additionally, greater reactivity 
of the glycolic acid during copolymerization has been hypothesized to cause formation of 
glycolide blocks within the copolymer backbone that are separated by single lactide units30. 
Larger monomer block size of the PLGA28 might therefore explain the slower degradation rate 
that is sometimes observed compared to the PLGA64. 
Similar to the release data shown in Figure 4.9, a slight increase in the measured amount 
of 14C-dextran can be seen in Figure 4.10 when the 125I-HGH releases were detected from this 
device, most likely due to the contribution of the 125I radiation to the scintillation counts for the 
14C isotope. The large cumulative amounts of 125I-HGH measured over the course of the study 
may be due to the fact that this device was loaded first out of the three that had both 125I-HGH 
and 14C-dextran. If no test injections were done on a glass slide prior to loading of the first 
device, the solution may have been more concentrated at the needle tip due to evaporation (see 
section 3.3.1.1) and therefore more HGH may have been loaded into the reservoirs than was 
thought. 
4.3.2.2.2 3H-heparin and 14C-dextran 
The release results for a representative device loaded with 3H-heparin and 14C-dextran 
(device 24 from Table 4-3) are shown in Figure 4.11 below. The reservoir that had a PLGA4.4 
membrane and that was loaded with 3H-heparin opened at day one. The reservoir that had a 
PLGA11 membrane was loaded with 14C-dextran, and opened on day 16. The reservoir that had 
a PLGA28 membrane and was loaded with 3H-heparin, showed release on day 33, and the 
reservoir having a PLGA64 membrane and loaded with 14C-dextran showed release on day 38. 
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Figure 4.11 Cumulative percentages of initial 3H-heparin (●) and 14C-dextran (×) loadings released over time from a 
single device. 3H-heparin released from reservoirs having PLGA4.4 and PLGA28 membranes, 14C-dextran released 
from reservoirs having PLGA11 and PLGA64 membranes. Experiment performed in saline solution at 28–33°C in 
vitro. 
Totals of 80% of the initial 3H-heparin loading and 93% of the initial 14C-dextran loading 
were measured after 60 days. Each chemical was released in two almost exactly equal pulses. 
The mathematical method used by the scintillation counter to separate the counts due to each 
isotope, as well as the calibration based on a quench curve, may account for the fact that the 
measured amount of each chemical released is less than 100%. 
Similar to the devices that were loaded with 125I-HGH and 14C-dextran discussed in 
section 4.3.2.2.1, one out of four of these devices loaded with 3H-heparin and 14C-dextran 
showed release from the reservoir having a PLGA64 membrane prior to the release from the 
reservoir having a PLGA28 membrane. The results for this device (device 25 in Table 4-3) are 
shown in Figure 4.12 below. 
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Figure 4.12 Cumulative percentages of initial 3H-heparin (●) and 14C-dextran (×) loadings released over time from a 
single device. 3H-heparin released from reservoirs having PLGA4.4 and PLGA28 membranes, 14C-dextran released 
from reservoirs having PLGA11 and PLGA64 membranes. The reservoir having a membrane made from the 
PLGA64 polymer opened earlier than the reservoir having a membrane made from the PLGA28 polymer on this 
device. Experiment performed in saline solution at 28–33°C in vitro. 
 The release of the 3H-heparin was detected from the reservoir having a PLGA4.4 
membrane at day one, followed by the release of 14C-dextran from the reservoir having a 
PLGA11 membrane at 15 days. The 14C-dextran was released from the reservoir having a 
PLGA64 membrane at 42 days. The 3H-heparin appeared to start releasing from the reservoir 
with a PLGA28 membrane at around 37 days, but a large burst was not seen until 45 days. 
4.3.2.2.3 Discussion 
The release times for these studies showing release of multiple chemicals from single 
devices correlate well with those shown in the initial single chemical studies described in section 
4.3.2.1 above. The average release times for the devices having a single chemical loading are 
reproduced below in Table 4-5 for ease of comparison with the release times for the devices 
having double chemical loadings, which are summarized in Table 4-6 below. 
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Table 4-5 Average release times ± standard deviations (in days) from reservoirs on devices loaded with one of 14C-
dextran, 3H-heparin, or 125I-HGH and having membranes made from PLGA4.4, PLGA11, PLGA28, and PLGA64. 
(Reproduced from Table 4-4) 
  Membrane Polymer 
Device #’s
Molecule  
(single chemical loading expts)
PLGA4.4 PLGA11 PLGA28 PLGA64 
1-3 14C-dextran 1±0 14±1 30±4 33±3 
4-6 3H-heparin 1±0 17±1 38±2 43±3 
7-9 125I-HGH 1±0 8±2 19±2 25±6 
Table 4-6 Range of observed release times (in days) from reservoirs on devices loaded with either 125I-HGH and 
14C-dextran, or 3H-heparin and 14C-dextran, and having membranes made from PLGA4.4, PLGA11, PLGA28, and 
PLGA64. 
  Membrane Polymer 
Device # 
Molecule  
(double chemical 
Loading expts) 
PLGA4.4 PLGA11 PLGA28 PLGA64 
125I-HGH 1  23  
22 
14C-dextran  16  36 
125I-HGH  10  28 
23 
14C-dextran 1  38  
3H-heparin 1  33  
24 
14C-dextran  16  38 
3H-heparin 1  37-45  
25 
14C-dextran  15  42 
Devices 22 and 24 showed the expected order of release, while devices 23 and 25 showed 
release from the reservoirs having PLGA64 membranes prior to release from the reservoirs 
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having PLGA28 membranes. Comparison of the results in Table 4-5 and Table 4-6, however, 
reveals that in the case of device 23, although the reservoir with a PLGA64 membrane released 
earlier than the reservoir with a PLGA28 membrane, the release times for these two reservoirs 
are fairly consistent with the results obtained for the devices loaded with a single chemical. For 
example, Table 4-5 shows that 125I-HGH was detected at 25±6 days from the reservoirs having 
membranes made from PLGA64. The release of 125I-HGH at 28 days from the reservoir on 
device 23 having a PLGA64 membrane is consistent with this result. Release of the 14C-dextran 
from the reservoir having a PLGA28 membrane on this device, however, occurred at 38 days, 
which is slightly longer than the range of 30±4 days seen for the devices in Table 4-5 loaded 
with 14C-dextran. Nevertheless, the fact that the 125I-HGH release times were consistently earlier 
than those for the reservoirs loaded with 14C-dextran on any of the devices explains why the 
results for this device show opening of the PLGA28 reservoir membrane prior to that of the 
PLGA64 reservoir membrane.  
Similarly, the results obtained for device 25 are consistent with the results for the devices 
in Table 4-5 that had single chemical loadings. The release time of 37–45 days for the PLGA28 
reservoir loaded with 3H-heparin overlaps with the range of 38±2 days seen for devices in Table 
4-5. The release time of 42 days for the 14C-dextran from the PLGA64 reservoir is only slightly 
later than the range of 33±3 days seen for devices in Table 4-5. Even if these reservoirs had 
released their contents within the time period observed for release from the devices with single 
chemical loadings, however (38±2 days for 3H-heparin in PLGA28 reservoir and 33±3 days for 
14C-dextran in PLGA64 reservoir), the PLGA64 reservoir would still have showed release 
earlier than the reservoir with a PLGA28 membrane.  
The results in Table 4-5 clearly show that the release times from reservoirs with a 
membrane of a given polymer vary depending on the chemical that is loaded into the reservoir. 
Reservoirs loaded with 125I-HGH showed the fastest release, while reservoirs loaded with 3H-
heparin showed the slowest release. These results suggest that the chemistry of the drug loaded 
into the reservoirs may affect the observed release time. This hypothesis is discussed further in 
Chapter 5, but can be grasped by the representation of data in Figure 4.13 below. This graph 
shows the observed release times for each chemical from reservoirs having each of the different 
membrane polymers, and includes the results from both the single and double chemical release 
studies. 
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Figure 4.13 Compiled release times for single and double loaded devices having PLGA4.4 (Mw 4400), PLGA11 
(Mw 11,000), PLGA28 (Mw 28,000) and PLGA64 (Mw 64,000) ~150 µm thick reservoir membranes. 125I-HGH: ○ 
experimental data, solid line is linear least-squares fit. 14C-dextran: □ experimental data, dashed line is linear least-
squares fit. 3H-heparin: × experimental data, dotted and dashed line is linear least-squares fit. 
Linear least-squares fits were performed (solid, dashed, and dotted and dashed lines) for 
each molecule (125I-HGH, 14C-dextran, and 3H-heparin, respectively) with the y-intercepts set to 
zero. The results clearly demonstrate that the 125I-HGH (solid line) shows on average faster 
release than the other two radiolabeled molecules, as evidenced by the smaller slope of the trend 
line (0.402 days/Kd versus 0.516 days/Kd for the dashed line representing 14C-dextran, and 
0.760 days/Kd for the dashed and dotted line representing 3H-heparin). Figure 4.13 also clearly 
shows the overlap in release time ranges for the PLGA28 and PLGA64 membranes. 
Overall, the devices exhibited better reproducibility of release times for the reservoirs 
having membranes of the lower molecular weight polymers (PLGA4.4 and PLGA11). The key 
point, however, is that four pulses of one or two chemicals have been demonstrated from 
individual devices. This is the first time that such a result has been demonstrated from a 
polymeric system without the application of an external stimulus. Other reports in the literature 
of pulsatile release from programmable biodegradable implants have shown only one31 or two32 
pulses from encapsulation-type compression molded devices having several concentric layers of 
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dye-loaded and dye-free polymer matrices. Devices having a polyanhydride dye-loaded core and 
PLGA 50:50 Mw 17,000 mantle that was tempered at 110°C showed onset of release between 14 
and 17 days, but generally took between 6 and 13 days to release 80% of the loading, making 
these PLGA devices less useful for applications requiring pulsatile release. Devices fabricated in 
the same fashion but having PLGA 50:50 Mw 10,500 or PLA Mw 30,000 tempered mantles 
showed more pulsatile release (approximately one to two days elapsed between onset of release 
and achieving approximately 80% release), but the fabrication method may limit the ability 
deliver multiple pulses from these types of devices. 
4.4 Summary and Conclusions 
We have demonstrated the ability to reproducibly release four pulses of 14C-dextran, 3H-
heparin, and 125I-HGH from the polymeric microreservoir devices. We have also demonstrated 
two releases of each of two chemicals (125I-HGH and 14C-dextran, or 3H-heparin and 14C-
dextran) from single devices. The observed release times for the lower molecular weight 
(PLGA4.4 and PLGA11) membranes showed greater reproducibility and less variation than the 
release times for the higher molecular weight polymers (PLGA28 and PLGA64), which actually 
showed overlap of their ranges of release times. Further discussion of the degradation of these 
membrane polymers will be presented in Chapter 5.  
Although one out of three of the devices loaded with 125I-HGH and 14C-dextran, and one 
out of four of the devices loaded with 3H-heparin and 14C-dextran, showed release of the 
reservoir having a PLGA64 membrane prior to release of the reservoir having a PLGA28 
membrane, this was most likely due to the different chemistries of the molecules, although 
unexpected variation in the polymer degradation rates may have been a contributing factor. The 
chemistries of the 14C-BCNU and 14C-IAP are also likely responsible for the absence of pulsatile 
releases from devices loaded with these chemicals. 
The results obtained here clearly show that it is possible to deliver multiple (more than 
two) pulses of different chemicals from a polymeric device without the application of a stimulus 
or trigger, something which heretofore has not been demonstrated by others.  
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5 Poly(Lactic-co-Glycolic Acid) Dimension and Temperature-
Dependent Degradation 
5.1 Introduction and Motivation 
5.1.1 Introduction 
 A key goal in the design and commercialization of drug delivery devices is the ability of 
the manufacturer to achieve reliable, reproducible performance from the device of interest. It is 
nearly impossible to achieve this goal without a thorough understanding of the mechanisms and 
phenomena that control device performance. In the case of the microreservoir devices that we 
have developed, it is quite clear that the membranes which seal the drug-containing reservoirs 
are the most important component of the device for controlling device performance. Changing 
the membrane material, molecular weight, copolymer ratio, crosslink density, or thickness, for 
example, will change the time at which the reservoirs release their contents. The release studies 
presented in Chapter 4 also suggest that the chemical that is loaded into the reservoirs may 
slightly affect the time at which the drug is observed to be released from the reservoirs. It is 
vitally important to understand the mode(s) by which the membranes open in order to achieve 
reproducible performance of these devices. Characterizing the factors that influence the 
membrane degradation is thus an important endeavor. 
 The degradation mechanisms and molecular weight change over time of PLGA 
copolymers have been reported on quite thoroughly in the literature. Poly(lactic acid), 
poly(glycolic acid), and their copolymers undergo heterogeneous degradation, possibly as a 
result of the fact that several processes occur simultaneously in the in vitro and in vivo 
environments (water uptake, swelling, ester hydrolysis, diffusion of oligomers and degradation 
products, and local pH drop)1–3. Some evidence has been presented for the theory that the rate of 
PLGA degradation is dependent on the size of the polymer object being studied1,4,5. The 
diffusion of degradation products out of large polymer objects and into the surrounding medium 
is hindered. The accumulation of acidic degradation products within the polymer object causes a 
local drop in pH inside the object, which catalyzes further degradation6. Thus, larger objects 
degrade more rapidly in the center than at the edges, and the overall degradation rate is faster 
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than that observed for small objects. This phenomenon is of particular interest for the 
microreservoir devices that we have developed, because of our interest in controlling the 
degradation rates of the reservoir membranes and hence the release of drugs from the reservoirs.  
The temperature dependence of PLGA degradation rate has not been extensively studied, 
but some authors have reported faster degradation of polylactide and polyglycolide homo- and 
co-polymers at elevated temperature4,7–9. While some of our studies of the microreservoir 
devices are performed at 37°C, others have been at lower temperatures. Correlation of the 
membrane degradation rates at these two different temperatures was desired in order to fully 
characterize the effect of temperature on device performance.  
5.1.2 Motivation 
The goal of the studies reported here was to characterize the degradation behavior of the 
reservoir membrane materials used in our devices, both to determine whether or not the size-
dependent degradation phenomenon was observed at size scales typical for membranes on a 
microreservoir device if we increased the membrane thickness, and also to quantify the size and 
temperature dependence of the degradation rate. Specifically, we wanted to determine whether 
the observed “release time” of a reservoir (time at which the release of a given reservoir’s 
contents is detected) is correlated with 1) the initial membrane thickness, 2) the initial molecular 
weight of the membrane material, 3) the mass loss and molecular weight change of the 
membrane material, and 4) the temperature at which the membranes are degraded. These 
parameters were chosen based upon the accepted methods in the literature of characterizing the 
degradation of polyesters, as well as consideration of the environment that the devices will be 
exposed to in vivo.  
5.2 Materials and Methods 
5.2.1 Materials 
Poly(L-lactic acid) (PLA, Mw 194 Kilodaltons (Kd), Medisorb® 100 L), and poly(D,L-
lactic-co-glycolic acid) polymer powders of molecular weights (Mw) 4.4 Kd (PLGA4.4, 
Medisorb® 5050 DL 1A), 11 Kd (PLGA11, Medisorb® 5050 DL 2A), 28 Kd (PLGA28, 
Medisorb® 5050 DL 3A), and 64 Kd (PLGA64, Medisorb® 5050 DL 4A) were obtained from 
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Alkermes (Cincinnati, Ohio). Each PLGA copolymer had approximately a 50:50 mole ratio of 
lactic acid:glycolic acid units. Reagent grade dichloromethane, 1,1,1,3,3,3-hexafluoro-2-
propanol (HFIP), HPLC grade methyl alcohol, and 14C-dextran (Mw = 70,000) were purchased 
from Sigma-Aldrich (St. Louis, MO). HPLC reagent grade chloroform was purchased from J.T. 
Baker (Phillipsburg, NJ). Ideal 9144 Masking Tape was obtained from American Biltrite, Inc. 
(Lowell, MA). Polystyrene standards for GPC analysis were obtained from PolySciences, Inc. 
(Warrington, PA). ScintiSafe Plus 50% was purchased from Fisher Scientific (Suwanee, GA). 
Mylar® sheets were donated from the laboratory of Dr. James Anderson at Case Western 
Reserve University.  
5.2.2 Methods 
5.2.2.1 In vitro measurement of release time as a function of membrane thickness 
Twenty devices were fabricated as described in Chapter 2. Devices were loaded with 
14C-dextran or 3H-heparin. Devices that were loaded with 14C-dextran had four reservoirs on 
each device loaded and sealed with a different PLGA membrane (PLGA4.4, PLGA11, PLGA28, 
or PLGA64). Two devices had membranes that were approximately 175 µm thick, while the 
other two had membranes that were approximately 250 µm thick. Nine nCi of 14C-dextran were 
loaded into each reservoir having a membrane. The devices that were loaded with 3H-heparin (72 
nCi per reservoir) had one reservoir filled on each device. Four devices were fabricated with 
each type of membrane material (PLGA4.4, PLGA11, PLGA28, or PLGA64), two of the 
devices having membrane thicknesses of approximately 150 µm, and two having membrane 
thicknesses of approximately 250 to 275 µm. The heparin devices only had one membrane per 
device, as when this study was conducted the release times from reservoirs loaded with 3H-
heparin had not been fully investigated, and it was unknown whether the PLGA64 membrane 
might release earlier than the PLGA28 membranes, as discussed in Chapter 4. In order to ensure 
accurate correlation of an observed release with the correct membrane polymer, the 3H-heparin 
devices therefore each had only one membrane. In contrast, the release times for 14C-dextran had 
been fairly well characterized, and therefore the devices loaded with dextran had four reservoir 
membranes (one of each type of polymer) on each device. 
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The devices were sealed and affixed to the bottom of polystyrene 6-well tissue culture 
plates using American Biltrite 9144 masking tape, and 5 mL of 1X phosphate buffered saline 
(PBS, prepared with milliQ deionized water) was added to each well. The 6-well plates were 
placed on an orbital shaker (Thermolyne Rotomix Type 50800) at 60 rpm and room temperature 
(approximately 22–25°C). Typically, 200 µL of the medium in each well was pipetted into 7-mL 
glass scintillation vials at 8- and 16-hour intervals daily. Five milliliters of ScintiSafe Plus 50% 
were added to each sample vial and the samples were analyzed on a Packard Tri-Carb liquid 
scintillation counter using either a 14C or 3H protocol. Confirmation of reservoir opening was 
obtained by optical microscopy of the devices at the conclusion of the study. 
5.2.2.2 In vitro degradation: GPC characterization and mass loss of membrane polymers 
Films of each membrane polymer (PLGA4.4, PLGA11, PLGA28, and PLGA64) were 
cast from HFIP solutions (volume fractions of the polymer in solution ranged from 7 to 15%) 
onto Mylar® sheets. The total weight and volume of polymer as well as volume of solvent were 
calculated in order to give the desired film thicknesses (either approximately 50 µm or 150 µm) 
when cast over a specified area. The solutions were allowed to become homogenous (dissolution 
of the polymers) over the course of a few hours before being cast onto Mylar® film, 
approximately 130 µm thick, which had been cleaned with acetone and Kimwipes®. The desired 
area of each film was marked on the Mylar® and then enclosed by placing several layers of 
VWR brand time tape onto the Mylar®. The solutions were poured onto the Mylar® areas in 
several layers. The cast polymer solutions were typically left to dry in a chemical hood for one to 
two hours. They were then dried in a Napco Vacuum Oven Model 5831 for either 24 or 48 hours 
at between 76 and 81°C under 6.7 kPa (28 in Hg VAC, 93.5% vacuum) house vacuum. After the 
oven heaters were turned off, the oven was left to cool for at least one hour before removing the 
films. Film thicknesses were measured with a Fowler micrometer. The 50 µm films were cut into 
1 × 1.5 cm2 samples, while the 150 µm films were cut into 1 × 1 cm2 samples (a smaller area was 
required in order to obtain adequate polymer mass for the GPC characterization due to the larger 
thicknesses of these films). Each film was weighed and placed in a micro-centrifuge (microfuge) 
tube. One and one-half milliliters of PBS made with milliQ water (resistivity ~18 MΩ) were 
added to each tube before it was capped, and the tubes were agitated on Thermolyne Rotomix 
Type 50800 orbital shakers at 60 rpm.  
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The experimental matrix is shown in Table 5-1 below. The goals of this study were to 
investigate the effect of temperature, film thickness, and media conditions on the degradation 
rate of the films, as characterized by molecular weight, polydispersity index (PDI), pH of the 
media surrounding the samples, and mass loss measurements. The samples that had the media 
changed were designed to mimic the experimental conditions that reservoir membranes are 
subjected to during an in vitro release experiment. Typically 1/20 of the release medium volume 
is changed at each time point (twice daily) in a release experiment. This corresponds to a 
complete volume change every ten days, which is similar to the media changes that occurred on 
average every seven days in this degradation study. The samples that did not have the media 
changed were designed to investigate what effect the local accumulation of degradation products 
would have on the pH and degradation rate of the films. Each sample group typically consisted 
of three films of each material at each time point. 
Table 5-1 Experimental matrix for in vitro degradation study. 
 50 µm 150 µm
25°C, no medium change X X 
25°C, with medium change  X 
37°C, with medium change  X 
 
Batches of samples were removed from the microfuge tubes at 7, 14, 21, 28, 35, 42, and 49 
days (some groups had additional samples at three, four, or ten days), rinsed with deionized 
water, dried under 6.7 kPa (28 in Hg VAC, 93.5%) vacuum at room temperature for 48 hours, 
and weighed. pH measurements were taken using colorpHast pH paper at 4, 7, 14, 21, 28, 35, 42, 
and 49 days for the 150 µm thick films as they were removed from the media for analysis. After 
drying, the samples were placed in 7-mL glass vials, and one milliliter of chloroform was added 
with a B-D polypropylene 1-mL syringe in order to dissolve the PLGA off of the Mylar® film. 
The vials were wrapped with ParaFilm M® to prevent evaporation of the chloroform. The 
samples were left to dissolve in chloroform for between six and 72 hours and then vortexed until 
no PLGA was visibly remaining on the Mylar® films. The solutions were transferred to 1-mL 
glass GPC vials (Waters Corporation) using 1-mL polypropylene syringes and 0.2 µm PTFE 
syringe filters. GPC analysis was performed on the polymer solutions in chloroform at 1 mL/min 
flow rate on a Waters GPC system consisting of a 515 HPLC Pump, 717plus Autosampler, 
Styragel Guard Column, two Styragel HR 4 columns or one each of Styragel HR 4 and HR 3 
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columns, and 2410 refractive index detector.  Polymer molecular weights were calculated 
relative to selected polystyrene standards of molecular weights 400,000, 300,000, 200,000, 
50,000, 25,000, 20,000, 17,500, 9,000, 4,000, 2,000, and 1,000 daltons. Data was analyzed using 
Millenium v.3.20 software.  
5.3 Results and Discussion 
5.3.1 In vitro measurement of release time as a function of membrane thickness 
The observed release times according to the membrane materials and thicknesses for the 
devices loaded with 14C-dextran or 3H-heparin are summarized in Table 5-2 below. 
Table 5-2 Summary of observed release times (in days) of devices having PLGA reservoir membranes of various 
thicknesses and molecular weights, loaded with 14C-dextran or 3H-heparin. 
  Reservoir Membrane Material 
Chemical 
Reservoir Membrane 
Thickness (µm) PLGA4.4 PLGA11 PLGA28 PLGA64 
175 0.9 25-26 63-92 100-121 14C-dextran 
250 0.6-0.9 27-36 56-60 66-69 
150 0.6 23-32 58-59 66-71 3H-heparin 
275 0.6 23-24 45 51-52 
 
5.3.1.1 14C-dextran 
Figure 5.1 and Figure 5.2Figure 5.2 show the release data for devices loaded with 14C-
dextran. For the two lowest molecular weight membranes (PLGA4.4 and PLGA11), the devices 
showed very similar release times. The PLGA4.4 membranes uniformly released on day 1 for all 
four devices, while the PLGA11 reservoirs released between 25 to 36 days for all four devices. 
However, the higher molecular weight membrane materials showed greater variation. The 
devices that had 175 µm thick membranes showed, on average, release at later times than the 
devices that had 250 µm thick membranes. The 250 µm thick PLGA28 membranes showed 
release between 56 and 60 days, while the 175 µm thick membranes of the same material showed 
release between 63 and 92 days.  
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Figure 5.1 Cumulative percentage of initial 14C-dextran loading released over time in vitro at 25°C from two 
devices having ~175 µm thick membranes made from PLGA4.4, PLGA11, PLGA28, and PLGA64. 
Similarly, the 250 µm thick PLGA64 membranes showed release at approximately 66 to 
69 days, while their 175 µm counterparts showed release between 100 and 121 days. The thicker 
membranes show faster degradation as evidenced by the earlier release times, as well generally 
more uniform release times (smaller variation in release times).  
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Figure 5.2 Cumulative percentage of initial 14C-dextran loading released over time in vitro at 25°C from two 
devices having ~250 µm thick membranes made from PLGA4.4, PLGA11, PLGA28, and PLGA64. 
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 The high cumulative percentages indicated on the graphs (>100%) are most likely due to 
the fact that it was extremely difficult to prevent evaporation of the PBS media over the course 
of the study from the wells in which the devices were situated. It is likely that evaporation of the 
media caused subsequently higher concentrations of the radiolabel to be measured. Small 
aliquots of the media were used for the measurements of the 14C-dextran present, and the error 
introduced by the mathematical calculations, combined with the difficulty in keeping the volume 
of PBS constant, most likely caused the high measured percentages.  
5.3.1.2 3H-heparin 
The results for the devices loaded with 3H-heparin are shown in Figure 5.3 and Figure 
5.4. Similar to the 14C-dextran devices, we see for the 3H-heparin that the devices with thicker 
reservoir membranes exhibited earlier release of their contents as well as less variation in release 
times than those having thinner membranes. Although the differences in release times were not 
as dramatic for the devices loaded with 3H-heparin as for the ones loaded with 14C-dextran in this 
study, they were nevertheless quite notable. Similar to the results obtained for the 14C-dextran, 
the PLGA4.4 and PLGA11 membranes did not show very different release times as a function 
of membrane thickness. However, we again see that the PLGA28 ~275 µm membranes showed 
release earlier (day 45) than the PLGA28 ~150 µm membranes (days 58 to 59). Similarly, the 
PLGA64 ~275 µm membranes showed release at 51 to 52 days, while their thinner counterparts 
showed release at between 66 and 71 days. 
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Figure 5.3 Cumulative percentage of initial 3H-heparin loading released over time in vitro at 25°C from devices 
having 150 µm thick membranes: { PLGA4.4, ° PLGA11, U PLGA28, and  PLGA64. 
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Figure 5.4 Cumulative percentage of initial 3H-heparin loading released over time in vitro at 25°C from devices 
having 275 µm thick membranes: { PLGA4.4, ° PLGA11, U PLGA28, and  PLGA64. 
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Similar to the devices that were loaded with 14C-dextran, the >100% cumulative release 
detected for the devices that released the 3H-heparin towards the end of the study is most likely 
due to evaporation of the release media and subsequent concentration of the remaining radiolabel, 
which gave rise to an artificially high quantitative value when the cumulative amount of release 
was calculated. 
Overall, the PLGA4.4 and PLGA11 reservoir membranes did not appear to show 
significant differences in release time as the membrane thickness was changed. However, the 
release times were faster and showed less variation for the thicker PLGA28 and PLGA64 
reservoir membranes. Additionally, the release times observed for the different membrane 
polymers appeared to vary depending on the chemical that was loaded into the reservoirs. The 
reservoirs having 150–175 µm thick PLGA64 membranes, for example, showed release between 
66–71 days when loaded with 3H-heparin, and between 100–121 days when loaded with 14C-
dextran. While the molecular weight of the chemical loaded into the reservoir may affect the 
opening time of the membrane (see Chapter 7 for further discussion), it also appears that the 
chemistry of the molecule may affect the release time.  
5.3.2 In vitro degradation: GPC characterization and mass loss of membrane polymers 
Although the studies described above have given us quantitative data correlating the 
observed release time with the initial membrane thickness, our ultimate goal is to thoroughly 
understand the mechanisms and factors that determine the opening of the membranes in order to 
better control device performance. A more thorough characterization of the molecular weight, 
mass loss, and polydispersity index (PDI = Mw/Mn) of the membrane polymers over time in 
vitro, as well as the pH of the release media, was therefore performed. The molecular weight of 
the membrane materials and pH of the media can provide us with information about the 
degradation rate of the materials, while the PDI can indicate whether or not size-dependent 
degradation is taking place. A high PDI is due to a broad distribution of molecular weights, 
which may indicate that size-dependent degradation is occurring (both extremely low molecular 
weight oligomers and higher molecular weight chains are present). Conversely, a low PDI 
indicates a narrow distribution of chain molecular weights, which is more likely in the case 
where oligomers can diffuse out of the polymer objects (no size-dependence of degradation rate). 
Most importantly, however, characterization of the molecular weight and mass loss can give us a 
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better understanding of whether or not the membrane opening is correlated with either a 
threshold molecular weight or percentage of membrane mass remaining.  
5.3.2.1 PLGA4.4 
The weight-average molecular weight (Mw) reported by the manufacturer for this 
polymer is approximately 4,400 daltons, with a polydispersity index (PDI) of 2. Undegraded 
polymer powder (stored dry at –4°C since receipt from the manufacturer) that was analyzed on 
the GPC along with various sample batches showed a molecular weight ranging from 3,660 to 
5,220 daltons and PDI values from 1.73–2.59. 
The results of the in vitro degradation study of the PLGA4.4 materials are shown in 
Figure 5.5 to Figure 5.9. Figure 5.5 shows the change in molecular weight over time for the 
PLGA4.4 films. 
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Figure 5.5 Mw over time of PLGA4.4 film samples degraded in vitro: ● 50 µm films at 25°C with no media change, 
○ 150 µm films at 25°C with no media change, ■ 150 µm films at 25°C with media change, □ 150 µm films at 37°C 
with media change. 
 As is expected, the samples that were kept at 37°C (□ symbols) showed the most rapid 
drop in molecular weight. Faster degradation of PLGA copolymers at higher temperatures has 
128 
been reported elsewhere4,7,8. The 150 µm films at 25°C with no media change (○ symbols) show 
a lower molecular weight at 49 days than both the 50 µm films at 25°C with no media change (● 
symbols) and the 150 µm thick films at 25°C with media change (■ symbols). This suggests that 
the thicker films undergo more rapid degradation, and that the local accumulation of the acidic 
degradation products helps to autocatalyze further degradation of the polymer, in the case of the 
samples that did not have the media changed. A comparison of the 150 µm films at 25°C (■ 
symbols) and 37°C (□ symbols) clearly shows that the samples at 37°C undergo more rapid 
degradation and molecular weight decrease. 
The pH results in Figure 5.6 confirm the hypothesis presented above based on the 
molecular weight data, namely that local accumulation of the degradation products was 
occurring in the case of the samples that did not have the media changed. The pH values 
obtained for 150 µm thick samples at 25°C that did not have the media changed  (○ symbols) 
were much lower than that of the samples that did have the medium changed (■ symbols). All 
sample groups showed an initial drop in the measured pH value, most likely due to the rapid 
onset of degradation of the polymer. The 37°C sample group (□ symbols) showed a large drop in 
pH at day 14, with subsequent recovery to pH 7.4 at days 35 to 49. The lower pH seen for this 
sample group over the first days of the study can be attributed to the faster degradation rate of the 
material at elevated temperature. 
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Figure 5.6 pH over time of media surrounding PLGA4.4 film samples degraded in vitro: ○ 150 µm films at 25°C 
with no media change, ■ 150 µm films at 25°C with media change, □ 150 µm films at 37°C with media change. 
The change in mass of the samples over time is shown in Figure 5.7. The samples at 
37°C showed the largest drop in the sample mass, with nearly complete loss of the material after 
21 days. Although the 37°C samples appeared to have no sample remaining after this time, there 
may have been a very small amount of material remaining that was difficult to quantify using our 
microbalance, but which was sufficient to be analyzed on the GPC. However, many of these 
samples showed exceedingly small peaks on the GPC chromatograms. 
Reservoirs having membranes made from the PLGA4.4 polymer have shown universal 
release times between zero and one days in release studies performed in vitro (as discussed in 
Chapter 4). Although the mass lost from the PLGA4.4 polymers was not characterized in this 
study at day one, the results presented here show that 60–80% of the PLGA4.4 mass remained at 
three or four days. This suggests that either a very high threshold of remaining mass (or 
alternatively a very small mass loss) is correlated with the observed opening of the PLGA4.4 
membranes, or that no threshold of remaining mass exists, and that the opening of the reservoir is 
correlated with some other parameter, such as molecular weight. 
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Figure 5.7 Mass remaining over time of PLGA4.4 film samples degraded in vitro: ● 50 µm films at 25°C with no 
media change, ○ 150 µm films at 25°C with no media change, ■ 150 µm films at 25°C with media change, □ 150 
µm films at 37°C with media change. 
 The calculated mass loss in mg/cm2 is shown in Figure 5.8 below for the PLGA4.4 films 
in various degradation conditions. Normalization of the mass loss by the film area (the 50 µm 
thick films had a larger surface area) highlights the much larger mass loss for the 150 µm thick 
films at all time points compared to the 50 µm thick films (● symbols). 
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Figure 5.8 Mass loss (mg/cm2) at each time point for PLGA4.4 films degraded in PBS in vitro: ● 50 µm films at 
25°C with no media change, ○ 150 µm films at 25°C with no media change, ■ 150 µm films at 25°C with media 
change, □ 150 µm films at 37°C with media change. 
The polydispersity indices (PDI) of the PLGA4.4 samples under different degradation 
conditions are shown in Figure 5.9. In general, the 150 µm films at 25°C (both without media 
change, ○ symbols, and with media change, ■ symbols) showed a higher PDI value than the 50 
µm films at 25°C. This could be due to size-dependent degradation, which would cause faster 
and slower degrading regions of the films to have lower and higher molecular weights, 
respectively, and a correspondingly higher PDI value. The 150 µm films at 37°C (□ symbols) 
had consistently low values of PDI for the entire course of the study. This is most likely due to 
the extremely rapid degradation of the PLGA4.4 at 37°C, as reflected by both the molecular 
weight (Figure 5.5) and mass loss (Figure 5.7) results. The increase in PDI for most of the 
samples at days 42 and 49 may be due to the extremely low molecular weight values obtained. 
The lowest molecular weight cutoff of the GPC columns used was either 500 or 5,000 daltons, 
and at the later time points of this study, the PLGA4.4 material had reported Mn and Mw results 
that approached or were below these values. Therefore, the accuracy of the PDI values at days 42 
and 49 may not be very high. 
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Figure 5.9 PDI over time of PLGA4.4 film samples degraded in vitro: ● 50 µm films at 25°C with no media 
change, ○ 150 µm films at 25°C with no media change, ■ 150 µm films at 25°C with media change, □ 150 µm films 
at 37°C with media change. 
5.3.2.2 PLGA11 
The weight-average molecular weight (Mw) reported by the manufacturer for this 
polymer is approximately 11,000 daltons, with a polydispersity index (PDI) of 2.5. Undegraded 
polymer powder (stored dry at –4°C since receipt from the manufacturer) that was analyzed on 
the GPC along with various sample batches showed a molecular weight ranging from 8,550 to 
12,700 daltons and PDI values of 1.73–2.83. 
The PLGA11 material showed degradation behavior that was similar to that seen for the 
PLGA4.4 material, although the degradation rate was slower. The results are summarized in 
Figure 5.10 to Figure 5.14. The molecular weight results for this material are shown in Figure 
5.10. Similar to the PLGA4.4 results, the samples that were kept at 37°C showed the most rapid 
drop in molecular weight, and the lowest molecular weight at the end of the study. The other 
three sets of samples showed similar trends in both the change in molecular weight over the 
course of the study, and the final molecular weight at day 49, although the 150 µm films at 25°C 
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with media change (■ symbols) showed an overall flatter curve and higher molecular weight at 
day 49 than the other two sample groups at 25°C. This may be due simply to the effect of the 
media change, which may have maintained the pH at a higher value and therefore slowed the 
degradation of these samples. A comparison of the two sample groups that did not have the 
media changed (● 50 µm films and ○ 150 µm films) shows that the degradation rate and change 
in molecular weight over time appear to be similar for these sample groups. 
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Figure 5.10 Mw over time of PLGA11 film samples degraded in vitro: ● 50 µm films at 25°C with no media 
change, ○ 150 µm films at 25°C with no media change, ■ 150 µm films at 25°C with media change, □ 150 µm films 
at 37°C with media change. 
 The measured pH of the media surrounding the PLGA11 samples is shown in Figure 
5.11. Similar to the PLGA4.4 results, the samples at 37°C showed a much lower pH value 
during the initial part of the study. Again, this is not surprising since the higher temperature 
appears to cause more rapid degradation of the polymer. The 150 µm samples at 25°C with no 
media change (○ symbols) showed a similar trend initially as that presented by the 150 µm 
samples at 25°C with media change (■ symbols). However, after day 35, the samples that did not 
have the media changed showed a continuing drop in the pH compared to those samples that did 
have the media changed. These results are loosely similar to the molecular weight data shown in 
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Figure 5.10, where the samples that did not have the media changed (○ symbols) show a 
continued drop in molecular weight after day 35, while the samples that had fresh media (■ 
symbols) showed a decrease in the rate of molecular weight drop. This is consistent with 
sustained faster degradation of the sample groups that did not have the media changed. 
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Figure 5.11 pH over time of medium surrounding PLGA11 film samples degraded in vitro: ○ 150 µm films at 25°C 
with no media change, ■ 150 µm films at 25°C with media change, □ 150 µm films at 37°C with media change. 
The PLGA11 samples showed significantly more mass remaining over the course of the 
study (Figure 5.12) compared to the PLGA4.4 samples, as is expected. The samples at 37°C (□ 
symbols) show the largest drop in mass remaining, with essentially all of the material lost after 
28 days. This is confirmed by the mass loss per unit area calculations shown in Figure 5.13. The 
other three sample groups had consistent results, with approximately 50% of the initial mass 
remaining on the Mylar® substrate after 49 days of in vitro degradation. This compares 
favorably with the molecular weight results (Figure 5.10), which showed much greater 
degradation of the 37°C samples than the other three groups. Interestingly, the molecular weight 
and pH results suggest that the 150 µm films at 25°C with no media change (○ symbols) undergo 
more rapid degradation towards the end of the study than the other 25°C sample groups, while 
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the mass data in Figure 5.12 indicate that all three of the sample groups have roughly the same 
amount of polymer remaining on the substrate after 49 days. These two results suggest that 
although the 150 µm films at 25°C with no media change may have the same amount of polymer 
remaining on the Mylar® substrates, on average, as the other sample groups at 25°C, the 
remaining polymer material in this sample group is of a lower molecular weight. 
-20
0
20
40
60
80
100
120
0 7 14 21 28 35 42 49
Time (days)
M
as
s r
em
ai
ni
ng
 (%
 o
f i
ni
tia
l)
 
 
Figure 5.12 Mass remaining over time of PLGA11 film samples degraded in vitro: ● 50 µm films at 25°C with no 
media change, ○ 150 µm films at 25°C with no media change, ■ 150 µm films at 25°C with media change, □ 150 
µm films at 37°C with media change. 
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Figure 5.13 Mass loss (mg/cm2) at each time point for PLGA11 films degraded in PBS in vitro: ● 50 µm films at 
25°C with no media change, ○ 150 µm films at 25°C with no media change, ■ 150 µm films at 25°C with media 
change, □ 150 µm films at 37°C with media change. 
The PDI results for the PLGA11 sample groups are shown in Figure 5.14. With the 
exception of the 150 µm films at 25°C with no media change (○ symbol), which showed a peak 
at day 42, the PDI values obtained for the PLGA11 samples were similar to those obtained for 
the PLGA4.4 materials. The 37°C sample group showed the lowest PDI, most likely due to the 
rapid degradation of the PLGA11 at that temperature. The 150 µm films at 25°C with no media 
change (○ symbols) showed slightly higher PDI values than the 50 µm films at 25°C with no 
media change (● symbols). This result suggests that the 150 µm films are degrading more 
rapidly, supporting the hypothesis that size-dependent degradation occurs at the thicknesses 
investigated here. 
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Figure 5.14 PDI over time of PLGA11 film samples degraded in vitro: ● 50 µm films at 25°C with no media 
change, ○ 150 µm films at 25°C with no media change, ■ 150 µm films at 25°C with media change, □ 150 µm films 
at 37°C with media change. 
5.3.2.3 PLGA28 
The weight-average molecular weight (Mw) reported by the manufacturer for this 
polymer is approximately 28,000 daltons, with a polydispersity index (PDI) of 6.6. Undegraded 
polymer powder (stored dry at –4°C since receipt from the manufacturer) that was analyzed on 
the GPC along with various sample batches showed a molecular weight ranging from 23,900 to 
49,000 daltons and PDI values from 1.29–6.12. 
Figure 5.15 to Figure 5.19 summarize the results obtained for the PLGA28 sample 
groups. The molecular weight results for the PLGA28 material are shown in Figure 5.15. 
Similar to the PLGA4.4 and PLGA11 materials, again we see that the sample group at 37°C (□ 
symbols) showed the most rapid degradation and the lowest molecular weight after 49 days. The 
50 µm films at 25°C with no media change (● symbols) initially showed a more rapid drop in 
molecular weight compared to the remaining sample groups, but then seemed to slow down. The 
150 µm films at 25°C with no media change (○ symbols) had a slightly higher initial molecular 
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weight than the 50 µm thick films, and a slightly lower molecular weight at day 49. Thus 
although there was a peak in the curve at day 28, the overall degradation rate of the 150 µm thick 
films seems to be slightly more rapid than the 50 µm films under the same degradation 
conditions. Comparing the 150 µm films at 25°C with (■) and without (○) media change, it 
appears that the molecular weight changed similarly over time, but that the act of changing the 
media slightly slowed down the degradation of the polymer, resulting in a higher measured 
molecular weight at day 49. The effect of temperature on the degradation rate is quite obvious 
when the 150 µm samples at 25°C (■) and 37°C (□) are compared in Figure 5.15. The samples 
at 25°C still showed a measured molecular weight of approximately 15,000 daltons at day 49, 
while the samples degraded at 37°C were just 500 daltons, on average. 
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Figure 5.15 Mw over time of PLGA28 film samples degraded in vitro: ● 50 µm films at 25°C with no media 
change, ○ 150 µm films at 25°C with no media change, ■ 150 µm films at 25°C with media change, □ 150 µm films 
at 37°C with media change. 
The measured pH values for the media surrounding the PLGA28 samples are shown in 
Figure 5.16. Only the PLGA28 samples maintained at 37°C (□ symbols) showed a change in the 
measured pH over time. The pH value for this sample group reached a minimum of 
approximately 3 on day 28, and then recovered to pH 6.8 at day 49. The minimum pH value 
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measured for this sample group was similar to that measured for 37°C sample groups of other 
materials (PLGA4.4 and PLGA11), as well as the PLGA4.4 150 µm sample group at 25°C with 
no media change, which all showed significant mass losses and decreases in their molecular 
weights. 
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Figure 5.16 Measured pH over time of media surrounding PLGA28 film samples degraded in vitro: ○ 150 µm films 
at 25°C with no media change, ■ 150 µm films at 25°C with media change, □ 150 µm films at 37°C with media 
change. 
The characterization of mass remaining for the PLGA28 sample groups is shown in 
Figure 5.17. Similar to the other materials investigated in this study, the PLGA28 samples 
maintained at 37°C (□ symbols) show the most rapid and complete mass loss. This sample group 
appeared to have completely lost all polymer from the surface of the Mylar® substrates after 35 
days in vitro. The other three sample groups, however, were in striking contrast to the 37°C 
samples. They showed almost no mass lost over the entire 49 days of the degradation study. 
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Figure 5.17 Mass remaining over time of PLGA28 film samples degraded in vitro: ● 50 µm films at 25°C with no 
media change, ○ 150 µm films at 25°C with no media change, ■ 150 µm films at 25°C with media change, □ 150 
µm films at 37°C with media change. 
 The mass loss per unit area values for the different PLGA28 sample groups are shown in 
Figure 5.18 below. These results also show, as expected, that the samples maintained at 37°C 
had much greater mass loss per unit area than the other three sample groups at all time points. 
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Figure 5.18 Mass loss (mg/cm2) at each time point for PLGA28 films degraded in PBS in vitro: ● 50 µm films at 
25°C with no media change, ○ 150 µm films at 25°C with no media change, ■ 150 µm films at 25°C with media 
change, □ 150 µm films at 37°C with media change. 
The PDI results for the PLGA28 sample groups are shown in Figure 5.19. The 150 µm 
thick samples at 25°C with no media change (○) showed an increasing trend in PDI starting at 
day 14 and continuing to day 49. When comparing the 50 µm (●) and 150 µm (○) thick films at 
25°C with no media change, the 150 µm thick films show a higher PDI than the 50 µm films at 
most time points, supporting the hypothesis of size-dependent degradation effects. The 150 µm 
thick samples at 25°C with media change (■) also showed an increase in PDI to greater than a 
value of 3 beginning at day 21 and continuing to increase up to day 49, at which time the 
measured PDI value was 10. When comparing the effect of media change on the 150 µm films at 
25°C (○ = no media change, and ■ = media change), the samples that did not have the media 
changed showed an earlier increase in PDI and higher PDI values at most time points, again 
supporting the theory that changing the media helps to remove the acidic degradation products, 
thereby slowing the degradation rate. When comparing the 150 µm samples at 25°C (■) and 
37°C (□), it is evident that the 37°C samples did not show a large increase in PDI over the course 
of the study, while the 25°C samples showed a delayed increase in the measured PDI. This 
result, along with the Mw, mass loss, and pH results, suggests that the 37°C samples degraded 
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quite rapidly. Overall, the PDI results for the PLGA28 samples appear to correlate well with the 
molecular weight results. 
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Figure 5.19 PDI over time of PLGA28 film samples degraded in vitro: ● 50 µm films at 25°C with no media 
change, ○ 150 µm films at 25°C with no media change, ■ 150 µm films at 25°C with media change, □ 150 µm films 
at 37°C with media change. 
5.3.2.4 PLGA64 
The weight-average molecular weight (Mw) reported by the manufacturer for this 
polymer is approximately 64,000 daltons, with a polydispersity index (PDI) of 1.9. Undegraded 
polymer powder (stored dry at –4°C since receipt from the manufacturer) that was analyzed on 
the GPC along with various sample batches showed a molecular weight ranging from 40,280 to 
61,500 daltons and PDI values of 1.09–2.05. 
The results for the PLGA64 sample groups are summarized in Figure 5.20 to Figure 
5.24. The molecular weights of the PLGA64 sample groups are shown in Figure 5.20. 
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Figure 5.20 Mw over time of PLGA64 film samples degraded in vitro: ● 50 µm films at 25°C with no media 
change, ○ 150 µm films at 25°C with no media change, ■ 150 µm films at 25°C with media change, □ 150 µm films 
at 37°C with media change. 
A comparison of the curves for the 50 µm films (●) and 150 µm films (○) at 25°C with 
no media change shows that the initial degradation rates (slopes of the curves) for the two 
materials are similar. However, the 150 µm films initially had a higher measured molecular 
weight, but had a lower molecular weight at the conclusion of the study on day 49. This seems to 
support the size dependent degradation rate theory, with the thicker films showing faster 
degradation overall than the thinner ones. A comparison of the curves for the 150 µm films at 
25°C with (○) and without (■) media change shows very similar behavior for the samples in 
these two groups. Changing the media does not appear to significantly affect the molecular 
weight change of this polymer, although the 150 µm films at 25°C without media change (○) 
show a slightly lower molecular weight at 49 days compared to the films with media change (■). 
The effect of temperature can clearly be seen in a comparison of the curves for the 150 µm thick 
films at 25°C (■) and at 37°C (□). Similar to the other polymers examined in this study, the 
PLGA64 showed a much faster drop in molecular weight for the samples that were maintained 
at 37°C.  
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The measured pH of the media surrounding the different samples groups is shown in 
Figure 5.21. Similar to the results obtained for the PLGA28 materials (see Figure 5.16), the 150 
µm films at 37°C were the only group to show a significant change in pH over the course of the 
study. Interestingly, however, the 150 µm films at 25°C with no media change (○) showed a 
small drop in pH at day 49, which was not observed for PLGA28 films under the same 
conditions (see Figure 5.16). 
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Figure 5.21 Measured pH over time of medium surrounding PLGA64 film samples degraded in vitro: ○ 150 µm 
films at 25°C with no media change, ■ 150 µm films at 25°C with media change, □ 150 µm films at 37°C with 
media change. 
The masses remaining of the various samples groups are shown in Figure 5.22. Similar 
to the results obtained for all of the other polymers investigated in this study, the PLGA64 
material showed the greatest mass loss for the films maintained at 37°C (□ symbols). Both the 50 
µm and 150 µm thick films at 25°C with no media change (● and ○ symbols, respectively) 
showed slight mass loss over the course of the study, but the 150 µm films at 25°C with media 
change (■ symbols) did not appear to show any significant mass loss. This confirms the 
molecular weight results in Figure 5.20, which indicated that the 150 µm PLGA films at 25°C 
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with media change (■ symbols) showed less degradation and a higher molecular weight than the 
samples without media change (● and ○ symbols). 
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Figure 5.22 Mass remaining over time of PLGA64 film samples degraded in vitro: ● 50 µm films at 25°C with no 
media change, ○ 150 µm films at 25°C with no media change, ■ 150 µm films at 25°C with media change, □ 150 
µm films at 37°C with media change. 
The normalized mass loss per unit area (shown in Figure 5.23) is much larger at each time 
point over the course of the study for the samples maintained at 37°C than for any of the other 
sample groups, which is consistent with the results obtained for the other polymers that were 
investigated in this study. 
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Figure 5.23 Mass loss (mg/cm2) at each time point for PLGA64 films degraded in PBS in vitro: ● 50 µm films at 
25°C with no media change, ○ 150 µm films at 25°C with no media change, ■ 150 µm films at 25°C with media 
change, □ 150 µm films at 37°C with media change. 
The PDI of the various PLGA64 sample groups are shown in Figure 5.24. Overall, the 
150 µm films at 25°C with no media change (○ symbols) showed the highest measured PDI, 
followed by the 150 µm films with media change at 25°C (■ symbols), the 50 µm films at 25°C 
with no media change (● symbols), and the 150 µm films at 37°C (□ symbols). The low PDI 
measured for the samples at 37°C is not surprising, considering the rapid loss of molecular 
weight seen in Figure 5.20. The slightly higher PDI of the 150 µm samples (○) compared to the 
50 µm films (●) at 25°C with no media change suggests that this polymer may be exhibiting 
size-dependent degradation. The larger PDI value may be attributed to the presence of a wider 
range of molecular weight chains, with perhaps lower molecular weight chains existing in the 
interior of the film, and higher molecular weight chains towards the outside of the film. 
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Figure 5.24 PDI values over time of PLGA64 film samples degraded in vitro: ● 50 µm films at 25°C with no media 
change, ○ 150 µm films at 25°C with no media change, ■ 150 µm films at 25°C with media change, □ 150 µm films 
at 37°C with media change. 
5.3.2.5 Discussion 
A half-life (t½, time at which the molecular weight is half of the initial molecular weight) 
was calculated for each sample group. The experimentally obtained molecular weight data were 
fit to the following equation: 
t
w bmM =  
Equation 5-a 
where Mw = molecular weight at time t, and b and m are constants determined using the 
LOGEST function in Windows Excel 2002, which uses regression analysis to fit an exponential 
curve to the data. The half-life was therefore found by using Equation 5-a with the 
experimentally calculated values of b and m, and setting M ww = 0.5 × Mwt=0. The calculated half-
lives for each sample group are summarized in Table 5-3 below. 
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Table 5-3 Calculated half-lives (time in days at which molecular weight is predicted to be one-half the initial 
molecular weight) for 50 and 150 µm thick PLGA4.4, PLGA11, PLGA28, and PLGA64 films degraded in vitro 
under various conditions. 
 
Polymer 
50 µm films 
at 25°C,  
no media change 
150 µm films  
at 25°C,  
no media change 
150 µm films  
at 25°C, 
with media change 
150 µm films 
at 37°C, 
with media change 
PLGA4.4 46 26 NA (∞) 9 
PLGA11 19 20 29 6 
PLGA28 74 36 54 7 
PLGA64 12 14 16 NA (<4) 
 
Overall, the degradation rates of the four different polymers (PLGA4.4, PLGA11, 
PLGA28, and PLGA64) generally exhibited the expected behavior, with the lowest molecular 
weight material (PLGA4.4) showing the most rapid degradation rate as measured by the 
experimentally obtained values for Mw, PDI, pH, and mass loss.  
In general, the 150 µm thick films showed more rapid degradation than the 50 µm films. 
This is evidenced by the t1/2 values in Table 5-3 for the PLGA4.4 and PLGA28 samples, as well 
as by the experimental results. The 150 µm films typically had higher PDI values than the 50 µm 
films at 25°C, and the 150 µm films at 25°C always had an average molecular weight at 49 days 
that was lower than that of the 50 µm films at 25°C after 49 days. Both of these results indicate 
that the 150 µm films undergo size dependent degradation, with a resulting wider range of chain 
molecular weights (high PDI values) and greater drop in molecular weight over the course of the 
study. Further evidence for the more rapid degradation of the thicker membranes is provided by 
the figures which show the mass loss per unit area, particularly Figure 5.8 and Figure 5.13. 
Although some authors have speculated that the critical thickness above which the hydrolytic 
degradation of PLGA polymers becomes heterogeneous is 200 to 300 µm1, others have reported 
differential rates of degradation for samples having dimensions from 100 µm to as small as 0.53 
µm4,14. Faster degradation, as characterized by gel permeation chromatography of polymer 
molecular weights, has been reported for poly(lactide-co-glycolide) microspheres 22.5 µm in 
diameter compared to both 6.87 and 0.53 µm diameter microspheres4. Similarly, 100 µm thick 
films of poly(D,L-lactic-co-glycolic acid) had both faster mass loss and a faster decrease in 
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molecular weight than ten µm thick films when degraded over a period of ten weeks in PBS at 
37°C in vitro14. Our results tend to support these studies, as we observed a difference in 
degradation rates between the 50 and 150 µm thick films. 
The 150 µm films at 25°C that had the media changed typically showed an increase in 
PDI values at later times than the 150 µm films at 25°C that did not have the media changed. 
Error! Reference source not found. also shows longer t1/2 values for 150 µm thick films that 
had media changed than for 150 µm thick films that did not have the media changed. This 
indicates that the accumulation of acidic degradation products (confirmed by the pH 
measurements) contributed to the faster degradation of the sample groups that did not have the 
media changed. 
The effect of temperature on the degradation rate was clearly visible for all four of the 
materials studied. The sample groups at 37°C showed much more rapid decreases in molecular 
weight, faster drops in pH, earlier onset of mass loss, and lower PDI values compared to the 
samples at 25°C. The difference in degradation rates between the samples maintained at 37°C 
and at 25°C is quite dramatic when comparing the t1/2 values in Table 5-3. These results all 
suggest extremely rapid degradation at this temperature. 
The PLGA64 material shows a surprisingly steep decrease in the molecular weight over 
time compared to the PLGA28 material, as evidenced by the smaller t1/2 values for the PLGA64 
compared to the t1/2 values for the PLGA28 in Table 5-3. In fact, the PLGA64 polymer had a 
lower measured molecular weight after 49 days than the PLGA28 in all sample groups. 
Additionally, when comparing the pH results for these two materials for the groups of 150 µm 
films at 25°C with no media change (○ symbols) in Figure 5.16 and Figure 5.21, the PLGA64 
sample group shows a slight drop in the pH at day 49, while the PLGA28 sample group does 
not. This result also indicates faster degradation of the PLGA64 material. As was discussed in 
section 4.3.2.2.1 (125I-HGH and 14C-dextran in vitro release studies), these two polymers were 
nearly identical in chemical composition: both polymers were 54 mole % D,L-lactic acid and 46 
mole % glycolic acid, with 1.2% residual D,L-lactide monomer. The PLGA28 had 0.2% residual 
glycolide monomer, while the PLGA64 had 0.1% residual glycolide monomer. Thus although it 
is unlikely that any chemistry difference can account for the faster degradation rate of the 
PLGA64 in some cases, greater blockiness of the PLGA28 could explain the unexpected 
degradation behaviors. X-ray diffraction of these two materials, however, did not show any 
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significant crystallinity. Additionally, the observation of a lower molecular weight of the 
PLGA64 polymer compared to the PLGA28 polymer at day 49 offers an explanation for the 
observed opening of reservoirs having PLGA64 membranes prior to those having PLGA28 
membranes in some instances, as discussed in Chapter 4.  
The molecular weight results for the PLGA28 correlate well with data at short times 
from the literature10, which indicate a molecular weight of 22,500 daltons after 10 days in pH 7.4 
PBS at 37°C for a similar polymer of 29,270 Mw. However, at longer times, the 29,270 Mw 
polymer was reported to show a continually rapid decrease in molecular weight with a final 
molecular weight of less than 2,500 after 40 days, while the PLGA28 polymer samples in our 
study had a molecular weight of nearly 600 after 42 days in vitro at 37°C. Another study 
reported a final Mw close to 500 daltons for a polymer having an initial Mw of 18,000 daltons 
after 14 days in deionized water at 37°C11. The comparable polymer in our study, PLGA11, 
showed an average molecular weight of ~3,500 daltons after 14 days. The faster apparent 
degradation of the Mw 18,000 polymer may be due to the larger size of the specimens studied 
(300 µm thick films) in the reported investigation, as well as the fact that the media in which the 
samples were immersed was not refreshed over the course of the study, in contrast to the 
PLGA11 samples maintained at 37°C in our study, which did have the media replaced once per 
week. The molecular weight of the PLGA4.4 material was difficult to reliably characterize over 
the entire course of our study due to its rapid degradation and the lower molecular weight limits 
of the GPC columns. 
In general, most of the sample groups studied exhibited a drop in molecular weight 
followed by mass loss. In the specific example of the 150 µm films at 37°C, the PLGA11 films 
did not begin to lose mass until after day 7, at which time the Mw had already dropped to 
approximately 4,400 daltons. Similarly, the PLGA28 and PLGA64 did not show appreciable 
mass loss until after 14 days, at which point the measured molecular weights were between 5,000 
to 7,000 daltons. An initial drop in molecular weight followed by mass loss has been reported 
elsewhere for degradation studies of PLA and PGA homo- and co-polymers1,2,7–10,12. It is 
hypothesized that although the PLGA objects show a decrease in their molecular weights as soon 
as hydrolytic scission of the chains begins (when the samples come into contact with water), the 
polymer chains are still too large to diffuse out of the polymer object. Only at longer degradation 
times, after continued chain scission, will the chains become short enough to diffuse out of the 
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object and cause a subsequent loss in mass8. For example, poly(lactide-co-glycolide) having an 
initial molecular weight of 29,270 daltons had a measured molecular weight around 5,000 to 
10,000 daltons after 30 days in pH 7.4 PBS at 37°C in vitro, at which point mass loss began and 
was complete by 50 to 60 days10. These results are very similar to the molecular weight and mass 
loss results that were obtained for the PLGA28 material, shown in Figure 5.15 and Figure 5.17. 
Data reported in the literature for polymers of 65,000 to 67,000 daltons (degraded in PBS at 
37°C in vitro), however, are slightly different from the results we obtained. PLGA 50:50 
copolymers having an initial Mw of 65,000 show a delay of 7 weeks before mass loss began2. 
Other studies have reported a 5–6% initial weight loss for Mw 67,000 PLGA 50:50 copolymers, 
followed by no further weight loss until 25 weeks1. However, the discrepancy between these 
results and the results obtained for our PLGA64 are consistent with the fact that the PLGA64 
appears to degrade more rapidly than expected (i.e. faster than the PLGA28 polymer in this 
study). Finally, for PLGA 50:50 copolymers with a molecular weight of 94,500 that were studied 
for 6 weeks, the maximum erosion rate appears to occur between 18 and 20 days13. Our results 
are in agreement with the general trend shown by others, that the polymers having lower initial 
molecular weights have an earlier onset of mass loss, and that mass loss is preceded by a 
decrease in the measured molecular weight. 
Finally, comparison of results from release studies with the molecular weight data 
obtained in the degradation study of the 150 µm films (Figure 5.5, Figure 5.10, Figure 5.15, 
and Figure 5.20) suggest that perhaps a threshold molecular weight might exist that is correlated 
with release of the reservoir contents due to mechanical weakness of the membranes. Table 5-4 
below shows the observed release times for the devices that were loaded with 14C-dextran and 
that had 150–175 µm thick membranes (release results are shown in Figure 5.1 and discussed in 
section 5.3.1.1). The PLGA4.4 and PLGA11 samples in the degradation study had a molecular 
weight near 4,400 during the time period in which release was detected from reservoirs on the 
14C-dextran loaded devices that had membranes made from those two polymers. The 150 µm 
thick PLGA28 and PLGA64 polymer samples had average molecular weights of 15,770 and 
8,040, respectively, at the conclusion of the in vitro degradation study, while release of 14C-
dextran was detected from reservoirs having PLGA28 and PLGA64 membranes from 58–92 and 
66–121 days, respectively. Although a direct comparison of the molecular weight data from the 
degradation study with the observed release times from the release study cannot be made due to 
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conclusion of the in vitro degradation study prior to observed release, the overall results 
nevertheless suggest that the release of chemicals from the devices may be correlated with a 
critical membrane molecular weight of around 5,000 daltons. 
Table 5-4 Release times in vitro at 25°C for devices loaded with 14C-dextran and having ~150-175 µm thick 
PLGA4.4, PLGA11, PLGA28, and PLGA64 membranes compared with molecular weight results from in vitro 
degradation study of 150 µm thick films at 25°C with media change. 
Membrane Time to Release Measured Mw
Polymer (days) of film samples
PLGA4.4 <1 4,400 @ 0 days
PLGA11 25-32 4,400 @ 28 days
PLGA28 58-92 15,770 @ 49 days
PLGA64 66-121 8,040 @ 49 days  
Similarly, comparison of release results at 37°C in vitro from devices having 150 µm 
thick PLGA11 and PLGA64 membranes and loaded with 14C-mannitol (experimental methods 
are presented in Chapter 9) show excellent agreement with results obtained for the 150 µm thick 
films at 37°C with media change in the in vitro degradation study presented in this chapter. The 
compiled data are shown in Figure 5.25 below. 14C-mannitol was released from the reservoirs 
having PLGA11 membranes around four to six days, and the PLGA11 films in the degradation 
study had an average molecular weight in the range of 5,000 to 7,000 during this time period. 
Similarly, 14C-mannitol was released from the reservoirs having PLGA64 membranes between 
days 12 to 15, at which time the PLGA64 films in the degradation study had an average 
molecular weight close to the range of 5,000 to 7,000. 
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Figure 5.25 Comparison of release results obtained in vitro at 37°C for four devices (▲■●♦) loaded with 14C-
mannitol and having 150 µm thick PLGA11 and PLGA64 reservoir membranes with molecular weight data 
obtained for 150 µm thick PLGA11 (□) and PLGA64 (○) film samples degraded at 37°C in vitro with media 
change. Horizontal dashed lines indicate range of 5,000 to 7,000 molecular weight on right y-axis. 
These results suggest that perhaps once the molecular weight of the membrane material 
drops below a critical value, in the range of 4,000 to 7,000 daltons, the membrane becomes so 
mechanically weak that it ruptures and releases the contents of the reservoir. It seems unlikely 
that the membrane opens due to simple dissolution of the low molecular weight chains, as others 
have reported a critical weight average molecular weight of 1,050 to 1,150 for water solubility of 
poly(D,L-lactic acid) oligomers15, which is much lower than the 4,000–7,000 molecular weight 
that seems to be significant for membrane opening in the studies reported here. 
5.4 Conclusions 
The results obtained for the in vitro release studies presented here clearly show a 
dimension-dependence of the membrane degradation rate with consequent changes in the release 
times of chemicals from the microreservoir device. This is confirmed by the results of the 
degradation study that was conducted. Higher environmental temperatures appear to cause faster 
degradation of the materials, but changing the media in which the samples are maintained 
appears to slow the degradation process, as the removal of the acidic degradation products tends 
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to maintain the pH of the medium at a higher value. Perhaps most significantly, comparison of 
the results of release studies with the degradation study suggest that a threshold molecular weight 
for the reservoir membranes may exist which is correlated with drug release from the reservoir. 
Further study of the mechanical properties of the membrane materials may aid in elucidating the 
exact relationship between membrane molecular weight and reservoir release time. 
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6 Calculation of Partition Coefficients 
6.1 Introduction and Motivation 
6.1.1 Introduction 
The reliability and reproducibility of drug delivery devices is a vital factor when 
considering end-stage application and use in human patients. In the case of our biodegradable 
microreservoir devices, there are numerous factors that may affect the performance of the 
devices, including the degradation behavior of the reservoir membranes as discussed in Chapter 
5. However, the performance of the device may also be affected by the characteristics of the 
drugs that are released from the reservoirs. The results obtained in Chapter 4 showed different 
release times for reservoirs having the same polymer membranes but different chemicals loaded 
into the reservoirs. One possible reason for this is that the partitioning of the drug into the 
membrane itself may affect the observed release kinetics. The complex mechanisms by which 
the PLGA membrane materials undergo degradation (swelling, diffusion of oligomers, and 
production of a porous structure1) may mean that partitioning of the chemicals into the 
membranes could affect the observed release times and kinetics. In the case of 1,3-bis(2-
chloroethyl)-1-nitrosourea (BCNU), the release kinetics may be further complicated by the 
formation of hydrolysis products, which might themselves diffuse through the reservoir 
membranes or affect the degradation rate of the membrane materials. Understanding the 
chemistry and physics of the interactions between the drug of interest and the membrane 
materials is essential in order to reliably predict and control device performance. Thus, our long-
term goal is to design our microreservoir drug delivery system such that the release 
characteristics and device performance are either a) independent of the drug being released, or b) 
vary according to the properties of the drugs in a predictable and well-understood manner. 
6.1.2 Motivation 
Previous release experiments suggested that the release times for various reservoir 
membrane materials might be partially controlled by the molecule of interest that is released 
from the reservoirs, but it is not clear that this is solely either a size or chemistry effect. In 
Chapter 4, for example, reservoirs loaded with 14C-labeled 1,3-bis(2-chloroethyl)-1-nitrosourea 
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(BCNU) showed much different release kinetics than reservoirs loaded with 14C-dextran or 3H-
heparin, even when the reservoir membranes were fabricated from the same PLGA copolymer. 
The goal of the experiments reported in this chapter was to determine whether the observed 
kinetic behavior of chemicals that have been investigated in prior release studies could be 
systematically explained by their molecular chemistry or size. Specifically, we desired to 
determine the partition coefficients of various molecules in four membrane materials of interest, 
and compare and contrast our results with release data obtained in prior experiments. 
6.2 Materials and Methods 
6.2.1 Materials 
Poly(L-lactic acid) (PLA, Mw 194 Kilodaltons (Kd), Medisorb® 100 L) and poly(D,L-
lactic-co-glycolic acid) polymer powders of molecular weights (Mw) 4.4 Kd (PLGA4.4, 
Medisorb® 5050 DL 1A), 11 Kd (PLGA11, Medisorb® 5050 DL 2A), 28 Kd (PLGA28, 
Medisorb® 5050 DL 3A), and 64 Kd (PLGA64, Medisorb® 5050 DL 4A) were obtained from 
Alkermes (Cincinnati, Ohio). Reagent grade dichloromethane, 1,1,1,3,3,3-hexafluoro-2-propanol 
(HFIP), HPLC grade methyl alcohol, and 14C-dextran (Mws = 40,000 and 70,000) were 
purchased from Sigma-Aldrich (St. Louis, MO). 14C-carmustine (1,3-bis(2-chloroethyl)-1-
nitrosourea, or BCNU) was purchased from Moravek Biochemicals (Brea, CA). 3H-heparin 
sodium salt and 125I-interleukin-2 (IL-2) were purchased from PerkinElmer Life Sciences 
(Boston, MA). 14C-iodoantipyrine (IAP) was purchased from New England Nuclear Life Science 
Products (Boston, MA). Ideal 9144 Masking Tape was obtained from American Biltrite, Inc. 
(Lowell, MA). Mylar® sheets were donated from the laboratory of Dr. James Anderson at Case 
Western Reserve University. 
6.2.2 In vitro measurement of partition coefficients 
Solutions of PLA, PLGA4.4, PLGA11, PLGA28, and PLGA64 were prepared in HFIP. 
The solutions were cast onto Mylar® sheets that had been cleaned with Kimwipes® and acetone, 
and that had 3.5 × 3 cm2 areas marked off with several layers of VWR time tape. Films were 
designed to be 50 µm thick. After casting, the films were dried at 93.5% vacuum (6.7 kPa, 28 in 
HgVAC) and approximately 80°C for 48 hours. After drying, the films were cut into samples 
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having an area of approximately 1 × 0.5 cm2 and placed in microcentrifuge (microfuge) tubes. 
Mylar® control samples with no cast polymer films, 1 × 0.5 cm2 in area, were also prepared and 
placed in microfuge tubes. Aliquots of the stock radiolabeled solutions (14C-BCNU, 14C-IAP, 
14C-dextran Mw 40,000, 14C-dextran Mw 70,000, 3H-heparin, and 125I-IL-2) were analyzed on a 
Packard Tri-Carb Liquid Scintillation Analyzer, model U2200, using either a 14C, 3H, or 125I 
counting protocol to verify the specific activities of the solutions (µCi/mL). One and one-half 
milliliters of a given stock solution were added to a microfuge tube containing one of the 
polymer films. Samples were prepared in triplicate. The experimental matrix is summarized in 
Table 6-1 below.  
Table 6-1 Sample labels for partition coefficient experiment. 
Polymer PLA PLGA4.4 PLGA11 PLGA28 PLGA64 Mylar control
Chemical
14C-dextran, 40K L40K1 140K1 240K1 340K1 440K1 M40K1
L40K2 140K2 240K2 340K2 440K2 M40K2
L40K3 140K3 240K3 340K3 440K3 M40K3
14C-dextran, 70K L70K1 170K1 270K1 370K1 470K1 M70K1
L70K2 170K2 270K2 370K2 470K2 M70K2
L70K3 170K3 270K3 370K3 470K3 M70K3
14C-IAP LIAP1 1IAP1 2IAP1 3IAP1 4IAP1 MIAP1
LIAP2 1IAP2 2IAP2 3IAP2 4IAP2 MIAP2
LIAP3 1IAP3 2IAP3 3IAP3 4IAP3 MIAP3
14C-BCNU LB1 1B1 2B1 3B1 4B1 MB1
LB2 1B2 2B2 3B2 4B2 MB2
LB3 1B3 2B3 3B3 4B3 MB3
3H-heparin LHEP1 1HEP1 2HEP1 3HEP1 4HEP1 MHEP1
LHEP2 1HEP2 2HEP2 3HEP2 4HEP2 MHEP2
LHEP3 1HEP3 2HEP3 3HEP3 4HEP3 MHEP3
125I-IL-2 LIL1 1IL1 2IL1 3IL1 4IL1 MIL1
LIL2 1IL2 2IL2 3IL2 4IL2 MIL2
LIL3 1IL3 2IL3 3IL3 4IL3 MIL3  
The microfuge tubes were placed on an orbital shaker (Thermolyne Rotomix Type 
50800) at 60 rpm and room temperature. After 48 hours, 100 µL aliquots of the solutions were 
pipetted from each microfuge tube into 7-mL scintillation vials. Five mL of ScintiSafe Plus 50% 
scintillation cocktail (Fisher Scientific, Suwanee, GA) were added to each vial, and the activities 
were measured on the Scintillation Analyzer using either a 14C, 3H, or 125I counting protocol. 
Each film was then removed from the microfuge tube using tweezers, rinsed with milliQ 
deionized water, and placed in a 7-mL glass scintillation vial along with 5 mL of fresh milliQ 
deionized water. The films were left in the deionized water for a total of 30 days. At two, four, 
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seven, 18, and 30 days, aliquots of solution (one mL at each time point except 0.5 mL at 30 days) 
were pipetted from each microfuge tube into scintillation vials and assayed following the 
procedure described above. The measured activity (µCi) and the specific activity (µCi/µg) of the 
radiolabeled molecules were used to calculate the amount of radiolabel released from the films 
into the solution at each of the time points. 
The partition coefficients (Kp) were calculated according to the following relation2: 
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Equation 6-a 
where Cfilm = concentration of solute in the polymer film of interested, Csolution = C1 = initial 
concentration of solute in which the membrane is equilibrated for 48 hours, C2 = concentration 
of solute released into volume V2 after desorption equilibrium has been reached, and Vm = 
volume of the polymer membrane or film of interest. The amount of solute in the solution in 
which the membrane was equilibrated for 48 hours was much larger than the amount of solute 
extracted from the films. 
6.3 Results and Discussion 
6.3.1 Stock Solution Activities and Film Characterization 
The measured stock solution concentrations are summarized in Table 6-2 below. 
Table 6-2 Specific activities of radiolabeled stock solutions used to determine partition coefficients. 
Stock Solution
Chemical Specific Activity (µ Ci/mL)
14C-dextran, 40k 1.04
14C-dextran, 70k 3.42
14C-IAP 3.96
14C-BCNU 0.61
3H-heparin 3.17
125I-IL-2 1.23  
The area of each film was individually measured using a ruler. Film widths varied from 
0.4 to 0.55 cm, while film lengths ranged from 0.85 to 1.05 cm. The partition coefficients for the 
various chemicals in each of the polymers were calculated according to Equation 6-a at each of 
the time points (two, four, seven, 18, and 30 days), taking into account the media that was 
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removed at previous time points. Partition coefficients for the various radiolabeled molecules 
were calculated including the contribution from the Mylar® backing. Scintillation measurements 
for iodine labeled samples were corrected for half-life decay of the isotope. 
6.3.2 Small molecules (14C-iodiantipyrine and 14C-carmustine)  
The partition coefficients calculated after 30 days for the small molecules of interest (14C-
IAP and 14C-BCNU) are shown in Figure 6.1 below. 
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Figure 6.1 Partition coefficients of small molecules in various polymers: □ 14C-IAP, ○ 14C-BCNU. 
Figure 6.1 clearly shows that the small molecules have a much higher partition 
coefficient in the lowest molecular weight PLGA (PLGA4.4) than any of the other polymers 
investigated. Although all of the PLGA materials have essentially the same chemical 
composition, the larger partitioning of the lower molecular weight molecules in the PLGA4.4 
may be due to the shorter polymer chain length and therefore greater free volume available in 
which the solute can reside. The free volume of a polymer is closely correlated with its glass 
transition temperature according to the following relation3: 
 
( ) fgg TTff α−+=  
Equation 6-b 
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where f = fractional free volume at temperature T above the glass transition temperature Tg, fg = 
free volume at or below Tg (a constant for a given polymer), and αf = thermal expansion 
coefficient. Given this relation between the glass transition temperature and free volume of a 
polymer, it is therefore not surprising that the PLGA4.4 polymer, which has the lowest Tg of all 
the materials investigated here (PLGA4.4 Tg = 31.4°C, PLGA11 Tg = 37.8°C, PLGA28 Tg = 
45.2°C, PLGA64 Tg = 47.7°C, PLA Tg = 45–50°C as reported by the manufacturer, Mylar® Tg 
= 99–102°C, determined experimentally – see section 10.3.3.1), showed the largest partitioning 
of these small molecules. A study reported in the literature of the permeability of homo- and 
copolymers of poly(ε-caprolactone) and poly(DL-lactic acid) provides further evidence for this 
theory, as the poly(DL-lactic acid) (Tg = 57°C) showed a much lower partition coefficient of 
progesterone compared to poly(ε-caprolactone) (Tg = –65°C)4,5.  
Although the octanol-water partition coefficient reported for BCNU (carmustine) in the 
literature6 is much larger (approximately 33.8, log Po:w = 1.53) than the value measured here, this 
is not unexpected since our study measured the partitioning into a solid substrate, rather than into 
another liquid.  
Sorption of BCNU (carmustine) to polymer surfaces has been reported elsewhere7,8. The 
lipophilicity and low molecular weight of this molecule have been cited as contributing factors to 
its sorption to plastic surfaces. A loss of approximately 80% of carmustine concentration over 
120 minutes was seen when the molecule was retained in solution in polyurethane infusion sets7. 
Similar results were obtained in ethylenevinyl acetate copolymer (EVA, approximately 60% 
loss) and polyvinyl chloride (PVC, approximately 65% loss) infusion sets. 
Iodoantipyrine (IAP) has a slightly lower octanol-water partition coefficient (18.62, log 
Po:w = 1.27)9 than BCNU, meaning that it is slightly more hydrophilic. Thus we would expect 
slightly less partitioning of the IAP into the polymers when compared to the BCNU. Although 
the results shown in Figure 6.1 actually show slightly greater partitioning of the IAP into the 
polymers compared to the BCNU, the results are within one standard deviation of each other and 
therefore the difference is not statistically significant. 
6.3.3 Polysaccharides (14C-dextrans and 3H-heparin) 
 The calculated partition coefficients of various polysaccharides (14C-dextran of 40,000 
and 70,000 dalton molecular weights, as well as 3H-heparin) are shown in Figure 6.2. 
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Figure 6.2 Partition coefficients of polysaccharides in various polymers: □ 14C-dextran Mw~40,000, ■ 14C-dextran 
Mw~70,000, ° 3H-heparin. 
The behavior of the polysaccharides appears significantly different from that of the small 
molecules in several respects. The first is that the partition coefficients do not exhibit a 
maximum for the PLGA4.4 polymer. While the PLGA28 polymer showed the greatest 
absorption of the 40,000 molecular weight 14C-dextran, however, this result was not significant 
due to the large standard deviation. In fact, the differences in calculated partition coefficients for 
both the 14C-dextrans (40,000 and 70,000 molecular weights) as well as the 3H-heparin were not 
significantly different (greater than one standard deviation) for any of the membrane polymers 
(PLGA4.4, PLGA11, PLGA28, and PLGA64) or the PLA. This result suggests that perhaps 
these molecules are above a threshold size at which permeation into the polymer films can occur. 
This hypothesis is supported by the fact that the partition coefficient values are generally equal to 
or less than those calculated for the small molecules shown in Figure 6.1. Additionally, 
partitioning of these molecules into the Mylar® films was small but non-zero (Kp values of 0.5 to 
1.28), and the values obtained for the partition coefficients in the other polymers were typically 
within one standard deviation of the Kp values obtained in the Mylar®. This suggests that some 
of the adsorption of these molecules may have been due to their interactions with the Mylar® 
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substrate. This is a surprising result, since Mylar® is known to be relatively chemically inert, and 
partially crystalline. In the case of the heparin molecule that was used in this study, however, this 
result could be explained by the fact that the heparin sulfate was in the form of an ammonium 
salt. Hydrogen bonding or other ionic association of the sulfate groups on the heparin 
polysaccharide with the carbonyl in the Mylar® backbone or the ammonium ions with the benzyl 
ring in the Mylar® backbone could explain the larger apparent partitioning of the 3H-heparin (× 
symbols in Figure 6.2) into the Mylar® compared to the other polymers in this study. 
6.3.4 Proteins (125I-IL-2) 
The calculated partition coefficients for 125I-IL-2 are shown in Figure 6.3 below. 
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Figure 6.3 Partition coefficients of 125I-IL-2 in various polymers. 
The calculated partition coefficients for the 125I-IL-2 are quite low, showing a maximum 
of only 0.4 for the PLGA4.4 films. This is not surprising, given the high molecular weight of the 
protein (approximately 15,000 daltons) and its relative hydrophobicity. Another factor that may 
contribute to the low measured absorption by the polymers of IL-2 is that the recombinant IL-2 
that was used in this study is known to stick to glass and plastics10. Sticking of IL-2 to the 
surface of the microfuge tube during the initial equilibration phase of the study would cause the 
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concentration of the molecule in solution to be less than expected. Thus the solution 
concentration C1 in the denominator of Equation 6-a used to calculate the partition coefficients 
would be larger than the actual value, resulting in an artificially low value of Kp for this molecule. 
Further, sticking of the IL-2 to the surface of the polymer film during the desorption phase of the 
study would result in an artificially low value of C2 (concentration of the solute released into the 
medium after desorption equilibrium was reached), which would also result in a lower value of 
Kp according to Equation 6-a. 
6.3.5 Discussion 
The values of partition coefficients obtained for the various chemicals in this study help 
to explain, to some extent, the sustained release that was observed for 14C-BCNU and 14C-IAP in 
some of the release experiments reported (see Chapter 4). The high partition coefficients of the 
14C-BCNU and 14C-IAP in the PLGA4.4 may partially explain the diffusional release seen in 
Chapter 4 for devices loaded with both 14C-BCNU and 14C-IAP, although the reservoirs having 
PLGA11, PLGA28, and PLGA64 membranes also showed diffusional release. This suggests 
that perhaps the driving force for diffusion due to the concentration gradient across the reservoir 
membranes on a microreservoir device may be responsible for the observed diffusional release, 
rather than just the partitioning of the molecule. In the case of our partitioning study reported 
here, the system is allowed to come to equilibrium in order to determine the partition coefficient. 
An actual release study, in contrast, is not in equilibrium due to the high concentration gradient 
of the drug across the reservoir membrane. Although the equilibrium partitioning of the drug into 
the membrane may not necessarily be large, if the driving force for diffusion is large there will 
be a continual flux of the drug through the membrane, and consequently diffusional release of 
the drug from the device will be observed. In contrast, we would expect that although the 
concentration gradient across the membranes may be comparable for the large molecules 
investigated here (14C-dextrans, 3H-heparin, and 125I-IL-2), the diffusion coefficients are likely 
much smaller due to the large sizes of the molecules, and this may be the reason that no 
diffusional release of these molecules was seen in our release studies presented in Chapter 4 over 
the time period of interest. 
While the partition coefficients obtained here are small but non-zero for all of the 
polymers that were investigated, it is important to keep in mind that the experimental conditions 
166 
that were used here are dissimilar to those that would be experienced by a drug for either in vitro 
or in vivo release. The circumstances of interest for chemicals partitioning into the reservoir 
membranes in a release study will be the situation in which chemical solids are dried on the 
inside of the device reservoir and are in contact with the cast (or microinjected) polymer film 
membrane at 37°C. It is expected that the partitioning and diffusion would be much lower in that 
case than in the studies reported here, as the reservoir membranes would not be as hydrated and 
swollen on the inside of the reservoirs as they presumably were in the study reported here. In the 
absence of an experimental setup that exactly mimics that of an in vitro or in vivo release study, 
however, a qualitative evaluation of the partition coefficients can simply be deduced from the 
shape of the release curves for a given microreservoir device. In the case of the large molecules 
investigated (14C-dextran having a molecular weight of 70,000, 3H-heparin, and 125I-IL-2 at short 
times), pulsatile release without significant diffusion is clearly achievable and demonstrable as 
was shown in Chapter 4. 
None of the chemicals studied showed significant partitioning into the PLA films over 
the course of the study. This suggests that permeation of drugs from the reservoir chambers into 
the substrate of the device will not be significant over the first 30 days of device usage. 
However, the microreservoir device substrate is hot compression molded rather than solvent cast, 
as was the case for the PLA films used in this study, so these results should be extrapolated with 
care. 
6.4 Conclusions 
While most of the chemicals investigated did not appear to undergo significant 
partitioning into the various membrane materials, both 14C-BCNU and 14C-IAP showed large Kp 
values for both the PLGA4.4 and PLGA11 membrane materials. This is generally consistent 
with results reported in the literature for other polymers having low glass transition temperatures 
that showed significant permeability of solutes. These results are also consistent with release data 
obtained and reported in Chapter 4 that show no significant burst or diffusional release of 
chemicals from the reservoirs prior to membrane opening, except in the cases of 14C-BCNU or 
14C-IAP loaded reservoirs. This result bodes well for device scale up and commercialization for 
large molecules, as the release kinetics of the chemicals appear to be dictated only by the 
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degradation times of the reservoir membrane materials and not by the partitioning and/or 
diffusion of these large molecules into and through the reservoir membranes.  
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7 Chemical Release: Characterization of Membrane Swelling and 
Dependence of Chemical Release on Osmotic Pressure and 
Molecular Chemistry 
7.1 Introduction and Motivation 
7.1.1 Introduction 
Thus far we have seen that a number of factors can affect the performance of our drug 
delivery microreservoir devices. The chemistry and size of the drug molecule may play a role in 
the observed release kinetics, and changing the molecular weight of the membrane polymer can 
control the release time of the drug. Although it is well known that PLGA copolymers are 
subject to a complex degradation process, one of the least studied aspects is the swelling of the 
polymer prior to the commencement of hydrolysis. While PLGA swelling seems to be of minor 
interest when studying most PLGA implants, such as microspheres, in the case of our devices the 
swelling may cause or be related to the time at which the reservoir membranes open. Thus the 
water uptake and swelling behaviors of the reservoir membranes on our device are of great 
interest. Further, although no diffusion of the drug has been observed through the reservoir 
membranes on our microreservoir devices in most cases (with the exceptions of BCNU and IAP), 
it is possible that water may diffuse into the reservoir from the surrounding environment. This 
might cause a loading-dependent osmotic pressure within the reservoir. In order to reliably 
predict device operation it is vital to know whether or not such an osmotic pressure effect exists.  
While the degradation of PLGA copolymers has been fairly extensively studied and 
reported on in the literature1, the changes in their mechanical properties over time in both the in 
vitro and in vivo environments are less well understood. This may be due to the fact that these 
polymers are largely used in drug-delivery2–8 and tissue engineering9–11 applications rather than 
in load-bearing applications, with the exception of some types of orthopedic implants12–16. 
However, the mechanical properties and behavior over time of these PLGA copolymers are 
extremely important when considering their use as membrane materials in our polymeric 
microreservoir devices, as the ultimate failure of the membrane and release of the drug from the 
reservoir may depend on the loss of mechanical strength of the membrane polymer.  
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7.1.2 Motivation 
The experiments presented here were designed to achieve several goals. First, we desired 
to quantify the extent of swelling of the membranes during a typical release experiment. Second, 
we wanted to correlate the membrane swelling with the observed release time of molecules from 
the reservoirs. Third, we wanted to determine whether or not the observed swelling varied 
depending on the molecule that was loaded into the reservoirs. Lastly, we wanted to determine 
whether the loading of the reservoir affected the extent of membrane swelling that was observed. 
A correlation between these two phenomena would suggest that the observed membrane swelling 
is at least partially due to an osmotic pressure effect within the reservoir, rather than solely due to 
water uptake, and that therefore the reservoir loading could affect the observed release time. 
7.2 Materials and Methods 
7.2.1 Materials 
Poly(L-lactic acid) (PLA, Mw 194 Kilodaltons (Kd), Medisorb® 100 L), and poly(D,L-
lactic-co-glycolic acid) polymer powders of molecular weights (Mw) 4.4 Kd (PLGA4.4, 
Medisorb® 5050 DL 1A) and 11 Kd (PLGA11, Medisorb® 5050 DL 2A) were obtained from 
Alkermes (Cincinnati, Ohio). Each PLGA copolymer had approximately a 50:50 mole ratio of 
lactic acid:glycolic acid units. Reagent grade 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP), and 14C-
dextran (Mws = 10,000, 40,000, and 70,000) were purchased from Sigma-Aldrich (St. Louis, 
MO). 14C-glucose, 14C-glycerol, 14C-glycerol 3-phosphate (ammonium salt), and 14C-glycerol 
trioleate were purchased from Amersham Pharmacia Biotech (Buckinghamshire, England). Ideal 
9144 Masking Tape was obtained from American Biltrite, Inc. (Lowell, MA). 
Hexamethyldisilazane was purchased from Polysciences, Inc. (Warrington, PA). Ethyl alcohol, 
200 proof, was purchased from Pharmco (Brookfield, CT). 
7.2.2 Methods  
Twenty-two devices were fabricated as described in Chapter 2. On each device, one 
reservoir was sealed with a membrane of PLGA4.4, and one reservoir was sealed with a 
PLGA11 membrane. Predicted membrane thicknesses ranged from 151 to 161 µm. One control 
device had no chemical loaded into the reservoirs. The devices were loaded with a calculated 
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amount of 14C-glucose, 14C-dextran (Mw~10,000, or 40,000 daltons), 14C-glycerol, 14C-glycerol 
3-phosphate, or 14C-glycerol trioleate that corresponded to an osmotic pressure of approximately 
40 kPa. Three identical devices were fabricated for each chemical. Devices loaded with 14C-
dextran (Mw~70,000) had a loading that corresponded to osmotic pressures of 20, 40, or 80 kPa.  
The loading of each chemical, with the exception of the dextrans of various molecular 
weights, corresponded to a specified osmotic pressure and was calculated using the equation: 
 
MRT=Π  
Equation 7-a 
where Π = osmotic pressure (in atmospheres), M = molarity of the solution, R = the ideal gas 
constant, and T = temperature (K), assumed to be 270°K. The molarity of the solution was 
understood to be the molarity of the solution if the reservoir were completely filled with water. 
In this case, the molarity M can be found from the following relation: 
 
VM
WM
w
=  
Equation 7-b 
where W = the weight of solute in the reservoir in grams, Mw = the molecular weight of the 
solute in grams per mole, and V = the total volume of the reservoir, taken to be 126 nL based on 
the geometry of the device (see Chapter 2). 
 The osmotic pressure due to the dextran molecules cannot be accurately calculated using 
Equation 7-a, as the polymeric nature of the chains causes nonlinear behavior. Equations for 
calculating osmotic pressure effects in the case of dextran are thus often determined 
experimentally. The osmotic pressure Π (in dynes/cm2) due to dextran in solution can be found 
using the following equation17: 
 
c
pWba )(log ⋅+=Π  
Equation 7-c 
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where a, b, and c are experimentally determined constants, and Wp = weight percent of the 
dextran in solution. This equation is applicable over the range of 14–34% solutions by weight for 
dextran having a molecular weight of 10,000 daltons, and the constants have the following 
values: a = 4.52, b = 0.28, and c = 0.6017. The constants have values of a = 3.009, b = 0.97602, 
and c = 0.393 and the equation is applicable for 0.4% < Wp < 20%17 for dextran having a 
molecular weight of 40,000 daltons. The parameters a, b, and c are not reported in the case of 
70,000 molecular weight dextran, but they are reported for dextran having a molecular weight of 
110,000 daltons (a = 1.385, b = 2.185, c = 0.2436 for Wp < 10%). Therefore, interpolation of 
osmotic pressure data reported elsewhere for 40,000 and 110,000 dalton dextran was used to 
determine the parameters a, b, and c for 70,000 molecular weight dextran as follows: 
07.2)(
7
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Equation 7-d 
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Equation 7-e 
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404011070 =+−= kkkk cccc  
Equation 7-f 
It was found that using the ratio of 3/7 in Equation 7-d produced osmotic pressure values for the 
70,000 molecular weight dextran that were larger at a given weight percentage than for dextran 
having a molecular weight of 40,000, which is not consistent with the trends observed for 
increasing molecular weights of dextran. The ratio of 4/7 was therefore used instead. 
The devices were sealed and affixed to glass slides for stability using American Biltrite 
9144 masking tape after they were loaded with the calculated amounts of radiolabeled molecules. 
Each device was then put in a screw-cap jar containing 20 mL stirred 1X phosphate-buffered 
saline (PBS). A magnetic stir bar was also added to each jar, and the jars were placed on a 
magnetic stir plate at room temperature. One mL samples of media were taken from the jars once 
per day and pipetted into 7-mL glass scintillation vials. One milliliter of fresh PBS was added to 
the jars to keep the volume of release medium constant. The amount of radiolabel present in the 
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scintillation vials was quantified using a 14C-protocol on a Packard Tri-Carb liquid scintillation 
counter (Model U2200). Also once per day, one device from each sample group was removed 
from its jar, carefully blotted dry with a paper towel, and viewed under an Olympus BH2 
microscope using either an Olympus TH3 light source (Olympus, Melville, NY), or Series 180 
Fiber-Lite high intensity illumination source (Dolan-Jenner Industries, Inc., Lawrence, MA). The 
maximum height of the membrane surface was measured relative to the surface of the substrate 
by observing the locations of the numerically marked fine focus knob for each surface, and 
multiplying the numerical difference between the two numbers by two µm/mark. The average 
and standard deviation at each time point were found by combining the measurements at the two 
magnifications. Digital photos were taken with a Pixera digital camera using Pixera Viewfinder 
software on a Dell Dimension L566cx computer. 
An estimation of the percentage (by weight) of water uptake can be found by performing a 
series of calculations as follows. The percentage of water uptake can be calculated based on the 
mass of water absorbed (Mw) and the initial mass of the membrane polymer (Mp:): 
 
100% ×=
p
w
M
Muptake  
Equation 7-g 
The mass of water absorbed was not measured, but it can be estimated based on the change in 
volume of the membrane. If we assume that the portion of the membrane above the surface of the 
device swells in the shape of a spherical section, having a radius r1 = radius of the reservoir 
opening, and height h = measured maximum membrane height, then the volume of the swollen 
region Vs can be found as follows: 
 
( )hhrVs 22136 += π  
Equation 7-h 
We assume that the actual membrane itself does not swell inside the reservoir, but that the 
membrane swells perpendicular to the surface of the device, and that all of the swelling is 
reflected in the measured increase in membrane height. Additionally, we make the simplifying 
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assumption that the polymer itself does not undergo any change in density or swelling due to 
solvent interactions, but that all of the observed change in volume is solely due to the absorption 
of a volume of water. Then the percentage of water uptake can be calculated as: 
 
pp
ws
V
Vuptake ρ
ρ
×
×=%  
Equation 7-i 
where ρw = density of water, Vp = volume of polymer in membrane, and ρp = density of the 
membrane polymer. One additional simplifying assumption that is used in calculating the 
percentage of water uptake is to assume that, for devices in which the height of the membrane 
was initially below the surface of the device, the difference in swollen volume is negligible 
whether calculated as the frustum of a cone or as a spherical section. Therefore, for devices in 
which this was the case, the maximum height of the membrane h used in Equation 7-h was the 
measured maximum membrane height minus the initial membrane height. 
The devices were dehydrated in a series of ethanol washes of increasing concentrations 
(50%, 75%, 90%, 100%, and 100%) after completion of the release experiments. The devices 
were then removed from the glass slides to which they were affixed, and placed in 12-well 
polystyrene tissue culture plates. One milliliter of hexamethyldisilazane (HMDS), a dehydrating 
agent that is purported to preserve the structure of tissue and other organic materials, was added 
to each well. The HMDS was left in each well for one to two minutes before being pipetted out 
and replaced with fresh HMDS for another one to two minutes. The second volume of HMDS 
was then pipetted out of the wells, and the devices were left in a hood until they were dry. The 
devices were sputter coated with gold for 60 seconds at 24 mA (Pelco SC-6 sputter coater), and 
imaged in a scanning electron microscope (SEM, Hitachi model S-530) at two keV. Digital 
photos were taken using Oxford Instruments Link ISIS software. 
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7.3 Results and Discussion 
7.3.1 In vitro release and swelling measurements of radiolabel loaded devices 
7.3.1.1 Control device 
The swelling measurements for the membranes on the control device are shown in 
Figure 7.1. The arrows on the figure indicate when the membrane appeared to be “open” when 
viewed under the microscope. Large holes were seen in the centers of the reservoir membranes in 
the case of this control device. 
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Figure 7.1 Maximum measured membrane height relative to device surface for ~150 µm thick PLGA4.4 (dotted 
line) and PLGA11 (solid line) membranes on unloaded control device. 
This device exhibited large decreases in the maximum membrane heights on the same 
days that the reservoirs appeared open when viewed under the microscope. This result was also 
observed for some of the other devices that will be discussed.  
Figure 7.2 shows photographs of the two reservoir membranes taken at various times 
during the experiment.  
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(a)  (d)  
(b)  (e)  
(c)  (f)  
Figure 7.2 ~150 µm thick membranes on control (unloaded) device, viewed under optical microscope: (a) PLGA4.4 
membrane at day zero, (b) PLGA4.4 membrane at day five, (c) PLGA4.4 membrane at day 12, (d) PLGA11 
membrane at day zero, (e) PLGA11 membrane at day five, (f) PLGA11 membrane at day six. 
The membranes initially were transparent and planar, as can be seen in Figure 7.2(a) and 
(d). However, the membranes began to swell within a few days of being immersed in the saline 
solution, as can be seen in Figure 7.2(b) and (e) for the PLGA4.4 and PLGA11 membranes, 
respectively. In the case of both the PLGA4.4 and PLGA11 membranes, the time at which a 
hole appeared in the reservoir membrane (shown in Figure 7.2(c) and (f)) corresponded with a 
drop in the maximum height of the membrane. The PLGA4.4 membrane showed a sudden drop 
in height between days 11 and 12, and the membrane exhibited a large hole at day 12. Similarly, 
the PLGA11 membrane showed a large drop in height between days five and six, and had a large 
hole at day six as shown in Figure 7.2(f). It is hypothesized that the region of the membrane that 
underwent the maximum swelling was most likely to be under the largest amount of stress. This 
large stress may have ultimately caused that swollen region of the membrane to fail and detach 
200 µm 200 µm 
200 µm 200 µm 
200 µm 200 µm 
177 
from the device. Measurement of the maximum membrane height during subsequent 
examination under the microscope would therefore result in a smaller measured membrane 
height relative to previous measurements, as borne out by our results.  
 One unexpected result was that the opening time for the PLGA11 membrane was earlier 
than that for the PLGA4.4 membrane. This result was not seen for any of the other devices in 
this study. Although it is possible that the PLGA11 actually degraded faster than the PLGA4.4, 
thus causing the membrane to fail earlier, this is highly unlikely given the difference in 
molecular weights of the two materials, as well as the observed changes in molecular weights 
over time for these two materials (see sections 5.3.2.1 and 5.3.2.2 for GPC characterization of 
150 µm films of these materials). One possible explanation for the observed results may be the 
limited depth of field of the microscope. Due to the large vertical swelling of the membranes, 
viewing the entire surface of the membranes in the field of view was difficult to achieve. 
Features such as crevices or flaps that have a large variation in three-dimensional topography are 
thus difficult to see under the optical microscope. Therefore, although the PLGA11 membrane 
exhibited a large hole earlier than the PLGA4.4 membrane, it is possible that a crack or other 
break in the surface of the PLGA4.4 membrane may have occurred earlier than the observed 
hole in the PLGA11 membrane. In the case of these control devices, no chemical was loaded 
into the reservoirs and therefore confirmation of reservoir opening via a pinhole or crack could 
not be obtained from detection of chemical release. 
The PLGA4.4 membrane showed a difference in height of approximately 350 µm (315 
µm maximum on day one and –31 µm on day zero) over the course of the experiment, while the 
PLGA11 membrane showed a difference in height of approximately 440 µm (324 µm maximum 
on day five and –117 µm minimum on day zero). These correspond to 230 and 290% 
approximate increases in membrane height, respectively, from the initial ~150 µm membrane 
thickness. 
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7.3.1.2 14C-glucose 
The release data for the three devices loaded with 14C-glucose are shown in Figure 7.3. 
The swelling data for one of these devices that was inspected under the microscope (solid line in 
Figure 7.3) is shown in Figure 7.4. 
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Figure 7.3 Cumulative percentage of 14C-glucose loading released over time from three devices having ~150 µm 
thick PLGA4.4 and PLGA11 reservoir membranes. 
All three of the devices that were loaded with 14C-glucose showed release from the 
reservoirs having PLGA4.4 membranes on day one, consistent with results seen in other in vitro 
studies (see sections 5.3.1 and 4.3.2). Larger variation was seen in the release times for the 
PLGA11 membranes. Two of the devices (dotted and dashed lines in Figure 7.3) showed release 
from the PLGA11 reservoirs between 11–12 days, while the third device (solid line, device that 
was viewed on the microscope) showed much earlier release at approximately six days. 
Additionally, the total amount of radiolabel recovered for the three devices showed a large 
variation. The device viewed under the microscope showed only approximately 60% release of 
the 14C-glucose, while between 100 and 120% of the initial loading was detected from the other 
two devices. The variation in amount of radiolabel detected may be due to several factors. In the 
case of the device that was viewed under the microscope, the device was blotted with a paper 
towel prior to microscopy in order to eliminate any water on the surface of the device so that 
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clear photographs could be obtained. Some of the radiolabeled glucose may have been removed 
from the surface of the device during this procedure. In the case of the other two devices that 
were not photographed, the variation in the amount of radiolabel detected may be due to the 
evaporation from and subsequent addition of saline solution to the vessel in which the 
experiments were conducted. Although efforts were made to maintain the volume of saline 
solution (the release medium) constant at 20 mL, some variation undoubtedly occurred, and the 
solution would have become more concentrated when evaporation occurred. This may have 
caused the variations seen in Figure 7.3 when the cumulative amount of 14C-glucose released 
was calculated. 
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Figure 7.4 Maximum measured membrane height relative to device surface for ~150 µm thick PLGA4.4 (dotted 
line) and PLGA11 (solid line) membranes on device loaded with 14C-glucose. 
The maximum measured membrane heights for one of the devices loaded with 14C-
glucose are shown in Figure 7.4 above. Optical microscopy photographs taken over the course 
of the study, as well as SEM photos of the reservoirs at the conclusion of the experiment (after 
30 days in saline solution) are shown in Figure 7.5 below. A crack in the surface of the 
PLGA4.4 membrane appeared at day seven, as indicated by the arrow in Figure 7.5(c). 
Surprisingly, 14C-glucose was detected from this device at day one, but a decrease in the 
maximum measured membrane height was observed between days five and six. These three 
pieces of seemingly conflicting evidence do not seem to support our theory that the drop in 
180 
membrane height is indicative of or correlated with membrane opening. In the case of this 
PLGA4.4 membrane, it may be likely that a small fissure on the side of the membrane began at 
day one, causing the radiolabel release, and that the swelling continued after release of the 14C-
glucose had already begun. 
 In the case of the PLGA11 membrane, the radiolabel data in Figure 7.3 for this device 
(solid line) indicate that release from the reservoir occurred between days five and six. The 
measurements of membrane height in Figure 7.4, however, show a drop in membrane height 
between days ten and 11, and optical microscopy of the device revealed the appearance of a hole 
in the membrane at day nine. Interestingly, the maximum membrane height occurred on day five 
(a photograph of the PLGA11 reservoir membrane at day five is shown in Figure 7.5(f)). These 
results suggest that the time at which the maximum membrane height is measured may 
correspond with the time at which release from the reservoir occurs. Although no large hole was 
visible in the PLGA11 membrane until day nine, it is possible that a fissure on the side of the 
membrane or some other type of breach in the structure that was not visible at the magnification 
we used occurred between days five and six, which would have caused release of the radiolabel 
from the reservoir. 
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(a)  (e)  
(b)  (f)  
(c)  (g)  
(d)  (h)  
 
Figure 7.5 ~150 µm thick membranes on device loaded with 14C-glucose, viewed under optical microscope or 
viewed under SEM: (a) PLGA4.4 membrane at day zero, (b) PLGA4.4 membrane at day five, (c) PLGA4.4 
membrane at day seven, (d) SEM of PLGA4.4 membrane after 30 days in saline solution, (e) PLGA11 membrane at 
day zero, (f) PLGA11 membrane at day five, (g) PLGA11 membrane at day nine, (h) SEM of PLGA11 membrane 
after 30 days in saline solution. 
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The maximum measured increase in height for the PLGA4.4 membrane was 
approximately 740 µm, corresponding to a 490% increase in the membrane thickness. The 
PLGA11 membrane height increased by approximately 280 µm, or approximately 190%.  
7.3.1.3 14C-dextran: Mw~10,000 
The radiolabel release data for the three devices loaded with 14C-dextran having a 
molecular weight of ~10,000 daltons are shown in Figure 7.6 below. Again we see that the 
reservoirs sealed with the PLGA4.4 material uniformly released on day one. The PLGA11 
membranes show much greater consistency in release times (days 10–12) compared to the results 
obtained for the 14C-glucose devices (6–12 days, Figure 7.3). 
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Figure 7.6 Cumulative percentage of 14C-dextran (Mw~10,000) loading released over time from three devices 
having ~150 µm thick PLGA4.4 and PLGA11 membranes. 
The maximum measured membrane heights for one of these devices (solid line in Figure 
7.6) are shown in Figure 7.7 below. The swelling data in Figure 7.7 indicate a decrease in the 
maximum measured PLGA4.4 membrane height between days two and three. Optical and SEM 
photographs of this reservoir are shown in Figure 7.8. The opening in the PLGA4.4 membrane 
at day two can be seen as a crack in the center of the membrane in Figure 7.8(b). Similar to the 
results obtained for the 14C-glucose loaded device, detection of the radiolabel released from the 
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reservoir sealed with a PLGA4.4 membrane occurred prior to the membrane appearing open 
under the microscope. 
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Figure 7.7 Maximum measured height of reservoir membranes relative to device surface for ~150 µm thick 
PLGA4.4 (dotted line) and PLGA11 (solid line) membranes on device loaded with 14C-dextran (Mw~10,000). 
(a)   (c)  
 
(b)                   
Figure 7.8 ~150 µm thick PLGA4.4 membrane on device loaded with 14C-dextran (Mw~10,000) viewed under 
optical microscope or viewed under SEM: (a) PLGA4.4 membrane at day zero, (b) PLGA4.4 membrane at day two, 
(c) SEM of PLGA4.4 membrane after being in saline solution for 30 days. 
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 The swelling data in Figure 7.7 indicate a large decrease in the PLGA11 membrane 
height between days ten and 11. However, radiolabel release was not detected from this reservoir 
until day 12, as shown by the solid line in Figure 7.6. Additionally, optical microscopy showed 
what appeared to be a small pinhole in this membrane and a fissure near the reservoir perimeter 
at day ten, as indicated by the arrows in Figure 7.9(d), although a large hole did not appear in the 
membrane until day 11, as shown in Figure 7.9(e). One possible coherent explanation for these 
seemingly disparate data is that the pinhole may not have penetrated completely through the 
PLGA11 membrane at day ten, but may in fact just have been a dimple in the surface of the 
membrane. Depth of field limitations of the microscope made it difficult to resolve how deep the 
feature was and whether it penetrated completely through the membrane. Additionally, the large 
molecular weight of the dextran may have slowed the dissolution of the molecule within the 
reservoir. Thus even if the pinhole may have completely penetrated through the membrane, it 
may have taken some time for the dextran to dissolve, diffuse out of the reservoir, and be 
measured. Further, the media aliquots that were used for scintillation measurements of the 
radiolabel were removed from the release vessel prior to microscopy of the devices at any give 
time point. Thus it is possible that although no radiolabel was detected at the day 11 time point, 
perhaps the membrane was dislodged from the surface of the reservoir between the time at which 
the media aliquot was taken and the subsequent microscopy, during which a hole appeared in the 
membrane. This would be consistent with the radiolabel detection that was observed at day 12. 
 The maximum measured height for the PLGA4.4 membrane was approximately 690 µm 
greater than the initial membrane height, corresponding to a 460% increase in the membrane 
thickness. The PLGA11 membrane exhibited a height change of 600 µm at ten days, 
corresponding to a 400% increase in the membrane thickness. 
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(a)  (d)  
(b)  (e)   
(c)  (f)  
Figure 7.9 ~150 µm thick PLGA11 membrane on device loaded with 14C-dextran (Mw~10,000) viewed under 
optical microscope or viewed under SEM: (a) PLGA11 membrane at day zero, (b) PLGA11 membrane at day eight, 
(c) PLGA11 membrane at day ten, box indicates region enlarged in (d) showing pinhole and fissure in PLGA11 
membrane at day ten, (e) PLGA11 membrane at day 11 showing large hole in membrane, (f) SEM of PLGA11 
membrane after 30 days in saline solution. 
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7.3.1.4 14C-dextran: Mw~40,000 
The release results for three devices loaded with 14C-dextran having a molecular weight 
of 40,000 daltons are shown in Figure 7.10. The device indicated by a solid line in Figure 7.10 
was viewed under the microscope, and the measured membrane heights relative to the device 
surface are plotted in Figure 7.11. 
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Figure 7.10 Cumulative percentage of 14C-dextran (Mw~40,000) loading released over time from three devices 
having ~150 µm thick PLGA4.4 and PLGA11 membranes. 
The reservoirs having membranes made from PLGA4.4 uniformly released on day one. 
The reservoirs having PLGA11 membranes showed more variation in release times than was 
seen for the devices loaded with either 14C-glucose or 14C-dextran having a molecular weight of 
10,000 daltons. With the exception of the device that showed release from the PLGA11 reservoir 
at 19 days, however, these devices showed similar release times (eight to nine days) to those 
loaded with 14C-glucose (six to 12 days) and 14C-dextran having a molecular weight of 10,000 
daltons (ten to 12 days). 
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Figure 7.11 Maximum measured membrane height relative to device surface for ~150 µm PLGA4.4 (dotted line) 
and PLGA11 (solid line) membranes on device loaded with 14C-dextran (Mw~40,000). 
The measured membrane heights for the device represented by the solid line in Figure 
7.10 are shown in Figure 7.11 above, and photographs of the membranes over the course of the 
experiment are shown in Figure 7.12 and Figure 7.13. The PLGA4.4 membrane did not appear 
open until day three (Figure 7.12(c)), and showed a sudden decrease in the maximum measured 
membrane height between days two and three. However, the radiolabel was detected from this 
reservoir on day one. These results are similar to those obtained for the devices loaded with 14C-
glucose and 14C-dextran having a molecular weight of 10,000 daltons. The PLGA11 membrane 
showed a decrease in membrane height between days 12 and 13, but the membrane did not 
appear open until a very small pinhole appeared at day 15 (indicated by the arrow in Figure 
7.13(c) below). Radiolabel release was detected from this reservoir starting at day eight (solid 
line in Figure 7.10 above).  
It is somewhat surprising that radiolabel release was detected from both of these 
reservoirs before opening of the membranes was seen, that is to say that there did not appear to 
be a correlation between the observed opening time (via microscopy) and the actual opening time 
(via scintillation measurements). Again this may be explained by the consideration that the 
membranes were highly swollen and that it is quite difficult to obtain an accurate image of them 
given the limited depth of field of the microscope. Further, the PLGA11 membrane on this 
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device never exhibited a large hole similar to that seen for some of the devices. Even after 28 
days (see Figure 7.13(d)), most of the membrane was still present within the reservoir opening. 
Although some swelling of the central region was evident, it was very difficult to determine the 
existence of holes or ruptures in the membrane even at this late time point, although radiolabel 
release had already been detected. 
 
 
 
(a)  (c)  
(b)  (d)  
Figure 7.12 ~150 µm thick PLGA4.4 membrane on device loaded with 14C-dextran having a molecular weight of 
40,000 daltons, viewed under optical microscope or viewed under SEM: (a) PLGA4.4 membrane at day zero, (b) 
PLGA4.4 membrane at day one, (c) PLGA4.4 membrane at day three, (d) SEM of PLGA4.4 membrane after being 
in saline solution for 30 days. 
The maximum swelling measured of the PLGA4.4 membrane was approximately 710 
µm on day one (Figure 7.12(b)), or approximately a 470% increase in membrane thickness, 
similar to that seen for the devices loaded with both 14C-glucose (490%) and 14C-dextran having 
a molecular weight of 10,000 daltons (460%). The PLGA11 membrane attained a maximum 
swelling of approximately 530 µm at day 12 (Figure 7.13(b)), corresponding to an increase of 
approximately 350% in membrane thickness, slightly less than that seen for the device loaded 
with 14C-dextran having a molecular weight of 10,000 daltons (400%). 
 
 
 
200 µm 200 µm 
200 µm 
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(a)   (d)  
(b)    (e)  
(c)        
Figure 7.13 ~150 µm thick PLGA11 membrane on device loaded with 14C-dextran having a molecular weight of 
40,000 daltons, viewed under optical microscope or viewed under SEM: (a) PLGA11 membrane at day zero, (b) 
PLGA11 membrane at day 12, (c) PLGA11 membrane at day 15 with arrow indicating location of pinhole, (d) 
PLGA11 membrane at day 28, (e) SEM of PLGA11 membrane after being in saline solution for 30 days. 
7.3.1.5 14C-dextran: Mw~70,000 
The release results for devices loaded with 14C-dextran having a molecular weight of 
70,000 daltons are shown in Figure 7.14 below. Three different loadings of 14C-dextran were 
used, corresponding to osmotic pressures of 20 (low loading, solid line in Figure 7.14), 40 
(intermediate loading, dashed line), and 80 (high loading, dotted line) kPa if the remaining 
volume of the reservoirs were to fill with water. 
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Figure 7.14 Cumulative percentage of 14C-dextran (Mw~70,000) released from three devices having ~150 µm thick 
PLGA4.4 and PLGA11 membranes. Solid line = 20 kPa loading, dashed line = 40 kPa loading, dotted line = 80 kPa 
loading. 
The reservoirs sealed with PLGA4.4 membranes appeared to uniformly release their 
contents on day one. The reservoirs sealed with PLGA11 membranes showed surprisingly little 
variability in release times. The device with the lowest loading showed release on day 14, while 
the device with the highest loading showed release between days 15–16, and the device with 
intermediate loading between 17 and 18 days. In comparison, the devices loaded with 14C-
dextran having a molecular weight of 10,000 daltons (same loading for all three devices, see 
Figure 7.6 in section 7.3.1.3) showed variation in the release time from the PLGA11 reservoirs 
of only ±1 day. In contrast, devices loaded with 14C-glucose (same loading for all three devices, 
see Figure 7.3 in section 7.3.1.2) showed release times from six to 12 days, or a variation of ±3 
days, from reservoirs having PLGA11 membranes. Devices loaded with 14C-dextran having a 
molecular weight of 40,000 daltons showed even greater variation, with release times from the 
PLGA11 reservoirs ranging from six to 19 days (see Figure 7.10 in section 7.3.1.4). The fact 
that no greater variation in release times was seen for the devices loaded with different amounts 
of 70,000 molecular weight 14C-dextran compared to devices loaded with other radiolabels 
suggests that the amount of drug that is loaded into the reservoir does not noticeably affect the 
release time over the range of different loadings that were investigated. More specifically, it is 
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evidence that there is no osmotic pressure effect on the rupturing of the membrane. If such an 
osmotic pressure effect were to exist, we would expect that the device with the highest loading 
(dotted line in Figure 7.14) would show the earliest release, due to higher pressure within the 
reservoir, while the device with the lowest loading (solid line in Figure 7.14) would show the 
latest release time. The device with the lowest loading, however, showed the earliest release at 
day 14, followed next by the device with the highest loading at 15 days, and finally the device 
with intermediate loading at day 17. The lack of an apparent loading or osmotic pressure effect 
suggests that diffusion of water through the PLGA11 membrane into the reservoir is not 
significant on the time scale at which the membrane fails, and that therefore the membranes are 
completely dense. 
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Figure 7.15 Maximum measured membrane height relative to device surface for ~150 µm thick PLGA4.4 (dotted 
line) and PLGA11 (solid line) membranes on device loaded with 14C-dextran (Mw~70,000) corresponding to 
osmotic pressure of 20 kPa. 
The maximum measured membrane heights for the device with a loading of 70,000 
molecular weight 14C-dextran corresponding to Π = 20 kPa (low loading) are shown in Figure 
7.15 above, while photographs of the PLGA4.4 and PLGA11 membranes at various times are 
shown in Figure 7.16 below.  
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(a)  (e)  
(b)  (f)  
(c)  (g)  
(d)  (h)  
Figure 7.16 ~150 µm thick membranes on device loaded with 14C-dextran having a molecular weight of 70,000 
daltons (loading corresponds to an osmotic pressure of 20 kPa), membranes viewed under optical microscope or 
viewed under SEM: (a) PLGA4.4 membrane at day zero, (b) PLGA4.4 membrane at day one, (c) SEM of PLGA4.4 
membrane after 30 days in saline solution, (d) PLGA11 membrane at day zero, (e) PLGA11 membrane at day 14, 
(f) PLGA11 membrane at day 15, (g) PLGA11 membrane at day 21, (h) SEM of PLGA11 membrane after 30 days 
in saline solution. 
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200 µm 
193 
The PLGA4.4 membrane showed a rapid increase in height at day one (see Figure 
7.16(b)), followed by a decrease at day two and an even larger decrease between days two and 
three, as was observed for devices loaded with other radiolabeled compounds. After the reservoir 
appeared to open, the membrane continued to swell as indicated by the slow drift upwards in the 
measured membrane height plotted in Figure 7.15. The PLGA11 membrane, on the other hand, 
showed a fairly steady increase in the measured membrane height up to day 13, when it 
increased more rapidly. Radiolabel release was detected from this reservoir on day 14, followed 
by the appearance of a hole in the membrane on day 15 (indicated by the arrow in Figure 
7.16(f)). A large decrease in the PLGA11 membrane height was not seen for this device. The 
most likely reason for the absence of a large drop in the PLGA11 membrane height after 
chemical release from the reservoir is that the membrane was not very smooth and most of the 
membrane remained attached to the reservoir after release was detected from the reservoir (see 
Figure 7.16(g) showing the PLGA11 membrane after 21 days, for example). No large hole 
appeared in the membrane, similar to the PLGA11 membrane on the device loaded with dextran 
having a molecular weight of 40,000 daltons. For many of the other devices inspected during this 
study, formation of a hole in the membrane was concurrent or followed by detachment of a large 
portion of the membrane from the edge of the reservoir. However, in some cases large remnants 
of the membrane remained attached to the surface of the device and continued to swell even after 
the membrane had opened. This phenomenon was observed in the case of this device having a 20 
kPa loading of 70,000 molecular weight 14C-dextran. 
 The maximum swelling measured for the PLGA4.4 membrane on this device was 
approximately 690 µm (460% swelling) at day one, shown in Figure 7.16(b). This membrane 
showed a similar amount of swelling as was observed for PLGA4.4 membranes on other devices 
loaded with different chemicals. The PLGA11 membrane exhibited a maximum swelling of 470 
µm (approximately 310% increase in membrane height) at day 16. Similar swelling percentages 
were seen for other PLGA11 membranes in this study. 
 The maximum measured membrane heights for the device with an intermediate loading 
of 70,000 molecular weight 14C-dextran are shown in Figure 7.17 below, and photos of the 
reservoir membranes at various times are shown in Figure 7.18 and Figure 7.19 below. Similar 
to results obtained for other devices, the radiolabel was detected from the reservoir having a 
PLGA4.4 membrane on day one, and a hole was clearly visible in the membrane after two days, 
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as shown in Figure 7.18(a). The membrane height showed a large decrease between days two 
and three, as shown by the dotted line in Figure 7.17. Although release of the radiolabel from the 
reservoir having a PLGA11 membrane was detected on days 17 and 18 (dashed line in Figure 
7.14), no hole was seen in the membrane until day 20 (Figure 7.19(d)). The maximum 
membrane height was seen at day 17 (a photograph of the membrane at day 17 is shown in 
Figure 7.19(e)), and was followed by a decrease in membrane height. 
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Figure 7.17 Maximum measured membrane height relative to device surface for ~150 µm thick PLGA4.4 (dotted 
line) and PLGA11 (solid line) membranes on device loaded with 14C-dextran (Mw~70,000) corresponding to an 
osmotic pressure of 40 kPa. 
The PLGA11 membrane on this device only exhibited a small drop in membrane height after 
a hole appeared. A significant portion of the PLGA11 membrane remained visible within the 
reservoir even after the radiolabel was detected from the reservoir, as can be seen in Figure 
7.19(d) and (e). Most likely these portions of the membrane detached from the perimeter of the 
reservoir over time, giving rise to the gradual decrease in measured membrane height seen in 
Figure 7.17. The absence of a hole in the PLGA11 membrane in the SEM photographs is 
explained by the continued presence of the PLGA11 membrane within the reservoir even up to 
day 28, just prior to dehydration of the samples and preparation for SEM analysis. 
The maximum measured increase in membrane height for the PLGA4.4 membrane on 
this device was approximately 170 µm at day 13, corresponding to a 110% increase in membrane 
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thickness. The PLGA11 membrane had a maximum increase in membrane height of 
approximately 270 µm, or a 180% increase in membrane thickness relative to the initial 150 µm 
thickness. 
 
(a)  (b)  
 
Figure 7.18 ~150 µm thick PLGA4.4 membranes on device loaded with 14C-dextran having a molecular weight of 
70,000 daltons (loading corresponding to 40 kPa osmotic pressure), viewed under optical microscope or viewed 
under SEM: (a) PLGA4.4 membrane at day two, (b) SEM of PLGA4.4 membrane after 30 days in saline solution. 
200 µm 
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(a)  (e)  
(b)  (f)  
(c)  (g)  
(d)       
Figure 7.19 ~150 µm thick PLGA11 membranes on device loaded with 14C-dextran having a molecular weight of 
70,000 daltons (loading corresponding to 40 kPa osmotic pressure), viewed under optical microscope or viewed 
under SEM: (a) PLGA11 membrane at day two, (b) PLGA11 membrane at day ten, (c) PLGA11 membrane at day 
17, (d) PLGA11 membrane at day 20, (e) PLGA11 membrane at day 28, (f) SEM of PLGA11 membrane after 30 
days in saline solution, (g) SEM of PLGA11 membrane after 30 days in saline solution, stage tilted 66°. 
200 µm 200 µm 
200 µm 
200 µm 
200 µm 
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 The maximum measured membrane heights for the device having a loading of 70,000 
molecular weight 14C-dextran corresponding to Π = 80 kPa (high loading) are plotted in Figure 
7.20 below, while photographs of the reservoir membranes over time are shown in Figure 7.21 
and Figure 7.22 below. 
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Figure 7.20 Maximum measured membrane height relative to chip surface for ~150 µm thick PLGA4.4 (dotted 
line) and PLGA11 (solid line) membranes on device loaded with 14C-dextran (Mw~70,000) corresponding to 
osmotic pressure of 80 kPa. 
The PLGA4.4 membrane appeared open at day two, as shown in Figure 7.21 (a)-(c). The 
membrane height decreased slightly between days two and three as shown in Figure 7.20, and 
then dropped more sharply between days five and six. Radiolabel release was detected from this 
reservoir on day one. Radiolabel release was detected from the reservoir having a PLGA11 
membrane starting at day 15 (see dotted line in Figure 7.14 above), but surprisingly the 
membrane did not appear open until day 28, as indicated by the arrow in Figure 7.22(d). 
However, the membrane swelling showed a large increase between days 14 and 15, and 
remained at a plateau value for essentially the rest of the study. This membrane had a very rough 
surface, with several large protrusions which can clearly be seen in Figure 7.22(b)-(d). This is 
most likely the reason why no hole or rupture was seen in the membrane until such a late time 
during the experiment. The topography of the membrane surface would make it quite difficult to 
observe any features that were underneath or on the side of the protrusions. This may also 
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explain why no decrease in the membrane height was observed when the radiolabel release was 
detected. If it is the case that the membrane rupture occurred on the side of the membrane, or 
underneath a protruding feature, this would not be reflected in a decrease in the measured 
maximum membrane height. 
 
(a)  (c)  
(b)  (d)   
Figure 7.21 ~150 µm PLGA4.4 membranes on device loaded with 14C-dextran having a molecular weight of 70,000 
daltons (loading corresponds to 80 kPa osmotic pressure), viewed under optical microscope or viewed under SEM: 
(a) PLGA4.4 membrane at day two, (b) PLGA4.4 membrane at day two shown at higher magnification, arrow 
indicates hole in membrane, (c) PLGA4.4 membrane at day two viewed at yet higher magnification, arrow indicates 
hole in membrane, (d) SEM of PLGA4.4 membrane after 30 days in saline solution. 
The PLGA4.4 membrane showed a maximum increase in height of approximately 450 
mm, or a 300% increase in the membrane thickness relative to the initial thickness of 150 µm. 
The PLGA11 membrane showed a maximum swelling of approximately 320 µm at day 20, or 
approximately a 210% increase in the membrane thickness. 
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(a)    (d)  
(b)    (e)  
(c)       
Figure 7.22 ~150 µm PLGA11 membranes on device loaded with 14C-dextran having a molecular weight of 70,000 
daltons (loading corresponds to 80 kPa osmotic pressure), viewed under optical microscope or viewed under SEM: 
(a) PLGA11 membrane at day two, (b) PLGA11 membrane at day 15, (c) PLGA11 membrane at day 22, (d) 
PLGA11 membrane at day 28, (e) SEM of PLGA11 membrane after 30 days in saline solution. 
7.3.1.6 14C-glycerol 
The release results for three devices loaded with 14C-glycerol are shown in Figure 7.23. 
The device represented by the solid line in Figure 7.23 was viewed under the microscope in 
order to measure the height of the reservoir membranes over time. The maximum measured 
membrane heights for this device are shown in Figure 7.24, and photographs of the reservoir 
membranes at different times are shown in Figure 7.25 and Figure 7.26. The cumulative 
amounts of 14C-glycerol measured and plotted in Figure 7.23 are much lower than those reported 
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for the other molecules discussed up to this point. This is somewhat surprising, as glycerol is 
readily soluble in water. 
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Figure 7.23 Cumulative percentage of 14C-glycerol released from three devices having ~150 µm thick PLGA4.4 
and PLGA11 membranes. 
Figure 7.23 shows that the reservoirs having membranes made from the PLGA4.4 
material all showed release on day one. Two of the devices appeared to show release from the 
reservoirs having PLGA11 membranes on day 14. However, the third device (solid line in 
Figure 7.23) did not appear to show release of any radiolabel from the PLGA11 reservoir. 
Microscopy of this device, however, clearly showed that the reservoir membrane was open on 
day 10, as can be seen in Figure 7.26(c). It is possible that the amount of 14C-glycerol that was 
released from the reservoir having the PLGA11 membrane was so small that blotting of the 
device with a paper towel prior to microscopy removed any excess 14C above the background 
concentration. Alternatively, the decrease in the cumulative amount of 14C-glycerol measured 
suggests that there may be an additional loss of the material from the release vessel other than 
that removed by pipetting the solution aliquots. Adsorption of the glycerol to the pipet tips, 
device surface, or surface of the glass release vessel might account for the decrease in the 
measured amount of glycerol over time.  
The measured membrane heights for both the PLGA4.4 and PLGA11 membranes on the 
device that was viewed under the microscope (indicated by the solid line in Figure 7.23) showed 
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a large increase in the first few days of the study before reaching a plateau up to day nine. Both 
membranes showed a large drop in the measured maximum membrane height between days nine 
and ten. The decrease in membrane height for the PLGA11 membrane at day ten is consistent 
with some of the other results discussed in this chapter, which correlate a decrease in membrane 
height with the opening of the membrane. 
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Figure 7.24 Maximum measured height of membranes relative to chip surface for ~150 µm thick PLGA4.4 (dotted 
line) and PLGA11 (solid line) membranes on device loaded with 14C-glycerol. 
The PLGA4.4 membrane showed a maximum change in height of approximately 700 µm 
(a 470% increase in the membrane thickness) at day nine, while the PLGA11 membrane showed 
a maximum change in height of approximately 620 µm (representing a 410% increase in 
membrane thickness) at day eight (a photograph of this membrane at day eight is shown in 
Figure 7.26(b)). These swelling percentages are consistent with the range of values seen for the 
other devices in this study. 
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(a)   (d)  
(b)    (e)  
(c)       
Figure 7.25 ~150 µm PLGA4.4 membranes on device loaded with 14C-glycerol, viewed under optical microscope 
or viewed under SEM: (a) PLGA4.4 membrane at day zero, (b) PLGA4.4 membrane at day one, (c) PLGA4.4 
membrane at day three, arrow indicates location of hole, which can be seen in the enlargement of boxed region in 
(d) showing PLGA4.4 membrane at day three with the hole in the membrane clearly visible as indicated by the 
arrow, (e) SEM of PLGA4.4 membrane after 30 days in saline solution. 
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(a)  (c)  
(b)  (d)  
Figure 7.26 ~150 µm PLGA11 membranes on device loaded with 14C-glycerol, viewed under optical microscope or 
viewed under SEM: (a) PLGA11 membrane at day zero, (b) PLGA11 membrane at day eight, (c) PLGA11 
membrane at day ten, (d) SEM of PLGA11 membrane after 30 days in saline solution. 
7.3.1.7 14C-glycerol 3-phosphate 
The release plots for three devices loaded with 14C-glycerol 3-phosphate are shown in 
Figure 7.27. While the amounts of radiolabel detected for the three devices are slightly higher 
than those seen for the 14C-glycerol loaded devices, they are still quite low in comparison to the 
results obtained for the glucose and dextran molecules. 
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Figure 7.27 Cumulative percentage of 14C-glycerol 3-phosphate released over time from three devices having ~150 
µm thick PLGA4.4 and PLGA11 membranes. 
Glycerol-3-phosphate is readily soluble in water, similar to glycerol, so it is surprising 
that such low amounts were detected over the course of the experiment. The only reasonable 
explanations for this result might be adhesion or adsorption of the molecule to the surface of the 
device, the pipet tips, or glass release vessel. One device showed release on day zero from the 
reservoir having a membrane made of the PLGA4.4 polymer, while the other two devices 
showed release on day one for reservoirs having PLGA4.4 membranes. Greater variation was 
seen in the release times of the reservoirs having PLGA11 membranes. One device (solid line in 
Figure 7.27) showed release at day ten, and another (dotted line) showed release at 16–18 days. 
The third device (dashed line) appeared to have a large spike at day four, which may indeed have 
been when the PLGA11 membrane opened, but the cumulative amount of radiolabel measured 
after day four dropped back down to approximately 15% of the initial loading and did not show 
any further increase during the course of the study. 
 The maximum measured membrane height for each of the PLGA4.4 and PLGA11 
membranes on one of the devices (device represented by a solid line in Figure 7.27) are shown 
in Figure 7.28, and photographs of the membranes over the course of the study are shown in 
Figure 7.29 and Figure 7.30. 
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Figure 7.28 Maximum measured membrane height relative to chip surface for ~150 µm thick PLGA4.4 (dotted 
line) and PLGA11 (solid line) membranes on device loaded with 14C-glycerol 3-phosphate. 
The PLGA4.4 membrane (dotted line in Figure 7.28) showed only a very small amount 
of swelling, reaching a maximum swelling of approximately 160 µm (110% increase in 
membrane thickness) on day 19. No large decrease in membrane height was seen on day one, 
when a large hole appeared in the membrane as shown in Figure 7.29(b). The PLGA11 
membrane, however, attained a maximum swelling of approximately 510 µm (340% increase in 
membrane thickness) on day eight (a photograph of the membrane at day eight is shown in 
Figure 7.30(b)), which was followed by a sharp drop in membrane height at day nine, at which 
time a hole appeared in the center of the membrane as shown in Figure 7.30(c). Release of the 
radiolabel from this reservoir was detected at day ten, as shown in Figure 7.27 above, even 
though the reservoir membrane appeared open a day earlier, at day nine. This result is similar to 
that obtained for the reservoir having a PLGA11 membrane that was loaded with 10,000 
molecular weight 14C-dextran, as discussed in section 7.3.1.3. Photographs of the devices were 
always taken after an aliquot of the media was removed, thus agitation of the media as the device 
was transferred from the incubator to the microscope may have dislodged the membrane after the 
day nine scintillation aliquot was removed (which did not show any release of radiolabel) but 
before the day nine photographs were taken (which showed a hole in the membrane). 
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 Interestingly, it appeared as though the PLGA11 membrane was still intact in the device 
reservoir when SEM was performed after the experiment was completed. Although the hole in 
the membrane was clearly visible at day nine when the device was viewed on the optical 
microscope, a large portion of the membrane remained visible even after 28 days, as shown in 
Figure 7.30(d). Thus it is possible that accretion of gold at the edges of the membrane hole 
during the sputter coating process prior to SEM analysis may have caused the formation of a 
gold plug or layer within the membrane hole, thus causing the smooth surface seen in the SEM 
photos in Figure 7.30(e) and (f). 
 
(a)  (c)  
 
(b)        
Figure 7.29 ~150 µm thick PLGA4.4 membranes on device loaded with 14C-glycerol 3-phosphate viewed under 
optical microscope or viewed under SEM: (a) PLGA4.4 membrane at day zero, (b) PLGA4.4 membrane at day one, 
(c) SEM of PLGA4.4 membrane after 30 days in saline solution. 
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(a)  (d)  
(b)  (e)  
(c)  (f)  
Figure 7.30 ~150 µm thick PLGA11 membranes on device loaded with 14C-glycerol 3-phosphate viewed under 
optical microscope or viewed under SEM: (a) PLGA11 membrane at day zero, (b) PLGA11 membrane at day eight, 
(c) PLGA11 membrane at day nine, (d) PLGA11 membrane at day 28, (e) SEM of PLGA11 membrane after 30 
days in saline solution, (f) SEM of PLGA11 membrane after 30 days in salt solution, stage tilted 66°. 
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7.3.1.8 14C-glycerol trioleate 
The release results for three devices loaded with 14C-glycerol trioleate are shown in 
Figure 7.31. The cumulative amounts of 14C-glycerol trioleate detected from the three different 
devices are even lower than the amounts measured for the devices loaded with 14C-glycerol and 
14C-glycerol 3-phosphate discussed in sections 7.3.1.6 and 7.3.1.7, respectively. This is not 
surprising, as glycerol trioleate is not very soluble in water (it is shipped from the manufacturer 
in toluene). Additionally, only one of the devices showed a significant release pulse over the 
entire course of the study, over the first three days after the device was immersed in the PBS.  
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Figure 7.31 Cumulative percentage of 14C-glycerol trioleate released over time from three devices having ~150 µm 
thick PLGA4.4 and PLGA11 membranes. 
Significant membrane swelling was measured for the device indicated by the solid line in 
Figure 7.31. The maximum measured membrane heights for this device are shown in Figure 
7.32. Photographs of the PLGA4.4 and PLGA11 membranes on this device are shown in Figure 
7.33 and Figure 7.34. The PLGA4.4 membrane appeared open after only one day, as shown in 
Figure 7.33(b). The PLGA4.4 membrane height reached a maximum on day one, and then 
decreased slowly until day eight, at which time the membrane height began to decrease more 
sharply. The maximum swelling measured for this membrane at day one was approximately 405 
µm, or 270% of the initial membrane thickness of 150 µm. 
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Figure 7.32 Maximum measured membrane height relative to chip surface for ~150 µm thick PLGA4.4 (dotted 
line) and PLGA11 (solid line) membranes on device loaded with 14C-glycerol trioleate. 
The PLGA11 membrane also showed a large amount of swelling, with the membrane 
height increasing steadily over approximately the first three weeks of the study before reaching a 
maximum on day 22. The maximum membrane height at that time was approximately 770 µm 
greater than at day zero (626 µm above the surface at day 22, versus 141 µm below the surface 
of the device at day zero), corresponding to a 510% increase in membrane thickness compared to 
the initial thickness of 150 µm. Although no significant amount of 14C-glycerol trioleate 
appeared to be released from this device based on scintillation measurements, Figure 7.33(b) 
and Figure 7.34(e) clearly show holes in the centers of the membranes on days one and 23, 
respectively. Thus it appears that although the membrane opened, perhaps the relative 
insolubility of the 14C-glycerol trioleate in water might explain the fact that no radiolabel was 
detected in the medium. 
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(a)   
(b)   
(c)  
Figure 7.33 ~150 µm thick PLGA4.4 membrane on device loaded with 14C-glycerol trioleate, viewed under optical 
microscopy or viewed under SEM: (a) PLGA4.4 membrane at day zero, (b) PLGA4.4 membrane at day one, (c) 
SEM of PLGA4.4 membrane after 30 days in saline solution. 
200 µm 
200 µm 
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(a)  (d)  
(b)  (e)  
(c)  (f)  
Figure 7.34 ~150 µm thick PLGA11 membrane on device loaded with 14C-glycerol trioleate, viewed under optical 
microscope or viewed under SEM: (a) PLGA11 membrane at day zero, (b) PLGA11 membrane at day seven, (c) 
PLGA11 membrane at day 14, (d) PLGA11 membrane at day 21, (e) PLGA11 membrane at day 23, (f) SEM of 
PLGA11 membrane after 30 days in saline solution. 
7.3.1.9 Discussion 
Three characteristic times were determined from the data collected in these studies. The 
time at which the maximum measured increase in membrane height occurred is designated as 
tmax swelling. The corresponding water uptake (as a percentage of the initial mass of membrane 
polymer) was calculated at tmax swelling using Equation 7-h and Equation 7-i. The characteristic 
release time, trelease, is the time at which detection of the radiolabel from a reservoir occurred. 
Finally, the time at which the reservoir membrane appeared open when viewed under the optical 
microscope is designated as topen. These characteristic times for devices loaded with 14C-glucose, 
14C-dextran (Mw 10,000 and 40,000), as well as the unloaded control device, are summarized in 
Table 7-1 and Table 7-2 below. 
 
200 µm 
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200 µm 
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Table 7-1 Maximum measured membrane height, calculated % water uptake, tmax swelling, trelease, and topen for 
PLGA4.4 membranes on unloaded control device, as well as devices loaded with 14C-glucose and 14C-dextran 
having molecular weights of 10,000 and 40,000. 
Device max ∆h (PLGA4.4 water uptake tmax swelling trelease topen
Loading membrane height) (% of initial 
(µ m) membrane weight)
none (control) 350 190 1 NA 12
glucose 740 680 1 1 7
10k dextran 690 750 1 1 2
40k dextran 710 680 1 1 3  
Table 7-2 Maximum measured membrane height, calculated % water uptake, tmax swelling, trelease, and topen for PLGA11 
membranes on unloaded control device, as well as devices loaded with 14C-glucose and 14C-dextran having 
molecular weights of 10,000 and 40,000. 
Device max ∆h (PLGA11 water uptake tmax swelling trelease topen
Loading membrane height) (% of initial 
(µ m) membrane weight)
none (control) 440 330 5 NA 6
glucose 280 80 5 6 9
10k dextran 600 520 10 12 10-11
40k dextran 530 340 12 8 15  
The fact that swelling was observed for the control device, although perhaps to a slightly 
lesser degree than for the other devices having a chemical loaded into the reservoirs, is evidence 
that at the very least, the membrane swelling cannot be solely attributed to a loading or osmotic 
pressure effect of the chemical in the reservoirs. Additionally, the molecular weight of the 
chemical that was loaded into the reservoirs did not appear to have a significant effect on either 
the maximum measured membrane height or trelease, as the devices loaded with 14C-glucose or 
either of the 14C-dextran molecules showed comparable swelling and release times. This is an 
important result, as it suggests that for the drugs investigated in this study, the performance of 
the device is independent of the size of the drug that is to be delivered from the device. Although 
previous release studies presented in Chapter 4 showed more continuous release of small 
molecules such as BCNU and IAP, 14C-glucose showed pulsatile release in the studies presented 
here. This suggests that the hydrophobicity or hydrophilicity of the drug may be a more 
important factor than the molecule size in determining the release characteristics of the drug 
from the microreservoir device. Other researchers have also shown little effect of protein or 
peptide molecular weight on the release kinetics from PLGA microspheres18,19, which supports 
the results obtained here for the devices loaded with glucose and dextran. 
The characteristic times, maximum membrane height, and water uptake for the devices 
loaded with dextran having a molecular weight of 70,000 are summarized in Table 7-3 and 
Table 7-4 below. 
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Table 7-3 Maximum measured membrane height, calculated % water uptake, tmax swelling, trelease, and topen for 
PLGA4.4 membranes on devices having three different loadings of 70,000 molecular weight 14C-dextran. 
Device max ∆h (PLGA4.4 water uptake tmax swelling trelease topen
Loading membrane height) (% of initial 
(µ m) membrane weight)
70k dex low 690 640 1 1 1
70k dex intermediate 170 40 13 1 2
70k dex high 450 220 2 1 2  
Table 7-4 Maximum measured membrane height, calculated % water uptake, tmax swelling, trelease, and topen for PLGA11 
membranes on devices having three different loadings of 70,000 molecular weight 14C-dextran. 
Device max ∆h (PLGA11 water uptake tmax swelling trelease topen
Loading membrane height) (% of initial 
(µ m) membrane weight)
70k dex low 470 250 16 14 15
70k dex intermediate 270 90 17 17 20
70k dex high 320 110 20 15 28  
There was no correlation between the loading and the maximum membrane height, water 
uptake, trelease, or topen for the different loadings of 70,000 molecular weight 14C-dextran which 
were investigated. The devices loaded with different amounts of 70,000 molecular weight 14C-
dextran showed surprisingly little variation (14–18 days) in trelease from the reservoirs sealed with 
PLGA11 membranes, even though the loading was increased by nearly a factor of two. Although 
tmax swelling for the PLGA11 membranes (Table 7-4) appears to occur at later times for higher 
loadings, this is opposite to the trend we would expect if the osmotic pressure due to the solute 
were a contributing factor to the membrane opening. The absence of a correlation between the 
release times and the reservoir loadings is an important result for two reasons. The first is that it 
suggests that no water penetrates into the reservoir. Our other release results support this theory 
as well, especially those obtained for small molecules that might be able to diffuse through small 
fissures or pores in the membranes. The apparent hermeticity of the reservoirs once they are 
sealed with the polymer membranes indicates that a) no leakage of the drug through the 
membrane will occur, barring significant diffusion or permeation into the membrane itself (see 
Chapter 6 for further discussion), and b) compounds that are unstable or prone to degradation in 
aqueous environments will stay dry and therefore active until the reservoir membrane ruptures 
and the drug is delivered from the device. The second reason that the results of the 70,000 
molecular weight dextran devices are important is that they are further evidence for the 
independence of device performance from the drug loading. These results show that for the 
chemical loadings we investigated, changing the loading of the chemical within the reservoir 
does not affect the release time of the drug from the device. If this result is borne out for other 
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chemicals and loadings, it could allow the device to be loaded with dosages of varying sizes, 
without having to change the membrane characteristics according to the reservoir loading. This is 
in contrast to other PLGA based systems reported in the literature, such as microspheres, that 
exhibit loading-dependent drug release kinetics20. 
The characteristic times, maximum membrane height, and water uptake for the devices 
that were loaded with different glycerol moieties are summarized in Table 7-5 and Table 7-6 
below. 
Table 7-5 Maximum measured membrane height, calculated % water uptake, tmax swelling, trelease, and topen for 
PLGA4.4 membranes on devices loaded with 14C-glycerol, 14C-glycerol 3-phosphate, and 14C-glycerol trioleate. 
Device max ∆h (PLGA4.4 water uptake tmax swelling trelease topen
Loading membrane height) (% of initial 
(µ m) membrane weight)
glycerol 700 570 3 1 3
glycerol 3-phosphate 160 40 19 1 1
glycerol trioleate 490 240 1 not observed 1  
Table 7-6 Maximum measured membrane height, calculated % water uptake, tmax swelling, trelease, and topen for PLGA11 
membranes on devices loaded with 14C-glycerol, 14C-glycerol 3-phosphate, and 14C-glycerol trioleate. 
Device max ∆h (PLGA11 water uptake tmax swelling trelease topen
Loading membrane height) (% of initial 
(µ m) membrane weight)
glycerol 620 430 9 not observed 10
glycerol 3-phosphate 510 380 8 10 9
glycerol trioleate 770 740 22 not observed 23  
The results for the devices that were loaded with the glycerol moieties clearly show that 
the hydrophilicity or hydrophobicity of the molecule that is loaded into the reservoir does not 
appear to affect the amount of maximum measured membrane swelling. Other researchers have 
suggested that the observed water uptake of PLA may be due to osmotic pressure driving the 
buffer solution (media) into the polymer matrix to neutralize the acidic end groups of the 
polymer chains23. This theory would explain the similar swelling seen for the membranes on 
reservoirs that had different chemical loadings, as the concentration of acidic end groups would 
be the essentially the same in all membranes made from a given polymer, no matter with what 
chemical the reservoir was loaded. Although the more hydrophilic molecules (glycerol and 
glycerol 3–phosphate) appeared to show earlier release (as indicated by topen) than the glycerol 
trioleate from the reservoirs having PLGA11 membranes, this is not conclusive due to the small 
number of devices in the study, as well as the fact that no confirmation of release (trelease) was 
215 
obtained by scintillation measurements for the devices loaded with 14C-glycerol or 14C-glycerol 
trioleate due to apparent chemical insolubility. 
Although trelease was not observed for the PLGA11 membranes on devices loaded with 
glycerol and glycerol trioleate (Table 7-6), the device that was loaded with glycerol 3-phosphate 
showed good agreement between the three characteristic times. This is consistent with the results 
obtained for the devices that were loaded with other chemicals. 
Overall, approximately 50% of the devices that were viewed under the microscope 
showed a correlation between tmax swelling and trelease. Some devices also showed a correlation 
between topen and trelease. One difficulty with drawing a parallel or correlation between these two 
phenomena, however, is that the failure mode of the membranes seemed to vary. Specifically, 
some devices suddenly exhibited a large hole in the membrane that corresponded temporally to 
the detection of radiolabel from the reservoir, while other membranes showed only small 
pinholes, some membranes stayed quite smooth and bulbous during the swelling process, and 
others showed a very nonuniform surface texture. Still other membranes never appeared to 
completely open, and large portions of the membrane remained in the reservoirs throughout the 
entire course of the study. Membranes that did not exhibit a large hole or catastrophic failure 
often did not show a large drop in the measured maximum membrane height when release of the 
radiolabel was detected from the reservoir. The fact that approximately half of the devices in this 
study, however, showed a correlation between tmax swelling and trelease suggests that the mechanical 
behavior of the membranes may be an important factor in drug release from the devices, in 
addition to the threshold molecular weight discussed in Chapter 5. 
Slightly more of the devices (six out of ten devices) showed greater swelling for the 
PLGA4.4 membranes than for the PLGA11 membranes (four out of ten devices). One 
explanation for this observed behavior might be that the shorter polymer chains in the PLGA4.4 
membrane may provide greater free volume due to the higher concentration of polymer chain 
ends. The larger amount of free volume present might allow for greater water uptake, which is 
reflected as a larger amount of swelling. This mechanism has been proposed by others, who 
observed greater water uptake for PLA copolymers having increasing ratios of D:L lactide 
monomer, and proposed that the lower Tg of those polymers reflects greater chain mobility and 
consequently greater water uptake21. Alternatively, some researchers have proposed that 
plasticization of PLGA copolymers occurs when the Tg of the polymer drops below 37°C after 
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hydration22. This theory has been advanced in order to explain the observation of partial collapse 
of PLGA microspheres, with the hypothesis that as the Tg of the polymer drops below the 
ambient temperature, the polymer chains become more mobile and seal off pores and channels 
that were originally present in the microspheres. A nonporous but completely dense microsphere 
was the result of this process. In the case of the membranes studied here, swelling of the 
membranes instead of collapse might be observed if the membranes were initially fabricated as 
nonporous, since in the absence of densification the morphological changes would be dictated by 
the enthalpic driving force for swelling. Greater morphological changes might be observed for 
the PLGA4.4 membranes due to their initially lower Tg compared to the PLGA11 membranes.  
Water absorption and swelling of PLA and PLGA polymers have been studied, to a 
limited extent, by others. While quantitative measurements of the volume change (swelling) are 
not typically performed, the change in weight due to water uptake is more routinely 
characterized. Compression molded parallelepiped PLA samples (15 × 10 × 2 mm3) having an 
initial Mw of 65,000 had a linear increase in water absorption up to approximately 50% at seven 
weeks, when aged in saline or PBS at 37°C24. PLA Mw 67,000 film samples 0.3 mm in thickness 
absorbed up to 50% water in one week in phosphate buffer at 37°C25. The amount of water 
absorption remained relatively constant until between 24 and 29 weeks, when the water 
absorption increased to 300%. However, for PLA Mw 43,000 compression molded plates (15 × 
10 × 2 mm3), initial water uptake was only 10% at four weeks, but rapidly increased between 11 
and 18 weeks to over 400%. A study of PLGA Mw 29,270 extruded samples showed 15% (by 
volume) swelling at just two days26. In contrast, solid PGA disks were found to have an increase 
in diameter of only approximately 1–2% over 15 days, with a measured water content of 
approximately 20%27. In general, we expect the membranes in our study, which are fabricated 
from PLGA, to exhibit more water uptake than the PLA objects reported in the literature, due to 
the more hydrophilic nature of the PGA in the copolymer membranes. Additionally, the lower 
molecular weight of the membrane materials investigated in our study most likely causes them to 
degrade more rapidly than the materials reported on in the literature, which may also explain the 
larger water uptake seen for the materials in the study presented here, as compared to the results 
reported in the literature.  
217 
7.4 Conclusions 
Both the PLGA4.4 and PLGA11 membranes showed a large amount of swelling and 
water uptake that did not appear to depend on the chemistry or molecular weight of the molecule 
that was loaded into the reservoirs. The calculated values of percentage of water uptake for the 
different membrane materials were larger in general than those reported in the literature for other 
PLA and some PLGA polymers. This may be explained by both the lower molecular weight of 
the membrane materials in our study, as well as the greater hydrophilicity of the 50:50 PLGA 
copolymers that were used to fabricate the membranes compared to the materials reviewed in the 
literature. PLGA4.4 membranes showed very uniform release behavior, similar to the release 
results presented in Chapters 4 and 5, while greater variation in release time was seen for 
PLGA11 membranes. Approximately 50% of the devices that were viewed under the optical 
microscope showed a correlation between tmax swelling and trelease. The loading of the molecules in 
the reservoirs did not appear to affect the observed release times, indicating that no water 
penetrates into the reservoirs to cause an osmotic pressure effect. These results indicate that the 
device performance is independent of the chemistries and dosages of the drugs investigated here. 
The ability to change the amount of drug loaded into a reservoir, without affecting the release 
time or release kinetics of the drug from the device, may provide great flexibility in device 
design for a variety of applications. 
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8 Measured Biological Activity of Heparin After Release from 
Microreservoir Devices 
8.1 Introduction and Motivation 
8.1.1 Introduction 
 The feasibility of delivering multiple chemicals from biodegradable microreservoir 
devices in vitro has been demonstrated by experiments presented in Chapter 4. An important 
consideration, however, is whether or not chemicals will be biologically active after they are 
released from the device. A device that is capable of releasing multiple pulses of drugs will be 
rendered useless if the drugs are no longer effective after delivery to the patient. 
 Biological activity can be measured in a number of different ways, depending on the 
molecule that is of interest. Proteins, for example, can be tested for activity via a variety of 
methods, including antibody binding and cell proliferation assays. However, these tests may be 
difficult to perform in vitro due to the associated complications of cell culture, antibody integrity, 
and difficulty in finding an appropriate clinical model system. Interleukin-2, for example, which 
we have shown to be released from the microreservoir devices (see section 4.3.2.1.4), can be 
assayed for activity via a lymphocyte proliferation assay1,2. However, this molecule is 
hydrophobic3 and has a propensity to adsorb to glass and plastic surfaces4, making it difficult to 
obtain quantitative results in vitro. Measurements of interleukin-2 activity in vivo are 
complicated by the fact that the molecule has a short half-life in the human body. 
 Biological activity measurements of other types of molecules such as polysaccharides are 
simpler due to the obviation of the need for cell-based assays. We chose to investigate the 
biological activity of heparin during an in vitro release experiment from the microreservoir 
devices using a colorimetric anti-Factor XA assay. This assay contains excesses of both 
antithrombin III and Factor XA. In the presence of excesses of these two molecules, the 
inhibition of Factor XA is proportional to the heparin concentration present. The use of a 
chromogenic Factor XA substrate allows the spectrophotometric measurement of the residual 
Factor XA activity, which is inversely proportional to the heparin concentration5.  
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8.1.2 Motivation 
 The goal of these experiments was twofold. First, it was desired to characterize the 
release times of heparin from devices having reservoir membranes made from PLGA4.4, 
PLGA11, PLGA28, and PLGA64 polymers. The second goal was to demonstrate that heparin 
retains its biological activity after it has been released from the microreservoir devices in vitro. 
Although heparin is and has been widely used therapeutically as an anticoagulant, its stability 
has not been extensively studied. However, we hypothesized that its polysaccharide nature would 
provide reasonable stability over the course of our in vitro release experiments.  
8.2 Materials and Methods 
8.2.1 Materials 
Poly(L-lactic acid) (PLA, Mw 194 Kilodaltons (Kd), Medisorb® 100 L), and poly(D,L-
lactic-co-glycolic acid) polymer powders of molecular weights (Mw) 4.4 Kd (PLGA4.4, 
Medisorb® 5050 DL 1A), 11 Kd (PLGA11, Medisorb® 5050 DL 2A), 28 Kd (PLGA28, 
Medisorb® 5050 DL 3A), and 64 Kd (PLGA64, Medisorb® 5050 DL 4A) were obtained from 
Alkermes (Cincinnati, Ohio). 3H-heparin, sodium salt, was purchased from Perkin Elmer Life 
Sciences (Boston, MA). Heparin sodium salt, fetal bovine serum (FBS), and ACCUCOLOR™ 
kits (heparin activity assays) were purchased from Sigma-Aldrich (St. Louis, MO). ScintiSafe 
Plus 50% was purchased from Fisher Scientific (Suwanee, GA). Ideal 9144 Masking Tape was 
obtained from American Biltrite, Inc. (Lowell, MA). 
8.2.2 Methods 
8.2.2.1 Device Fabrication 
Devices with reservoir membranes were fabricated according to the procedures described 
in Chapter 2. All reservoir membranes were designed to be approximately 150 µm thick in this 
study.  The membranes were inspected for defects after drying (such as air bubbles and pinholes) 
at 80X magnification using a PZMT Trinocular stereomicroscope.  Reservoirs having defect-free 
membranes were considered viable for use in release experiments, and selected reservoirs were 
loaded with the heparin to be released. The heparin solutions were allowed to dry in the 
223 
reservoirs for approximately 24 hours at room temperature and pressure before the devices were 
sealed opposite the membranes with Ideal Masking Tape 9144 (American Biltrite, Inc.).   
8.2.2.2 In Vitro Release and Activity Measurements 
Devices were affixed to the bottom of 6-well polystyrene tissue culture plates using 9144 
Masking Tape, and four milliliters of phosphate buffered saline (PBS, Roche, pH~7.4) were 
added to each well.  The plates were agitated on a Thermolyne Rotomix Type 50800 orbital 
shaker at 60 rpm and 25°C. Once daily, a 200 µL aliquot of the release medium from each was 
pipetted into a 7-mL glass scintillation vial, and 200 µL of fresh PBS were added to each well to 
keep the volume of release medium in the wells constant at approximately four milliliters. Five 
mL of Fisher Scientific ScintiSafe Plus 50% scintillation cocktail were added to each 
scintillation vial. The samples were analyzed on a Packard Tri-Carb liquid scintillation counter, 
Model U2200, using a 3H counting protocol. Detection of 3H above background levels was 
assumed to be indicative of the opening of a reservoir membrane (release of 3H-heparin from a 
reservoir). The amount of therapeutic heparin was quantitated using a Sigma Diagnostics 
ACCUCOLOR™ heparin kit after a reservoir release was detected.  Heparin standard dilutions 
of 0.1, 0.2, 0.4, and 0.8 USP/mL concentrations were prepared from a stock solution of unlabeled 
heparin in deionized milliQ water (8 USP/mL), and mixed with equal volumes of FBS prior to 
assay in 96 well plates. Aliquots of 100 µL of the media surrounding each device were mixed 
with equal volumes with FBS for performing the ACCUCOLOR™ assay on release samples. 
Optical density was measured on a spectrophotometer microplate reader (Dynatech MR5000 or 
Molecular Devices Spectramax 384 Plus) at 405 nm. A plot of measured optical density versus 
heparin concentration was obtained for the standard dilutions. A linear standard curve was 
assumed in the region of 0.1 to 0.8 USP/mL. Microsoft Excel LINEST function was used to 
calculate the slope (m) and intercept (A0, the extrapolated value for the absorbance at 0 USP/mL 
concentration of heparin) using a least squares method. The concentration of heparin in the 
release samples, C, was then quantitated according to the following relation: 
 
0405 AmCA +=  
Equation 8-a 
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where A405 = measured absorbance at 405 nm for a given sample. The standards and samples 
were analyzed in quadruplicate. 
8.3 Results and Discussion 
8.3.1 Device Fabrication 
 The thicknesses of the devices after polishing ranged from 516 to 534 µm, with 
corresponding reservoir openings ranging from 352 to 340 µm in diameter. Predicted membrane 
thicknesses were 153 to 154 µm, based on the volume of membrane polymer injected into each 
reservoir. 
Each device had three reservoirs loaded with heparin, one sealed with a membrane made 
from PLGA4.4, one sealed with a membrane made from PLGA11, and one sealed with a 
membrane made from either PLGA28 (three devices) or PLGA64 (three devices). Prior release 
experiments (see Chapter 4) have shown that reservoirs having PLGA28 and PLGA64 
membranes may show similar release times. PLGA28 and PLGA64 membranes were therefore 
used on separate devices in order to eliminate any uncertainty in correlating detection of released 
3H-heparin with the opening of a PLGA28 or PLGA64 membrane. Reservoirs were loaded with 
a combination of 3H-heparin sodium salt (0.2924 mCi/mg) and unlabeled heparin sodium salt.  
Total loading was 24.78 nCi of 3H-heparin and 8.79 USP heparin per device, accounting for 
3.45% loss of activity on drying. 
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8.3.2 In Vitro Release 
The objective of these release experiments was to determine the release profiles and 
characterize the biological activity of heparin in vitro from prototype microreservoir devices.  
The cumulative amounts of 3H-heparin detected from the two sets of devices are shown in 
Figure 8.1 and Figure 8.2 below. 
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Figure 8.1 Cumulative percentage of 3H-heparin loading released over time from three devices having PLGA4.4, 
PLGA11, and PLGA28 reservoir membranes. Experiments conducted at 25°C. 
For all six devices, the reservoirs having membranes fabricated from the PLGA4.4 
polymer uniformly released their contents within the first two days of the start of the experiment.  
Between 22 and 28% of the total initial loading was detected from these reservoirs. Similarly, the 
PLGA11 reservoir membranes showed release between days 40 and 48 for all six devices, and 
the cumulative percentage of the initial loading detected ranged from 41 to 52% at day 50. The 
PLGA28 reservoir membranes showed release between days 100 and 108 (Figure 8.1, 72 to 
83% cumulative of total loading released at 125 days), while the PLGA64 reservoir membranes 
showed onset of release between 132 and 139 days (Figure 8.2, a range of 68 to 77% cumulative 
of total initial loading released at 143 days).  
226 
0
10
20
30
40
50
60
70
80
90
100
0 20 40 60 80 100 120 140
Time (days)
C
um
ul
at
iv
e 
%
 o
f I
ni
tia
l
Lo
ad
in
g 
R
el
ea
se
d
PLGA64 membranes open
PLGA11 membranes open 
PLGA4.4 membranes open
 
Figure 8.2 Cumulative percentage of 3H-heparin loading released over time from three devices having PLGA4.4, 
PLGA11, and PLGA64 reservoir membranes. Experiments conducted at 25°C. 
The devices in each batch showed excellent agreement of release times, with each type of 
reservoir membrane opening within an 11-day window. Further, the devices appeared to release 
approximately equal pulses of heparin as each reservoir membrane opened, and there appeared to 
be no significant diffusional release of heparin from the reservoirs. This is in sharp contrast to 
the behavior typically seen with microspheres6. 
8.3.3 In Vitro Activity Measurements 
The results of the heparin activity assays are summarized in Table 8-1, which shows the 
percentage of heparin that was present in the release media that still retained biological activity, 
including a correction for 3.45% loss of activity upon drying when the solution was loaded into 
the reservoirs. The activity assays indicated that essentially all of the heparin that was released 
from the reservoirs having PLGA4.4 membranes was biologically active. Measured heparin 
activity was 105±16% of the material present in the PBS after opening of the PLGA11 
reservoirs. 80±30% of the heparin present in the PBS was active after the reservoirs having 
PLGA28 membranes opened, while 96±20% of the heparin present in the PBS was active after 
the reservoirs having PLGA64 membranes opened. A stock solution (8 USP/mL) was prepared 
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at the beginning of the experiment and stored at 4°C for the duration of the study as a control. 
The stock solution was assayed after 147 days and found to have retained 95% of its original 
activity.  
Table 8-1 Measured biological activity of heparin released from polymeric microreservoir devices having reservoir 
membranes made from PLGA4.4, PLGA11, PLGA28, or PLGA64. 
Device Release Assay Measured heparin activity, Release Assay Measured heparin activity, Release Assay Measured heparin activity,
Day(s) Day(s) % of heparin present Day(s) Day(s) % of heparin present Day(s) Day(s) % of heparin present
040202-05 0 0 106 41-43 43 114 107 109 60
040202-07 0 0 105 41 41 107 108 109 65
040202-08 0 0 96 41 41 107 100 102 114
040302-04 1 0 NA 43 43 129 132-136 136 110
040302-06 1 0 NA 40-41 41 85 139-143 142 73
040302-07 0 0 151 48-52 49 91 133-136 136 106
PLGA4.4 reservoirs PLGA11 reservoirs PLGA28 reservoirs
PLGA4.4 reservoirs PLGA11 reservoirs PLGA64 reservoirs
 
The relatively long-term stability of heparin seen in these experiments agrees with 
findings by other authors7. Stability studies of heparin at 30°C in 0.1 N hydrochloric acid and 0.1 
N sodium hydroxide showed a decrease in the molecular weight of the heparin chains over time, 
as well as β-elimination of uronic acid residues in basic conditions, and desulfation in acidic 
conditions. At neutral pH (7.0) and elevated temperature (100°C) in these studies, however, the 
heparin remained stable over approximately 500 hours (21 days), retaining 80–90% of its activity 
as measured by anti-Factor XA (the same method as was used in the studies reported here) and 
anti-Factor IIA amidolytic methods. However, the measured activity showed an extremely large 
drop at 1000 hours to just ~6% of the initial activity. While the conditions of our release studies 
were much milder than the conditions in the reported study, it is expected that the pH decreased 
at least slightly over time as the PLGA membranes degraded and released their acidic 
degradation products into the PBS. The fact that the heparin retained its activity over an extended 
period of time suggests that the pH change was not significant enough to cause the desulfation 
and loss of activity seen by others.  
8.4 Conclusions 
Microreservoir devices fabricated from PLA demonstrated release of heparin in three 
separate pulses over a period of 108 days for devices having PLGA4.4, PLGA11, and PLGA28 
membranes, and over a period of 143 days for devices having PLGA4.4, PLGA11, and 
PLGA64 membranes. Further, the heparin retained an average of 80 % of its activity over 102 to 
109 days for devices having PLGA28 membranes, and an average of 96 % of its activity over 
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136 to 142 days for devices having PLGA64 membranes. The conditions to which the heparin 
was exposed during the course of the study were not severe enough to cause uniform or complete 
loss of activity, as exhibited by the retention of biological activity through an anti-Factor XA 
assay.  
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9 In Vivo Release Studies 
9.1 Introduction and Motivation 
Although a number of polymeric drug-delivery implants have been designed and tested in 
vitro, reproducible performance in vitro is rarely a guarantee of in vivo operation. Several factors 
may contribute to the variable performance of drug-delivery implants in vivo, including (in the 
case of PLA, PGA, and their copolymers) their hydrolysis rate and degradation by biological 
entities such as enzymes that are not present during in vitro studies. Additionally, devices that 
are implanted for periods longer than a few weeks begin to be encapsulated by fibrous tissue. 
Different drug delivery behavior from a device may therefore be observed in vivo compared to in 
vitro, depending on the release kinetics of the device and the permeation or diffusion of the drug 
through the local tissue. Proof-of-principle studies of the release of a model radiolabeled 
molecule (14C-mannitol) were therefore performed in vivo in order to confirm our in vitro results, 
and to demonstrate that the polymeric microreservoir devices could be used for multipulse in 
vivo drug delivery. 
9.2 Materials and Methods 
9.2.1 Materials 
Poly(L-lactic acid) (PLA, Mw 194 Kilodaltons (Kd), Medisorb® 100 L) and poly(D,L-
lactic-co-glycolic acid) polymer powders of molecular weights (Mw) 11 Kd (PLGA11, 
Medisorb® 5050 DL 2A) and 64 Kd (PLGA64, Medisorb® 5050 DL 4A) were obtained from 
Alkermes (Cincinnati, Ohio). 1,1,1,3,3,3-hexafluoroisopropanol (HFIP) was purchased from 
Sigma-Aldrich (St. Louis, MO). 14C-mannitol was purchased from PerkinElmer Life Sciences 
(Boston, MA). ScintiSafe Plus 50% was purchased from Fisher Scientific (Suwanee, GA). Ideal 
9144 Masking Tape was obtained from American Biltrite, Inc. (Lowell, MA). 
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9.2.2 Methods 
9.2.2.1 Device Fabrication 
Eight devices were fabricated and loaded with chemicals as described in Chapters 2 and 3. 
Device thicknesses ranged from 649 to 692 µm, with corresponding reservoir openings of 255–
224 µm in diameter. Reservoir membranes were fabricated from approximately 12% by volume 
solutions of PLGA11 and PLGA64 in HFIP. Solutions were injected from a 1710RN 100 µL 
gas tight glass syringe with a 1" 31 gauge removable needle, blunt tip (part numbers 81030 and 
0160831, both items from Hamilton Co., Reno, NV). Predicted membrane thicknesses were 150 
µm for all devices. On each device, one reservoir having a PLGA11 membrane and one 
reservoir having a PLGA64 membrane were loaded with 0.1 µCi of 14C-mannitol, for a total 
device loading of 0.2 µCi. Devices were sealed with 9144 Masking Tape and affixed to glass 
slides for stability for in vitro release studies. Devices were sealed with 9144 masking tape but 
not affixed to slides for in vivo release studies. 
9.2.2.2 In Vitro 14C-Mannitol Control Release Study 
Devices were put in screw-cap jars containing 20 mL stirred 1X phosphate-buffered 
saline (PBS) at 37°C after drying and sealing. One mL samples of the medium were pipetted 
from the jars once per day, and fresh PBS was added to the release vessels to replace the volume 
of solution removed. Samples were pipetted into 7-mL glass scintillation vials, and five mL of 
Fisher Scientific ScintiSafe Plus 50% scintillation cocktail were added to each vial. The samples 
were analyzed on a Packard Tri-Carb liquid scintillation counter, Model U2200, using a 14C 
counting protocol to monitor for release of 14C-mannitol from the devices. 
9.2.2.3 In Vivo 14C-Mannitol Release Study 
Female Fischer 344 rats weighing 150–175 g were obtained from Charles River 
(Wilmington, MA). Their water was supplemented with sucrose at a concentration of 15g/500ml 
Baltimore city water. Animals were housed individually in metabolic cages (Nalgene, Rochester, 
NY; Model #650-0100 for rats 150–300 g). Animals were allowed free access to rodent chow 
and were treated in accordance with the policies and principles of laboratory care of the Johns 
Hopkins University School of Medicine Animal Care and Use Committee. 
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Prior to flank implantation, microreservoir devices were sterilized using a Mark1-68 
irradiator (JLS Shepherd, Glendale, CA) with a Cesium-137 source. Chips were sealed in 
autoclave bags and then exposed for 12 minutes to the source to equal a final gamma radiation 
dose of 48,000 Rad or 480 Gray. Upon flank implantation, devices were removed in a sterile 
fashion from the sealed bags and placed onto a sterile field.  
Twenty-four hours prior to flank implantation, rats were weighed and placed individually 
into metabolic cages. The following day their urine and feces were removed from the collection 
vials to obtain a baseline radioactive count for each animal. Rats were then anesthetized with an 
intraperitoneal injection of 5mL/kg solution containing 25mg/mL ketamine/2.5 mg/mL xylazine 
and 14.25% ethanol (v/v). The left flank of the anesthetized rat was shaved and prepped with 
70% ethanol and betadine. Under sterile conditions (sterile gloves, gowns, masks, sterile 
instruments and sterile fields), a 2-cm vertical incision was made in the flank. To accommodate 
the microreservoir device, a pocket was made by dissecting the subcutaneous tissue with sterile 
scissors. The sterilized device was then placed into the pocket and the incision was closed with 
staples. Animals then received a subcutaneous injection of the analgesic, buprenorphine, at 0.01 
mg/kg, and were placed back into their metabolic cages. Cages were returned to the animal care 
facility once animals were fully alert and demonstrating no complications from the procedure. 
Urine and feces were collected from the cages and collection vials were rinsed clean daily to 
avoid any day to day contamination. 
Control animals were weighed and caged individually in metabolic cages prior to flank 
injection to obtain baseline feces and urine radioactive counts. For flank injection, the animals 
were anesthetized and left flanks were shaved and prepped. The appropriate concentration of 
14C-mannitol was then injected subcutaneously in a 0.3 mL aliquot. Animals were returned in 
their cages to the central animal housing facility after they were fully alert. Urine and feces 
samples were removed periodically and counted for radioactivity.  
Urine and feces samples were counted for radioactivity using Ready Safe scintillation 
fluid (Beckman Coulter, Inc, Fullerton, CA). A 250 µL urine sample was placed into a 7-mL 
scintillation vial, along with one mL of distilled water and five mL of scintillation fluid. Fecal 
samples were placed directly into five mL of scintillation fluid and counted. Each sample was 
counted using a Beckman LS3801 scintillation counter (Beckman Coulter, Fullerton, CA) for a 
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duration of two minutes. The conversion factor used was disintegrations per minute (dpm) = 
counts per minute (cpm)/.96 counting efficiency.  
After experiments were concluded, all animals were euthanized by either CO2 inhalation 
or a sodium pentabarbitol overdose (200 mg/kg, to effect). Microreservoir devices were removed 
for inspection.  
9.3 Results and Discussion 
The release results for the in vitro control devices having PLGA11 and PLGA64 
membranes are shown in Figure 9.1 below. The corresponding results for the in vivo release of 
14C-mannitol from devices are shown in Figure 9.2 below. 
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Figure 9.1 Cumulative percentage of initial 14C-mannitol loading recovered over time from four devices having 
PLGA11 and PLGA64 reservoir membranes, each loaded with 0.2 µCi of 14C-mannitol and maintained in vitro in 
PBS at 37°C. 
Release of the 14C-mannitol from devices in vitro was detected from the reservoirs having 
PLGA11 membranes between five and six days, followed by release from the reservoirs having 
PLGA64 membranes at 12 to 15 days. The total cumulative amount of 14C-mannitol recovered 
ranged from 86 to 90%, excluding the device that showed a decrease in the cumulative amount 
of 14C-mannitol over the course of the experiment (○ symbol in Figure 9.1). It is not clear why 
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this device showed different release behavior than the others, although it is possible that the 
mannitol could have been ingested by contaminant microorganisms (the devices were in saline 
solution at 37°C). The other three devices showed release of the 14C-mannitol in two almost 
exactly equal pulses, and the range of release times for each type of membrane was relatively 
small, compared to release results previously presented in Chapter 4. Faster release was seen 
from these devices than for others at lower temperatures presented in Chapter 4. 
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Figure 9.2 Cumulative percentage of initial 14C-mannitol loading recovered over time from four devices (□U○) 
having PLGA11 and PLGA64 reservoir membranes, each loaded with 0.2 µCi of 14C-mannitol and implanted 
subcutaneously in rats, and from one subcutaneous injection (×) of 0.1 µCi in a rat. 
The observed release time in vivo of 14C-mannitol from the reservoirs having PLGA11 
membranes ranged from two to four days, while the reservoirs having PLGA64 membranes 
showed release between five and ten days. This was slightly greater variation than was seen for 
the devices in vitro. The release results for the devices implanted in vivo are similar to those for 
the in vitro devices, but the release times were faster. This is not surprising, as others have 
demonstrated more rapid release of chemicals from PLA1,2 and PLGA3 microspheres, as well as 
PLA and PLGA compression-molded implants4 in vivo than in vitro. Additionally, the reader is 
referred to Chapter 10, in which a study to characterize the in vivo and in vitro degradation of 
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two of the membrane polymers showed in general faster degradation in vivo than in vitro. 
Although the in vitro release studies reported here were performed at 37°C in saline solution, this 
environment cannot reproduce the biological milieu to which the devices are exposed in vivo and 
which may contain other agents or molecules, such as enzymes, that aid polymer degradation. 
Another factor which may contribute to the observed faster release in vivo is the method by 
which the devices were sterilized (480 Gray γ-irradiation). Decreases in the molecular weight of 
PGA sutures as the γ-irradiation sterilization dosage is increased have been reported by others5. 
Although the dosage that was used to sterilize the microreservoir devices prior to implantation 
was much lower than the dosage at which the observed decreases in PGA suture molecular 
weight became significant, the very low initial molecular weight of the membrane polymers on 
the microreservoir devices may nevertheless be affected by the sterilization procedure. It is 
expected that increasing the molecular weight of the reservoir membrane materials would shift 
the release curves to later times. Replacing the PLGA64 reservoir membrane with a higher 
molecular weight material might serve to more clearly separate the two pulses from a given 
device. 
The recovered yield at 14 days post-implantation from the devices in vivo was 29–40% of 
the initial device loading. Approximately 74% of the injected control was recovered over the 
same time span. The higher recovery of the injected control is not surprising, as the 14C-mannitol 
that is injected is in a volume of 0.3 mL, and forms a bolus with a large surface area from which 
it can diffuse away from the injection site. The microreservoir devices, in contrast, are loaded 
with 14C-mannitol in solid form, which is located in a very small reservoir (120-130 nL in 
volume) and that has an opening of limited size (224–255 µm diameter reservoir openings) from 
which the mannitol can diffuse. These two factors could explain the low yield seen from the 
microreservoir devices in vivo. 
 The only report in the literature of in vivo drug delivery from a device similar to the one 
described here shows one pulse of Evans’s blue dye from devices implanted subcutaneously in 
nude mice4. Comparative results obtained in vitro showed slower release than was observed in 
vivo, and neither quantitation of the amount of chemical released (% of initial loading released 
and/or detected) nor the duration of release in vivo were reported. In contrast, the results 
presented here from implanted polymeric microreservoir devices show release duration of two 
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days (with the exception of one device), and 29–40% of the loading detected over a span of two 
weeks.  
9.4 Conclusions 
The proof-of-principle studies reported here demonstrate the feasibility of delivering 
multiple pulses of drugs from the polymeric microreservoir devices in vivo. This has previously 
not been demonstrated by others. Further, even in vitro demonstration of multiple pulses from 
polymeric systems has typically required an applied stimulus (such as an electric field or 
ultrasound) or a change in the local environment (such as pH or temperature) in order to trigger 
drug release from the systems. Faster release was observed from devices implanted in vivo 
versus maintained in vitro, most likely due to enzymatic degradation and faster hydrolysis in vivo. 
Increasing the difference in molecular weights of the materials used for the reservoir membranes 
may therefore allow greater separation of the drug pulses from the device if so desired. 
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10 In Vivo Biodegradation of Reservoir Membrane Polymers 
10.1 Introduction and Motivation 
In previous chapters, we have demonstrated the feasibility of delivering multiple pulses 
of drugs from the polymeric microreservoir devices in vitro (Chapter 4) and in vivo (Chapter 9). 
It is of vital concern to understand the biocompatibility and/or biodegradation of the component 
materials of any implantable device when considering end-stage use in a patient. The implant 
must tolerate long-term exposure to the physiological environment, without inducing toxicity in 
the surrounding tissues. While the component materials of our drug delivery device (PLA and 
PLGA) have been extensively studied in regard to both biodegradation and biocompatibility1, the 
literature is often specific, especially in the case of PLGA, to a particular molecular weight 
polymer, certain in vitro degradation conditions, a specific copolymer ratio2,3, or even the size of 
the specimens studied4–7. Thus, it is important to study the biodegradation and biocompatibility 
of the specific materials used in our drug delivery device.  
With the goal of understanding how the component materials of our device will degrade 
in vivo, we have investigated the biodegradation of two of the membrane materials (PLGA4.4 
and PLGA64) in a rat model. The biodegradation of the materials of interest was characterized 
by gel permeation chromatography (GPC) as well as differential scanning calorimetry (DSC). 
Both methods are commonly used to characterize the degradation of polymers. GPC provides 
molecular weight data, while DSC provides information about the glass transition and melting 
temperatures of a material, which can be correlated with both the molecular weight and degree of 
crystallinity of a polymer. Understanding the difference between material degradation behaviors 
in vivo versus in vitro is an important step in the development of a viable, long-term implantable 
drug delivery device.  
10.2 Materials and Methods 
10.2.1 Materials 
Poly(L-lactic acid) (PLA, Mw 194 Kilodaltons (Kd), Medisorb® 100 L), poly(glycolic 
acid) (PGA, Medisorb® 100 PGA) and poly(D,L-lactic-co-glycolic acid) polymer powders 
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(50:50 mole ratio of lactic acid to glycolic acid units) of molecular weights (Mw) 4.4 Kd 
(PLGA4.4, Medisorb® 5050 DL 1A) and 64 Kd (PLGA64, Medisorb® 5050 DL 4A) were 
obtained from Alkermes (Cincinnati, Ohio). 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) was 
purchased from Sigma-Aldrich (St. Louis, MO). Mylar® sheets were donated from the 
laboratory of Dr. James Anderson (Case Western Reserve University, Cleveland, OH). 
Poly(methyl methacrylate) (PMMA) standards were obtained from Polysciences, Inc. 
(Warrington, PA).  
10.2.2 Methods 
10.2.2.1 Film Casting 
Mylar® sheets were cleaned with Kimwipes® and acetone. Solutions of PLA, PLGA4.4, 
PLGA64 (9 to 15 percent by volume) and PGA (1.4 to 5.5, or 15 percent by volume) were 
prepared in HFIP. A large area of Mylar® film was marked off with six layers of VWR brand  
time tape. The amount of polymer that was used in preparing each film was calculated using the 
density of the polymers, the cast area, and the desired thickness. The solutions were cast onto the 
Mylar® sheets in a hood, let dry until the films were partially opaque, and then transferred to a 
vacuum oven. The films were dried under vacuum at approximately 27 in Hg (8 kPa) and 80°C 
for 48 hours. After cooling, the films were cut into 2 cm × 1.25 cm rectangles, and the backs of 
the films were cleaned with acetone again before implantation. 
10.2.2.2 Cage Fabrication 
Test specimens of Mylar® backing, and Mylar® backing with PLA, PGA, PLGA4.4, 
and PLGA64 polymer films were placed singly into cylindrical stainless steel wire mesh cages 
measuring approximately 3.5 cm long and 1.0 cm in diameter. The mesh from which the cages 
were made was type 310 stainless steel with a mesh size of 24, a wire diameter of 0.254 mm 
(0.01 in), and interstices measuring 0.8 × 0.8 mm (Cleveland Wire Cloth and Manufacturing Co, 
Cleveland, OH). Prior to cage fabrication, the mesh was sonicated in ethanol (Pharmaco Products 
Inc., Brookfield, CT) for 15 minutes, followed by a 10-minute rinse with distilled water. The 
material test specimens were ethylene oxide sterilized (Amsco model 2057 sterilizer, University 
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Hospitals of Cleveland, OH) using an exposure time of 1 hour and 45 minutes at 130°F and an 
outgassing time of 12 hours at 120°F prior to placement in the cages.  
10.2.2.3 Film Implantation 
10.2.2.3.1 Subcutaneous Cage Implant 
Sterilized cages containing polymer films were implanted subcutaneously and bilaterally 
in the posterior back areas of 12 week old female Sprague-Dawley rats (Charles Rivers 
Laboratories, North Wilmington, MA), according to a previously published procedure8 and 
observing IACUC and NIH animal care guidelines. Aerrane® (Baxter, Deerfield, IL) was used in 
a continuous analgesic stream to keep the animals unconscious during implantation. The rats 
were shaved and their skin scrubbed with surgical grade Betadine® (The Purdue Frederick Co., 
Stamford, CT). An incision 1.0 to 1.5 cm long was made in the skin about 2 cm above the tail 
and along the midline. Then, 0.5% Marcaine® solution (Abbott Laboratories, North Chicago, IL), 
a local anesthetic, was applied onto the incision to minimize post-operative discomfort. Blunt 
dissection was used to prepare an implant pocket in the facial plane beneath the panniculus 
carnosus muscle from the underlying tissue from the incision to just above the hip. The sterile 
cage containing the material was then introduced through the incision and positioned within the 
pocket and away from the incision site. The incision was closed with 9 mm stainless steel 
surgical wound clips (Becton Dickinson, Sparks, MD) and washed with Betadine®. Sterile 
surgical techniques were observed. In addition, empty cages were gas sterilized and implanted 
into a separate group of animals as controls. The rats were maintained on Purina Rat Chow and 
water ad libitum at the Animal Research Facilities of Case Western Reserve University on 12 
hours light/dark cycles. All animals were sacrificed at day 21.  
10.2.2.3.2 Direct Subcutaneous Implant 
Polymer films and Mylar® controls were ethylene oxide sterilized and implanted without 
cages following the procedure described above, with one additional precaution. The size of the 
subcutaneous pocket was such that it would accommodate the film comfortably but not loosely. 
This precaution was taken in an attempt to minimize inflammatory response at the tissue-
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material interface that could have resulted from the movement of the device within the pocket. 
Animals (n = 3) were sacrificed at 4, 7, 14, 21, 28, 35, 42, and 49 days.  
10.2.2.3.3 In Vitro Controls 
Samples of PLA, PGA, PLGA4.4, and PLGA64 (n = 3) were placed in tissue culture 
polystyrene (TCPS) petri dishes (Becton Dickinson, Sparks, MD). Phosphate Buffer Saline 
(PBS) without Ca2+ and Mg2+ (Gibco Laboratories, Grand Island, NY) was added such that the 
films were completely submerged. The submerged films were maintained in a humidified 
atmosphere at 37°C (95% CO2, 5% O2) for 4, 7, 14, 21, 28, 35, 42, or 49 days.   
10.2.2.4 Gel Permeation Chromatography (GPC) 
After explantation and/or drying, one half of each polymer film (in vivo direct 
subcutaneous, in vivo cage, or in vitro control) was carefully removed from the Mylar® backing 
using a spatula and tweezers. The polymer residues were placed in 7-mL glass scintillation vials 
(VWR International, NJ) and one milliliter of HFIP was added to each vial using B-D 1 mL 
syringes. The vials were capped, wrapped with ParaFilm M® to prevent solvent evaporation, and 
left for approximately 24 to 48 hours to allow dissolution of the polymers. The vials were 
periodically agitated on a vortexer to aid polymer dissolution. Control samples of Mylar® and 
the PGA, PLA, PLGA4.4, and PLGA64 powders (previously stored at −4°C in an airtight 
container with desiccant since receipt from the manufacturer) were prepared in a similar manner. 
In addition, samples of fibrous capsule retrieved from 42 day old implants of PLA and PLGA4.4 
were dissolved in HFIP using 7-mL glass vials. Tissue samples were left to dissolve for 
approximately five hours before GPC analysis was performed. The PLA and PLGA4.4 polymer 
films from these tissue sections were prepared in the same manner as the Mylar® and other 
polymer samples. One sample of HFIP only, with no polymer in it, was prepared by letting it 
stand in a 1 mL B-D syringe for one minute.  
After dissolution, all polymer solutions were transferred to 1-mL glass GPC vials (Waters 
Corporation, Milford, MA) using 1-mL B-D syringes and PTFE Minispike 0.2 µm syringe filters 
(Waters Corporation). The samples were analyzed in HFIP at 0.2 mL/min flow rate for either 40 
or 45 minutes on a Waters GPC system consisting of a 515 HPLC Pump, 717plus Autosampler, 
Styragel Guard Column, Styragel HR 4 and HR 3 columns, and 2410 refractive index detector. 
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Sample molecular weights were quantitated relative to PMMA standards of molecular weights 
150,000, 125,000, 100,000, 75,000, 60,000, 30,000, 14,000, and 6,000 daltons. Data was 
analyzed using Millenium v.3.20 software. 
10.2.2.5 Differential Scanning Calorimetry (DSC) 
A 0.5 × 1.25 cm2 strip was cut off of each film using tweezers and scissors. This strip was 
cut into three squares, which were placed in the bottom of a 50 µL aluminum DSC pan 
(PerkinElmer, Shelton, CT) with the polymer side facing the bottom of the pan (Mylar® side 
facing the lid), in order to provide optimal thermal contact of the polymer with the pan. A 
PerkinElmer universal crimper press was used to seal the pans with aluminum lids. Samples 
were analyzed on a PerkinElmer Diamond DSC with autosampler AS-6. Dry nitrogen was used 
as a purge gas. Pyris Manager version 5.0 was used to program and monitor the DSC and 
analyze data. PLA samples were heated to an upper temperature limit of 200°C in order to 
capture both the melting (Tm, results not reported here) and glass (Tg) transition temperatures, 
while the PGA, PLGA4.4, and PLGA64 samples were heated to an upper temperature limit of 
100°C. The experimental parameters (temperature limits and heating rates) are summarized in 
Table 10-1. Each sample was heated and cooled twice. The reported data are the Tg values 
obtained on the second heating cycle, after erasing the thermal history of and any irreversible 
effects present in each polymer film.  
Table 10-1 Summary of experimental parameters for DSC analysis of polymer film samples degraded in vitro and in 
vivo. 
Sample Lower Limit Upper Limit Isothermal Hold
Group (°C) (°C) @ each endpoint
in vitro -20 200 2 3 minutes 20°C/min
in vivo -65 200 2 3 minutes 20°C/min
in vitro -20 100 2 3 minutes 20°C/min
in vivo -65 100 2 3 minutes 20°C/min
in vitro -65 100 2 3 minutes 20°C/min
in vivo -65 100 2 3 minutes 20°C/min
in vitro -65 100 2 3 minutes 20°C/min
in vivo -65 100 2 3 minutes 20°C/min
Material Number of Cycles Rate
PLA
PGA
PLGA4.4
PLGA64
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10.3 Results and Discussion 
10.3.1 Film Casting 
Several batches of films were made from each material. A Fowler micrometer was used 
to measure the thicknesses of the Mylar® substrates with cast polymer films, from which the 
thickness of the Mylar® substrate was subtracted in order to determine the thicknesses of the 
polymer films. The PLA films that were used were 67 µm thick, while the PGA films ranged in 
thickness from 76 to 133 µm, the PLGA4.4 from 68 to 83 µm, and the PLGA64 from 57 to 78 
µm. The PLA, PLGA4.4, and PLGA64 films were colorless and translucent in nature and 
adhered well to the Mylar® substrate. The PGA films, however, were white and opaque, and 
easily flaked off of the Mylar® substrate. The PLGA4.4 film was slightly tacky at room 
temperature, due to the low Tg of this material (31.4°C reported by the manufacturer), while the 
other films were non-sticky. 
10.3.2 Gel Permeation Chromatography (GPC) 
Molecular weight results are shown in Figure 10.1 to Figure 10.4. The dashed line on 
each graph indicates the average molecular weight measured for the powder standards of each 
polymer. Day zero cage and subcutaneous samples were unimplanted films taken from the same 
batches as those used for the cage and direct subcutaneous implants. The GPC software typically 
reports Mn (number average molecular weight), Mw (weight average molecular weight), and MP 
(the molecular weight corresponding to the maximum peak height) for a given peak. Figure 10.1 
to Figure 10.4 show MP results.  
The molecular weights reported by the software are not absolute values, but rather 
relative to the PMMA standards. Polyesters are typically analyzed in chloroform with 
polystyrene standards when performing GPC analysis. However, the insolubility of PGA in 
chloroform necessitated the use of 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) as a solvent for 
GPC analysis in this study. This solvent was used for GPC analysis of all the materials for 
experimental consistency. Although we used PMMA standards, which are used commercially in 
GPC analysis of polyesters in HFIP, we found that polyester samples analyzed in HFIP with 
PMMA standards yielded different molecular weight data than those run in chloroform using 
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polystyrene standards. Additionally, there was variation in the molecular weight values obtained 
for powder control samples that were run in different sample batches. Therefore, a correction 
factor was determined based on the molecular weight values obtained for powder controls in 
chloroform (CHCl3) and HFIP. This correction factor was then applied to the molecular weight 
values obtained for the rest of the samples in a given batch. This allowed comparison of the 
experimentally obtained molecular weight values with the data reported by the manufacturer for 
the various polyester materials used in this study. The results and correction factors are 
summarized in the below. The molecular weight values reported in the text below for the 
PLGA4.4, PLGA64, and PLA samples have been corrected using the factors listed in Table 
10-2 below. 
Table 10-2 Correction factors used in GPC calculations of molecular weight for PLGA4.4, PLGA64, PLA, and 
PGA samples. 
Manufacturer Average Mw Average Mw Correction Factor
specified Mw (in CHCl3) (in HFIP) (in CHCl3) (Mw,HFIP)/(Mw,CHCl3)
PLGA4.4 4,400 7,067/7,775 3,523 2.006 or 2.207
PLGA64 64,000 121,840/89,789/67,003 71,897 1.69 or 1.249 or 0.93
PLA (unpurified)
(used for films)
PLA (purified)
(used for powder controls)
PGA Not characterized 143,950 NA NA
Polymer
0.473303,760143,757NA
194,000 120,881 NA 0.623
 
10.3.2.1 Mylar® and HFIP 
Mylar® control samples (results not shown) typically produced three peaks on the GPC 
chromatograms, at approximately 32,000 to 45,000, 2,000 to 2,500, and 800 daltons. 
The sample of HFIP only (no polymer) showed peaks on the chromatogram at 760 and 
520 daltons. The presence of a peak at 750 or 800 daltons on both the Mylar® and HFIP 
chromatograms indicates that it is intrinsic to the GPC system, most likely due to residual solvent 
from previous batches that used a different mobile phase. 
Based on the results of these samples, the peaks at 2,000–2,500, ~800, and ~500 daltons 
were disregarded for most of the polymer samples and are not reported here. Additionally, peaks 
in the range of 35,000–45,000 were typically disregarded as due to the Mylar® if the samples 
had little visible polymer remaining on the surface of the Mylar® substrate. Figure 10.1 to 
Figure 10.4, which show the GPC results for the PLA, PGA, PLGA4.4, and PLGA64, include 
the data for the molecular weight corresponding to the peak with the largest area on the 
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chromatogram (the main peak), although the discussion below includes any additional peaks that 
were present.  
10.3.2.2 Fibrous Capsule Tissue With Implants 
The explanted tissue surrounding the PLA film implant showed a visible fibrous capsule, 
with vascularization localized over less than one-half the area of the PLA film. Some of the 
capsule tissue looked yellowish, possibly indicating scar formation. The tissue samples showed a 
main peak on the GPC chromatograms around 185,000 daltons, while the PLA film that was 
removed from the unfixed tissue showed a main peak at 117,000 daltons (results not shown). 
The tissue surrounding the PLGA4.4 film implant showed a visible fibrous capsule with 
a much greater degree of tissue vascularization than was seen in the tissue surrounding the PLA 
film. Blood vessels were distributed throughout most of the tissue that was in contact with the 
surface of the implanted film. The tissue sample showed a main peak on the GPC 
chromatograms at around 190,000 daltons, which was also evident for the PLGA4.4 film sample 
that was removed from the unfixed tissue. 
Based on these results, peaks with a molecular weight of 190,000 or greater were 
typically disregarded from sample chromatograms as being due to biological material on the 
surface of the films. Exceptions will be noted below. 
10.3.2.3 PLA 
The GPC results for the PLA samples are shown in Figure 10.1. The PLA powder 
control samples had a main peak of ~290,000 (dashed line in Figure 10.1) and a secondary peak 
at ~10,000 daltons. The PLA cage control film samples (day zero cage samples) had a main peak 
of ~207,000, a 29% drop in molecular weight compared to the powder control, and secondary 
peaks at ~12,000 and 3,000–5,000 daltons. The PLA subcutaneous control film samples (day 
zero subcutaneous samples in Figure 10.1) showed a main peak at an average molecular weight 
of 166,000, a 43% drop in molecular weight compared to the powder control. A shoulder was 
also evident at 5,000–12,000 daltons. 
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Figure 10.1 Measured peak molecular weight for PLA samples: - - - powder control samples,  in vitro samples, ● 
in vivo direct subcutaneous implants, ○ in vivo cage implants. 
The PLA cage samples (○ in Figure 10.1) typically showed four peaks on the GPC 
chromatograms over the course of the study. The main peak was at approximately 147,000–
435,000 daltons, with shoulder peaks at 25,000–30,000 and occasionally at 12,000–13,000 
daltons. This high molecular weight main peak for the cage samples was disregarded as due to 
tissue or other biological material for one of the day seven samples, but the peak on the 
remaining samples chromatograms showed a trend of slightly decreasing molecular weight over 
time. Additionally, the day 42 PLA film sample that was removed from unfixed tissue (section 
10.3.2.2) did not show a peak similar in molecular weight to that observed for the fibrous capsule 
tissue samples. This suggests that deposition of biological material in the surface of the PLA 
films was less pronounced than, for example, the PLGA4.4 films, which will be discussed below. 
The shoulder peaks at approximately 25,000–30,000 and 12,000–13,000 daltons increased in size 
over time. 
The PLA subcutaneous samples (● in Figure 10.1) showed a main peak that ranged in 
molecular weight over the course of the study from 270,000 down to 85,000 daltons, with a 
shoulder at 12,000–13,000 and a shoulder peak at 27,000 on one of the day seven explanted 
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samples. The high molecular weight peak at earlier time points seemed indicative of the 
decreasing molecular weight of the PLA. Two of the day 49 samples showed atypical results, 
having a main peak around the same molecular weight as that seen for Mylar®, as well as a 
secondary peak around 506,000–585,000 daltons. These very high molecular weight peaks at day 
49 were disregarded as due to biological material on the surface of these two samples. These day 
49 subcutaneous samples that showed atypical chromatograms were observed to have a much 
thinner layer of material on the Mylar® than the other subcutaneous PLA samples. It is possible 
that this material was actually deposited biological debris (material) which would be consistent 
with the observed ~500k dalton GPC peaks, rather than PLA remaining on the surface of the 
Mylar®. 
The in vitro samples appeared to undergo degradation similar to that seen for the 
subcutaneous samples. The in vitro PLA samples (■ in Figure 10.1) showed one large main 
peak on the chromatograms, which ranged in molecular weight from 270,000 at day 4 down to 
36,000 at day 49. This main peak showed a large variation in molecular weight for the day 49 
samples.  
10.3.2.4 PGA 
The GPC results for the main peaks of the PGA samples are shown in Figure 10.2 
below. The PGA powder control samples had a main peak with an average molecular weight of 
~155,000 (dashed line in Figure 10.2). A smaller peak was evident with a molecular weight 
ranging from 10,000 to 17,000 daltons (data not shown). 
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Figure 10.2 Measured peak molecular weight for PGA samples: - - - powder control samples,  in vitro samples, ● 
in vivo direct subcutaneous implants, ○ in vivo cage implants. 
The PGA cage control film samples (day zero cage samples) had a main peak on the 
GPC chromatograms that had an average molecular weight of ~110,000, a 29% decrease in the 
molecular weight compared to the powder controls. Secondary peaks were also visible with 
molecular weights ranging from 5,000–12,000 and 14,000–19,000 daltons. The PGA 
subcutaneous control film samples (day zero subcutaneous samples in Figure 10.2) had a main 
peak with an average molecular weight of ~121,000 daltons (22% decrease in molecular weight 
from that of the powder control) and two smaller peaks with molecular weights ranging from 
5,300–7,200 and 12,000–19,000 daltons (data not included in Figure 10.2). 
The PGA cage samples (○ in Figure 10.2) typically showed three peaks on the GPC 
chromatograms. There was a large peak at approximately 350,000–400,000 daltons (which 
increased in molecular weight over time), two other peaks at around 38,000 and 2,000–6,000, 
and a shoulder at 10,000. The largest peak for two of the day 4 samples was at 38,000, while for 
the rest of the samples the main peak occurred at a molecular weight of 5,000 or less. 
The PGA subcutaneous samples (● in Figure 10.2) for days 4, 7, 14, and 21 typically 
exhibited three peaks on the GPC chromatograms, similar to the cage samples. The main peak 
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was at approximately 5,000 daltons, with smaller peaks at ~40,000–55,000 and ~400,000 daltons, 
and a shoulder at 8,000–13,000 daltons. The ~40,000–55,000 peak and 8,000–13,000 shoulder 
decreased in size over time relative to the other peaks, while the ~5,000 peak increased in size 
relative to the other peaks. The chromatograms for the day 28 samples showed atypical shapes, 
with a main peak around 200,000 daltons and a secondary peak at ~1,400 daltons. The day 28, 
35, 42, and 49 film samples were very different in appearance from the rest of the PGA 
subcutaneous samples. No white polymer was visible on the surface of the Mylar®, but a very 
thin, transparent film was present. These samples showed similar chromatogram peaks to the day 
4, 7, 14, and 21 samples. The 400,000 dalton peak was larger in area than the 50,000 molecular 
weight peak for the day 35 samples, but decreased in size relative to the 50,000 peak for the day 
42 and 49 samples.  
A ~400,000 peak was seen on the chromatograms for nearly all of the in vivo PGA 
samples, but was absent from the PGA powder control and film control chromatograms. This 
peak is similar to that seen in the tissue samples, as well as the PLGA4.4 in vivo and PLGA64 
direct subcutaneous samples that are discussed below. 
 The PGA in vitro samples (■ in Figure 10.2) typically showed three peaks on the GPC 
chromatograms, around 63,000–101,000, 17,000–25,000, and 6,000–9,000 daltons. The two 
highest molecular weight peaks showed a decrease in molecular weight and peak area over time. 
The 6,000–9,000 peak did not show a large decrease in molecular weight over the 49 days, but 
the peak area increased relative to the higher molecular weight peaks until this 6,000–9,000 
molecular weight peak became the main peak (peak having the largest area) on the 
chromatograms. This is reflected by the large drop in molecular weight between days 4 and 49 
shown in Figure 10.2 for the in vitro PGA samples. 
10.3.2.5 PLGA4.4 
The GPC results for the PLGA4.4 samples are shown in Figure 10.3 below. The 
PLGA4.4 powder controls (dashed line in Figure 10.3) showed a main peak on the GPC 
chromatograms at approximately 3,500 daltons. One batch of powder controls showed a shoulder 
at 18,000 to 19,000 daltons (data not shown). 
249 
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
0 7 14 21 28 35 42 49
Time (days)
M
ol
ec
ul
ar
 W
ei
gh
t (
da
lto
ns
)
 
Figure 10.3 Measured peak molecular weight for PLGA4.4 samples: - - - powder control samples,  in vitro 
samples, ● in vivo direct subcutaneous implants, ○ in vivo cage implants. 
 The PLGA4.4 cage control film samples (day zero cage samples in Figure 10.3) had a 
main peak at approximately 2,500 daltons (a 29% decrease in molecular weight compared to the 
powder controls) with a shoulder at 18,000 daltons. The PLGA4.4 subcutaneous control film 
samples (day zero subcutaneous samples in Figure 10.3) had a main peak on the chromatograms 
at an average molecular weight of ~2,600 daltons, and a shoulder peak at ~18,000 daltons. The 
PLGA4.4 cage samples (○ in Figure 10.3) typically showed only one large peak on the GPC 
chromatograms at ~200,000 daltons. However, this peak was disregarded as due to biological 
material and therefore is not plotted in Figure 10.3. Occasionally a small peak was seen around 
2,000 to 3,000 daltons. The PLGA4.4 subcutaneous samples (● in Figure 10.3) typically 
showed a peak on the GPC chromatograms at ~200,000 daltons. This peak was shown on all of 
the day 7, 14, 42, and 49 day samples, as well as some of the day 21 and 35 samples. Similar to 
the PLGA4.4 cage samples, this peak was disregarded as due to biological material on the 
surface of the Mylar® substrate and therefore is not shown in Figure 10.3. 
The PLGA4.4 in vitro samples (■ in Figure 10.3) exhibited many different peaks on the 
chromatograms. In general, not all of the samples had either the same chromatogram shape 
(number of peaks) or all of the same peak locations (molecular weights). Additionally, some 
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shoulder peaks were difficult to resolve due to their small area. The chromatograms for the day 
four samples showed a main peak at 1,500 or 2,800 daltons, or a main double peak at 1,800 and 
3,500 daltons. One sample had a shoulder at 1,100 daltons, while another sample had a shoulder 
at 4,800 daltons. Two of the day seven samples exhibited double main peaks at 5,200 and 1,700–
2,200 daltons, while the third sample had a peak at 6,000 daltons and a larger peak at 1,100 
daltons. Similarly, two of the day 14 samples had peaks at 5,000 to 6,000 and 1,700 to 2,000 
daltons, while the third sample had a double main peak at 3,000 and 1,700 daltons. The 
chromatograms for the day 21 and 28 samples were more consistent, showing two main peaks at 
3,600–4,000 daltons, and 2,100–2,600 daltons. The day 35, 42 and 49 samples were also 
consistent, and all showed small peaks at 1,800–2,600 daltons.  
10.3.2.6 PLGA64 
The GPC results for the PLGA64 are shown in Figure 10.4 below. The chromatograms 
for the PLGA64 powder control (dashed line in Figure 10.4) showed a main peak at ~72,000 
daltons with shoulder peaks at 4,000 and 8,000 daltons. 
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Figure 10.4 Measured peak molecular weight for PLGA64 samples: - - - powder control samples,  in vitro 
samples, ● in vivo direct subcutaneous implants, ○ in vivo cage implants. 
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The chromatograms for the PLGA64 cage control films (day zero cage samples in 
Figure 10.4) showed a main peak at around 90,000 daltons, with shoulders at around 14,000 and 
4,500 daltons. This is a slight increase in the molecular weight of the main peak compared to the 
data obtained for the powder control. 
The chromatograms for the PLGA64 subcutaneous control films (day zero direct 
subcutaneous samples in Figure 10.4) showed a main peak at 135,000 daltons, with shoulders at 
4,000–8,000 and 10,000–20,000 daltons. These control films also showed an increase in the 
molecular weight of the main peak compared to the powder controls. 
The chromatograms for the PLGA64 cage samples (○ in Figure 10.4) typically showed 
large peaks around 60,000–140,000 daltons with a shoulder at around 18,000 daltons. Two of the 
day 21 samples were tan or slightly reddish in color, and showed large peaks at 130,000–140,000 
daltons. The PLGA64 cage implants showed a trend of decreasing molecular weight over the 
course of the study. 
The PLGA64 subcutaneous samples (● in Figure 10.4) up to day 21 typically showed 
only one large peak at 45,000–155,000 daltons with only very occasional shoulder peaks around 
12,000–16,000 daltons. One of the day 28 subcutaneous samples showed atypical results, 
exhibiting a high molecular weight peak at approximately 150,000 daltons. Two of the day 35 
samples, as well as all of the day 42 and 49 samples, showed this same peak at a molecular 
weight that increased from around 260,000 to 320,000 daltons. This peak was interpreted as due 
to biological material on the surface of the films, and therefore was not included in Figure 10.4. 
The day 28, 35, and 42 samples also occasionally showed a small peak at 3,000–4,000 daltons. 
The PLGA64 subcutaneous implants showed a trend of decreasing molecular weight over time. 
The chromatograms for the in vitro PLGA64 samples (■ in Figure 10.4) showed a main 
peak that started at 150,000 daltons on day four that rapidly decreased in molecular weight to 
approximately 63,000 daltons on one of the day 14 samples, and then disappeared. After day 14 
the main peak most often appeared in the molecular weight range of 7,000–15,000 daltons until 
day 49, when it dropped to 2,500–3,000 daltons. A very small peak was also visible at 
approximately 3,500 daltons, which increased in relative size at days seven and 14, and that 
slowly decreased in molecular weight from day 21 to day 49.    
252 
10.3.3 Differential Scanning Calorimetry (DSC) 
The results of the DSC analysis are summarized in Figure 10.5 to Figure 10.8. Data 
points typically represent the average of Tg values obtained from three samples for a given 
material and time point. The absence of data points or error bars at a given time point is due to 
the absence of a Tg for two or more of the samples at that time point.  
10.3.3.1 Mylar® 
Mylar® control samples (results not shown) produced a small glass transition peak at 
approximately 99–102°C, and a baseline of approximately 0.037 milliWatts/°C. For comparison, 
a Tg of approximately 80°C has been reported in the literature for amorphous Mylar® heated at 
10°C/minute9. Mylar® control samples were run with each batch of samples. This allowed for 
comparison of the Mylar® baseline and peaks with the sample results, in order to ensure that the 
thermal contribution from the Mylar® substrate did not interfere with the obtained sample 
results. 
10.3.3.2 PLA 
The measured Tg values of the PLA samples over the 49 days of the study are  shown in 
Figure 10.5 below. An average Tg of 52°C was measured for the PLA powder control samples 
(dashed line in Figure 10.5). The subcutaneous cage implants (○ symbols), direct subcutaneous 
implants (● symbols), and in vitro samples (■ symbols) did not show a clear trend of decreasing 
Tg in comparison to the powder control. The subcutaneous cage samples exhibited clearly visible 
Tg peaks for all time points. The direct subcutaneous implants also showed distinct Tg peaks for 
most samples up to 49 days. In contrast to these in vivo samples, only about half of the in vitro 
samples from days 14 or later had resolvable Tg peaks, and they were often much smaller in 
magnitude than those seen for the direct subcutaneous and the cage subcutaneous samples. 
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Figure 10.5 Measured Tg for PLA samples: - - - powder control samples, ■ in vitro samples, ● in vivo direct 
subcutaneous implants, ○ in vivo cage implants. 
10.3.3.3 PGA 
The measured Tg values for the PGA samples are summarized in Figure 10.6 below. The 
average Tg measured for the PGA powder control samples (dashed line in Figure 10.6) was 
approximately 45°C. The subcutaneous cage samples (○ symbols) showed only a slight trend of 
decreasing Tg over the time period of the study, and the Tg peaks were very difficult to resolve on 
the day 14 and 21 samples. The PGA direct subcutaneous samples (● symbols) showed a 
decrease in the measured Tg between days four (40°C) and 21 (27°C). At day 28 the average Tg 
increased to approximately 50°C, and then decreased for the remaining three time points. The in 
vitro samples (■ symbols) showed a drop in the measured Tg from 25°C at day four to 
approximately 19°C at day seven. The average measured Tg for the in vitro samples plateaued at 
between 14 and 19°C for the rest of the time points. 
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Figure 10.6 Measured Tg for PGA samples: - - - powder control samples,  in vitro samples, ● in vivo direct 
subcutaneous implants, ○ in vivo cage implants. 
10.3.3.4 PLGA4.4 
The measured Tg values for the PLGA4.4 samples over the course of the study are 
summarized in Figure 10.7 below. The powder control samples (dashed line in Figure 10.7) had 
an average Tg of 26°C. Neither the cage subcutaneous (○ symbols) nor the direct subcutaneous 
(● symbols) implant samples showed a decreasing Tg over time in comparison to the powder 
control. The direct subcutaneous samples had average measured Tg values greater than those of 
the powder controls for all time points of the study. The Tg peaks were very small and difficult to 
resolve for nearly all the samples at all time points for both the direct subcutaneous and the cage 
subcutaneous samples. The in vitro samples, in contrast, showed a decreasing trend in the Tg, 
from 9°C at four days to –7°C at 21 days. The Tg values obtained for the day 28 samples had a 
large amount of variation. After day 28 it became exceedingly difficult to reliably distinguish 
any Tg peaks for the in vitro samples, therefore no data for days 35, 42, and 49 are shown in 
Figure 10.7. 
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Figure 10.7 Measured Tg for PLGA4.4 samples: - - - powder control samples,  in vitro samples, ● in vivo direct 
subcutaneous implants, ○ in vivo cage implants. 
10.3.3.5 PLGA64 
The measured Tg values of the PLGA64 samples over the 49 days of the study are shown 
in Figure 10.8 below. The powder control samples (dashed line in Figure 10.8) had an average 
measured Tg of 46°C. Both the direct subcutaneous (● symbols) and cage subcutaneous (○ 
symbols) implant samples showed only a very slight drop in measured Tg over 21 days compared 
to the powder controls, to 37°C for the direct subcutaneous samples, and to 43°C for the cage 
subcutaneous samples. The cage subcutaneous samples, with the exception of one sample at 21 
days, all had clearly distinguishable Tg peaks. Similarly, the direct subcutaneous samples had 
distinct Tg peaks up to day 21, after which time no Tg peaks could be distinguished for any 
samples at the remaining time points (28, 35, 42, or 49 days). The in vitro samples had distinct Tg 
peaks out to day 35, but in contrast to the samples implanted in vivo, they showed a steady and 
large drop in the measured Tg, from 39°C at day four, to –23°C after 35 days. 
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Figure 10.8 Measured Tg for PLGA64 samples: - - - powder control samples, in vitro samples, ● in vivo direct 
subcutaneous implants, ○ in vivo cage implants. 
10.3.4 Discussion 
10.3.4.1 Mylar®, HFIP, and Tissue Samples 
The dissolution of the Mylar® and some tissue components in HFIP were unexpected 
results in this study. Mylar® is used in many applications whereby its chemical resistance is 
advantageous, and solubility of Mylar® in HFIP is not widely reported10–12. While the Mylar® 
control samples that were analyzed on the GPC were helpful in determining the Mylar® 
molecular weight, batch-to-batch variation in the reported molecular weights, as discussed in 
10.3.2, made it difficult to interpret some chromatograms. 
Filtration of the GPC samples prior to analysis was expected to remove any tissue or cell 
debris larger than 0.2 µm. However, extremely high molecular weight peaks were obtained for 
the tissue samples that were analyzed (see section 10.3.2.2), as well as for many of the polymer 
films that were implanted in vivo. This was particularly the case for the PGA and PLGA4.4, as 
well as some of the PLGA64 and PLA in vivo samples at longer implantation times. Solubility 
of proteins in fluoroalcohols has been reported in the literature13–16. HFIP has been used to 
dissolve peptide aggregates13, and has been shown to disrupt tertiary structure and strengthen 
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helical propensities of proteins13,14. If biological materials (proteins or collagen, for example) on 
the surface of the films are soluble in the HFIP, they may be the cause of this high molecular 
weight peak. Interestingly, the PLA film that was removed from the explanted tissue (at 42 days, 
see section 10.3.2.2) did not exhibit a high molecular weight peak from the biological material. 
This agrees with the results obtained for the PLA direct subcutaneous implant samples, which 
exhibited a biological material peak on the GPC chromatograms for only two of the day 49 
samples, suggesting less deposition of biological material than was seen for the PLGA4.4 
samples. The chromatograms for the PLGA4.4 film explanted at day 42 (see section 10.3.2.2), 
for example, showed only a peak from this biological material, and no peak due to the polymer 
itself. This also agrees with results obtained for the PLGA4.4 direct subcutaneous implant 
samples, which indicated that the polymer rapidly degraded within the first seven days of the 
study, leaving no polymer on the Mylar® substrate at subsequent time points. 
10.3.4.2 Biodegradable Polymers 
A half-life (t½) was determined for each sample group as the time period in which the 
experimentally measured average molecular weight dropped below one-half of the initial 
molecular weight for each sample group. The half-lives for each sample group are shown in 
Table 10-3 below, and will be discussed in further detail in the sections below. 
Table 10-3 Half-lives (time in days at which the average molecular weight of a sample group was one-half the 
initial molecular weight) for ~100 µm thick PLA, PGA, PLGA4.4, and PLGA64 films degraded under various 
conditions. 
Polymer In Vitro In Vivo In Vivo
Controls Direct Subcutaneous Cage Subcutaneous
PLA 28-35 49 >21
PGA 4-7 0-4 0-4
PLGA4.4 21-28 0-4 4-7
PLGA64 7-14 14-21 14-21  
 
10.3.4.2.1 PLA 
The half-lives in Table 10-3 of all of the PLA sample groups were larger than those for 
any of the other materials. This agrees with results in the literature which indicate that higher 
lactic acid content, as well as crystallinity of PLA samples, are correlated with slower 
degradation rates2,3,5. 
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The GPC data for the PLA control films, as well as the control films for the other 
materials, typically showed a significantly lower molecular weight for the main peak than was 
measured for the powder controls. Other studies on solvent cast and vacuum-dried 50:50 PLGA 
films have shown similar behavior5. A 22% drop in molecular weight was reported for 85–100 
µm thick films that were vacuum dried for 24 hours, with the hypothesis that the polymer 
degraded during fabrication. Between 17 and 40% loss in molecular weight has been reported for 
PLLA foams that were annealed above their Tm and then quenched and vacuum dried for 48 
hours5. Processing conditions for the films analyzed in this study were similar (annealed above 
Tg while drying under vacuum for 48 hours) to the latter experiments. 
While the GPC results indicate a steady slow loss of molecular weight for the PLA 
samples, the DSC results do not show a large change in the measured Tg over the course of the 
study. Two different types of phenomena have been reported in the literature with regard to DSC 
characterization of PLA, PGA, and PLGA degradation. The first type of behavior that has been 
observed is a decrease in the Tg of the polymer, reflecting a decrease in the molecular weight of 
the polymer chains and corresponding increase in the free volume of the polymer. The glass 
transition temperature (Tg) of a polymer and its molecular weight are related according to the 
following equation17: 
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Equation 10-a 
where Tg∞ = is the value of Tg for a polymer sample of infinite molar mass, ρ = polymer density, 
NA = Avogadro's number, θ = contribution of one chain end to the free volume of the polymer, αf 
= thermal expansion coefficient of the free volume, and Mn = number-average molar mass 
(molecular weight) of the polymer. The quantity (2ρNA/Mn) therefore represents the number of 
chain ends per unit volume. As the molecular weight of the polymer decreases, the number of 
chain ends per unit volume increases. The total contribution to the free volume due to the chain 
ends will therefore also increase, which is reflected in a lower measured Tg according to 
Equation 10-a (less thermal energy is needed to cause chain motion, since more free volume is 
already present). Physically this can be understood as the fact that for a higher concentration of 
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chain ends (lower chain molecular weight), greater free volume is present. Therefore, in order for 
short-range segmental motion to occur, correspondingly less thermal energy is required because 
the steric and energetic barriers to motion are smaller. This means that the onset of segmental 
motion, as reflected in the Tg, will occur at a lower temperature. Decreases in Tg due to a 
decrease in the molecular weight of the polymer have been observed in a number of studies that 
characterized PLA and PLGA degradation. Decreases in Tg over a period of up to 100 days have 
been observed for poly(D,L-lactic-co-glycolic acid) (50:50 ratio of lactide to glycolide) 
compression-molded samples18 that were degraded at 37°C in vitro. Microspheres fabricated 
from poly(D,L-lactic acid) have also shown a decrease in the measured Tg over periods up to 250 
days when degraded in saline at 37°C in vitro19,20. Similarly, microparticles made from both 
poly(D,L-lactic acid) and poly(D,L-lactic-co-glycolic acid) having a lactide:glycolide ratio of 
75:25 showed decreases in their Tg’s over the course of 120 days when degraded in saline at 
37°C in vitro21. 
 However, a second type of behavior has also been observed. An increase in the 
crystallinity of degrading polymer samples, as evidenced by higher Tg values and larger heats of 
fusion, has been observed for poly(glycolic acid)22, poly(L-lactic acid)23, and even poly(D,L-
lactic-co-glycolic acid)24 samples degraded in saline at 37°C in vitro. A hypothesis to explain 
this phenomena has been advanced, which proposes that as the polymer chains are degraded and 
cleaved into smaller chains, the oligomers that are formed can crystallize, resulting in the 
observed larger heats of fusion and higher Tg values24. Further, although one might expect that 
poly(D,L-lactic-co-glycolic acid) would not exhibit this behavior, due to the presumably random 
distribution of the lactic and glycolic acid units in the chain backbone, greater reactivity of 
glycolic units during ring-opening copolymerization of glycolide and lactide can lead to blocks 
of glycolide separated by as small as a single unit of lactide25. Faster hydrolysis of the glycolide 
regions of the PLGA copolymer might therefore leave behind crystallizable sequences of lactide. 
In the case of the PLA samples investigated in this study, a number of different reasons 
might explain the observation that the Tg values for the various sample groups did not appear to 
decrease over the course of the study. The measured molecular weight even after 49 days is still 
considerably larger (85,000 for the direct subcutaneous samples and 94,000, on average, for the 
in vitro samples) than the molecular weights measured for the other materials in this study. It 
may be that, according to Equation 10-a, the change in molecular weight was not significant 
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enough to be reflected in a change in the Tg of the samples. Additionally, crystallization of 
oligomers of the L-lactic acid may have counteracted any drop in the Tg due to the decrease in 
molecular weight of the chains. 
10.3.4.2.2 PGA 
The more rapid degradation of the PGA relative to the PLA, as evidenced by the shorter 
half-lives in Table 10-3, can be explained by the greater hydrophilicity of the PGA. Other 
studies of PLGA copolymers have demonstrated more rapid in vitro and in vivo degradation of 
50:50 (L:G) copolymers than other copolymers having higher fractions of lactic acid (75:25 or 
85:15), which was attributed to the more hydrophilic nature of the glycolic acid units2,3,5. A very 
rapid and large decrease in molecular weight was seen for all of the PGA sample groups in this 
study.  
The in vitro PGA samples had visible white polymer film present on the Mylar® out to 
day 49, which was easily removed from the surface of the Mylar®, while the in vivo samples had 
visible PGA up to day 21. Therefore, although a peak was typically seen on the PGA GPC 
chromatograms at approximately 38,000 daltons, similar to the molecular weight value obtained 
for the Mylar® controls, it seems unlikely that this peak is due to the Mylar® for many of the 
samples because of the ease with which the PGA could be separated from the Mylar® substrates. 
The PGA chromatograms were often bimodal, suggesting heterogeneous degradation. As was 
explored in Chapter 5, size-dependent degradation has been reported in the literature5,6. One 
study found more rapid molecular weight loss in thick (100 µm) PLGA films compared to thin 
(10 µm) films, but both types of films exhibited bimodal chromatograms5. The size of the 
samples used in this study (133 µm or less) is plausibly within the range where heterogeneous 
degradation may occur, and the results presented in Chapter 5 support this hypothesis. 
The DSC results for the PGA material do not initially appear to correlate well with the 
GPC results. The PGA direct subcutaneous samples show the expected behavior (a decrease in 
the measured molecular weight reflected by a drop in the Tg values) over the first 21 days of the 
study, but the day 28 samples showed a sudden increase in the measured Tg. This may be 
explained by our observations that the surface of two of the three explanted samples at this time 
point had tan and reddish patches on their surfaces. The presence of this biological material most 
likely caused the increase in the measured Tg. Although the day 35, 42, and 49 samples 
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subsequently showed a decrease in the measured Tg values, these values were still higher than 
those obtained for the day four to 21 samples. However, the higher measured Tg values for the 
explanted samples from these last three time points of the study may be explained by the fact that 
the Mylar® substrates had no visible PGA (thick white film) remaining on their surfaces, but 
instead a thin, translucent white film with some tan patches. Thus the Tg that was measured is 
most likely that of the biological residue on the surface of the explanted Mylar® film, and not 
that of the PGA material. The PGA cage samples also exhibited high Tg values and a high 
molecular weight peak on the GPC chromatograms, which it seems likely are both due to 
biological residue on the surface of the films, even though no biological material was visible 
when the explanted films were inspected with the naked eye. Although the in vitro PGA samples 
did not show a large drop in the measured Tg, the initial drop followed by a plateau is similar to 
the molecular weight results obtained by the GPC analysis.  
10.3.4.2.3 PLGA4.4 
Both the GPC and DSC results indicated that the PLGA4.4 degraded extremely rapidly 
in vivo and that it left only reminiscent traces of the polymer film on the Mylar® substrate after 
seven days. This hypothesis was confirmed by the visual inspection of the PLGA4.4 in vivo 
samples that was performed. Even after just seven days of implantation (both in the cage as well 
as directly under the skin of the animals), the films appeared to have only a very thin translucent 
coating on their surface, which could not reliably be identified as either polymer or biological 
material. The GPC results showed a large molecular weight peak similar to that observed in the 
tissue samples (see section 10.3.2.2) for all of the cage samples and most of the direct 
subcutaneous samples. Further, peaks at or less than the molecular weight specified by the 
manufacturer (4,400 daltons) were visible on very few of the in vivo sample chromatograms. 
These results support the hypothesis that the PLGA4.4 degraded rapidly in vivo. The molecular 
weight of the PLGA4.4 samples could be characterized out to 49 days in vitro, however, most 
likely due to the slower degradation in vitro compared to in vivo, as evidenced by the larger half-
life for the in vitro sample group in Table 10-3. Faster degradation rates of PLGA copolymers in 
vivo compared to in vitro have been reported in the literature, with the hypothesis that local 
accumulation of acidic degradation products may autocatalyze further degradation4. 
262 
The high Tg values measured for the PLGA4.4 samples that were implanted in vivo may 
be explained by the biological material that appeared to cause the high molecular weight peak 
(~200,000 daltons) on the GPC chromatograms. Evidence that these two phenomena are related 
may be found in the fact that the PLGA4.4 direct subcutaneous samples from days four and 28, 
which did not exhibit a high molecular weight peak (~200,000 daltons) on the GPC 
chromatograms had lower Tg values than the samples at other time points (see Figure 10.7). The 
difficulty in resolving Tg peaks for the PLGA4.4 in vitro samples after day 28 correlates well 
with the GPC results, which indicated a very low molecular weight (~2,000 daltons) at or after 
28 days. Further, visual inspection of the in vitro film samples prior to GPC or DSC preparation 
revealed that the samples for days 35, 42, and 49 had only a very sparse opaque white powder 
present. All of these indications suggest that the PLGA4.4 degraded very rapidly and that most 
of the polymer had been removed from the Mylar® substrate by the time the GPC and DSC 
analyses were performed.  
10.3.4.2.4 PLGA64 
The GPC results showed that the molecular weight of the PLGA64 samples took 35 days 
to plateau when implanted in vivo, indicating that this material degraded more slowly than both 
the PGA and the PLGA4.4. The half-lives in Table 10-3 suggest that this material degraded 
slightly more rapidly in vitro than in vivo, but this is not a conclusive result due to the large 
variation in sample molecular weights (as evidenced by the large error bars for the day seven, 14, 
and 21 samples in Figure 10.4).  
The day 21 PLGA64 direct subcutaneous samples showed noticeably broader peaks on 
the GPC chromatograms than samples explanted at earlier time points. The appearance of a high 
molecular peak (due to biological material) on one of the day 28 samples, similar to that seen for 
the PGA and PLGA4.4 in vivo samples, suggests that the period around 21 to 28 days may be 
critical for the onset of rapid degradation of the polymer. Further, the PLGA64 cage samples at 
day 21 showed a slight increase in the measured Tg, and two of the explanted films at this time 
point were tan and red in color. The presence of this biological debris on the surface of the 
polymer film again seems correlated with a higher measured Tg, and the appearance of the 
biological material after day 21 for both sets of in vivo samples (cage as well as direct 
subcutaneous) suggests a change in the immune response at that time frame. An increase in the 
263 
degradation rate of the polymer during this period or alternatively solubilization of the low 
molecular weight oligomers during this period may have caused a greater immune response in 
the animal, with correspondingly increased localization of cells that may have deposited 
biological material on the surface of the PLGA64 films. The GPC results for the in vitro 
PLGA64 samples also indicate that this polymer rapidly degrades over the first 21 days after 
implantation, but the molecular weight did not plateau even after 49 days of implantation. 
The PLGA64 samples implanted in vivo showed a higher measured Tg than the in vitro 
samples up to day 21, which correlates well with the higher molecular weight measured for these 
in vivo samples over the same time period.  
10.4 Summary and Conclusions 
Polymer films of PLA, PGA, and PLGA of two different molecular weights were 
fabricated on Mylar® substrates for an in vivo study of their biodegradation. The gel permeation 
chromatography and differential scanning calorimetry analyses indicate that the PGA degrades 
the most rapidly in vivo, followed by the PLGA4.4, PLGA64, and PLA. In general, more rapid 
degradation of the materials occurred in vivo than in vitro, most likely due to the autocatalytic 
effect of acidic degradation products that accumulate locally near the implant. This trend 
supports the results presented in Chapter 9, which indicated that release from the microreservoir 
devices was more rapid in vivo than in vitro, presumably due to the faster degradation rates of the 
membrane polymers in vivo. The GPC and DSC results suggest the presence of biological 
material on the surface of the explanted films (particularly the PLGA4.4, PGA, and PLGA64 at 
longer implantation times).  
10.5 Acknowledgements 
The in vivo and in vitro degradation studies reported here were performed by Gabriela 
Voskerician in the laboratory of Dr. James M. Anderson, M.D., Ph.D., Departments of 
Biomedical Engineering and Macromolecular Science, and Institute of Pathology in the School 
of Medicine at Case Western Reserve University in Cleveland, OH. Joyce Chan and Grace Kim 
performed sample preparation for the GPC and DSC analyses at MIT. 
264 
10.6 References 
1. J. M. Anderson and M. S. Shive, “Biodegradation and biocompatibility of PLA and PLGA 
microspheres,” Adv. Drug Deliv. Rev. 28 (1997) 5–24. 
 
2. R. A. Miller, J. M. Brady, and D. E. Cutright, “Degradation rates of oral resorbable implants 
(polylactates and polyglycolates): rate modification with changes in PLA/PGA copolymer 
ratios,” J. Biomed. Mater. Res. 11 (1977) 711–719. 
 
3. L. Lu, S. J. Peter, M. D. Lyman, H.-L. Lai, S. M. Leite, J. A. Tamada, S. Uyama, J. P. 
Vacanti, R. Langer, and A. G. Mikos, “In vitro and in vivo degradation of porous poly(DL-
lactic-co-glycolic acid) foams,” Biomaterials 21 (2000) 1837–1845. 
 
4. S. M. Li, H. Garreau, and M. Vert, “Structure-property relationships in the case of the 
degradation of massive aliphatic poly-(α-hydroxy acids) in aqueous media, Part 1: Poly(DL-
lactic acid),” Journal of Materials Science: Materials in Medicine 1 (1990) 123–130. 
 
5. L. Lu, C. A. Garcia, and A. G. Mikos, “In vitro degradation of thin poly(DL-lactic-co-
glycolic acid films),” J. Biomed. Mater. Res. 46 (1999) 236–244. 
 
6. I. Grizzi, H. Garreau, S. Li, and M. Vert, “Hydrolytic degradation of devices based on 
poly(DL-lactic acid) size-dependence,” Biomaterials 16 (1995) 305–311. 
 
7. M. Vert, J. Mauduit, and S. Li, “Biodegradation of PLA/GA polymers: increasing 
complexity,” Biomaterials 15 (1994) 1209–1213. 
 
8. M. S. Shive, ”In vivo studies of biomedical polymers,” M.S. thesis, Department of 
Biomedical Engineering, Case Western Reserve Univ., Cleveland, OH, 1998. 
 
9. N. A. Bailey, J. N. Hay, and D. M. Price, “A study of the enthalpic relaxation of 
poly(ethylene terephthalate) by conventional and modulated temperature differential 
scanning calorimetry,” Proceedings of the Twenty-Seventh Conference of the North 
American Thermal Analysis Society, September 20–22, 1999, Savannah, Georgia, pp. 731–
736. 
 
10. "Polyethylene Terephthalates" in The Merck Index, 13th edition, Eds: M.J. O'Neill, A. Smith, 
P.E. Heckelman, J.R. Obenchain, Jr., J.A.R. Gallipeau, M.A. D'Arecca, S. Budavari, Merck 
& Co., Inc., Whitehouse Station, NJ (2001) 1359. 
 
11. "Mylar® Chemical Properties," DuPont Teijin Technical Data Sheet H-37250-1, 
http://www.dupontteijinfilms.com/datasheets/mylar/productinfo/properties/h37250-1.pdf, 
DuPont Teijin, Wilmington, DE (1995). 
 
12. "Polyethylene terephthalate," in CRC Handbook of Polymer-Liquid Interaction Parameters 
and Solubility Parameters, A.F.M. Barton, CRC Press, Boca Raton, FL (1990) 202–206. 
 
265 
13. K. Gast, A. Siemer, D. Zirwer, and G. Damaschun, “Fluoroalcohol-induced structural 
changes of proteins: some aspects of cosolvent-protein interactions,” Eur. Biophys. J.  30 
(2001) 273–283. 
 
14. J. Cort, and N. Andersen, “Formation of a molten-globule-like state of myoglobin in aqueous 
hexafluoroisopropanol,” Biochem. Biophys. Res. Commun. 233 (1997) 687-691. 
 
15. N. Andersen, R. Dyer, R. Fesinmeyer, F. Gai, A. Liu, J. Neidigh, and H. Tong, “Effect of 
hexafluoroisopropanol on the thermodynamics of peptide secondary structure formation,” J. 
Am. Chem. Soc. 121 (1999) 9879–9880. 
 
16. N. Hirota, K. Mizuno, and Y. Goto, “Cooperative α-helix formation of Β-lactoglobulin and 
melittin induced by hexafluoroisopropanol,” Protein Sci. 6 (1997) 416–421. 
 
17. R. J. Young, P. A. Lovell, Introduction to Polymers, 2nd edition, Chapman and Hall, London 
(1996) 299. 
 
18. W. Vogelhuber, P. Rotunno, E. Magni, A. Gazzaniga, T. Spruß, G. Bernhardt, A. Buschauer, 
and A. Göpferich, “Programmable biodegradable implants,” J. Controlled Release 73 (2001) 
75–88. 
 
19. T. G. Park, “Degradation of poly(D,L-lactic acid) microspheres: effect of molecular weight,” 
J. Controlled Release 30 (1994) 161–173. 
 
20. M. F. Gonzalez, R. A. Ruseckaite, and T. R. Cuadrado, “Structural changes of polylactic-acid 
(PLA) microspheres under hydrolytic degradation,” J. Appl. Polym. Sci. 71 (1999) 1223–
1230.  
 
21. G. Reich, “Use of DSC to study the degradation behavior of PLA and PLGA microparticles,” 
Drug Development and Industrial Pharmacy 23 (1997) 1177–1189. 
 
22. R. M. Ginde and R. K. Gupta, “In vitro chemical degradation of poly(glycolic acid) pellets 
and fibers,” J. Appl. Polym. Sci. 33 (1987) 2411–2429. 
 
23. C. Migliaresi, L. Fambri, and D. Cohn, “A study on the in vitro degradation of poly(lactic 
acid),” J. Biomater. Sci. Polymer Edn. 5 (1994) 591–606. 
 
24. T. G. Park, “Degradation of poly(lactic-co-glycolic acid) microspheres: effect of copolymer 
composition,” Biomaterials 16 (1995) 1123–1130. 
 
25. D. K. Gilding and A. M. Reed, “Biodegradable polymers for use in surgery—
polyglycolic/poly(lactic acid) homo- and copolymers:1,” Polymer 20 (1979) 1459–1464. 
266 
267 
11 Conclusions and Future Work 
11.1 Summary of Results 
The results presented in this thesis clearly show the viability of using the polymeric 
microreservoir device to achieve multipulse delivery of drugs both in vitro and in vivo. While 
many other systems, such as three-dimensionally printed structures and compression molded 
devices, could also be used to deliver multiple pulses of drugs, thus far no proof-of-principle 
results have been reported. Therefore, the design we have developed and reported here represents 
a new class of device for controlled release drug delivery.  
11.2 Future Work 
While the results presented here demonstrate proof-of-principle of the device operation 
and give us some understanding of the factors that can affect system performance, further study 
will only serve to improve both our understanding as well as the functioning of the system. 
11.2.1 Membrane Degradation and Opening 
As was discussed extensively in Chapter 5, the degradation mechanisms of the PLGA 
copolymers that comprise the reservoir membranes are quite complicated. The local 
environmental temperature and pH can affect the degradation rate of the membranes and 
therefore change the time at which the drugs are released from the reservoirs. Additionally, the 
dimension dependence of the PLGA degradation rate and nonlinearity of the degradation rate as 
a function of polymer molecular weight make prediction of membrane degradation time difficult 
without prior in vitro and in vivo characterization.  
While the GPC characterization of polymer degradation in Chapter 5 suggested that 
perhaps membrane opening is correlated with the polymer molecular weight dropping below 
5,000–7,000 daltons, the results reported in Chapter 7, which showed a large amount of water 
uptake and membrane swelling during the course of a typical release experiment, suggest that 
there may also be a mechanical component which helps dictate membrane opening. Further 
elucidation of the mechanisms by which the membranes open will aid in gaining further control 
over device performance. Alternatively, other biodegradable materials, such as polyanhydrides, 
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polydioxanone, or polyethylene carbonate, may ultimately prove more amenable to achieving 
greater control over the release time of drugs from the devices.  
11.2.2 Drug Chemistry 
A number of the studies reported here aimed to gain an understanding of whether the 
drug itself that is released from the microreservoir device plays a role in changing the observed 
release time from the reservoirs. While some results appeared to indicate that this was indeed the 
case, other studies seemed to support the theory that the molecular weight of the drug did not 
affect release time. In the case of BCNU and IAP, the large partitioning coefficients calculated 
for the PLGA4.4 membrane material in Chapter 6 seemed to support the observed diffusion-type 
release behavior of these molecules from the microreservoir device that was observed in Chapter 
4. On the other hand, studies that investigated the effect of drug molecular weight and reservoir 
loading on the release time and membrane swelling (Chapter 7) showed no significant 
differences between 14C-glucose and higher molecular weight polymers of 14C-dextran (10,000, 
40,000, and 70,000 molecular weights). While the lipophilicity of the drug, rather than the 
molecular weight, may ultimately prove to be the determining factor for the release kinetics, at 
present the only way to understand the interaction between the drug and membrane material is to 
investigate each drug on an individual basis. More systematic study of this issue may help to 
delineate a set of general guidelines or expectations for release kinetics, based on certain 
characteristics of the drugs of interest (such as molecular weight, functional groups, pKa, 
partition coefficient, or hydrodynamic radius, for example) that would allow device performance 
to be predicted with confidence. Further, ameliorative measures may be developed that could 
eliminate the effects of drug chemistry on device performance.  For example, coating the inside 
of the reservoirs with a barrier layer of a hydrophilic material (such as a starch or sugar) might 
prevention diffusional release of small lipophilic molecules such as BCNU through the reservoir 
membranes prior to membrane opening.  
11.2.3 In Vivo Drug Release 
While the results presented in Chapter 9 show that in vivo drug delivery from the 
microreservoir device is possible, much more thorough study and testing will be necessary 
before this device will become a clinical reality. The need for a better correlation between in 
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vitro and in vivo results seen in general for PLGA-based drug delivery systems necessitates more 
extensive testing and redesign of these systems even when reproducible in vitro performance has 
been achieved. The rapid release times as well as closely spaced pulses that were observed for 
14C-mannitol released from these devices in vivo suggest that the first step towards robust in vivo 
device performance may be to increase the difference in molecular weights of the materials used 
for the reservoir membranes in order to achieve more distinctly separated pulses from the device. 
Once reproducible in vivo device performance has been achieved, demonstration of device 
efficacy for treatment of a disease condition would provide the ultimate confirmation of device 
utility. 
11.3 Conclusions 
The work reported here represents the first demonstration in the literature of multipulse 
chemical delivery from a polymeric reservoir-based system without reliance on external stimuli. 
This device could potentially be used in applications where pulsatile delivery of potent 
molecules is desired for maximum therapeutic efficacy, such as hormone treatments or multi-
dose vaccines. The separation of the drug formulations (reservoir contents) from the release 
formulations (reservoir membranes) may permit greater flexibility in device design and 
performance than is currently available for other implantable polymeric drug delivery systems, 
allowing greater applicability to a wider range of clinical indications.  
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A Factors Affecting Measured Fluorescence 
A.1 Introduction 
 It is well known that several factors may affect the measured fluorescence of a molecule. 
Most notable of these are the pH1 and ionic strength2,3 of the solution that contains the 
fluorescent molecule, and photobleaching4–6. Several of the studies reported in Chapter 3 and 
Appendix B that investigated the accuracy of the microinjector apparatus used sodium 
fluorescein or fluorescein-labeled dextran as the marker molecule. Fluorescein has many 
desirable properties, including high fluorescence yield and high water solubility. However, its 
fluorescence is significantly pH-dependent, and it can undergo rapid photobleaching under 
exposure to high or even moderate intensity light. Several studies were therefore conducted to 
determine if the changes in fluorescence caused by pH, the related factors of conductivity and 
ionic strength, and photobleaching were significant enough to explain some of the variation in 
fluorescence measured in the different studies.  
A.2 Materials and Methods 
A.2.1 Materials 
 Fluorescein sodium salt was purchased from Sigma-Aldrich (St. Louis, MO). Solutions of 
sodium fluorescein were made using either phosphate buffered saline (PBS) or milliQ deioinized 
water.  
A.2.2 Methods 
A.2.2.1 Photobleaching: Microinjected Cuvettes 
 For the first set of experiments, a sodium fluorescein solution of 1.32 × 10-2 mol/L was 
microinjected into cuvettes. The procedure that was used was similar to that described in Chapter 
3. Series of one, two, three, four, or five injections of 19.57, 49.72, 99.98, and 149.7 nL were 
performed. Two series of microinjections were performed. The first set was performed with both 
ambient lighting (overhead fluorescent lights as well as natural light from nearby windows) and 
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stage lighting on the microscope. The second set was performed with only stage lighting on the 
microscope. The overhead lights were turned off and the blinds were drawn on the windows to 
block as much natural light as possible. To each cuvette were added three milliliters of deionized 
water. The cuvettes were covered with Parafilm M® and shaken. 
The fluorescence (fluorescence counts/sec) of each cuvette was measured using λexc = 
494 nm and λemi = 520 nm on a spectrofluorometer (Photon Technology International, 
Lawrenceville, NJ) having an L-201M Illumination System, LPS-220 Lamp Power Supply, 
A1010 Arc Lamp Housing, two Model 101 Computer-Controlled Monochromators, MP-1 
Sample Compartment, Model 814 Analog/Photon-Counting Photomultiplier Detector, SC-500 
Shutter Controller, Computer Interface, and PTI Felix v.1.42a software on a Dell Optiplex 
466/Le computer. The concentration of fluorescent label in each cuvette (Cc) was calculated by 
subtracting the background fluorescence of a cuvette of deionized water (blank), and dividing by 
the slope in (fluorescence counts/sec)/(mol/L) of a standard curve. The measured microinjected 
volume Vmeas was then calculated by using the volume of solution in the cuvette (Vc), the 
appropriate dilution factors (Di), and the concentration of the fluorescently labeled solution in the 
syringe (Cinit) as follows: 
 
( )
( )iinit
CC
meas DC
CV
V ×
×=  
Equation 0-a 
A.2.2.2 Photobleaching: Pipetted Cuvettes 
Twenty microliters of a sodium fluorescein solution of 1.41 × 10-2 mol/L were pipetted 
into a cuvette containing three milliliters of phosphate buffered saline (PBS), n = 3. The 
solutions in these cuvettes were then diluted twice sequentially by pipetting 20 µL of the solution 
from each cuvette into a fresh cuvette with three milliliters of PBS. This procedure was used to 
produce two sets of cuvettes, designated A and B. Set A was kept wrapped in foil and not 
exposed to any light, while set B cuvettes were placed on the stage of the PZMT Trinocular 
stereo microscope with 13338 Adapter Ring Light, R-8-8-WPI01 fiber optic ring light, and 
NOVA Novaflex fiber optic light source (World Precision Instruments, Sarasota FL) for five 
minutes, with the microscope stage light on the lowest setting, the overhead lights off, and the 
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window blinds closed. The fluorescence of both sets of cuvettes was measured on the 
spectrofluorometer. Both sets of cuvettes were then placed on the microscope stage for eight 
minutes, with the same conditions as for the initial light exposure of set B. The fluorescence of 
the cuvettes was then measured again on the spectrofluorometer.  
A.2.2.3 Ionic Strength and pH 
 Various dilutions of PBS were made in order to more thoroughly investigate the effect of 
ionic strength and pH on the measured fluorescence of fluorescein sodium salt solutions. As 
received 10X PBS was diluted to 9X, 7X, 5X, 3X, and 1X solutions using milliQ deionized 
water. Fluorescein sodium salt solution (1.3 µmolar) was pipetted in 25, 50, or 100 µL 
increments into polystyrene cuvettes, and three milliliters of the PBS dilution of interest was 
added to the cuvette. This was repeated in triplicate for each volume size and PBS dilution, for a 
total of 54 samples (3 × 3 × 6 = 54). The fluorescence of each cuvette was then measured on the 
spectrofluorometer as described previously. The pH values of the samples were measured using a 
Corning model 430 pH meter. 
A.2.2.4 pH and Conductivity: Release Studies 
 Data from a number of release studies were compiled in order to determine if pH and 
conductivity effects on the observed fluorescence are significant over the course of a typical 
release study. Eleven devices were loaded with sodium fluorescein for in vitro release 
experiments. The cumulative percentage of the initial fluorescein loading was measured over 
time. The experiments were stopped at various points, ranging from 7 to 180 elapsed days. The 
pH of the release medium was measured using a Corning model 430 pH meter and the 
conductivity was measured using a Fisher Scientific Digital Conductivity Meter on the 20,000 
microohm (µohm) setting.  
A.3 Results and Discussion 
A.3.1 Photobleaching: Microinjected Cuvettes  
The results for the microinjected cuvettes are shown in Figure A.1 and Figure A.2 
below. 
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Figure A.1 Measured microinjected volume versus predicted microinjected volume (solid line) for bleached sodium 
fluorescein microinjected from a 10 µL syringe: ○ 19.57 nL injections, × 49.72 nL injections, ● 99.98 nL injections, 
■ 149.7 nL injections. Solid line indicates theoretical predicted microinjected volume, dashed line is linear least 
squares fit to experimental data points. 
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Figure A.2 Measured microinjected volume vs. predicted microinjected volume (solid line) for unbleached sodium 
fluorescein microinjected from a 10 µL syringe: ○ 19.57 nL injections, × 49.72 nL injections, ● 99.98 nL injections, 
■ 149.7 nL injections. Solid line indicates theoretical predicted microinjected volume, dashed line is linear least 
squares fit to experimental data points. 
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Solid lines indicate the predicted (theoretical) microinjected volume, while the experimentally 
obtained data are shown by the different symbols. A linear least-squares fit to the experimental 
data was used to determine R2 and the slope of the line. This fit is shown by the dashed lines in 
Figure A.1 and Figure A.2.  
The “bleached” fluorescein results shown in Figure A.1 indicate that the measured 
microinjected volume was only approximately 20% of the predicted volume. For the unbleached 
samples, shown in Figure A.2, the measured microinjected volume was approximately 40% of 
the predicted value. The 20% lower fluorescence seen for the “bleached” samples in Figure A.1 
suggests that the ambient and natural lighting to which the samples were exposed (overhead 
fluorescent lighting and natural light from the windows in the laboratory) caused measurable loss 
in fluorescence in this experimental setup. However, more importantly, the large difference 
between the measured and predicted volumes for both sets of samples indicates that the stage 
lighting on the microscope, which was present for both sets of microinjections, may account for 
the majority of the loss in the measured fluorescence. This most likely explains the low 
percentages of microinjected sodium fluorescein that were measured in some of the studies 
detailed in Appendix B for the studies that investigated the effect of the syringe volume on the 
accuracy of microinjection. 
A.3.2 Photobleaching: Pipetted Cuvettes 
 Table A-1 shows the initial and final average measured fluorescence and standard 
deviation for sets A and B cuvettes, as well as the calculated loss in fluorescence, in percent, due 
to the light exposure between the two sets of fluorescence measurements.  
Table A-1 Measured fluorescence of sodium fluorescein solution pipetted into cuvettes. Set A cuvettes received 
only eight minutes of exposure to microscope stage lighting, while Set B had an initial five-minute exposure to the 
microscope stage lighting, followed by a second exposure of eight minutes. 
 
 
Fluorescence 
(counts/sec) 
Standard Deviation 
(counts/sec) 
Standard Deviation 
(% of Average) 
Set A initial average: 1804667 91817 5.09 
Set A final average: 1663333 91566 5.50 
Percent decrease: 7.83   
Set B initial average: 1913667 17926 0.94 
Set B final average: 1763667 12741 0.72 
Percent decrease: 7.84   
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Contrary to what was expected, the set B cuvettes, which had an initial light exposure of 
five minutes before the first set of fluorescence measurements were taken, showed a higher 
average fluorescence than set A, which did not have any initial light exposure. However, this 
result is not statistically significant, as the average values plus or minus one standard deviation 
overlap for the two sets of cuvettes. Additionally, the difference between the averages for the 
two sets of measurements is only approximately five to six percent ((1913667-
1804667)/1913667 × 100 = 5.7%), which may simply be due to a slight variation in pipetting the 
concentrated solution of sodium fluorescein.  
Although standard deviations of each individual reading were not recorded for these 
samples, typically the standard deviation for a given reading is between 1 and 3 %. The decrease 
in fluorescence measured after the second light exposure is larger than this typical standard 
deviation for a single reading, as well as the standard deviations for the averaged initial readings 
(0.94% and 5.09%), and the differences between the average values of counts/sec for set A and 
set B. This indicates that the photobleaching caused by the eight-minute exposure to the 
microscope stage lighting was significant enough to be measurable, and confirms the results 
reported in section 0, which showed a significant loss in fluorescence for samples that were 
microinjected without precautions to minimize the exposure to ambient light. However, some of 
this loss in fluorescence may be due to the light exposure that the samples received while they 
were being read in the spectrofluorometer. The samples were exposed to the excitation light (75 
watt xenon lamp) of the spectrofluorometer for three seconds, and this may contribute to the 
measured photobleaching.  
 Further confirmation of these results can be found in the literature. The photobleaching of 
free (0.01 µM PBS solution) and bound (surface-labeled microspheres) fluorescein has been 
experimentally studied and theoretically modeled by others4. Air saturated free fluorescein 
solutions were found to bleach approximately 50 % after 80 minutes of exposure to a 100 W 
mercury arc lamp with a 450–490 nm excitation filter block, but were bleached only 
approximately 8 % after ten minutes of photobleaching under the same conditions. This 8% loss 
in fluorescence is similar to the magnitude of photobleaching seen in the study reported here. 
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A.3.3 Ionic Strength and pH 
The measured fluorescence values of various amounts of microinjected sodium 
fluorescein are shown in Figure A.3 for six different ionic strengths of PBS. 
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Figure A.3 Measured fluorescence of various microinjected amounts of sodium fluorescein (● 1.1 nmol, ■ 2.2 
nmol, × 4.4 nmol) in PBS of different ionic strengths. Ionic strength is greatest for 10X PBS. 
 Overall, the samples show a slight decreasing trend of measured fluorescence as the ionic 
strength is increased from 1X up to 10X. This can be explained by the fact that as the ionic 
strength of the release medium increases, greater screening of the fluorescent species and thus 
faster quenching occurs, leading to a lower measured fluorescence2. Another way in which to 
understand these results is to plot the fluorescence of the samples as a function of the medium 
pH. The pH is inversely related to the ionic strength (as ionic strength and hence [H+] 
concentration increase, the pH decreases), and thus we would expect the measured fluorescence 
to decrease as the pH decreases. This is exactly what is experimentally observed, as shown in 
Figure A.4 below. 
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Figure A.4 Measured fluorescence of cuvettes having different amounts of sodium fluorescein (● 1.1 nmol, ■ 2.2 
nmol, × 4.4. nmol ) in different ionic strengths of PBS, as a function of pH. 
 These results quite clearly show that the sodium fluorescein becomes more fluorescent as 
the release medium pH is increased ([H+] concentration decreases, ionic strength decreases, and 
thus the screening effect becomes less significant), and that this effect is quite large. 
Approximately a threefold increase in measured fluorescence was seen for 4.2 nmol of sodium 
fluorescein (× symbol in Figure A.4) as the pH was increased from 6.95 to 7.4. 
A.3.4 pH and Conductivity 
Results from a variety of release studies were collated with pH and conductivity 
measurements in order to determine whether the phenomena discussed thus far are significant 
over the course of a typical release study. Figure A.5 below shows the compiled measurements 
of release media pH versus the time (in days) at which the eleven release studies were concluded. 
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Figure A.5 Measured media pH over time for various release experiments. 
Although the experiments were performed in phosphate buffered saline, a drop in pH was 
seen as the length of the studies increased. This decrease in pH over time is most likely due to 
the release of lactic acid and glycolic acid monomers from the device substrate and membranes 
as the device degrades over the course of the experiment. Based on the results discussed in 
section A.3.3 above, we would therefore expect the cumulative amount of fluorescence measured 
at the conclusion of the release studies to show a decrease over time. This is indeed the case, as 
shown in Figure A.6 below. The measured cumulative percentage of loading released showed a 
marked decrease over the time period that was investigated. 
282 
0
20
40
60
80
100
120
0 50 100 150 200
Time (days)
Fl
uo
re
sc
ei
n 
M
ea
su
re
d
(%
 o
f I
ni
tia
l L
oa
di
ng
)
 
Figure A.6 Cumulative percentage of initial fluorescein loading measured at the conclusion of various release 
experiments. 
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Figure A.7 Percentage of initial fluorescein loading measured at the conclusion of various release experiments, as a 
function of pH. 
Combining the results from Figure A.5 and Figure A.6, Figure A.7 shows that the 
measured cumulative percentage of loading released shows a decreasing trend as the pH 
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decreases. This is consistent with our results shown in Figure A.4 that show lower fluorescence for 
a given amount of fluorescein as the pH is decreased (and therefore charge screening and 
fluorescence quenching are increased). However, this plot does not take into account that the 
devices that were left in the release media for the longest amount of time most likely had the 
largest amount of photobleaching from ambient light. Some of the decrease in measured 
fluorescence is thus due to photobleaching and not to the drop in pH. In fact, the fluorescence of 
fluorescein as a function of pH has been studied and showed less pH sensitivity than we have 
found1. A decrease in the measured fluorescence of fluorescein (normalized to the fluorescence 
measured above pH 8.2) has been reported as the pH was decreased. The normalized 
fluorescence decreased from 99.2% at pH 7.73, to 95.8% at pH 7.48, and to 82.7% at pH 6.99. 
Thus over the pH range measured for our in vitro release devices (7.06–7.7 in Figure A.5 and 
Figure A.7), we would expect to see a difference in measured fluorescence of only 
approximately 17%. The significantly greater observed drop in measured fluorescence may 
therefore be attributed to photobleaching, as was discussed in sections A.3.1 and A.3.2 above. 
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Figure A.8 Percentage of initial fluorescein loading measured at the conclusion of various release studies, as a 
function of release media conductivity. 
Finally, Figure A.8 above shows the percentage of the initial fluorescein loading 
recovered for these eleven microreservoir devices as a function of the release media conductivity, 
which is inversely proportional to the pH (pH = -log10[H+]). As the conductivity of the release 
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medium increases, the measured amount of fluorescein drops. This phenomenon is due to the 
faster quenching rate and shorter lifetime of the fluorescent species as the charge screening 
increases at higher ionic strengths2. 
A.4 Summary and Conclusions 
The studies presented here clearly show that sodium fluorescein is very sensitive to 1) 
photobleaching and 2) the related variables of pH, ionic strength, and conductivity. Furthermore, 
the effects of these variables on the fluorescence of the molecule appear to be significant over the 
time scale of a typical release study, as they are most likely exacerbated by 1) production of 
acidic degradation products from the PLGA membranes on the microreservoir device, and 2) 
concentration of the saline solution due to continuous evaporation of the release media over time. 
Therefore, radiolabeled molecules were used for all of the release studies reported in this thesis 
in order to eliminate as many factors as possible that might affect accurate quantitation of the 
microreservoir device performance. 
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B Microinjector Accuracy 
B.1 Introduction 
As was discussed in Chapter 3, a number of factors may affect the performance of the 
microinjector and therefore the amount of drug that is loaded into the reservoirs. The effects of 
drug solvent and surface geometry were investigated in Chapter 3, and it was found that both of 
these variables affected the measured microinjected volume to a quantifiable degree. However, 
two other factors may also affect the volume of solution that is delivered from the microinjector, 
namely the volume of the syringe that is used, and the amount of time that elapses between 
injections. Therefore, the goal of the microinjector studies reported here was to quantify the 
effect of these two variables on the microinjector performance in order to determine whether or 
not their effect on the amount of drug loaded into the microreservoir devices was significant.  
B.2 Materials and Methods 
B.2.1 Materials 
Fluorescein-dextran, Mw~70,000 daltons, was obtained from Molecular Probes (Eugene, 
OR). Fluorescein sodium salt was obtained from Sigma-Aldrich (St. Louis, MO). Ideal 9144 
Masking Tape was obtained from American Biltrite, Inc. (Lowell, MA). 
B.2.2 Methods 
B.2.2.1 Effect of Syringe Volume 
The first variable that may affect the amount of solution that is delivered from the 
microinjector is the volume of the syringe that is used in the microinjector. The dispensing of 
liquid from the syringe is controlled by the rotation of an internal seated screw. The screw has a 
defined pitch such that rotation of the screw causes the plunger seat to move the syringe plunger 
a certain distance. A single rotation of the screw corresponds to one step, which is equal to the 
plunger seat moving a distance of 0.000125”. For a syringe having a specified volume Vsyringe, 
the volume that will be injected as the plunger seat moves one step (Vstep) can be calculated as 
follows: 
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Equation B-a 
where Lsyringe is the distance that the plunger moves in order to inject Vsyringe. For example, the 
plunger in a ten µL syringe moves approximately 2.36” in order to inject the entire volume of the 
syringe. Therefore, it has a volume per step of: 
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Similarly, a 100 µL syringe has a volume of 5.29 nL/step, since the value of Lsyringe is the same 
for both the ten and 100 µL syringes and only Vsyringe differs by a factor of ten. The microinjector 
can therefore only dispense volumes that are integer multiples of the step size for a given syringe, 
and smaller volume syringes will have a greater resolution (smaller volume per step) than larger 
volume syringes. 
Polystyrene cuvettes (4.5 mL, Labnet International, Woodbridge, NJ) having four optical 
windows were microinjected with different volumes of sodium fluorescein solution. One, two, 
three, four, or five injections were performed with the programmed volume per injection set to 
20, 50, 100, or 150 nL. Solutions were injected from either a ten or 50 µL syringe with a 31 
gauge, 2”, blunt tip stainless steel metal hub needle (part 91031). To each cuvette were added 
three milliliters of deionized water. The cuvettes were covered with ParaFilm M® and shaken. 
The microinjected solutions were then further diluted by pipetting 50 µL from each cuvette into a 
second cuvette that contained three milliliters of deionized water. 
The fluorescence (fluorescence counts/sec) of each cuvette was measured using λexc = 
494 nm and λemi = 520 nm on a spectrofluorometer (Photon Technology International, 
Lawrenceville, NJ) having an L-201M Illumination System, LPS-220 Lamp Power Supply, 
A1010 Arc Lamp Housing, two Model 101 Computer-Controlled Monochromators, MP-1 
Sample Compartment, Model 814 Analog/Photon-Counting Photomultiplier Detector, SC-500 
Shutter Controller, Computer Interface, and PTI Felix v.1.42a software on a Dell Optiplex 
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466/Le computer. The concentration of fluorescent label in each cuvette (Cc) was calculated by 
subtracting the background fluorescence of a cuvette of deionized water (blank), and dividing by 
the slope in (fluorescence counts/sec)/(mol/L) of a standard curve. The measured microinjected 
volume Vmeas was then calculated by using the volume of solution in the cuvette (Vc), the 
appropriate dilution factors (Di), and the concentration of the fluorescently labeled solution in the 
syringe (Cinit) as follows: 
 
( )
( )iinit
CC
meas DC
CV
V ×
×=  
Equation B-b 
B.2.2.2 Effect of Elapsed Time Between Microinjections 
As was discussed in Chapter 3, evaporation of the drug solution in the needle can cause 
consequent concentration of the solution and variation in the measured volume of solution that is 
microinjected. While the studies reported in Chapter 3 showed that the vapor pressure of the 
solvent clearly affected the measured microinjected volume due to evaporation, the effect of 
elapsed time between microinjections was not quantified. Therefore, a series of experiments was 
performed in order to determine if increasing the elapsed time between microinjections would 
affect the measured concentration. A 50 µL syringe with a 31 gauge needle was used to inject 
18.48 nL of a fluorescein sodium solution onto a clean glass slide, followed by an injection onto 
the surface of a polystyrene cuvette. The elapsed time between the test injection on the glass 
slide and the injection into a cuvette was varied from one to four minutes. Four mL of deionized 
water were added to each cuvette before the fluorescence was measured on the 
spectrofluorometer using the procedures described in section B.2.2.1 above.  
B.3 Results and Discussion 
B.3.1 Effect of Syringe Volume 
Syringes having volumes of ten and 50 µL were used to determine the effect of syringe 
volume on the accuracy of the microinjector. A 1.3 × 10-4 mol/L solution of fluorescein sodium 
in water was loaded into the syringes. The MICRO4 microinjector controller was programmed to 
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deliver 20, 50, 100, or 150 nL per injection. The actual volumes injected were multiples of 19.57, 
49.72, 99.98, and 149.7 nL for the ten µL syringe, and multiples of 18.48, 47.52, 97.68, or 147.8 
nL for the 50 µL syringe. 
Figure B.1 shows the measured microinjected volume vs. predicted microinjected 
volume for the sodium fluorescein solution microinjected from the ten µL syringe, while the 
results for the 50 mL syringe are shown in Figure B.2. 
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Figure B.1 Measured vs. predicted microinjected volume for multiple injections of sodium fluorescein solution 
from a ten µL syringe: ○ 20 nL injections, × 50 nL injections, ● 100 nL injections, ■ 150 nL injections, solid line 
indicates theoretical predicted microinjected volume, dashed line indicates least-squares best fit to data points. 
289 
0
150
300
450
600
750
0 150 300 450 600 750
Predicted Microinjected Volume (nL)
M
ea
su
re
d 
M
ic
ro
in
je
ct
ed
V
ol
um
e 
(n
L)
R2 = 0.4336/0.9708
slope = 0.3250/0.3119
 
 
Figure B.2 Measured (calculated) vs. predicted microinjected volume for multiple injections of sodium fluorescein 
solution from a 50 µL syringe: ○ 20 nL injections, × 50 nL injections, ● 100 nL injections, ■ 150 nL injections, 
solid line indicates theoretical predicted microinjected volume, dashed line indicates least-squares best fit to data 
points. R2 and slope values calculated with/without 95.04 nL outlier. 
The ten µL syringe results indicate a measured microinjected volume of approximately 
40% (slope = 0.3952) of the predicted microinjected volume, on average, while the 50 µL results 
show approximately 30% (slope = 0.3250) of the predicted microinjected volume. The slopes 
and R2 values indicated in Figure B.2 were calculated for the 50 µL syringe samples both with 
and without the 95.04 nL outlier (2 x 47.52 nL injections). The small overall measured volumes 
may be due to the rapid photobleaching of fluorescein, which was discussed in Appendix A. The 
difference in the average measured microinjected volumes, however, indicates that the volume of 
the syringe affects the accuracy of the microinjector. This is not surprising, as the smaller syringe 
has a smaller volume per step and therefore a better resolution. Improper rotation of the internal 
microinjector screw by one step, for example, would create an error of 0.529 nL for a ten µL 
syringe, but an error of 2.65 nL for a 50 µL syringe. For a programmed microinjected volume of 
20 nL, these errors would turn out to be 2.65% and 13.25% of the programmed volume. This 
difference in syringe resolution could therefore explain the greater accuracy of the ten µL 
syringe as evidenced by the larger slope of the curve in Figure B.1. From this set of experiments, 
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we concluded that the syringe volume did have a measurable, although small, effect on the 
accuracy of microinjection. 
B.3.2 Effect of Elapsed Time Between Microinjections 
Although the results that were presented in Chapter 3 suggested an evaporation effect due 
to solvent vapor pressure, reconciliation of experimentally obtained values with predicted values 
was difficult. However, varying the time between microinjections of a solution and then 
measuring the microinjected amount of solute can provide a qualitative measure of whether 
evaporation significantly affects the microinjected volumes of interest for our studies. 
A solution of fluorescein sodium in water was injected into polystyrene cuvettes. The 
elapsed time between a test injection on a glass slide and the injection into the cuvette was varied 
from one to four minutes. The results of the experiment are shown in Figure B.3 below. 
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Figure B.3 Measured fluorescence as a function of elapsed time between microinjections. 
At one minute, the measured fluorescence is approximately equal to the predicted 
fluorescence. This may represent a balance between the three phenomena of concentration of the 
solution due to evaporation, photobleaching, and decreased wetting due to an increase in the 
solution viscosity as the solvent evaporates. As is expected, when the time between 
microinjections is increased, the measured fluorescence also increases. This is most likely due to 
the evaporation of the solvent and corresponding increase in concentration of the droplet, similar 
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to the results seen for 14C-iodoantipyrine in section 3.3.1.1. Predicted values of the adjusted 
concentration in the solution droplets can be obtained using the following equations from 
Chapter 3: 
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We assumed a pendant droplet volume of 18.48 nL, T = 290°K (20°C), and an initial 
solution concentration of 0.0132 mol/L. The calculated concentrations for the droplets after one, 
two, three, or four minutes of elapsed time are shown in Table B-1 below. 
Table B-1 Calculated concentrations of fluorescein sodium droplets 
after one, two, three, or four minutes elapsed time between 
microinjections. 
Elapsed Adjusted
Time (sec) Concentration (mol/L)
18.48 3.2000115 60 0.013200508
18.48 3.2000115 120 0.013201016
18.48 3.2000115 180 0.013201524
18.48 3.2000115 240 0.013202033
Vinj (nL) P (kPa)
Water
Solution
 
While our theoretical calculations show an increase in the droplet concentration, it is not 
a large enough increase to account for the experimentally observed doubling of the measured 
fluorescence. As was discussed in Chapter 3, the most obvious reason for this is that the vapor 
pressure calculations do not account for the continuing decrease in the size of a given droplet due 
to evaporation. As the droplet shrinks, the vapor pressure will increase, thereby further 
increasing the vapor pressure and hence the evaporation rate. 
This increase in concentration as the elapsed time increases seems to plateau at times 
longer than three minutes. One explanation for this might be that after approximately three 
292 
minutes, equilibrium is reached between the driving force to evaporate the solution from inside 
the needle, and the geometry of the liquid surface. From Equation B-c it can be seen that the 
vapor pressure P is proportional to exp(Rm-1), where Rm is the mean radius of curvature of the 
liquid surface. As the solution evaporates from the end of the needle, the liquid surface becomes 
flatter and the radius of curvature increases. In the case of a completely flat, planar surface, the 
radius of curvature becomes infinite. From Equation B-c it is evident that as the radius of 
curvature increases, the vapor pressure decreases. The vapor pressure and thus the driving force 
for evaporation will be zero when the quantity (γVm)/(RTRm) is equal to one. Alternatively, the 
plateau region seen in Figure B.3 may arise when the photobleaching rate of the fluorescein 
exactly counteracts the evaporation and hence concentration rate. 
B.4 Conclusions  
The studies presented here clearly show that the microinjection method that is used to load 
the devices with chemicals has a number of variables that can affect the accuracy of loading. 
First, the syringe volume appears to have a large effect on the microinjected volume. Larger 
volume syringes will have a correspondingly larger volume per step when used with the 
microinjector. This leads to less accuracy than can be achieved with smaller volume syringes. 
Additionally, greater elapsed time between microinjections appeared to increase the amount of 
solute that was measured for a given microinjected volume, most probably due to concentration 
of the solution within the syringe needle as the solvent evaporated.  
 Precautions were typically taken during loading of devices for a release study to 
minimize the effects of these two variables. At least one test microinjection was always 
performed on a glass slide just prior to microinjection of a drug solution into a reservoir on a 
given device in order to minimize the effect of evaporation. When loading reservoirs with drug 
solutions, ten µL syringes were typically used for 14C labeled chemicals, although 50 or 100 µL 
syringes were used for 125I chemicals, and a 100 µL syringe was used to load 3H-heparin. While 
the syringe volume may partially explain the variability seen for the amounts of 125I labeled 
chemicals recovered over the course of the release studies presented in Chapter 4, the devices 
loaded with 3H-heparin from a 100 µL syringe showed generally very reproducible and high 
amounts of loading released over the course of the release studies. Therefore, it is more likely 
that other factors such as the counting efficiency and sensitivity of the scintillation counters for 
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the various isotopes, as well as the partition coefficients of the chemicals, play a larger role in the 
determination of the measured amount of chemical released from the devices.  
A more critical issue for in vitro prototypes with regard to microinjector accuracy may be 
the fabrication of the reservoir membranes. Typically microinjection of the membrane solutions 
is performed with a 100 µL syringe due to the large volume of solution required when 
fabricating membranes in a batch of devices. The greater inaccuracy of the larger volume 
syringes, combined with the high vapor pressure of the solvent in which the membrane polymers 
are dissolved, may generate greater than expected variability in the volume of reservoir 
membrane polymers injected into the reservoirs. This could affect the final membrane 
thicknesses, which in turn may affect their degradation and the subsequent time at which release 
of chemicals from the reservoirs is observed, as discussed in Chapter 5. A more thorough study 
to correlate the predicted microinjected volume with the actual membrane thickness may prove 
valuable. 
 
